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Abstract 
Purpose The human epidermal growth factor receptors EGFR (erbB1) and HER2 
(erbB2/neu) are involved in mediating resistance to chemotherapy and ionising radiation 
(IR).  In vitro studies demonstrate that small molecule tyrosine kinase inhibitors (TKIs) which 
target these receptors can increase the effectiveness of DNA damaging agents. However, 
these combinations have failed to produce the clinical results anticipated and one potential 
explanation is that the inhibition of EGFR and HER2 cell signalling pathways by TKIs is short 
lived, with cells able to switch to alternative mechanisms of signalling through HER3. The 
purpose of this study was to examine whether the duration of exposure to TKIs modulates 
the induction and repair of DNA damage produced by chemotherapy or IR and describes 
attempts to elucidate the role of HER2 in mediating resistance to chemotherapy. 
Experimental design Two HER targeting TKIs, lapatinib and gefitinib were investigated. The 
effect of lapatinib in combination with cisplatin and doxorubicin on the inhibition of cell 
proliferation and the role of schedule were examined in drug combination assays. The 
influence of the duration of exposure to TKIs on the induction and repair of DNA lesions 
induced by cisplatin, IR, doxorubicin, etoposide and m-AMSA were investigated using the 
alkaline and neutral Comet assays and measurement of γH2AX and RAD51 foci. DNA 
expression arrays were used to identify the potential mechanisms through which HER2 
produces resistance to cisplatin in cells transfected with HER2. 
Results Lapatinib is able to synergistically inhibit cell proliferation in combination with 
cisplatin or doxorubicin in a schedule dependent manner. Duration of exposure to TKIs has 
no effect on the induction of DNA lesions by cisplatin or IR, but significantly reduces the 
production of DNA double strand breaks by doxorubicin, etoposide and m-AMSA in part 
through the down-regulation of the expression of topoisomerase IIα (Topo IIα), increasing 
resistance to these drugs. 
Conclusions These results indicate the scheduling of small molecule TKIs targeted against 
EGFR and HER2 is important and continuous exposure to these drugs induces resistance to 
doxorubicin, etoposide and m-AMSA, through reduced expression of their target, Topo IIα. 
The importance of schedule should be considered when combining TKIs with chemotherapy 
in clinical practice. 
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REVIEW OF THE LITERATURE 
1.1 CANCER  
The term ‘cancer’ is commonly used to describe a group of diseases caused by the 
uncontrolled growth of cells (due to self-sufficiency in growth signalling, limitless 
ability to replicate, disregulation of cell metabolism and evasion of growth suppression 
and cell death), with the potential to spread to other sites (metastasise), evade the 
immune system and obtain their own blood supply (angiogenesis) (Hanahan and 
Weinberg, 2000; Hanahan and Weinberg, 2011).  
 
Early in the twentieth century the ability of viruses to induce cancers was recognised 
with the isolation of a virus from chickens with avian erythroid leukaemia in 1908. This 
was followed by Peyton Rous in 1911, isolating a virus capable of inducing sarcomas in 
chickens, the Rous Sarcoma Virus (Rous, 1911). This led to the isolation of other viruses 
which could cause cancer, including the avian erythroblastic virus which induces 
erythroid leukaemia and fibrosarcoma in chickens (Beug et al., 1979). Cancer inducing 
viruses were recognised to transfer genetic material (oncogenes) into infected cells 
which were responsible for their transformation into cancers. It was also discovered 
that these same oncogenes were encoded by genes present within avian DNA (Stehelin 
et al., 1976), and to the understanding that normal cellular genes (proto-oncogenes) 
could become oncogenes and transform cells into cancers, a hypothesis for which 
Bishop and Varmus were awarded the Noble Prize in Medicine in 1989. Two oncogenes 
were isolated from the avian erythroblastic virus and named v-erbA and v-erbB 
(Roussel et al., 1979) with their cellular DNA counterparts denoted as cellular by the ‘c’ 
prefix, c-erbA and c-erbB (Vennstrom and Bishop, 1982). 
 
In the 1960’s Stanley Cohen isolated epidermal growth factor (EGF) and demonstrated 
that it stimulated cell proliferation both in vitro and in vivo (Cohen, 1964). He went on 
the isolate the protein to which EGF bound, now known as the epidermal growth 
factor receptor (EGFR) (Taylor et al., 1974). In 1984 Downward et al. identified that the 
out of 84 amino acids isolated from the EGFR gene, 74 were shared with the v-erbB 
oncogene (Downward et al., 1984). This discovery was closely followed by the 
identification of c-erbB2, a gene similar to, but distinct from EGFR and a human 
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homolog of the rat oncogene neu, responsible for the chemical induction of 
neuroblastoma and glioblastoma in rats (Schechter et al., 1985; Semba et al., 1985). 
This led to the recognition of c-erbB (c-erbB1/EGFR) and c-erbB2 as oncogenes as 
demonstrated by their ability to induce transformation and tumour formation in 
mouse fibroblast cells (Di Fiore et al., 1987; Hudziak et al., 1987; Velu et al., 1987). 
 
Both c-erbB1 and c-erbB2, together with two other receptors, belong to a family of 
membrane receptor tyrosine kinases known as the human epidermal growth factor 
receptor (HER) family (Figure 1.1); EGFR (c-erbB1/HER1), HER2 (c-erbB2/neu), HER3 (c-
erbB3) and HER4 (c-erbB4). In the late 1980’s Slamon et al. demonstrated that the 
HER2 gene was amplified in 30% of breast cancers and predicted for a disease with a 
poorer overall survival (OS) and reduced time to relapse (Slamon et al., 1987). This 
observation led to the development of drugs which target HER2 and their subsequent 
successful translation into the clinical management of breast cancer. 
 
 
 
Figure 1.1 Timeline of discovery of the human epidermal growth factor receptor family 
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1.2 BREAST CANCER 
The term ‘breast cancer’ describes a spectrum of malignancies arising in the breast, 
including in situ carcinomas and invasive tumours. It is the commonest cancer in 
England, with 39, 681 new cases diagnosed in 2008, accounting for 31% of all new 
cancer diagnoses with less than 1% of these cases occurring in men (Office for National 
Statistics, October 2010). Whilst the incidence of breast cancer has been increasing 
year on year since the 1970’s, mortality from the disease has been falling since the late 
1980’s. This fall is attributed to improvements in both diagnosis and treatment (Quinn 
et al., 2008). Despite this, metastatic disease cannot be eradicated and only 10% of 
patients with metastatic breast cancer live for more than 10 years following diagnosis 
(Statistics and Outlook for Breast Cancer, 2009) causing 10,000 deaths in 2008 (Office 
for National Statistics, October 2010) .  
 
1.2.1 Presentation of breast cancer 
30% of all breast cancers are diagnosed through screening, though this number rises to 
50% in those patients aged between 50 and 70 years old and therefore eligible for the 
breast cancer screening programme (West Midlands Cancer Intelligence Unit, 2009). 
This means that most patients present with symptomatic breast cancer, usually a self 
detected breast abnormality, though around 5% of patients have metastatic breast 
cancer at presentation (Statistics and Outlook for Breast Cancer, 2009) and may 
present with symptoms such as pain due to  bone or liver metastases . 
 
1.2.2 Diagnosis of breast cancer 
The standard for diagnosing breast cancer in those with a self or mammogram 
detected abnormality is triple assessment. This involves clinical examination of the 
breast, imaging with ultrasound and/or mammogram together with either a fine 
needle aspiration cytology or core biopsy (National Institute for Health and Clinical 
Excellence, 2009b). 
 
1.2.2.1 Pathology of breast cancer 
Pathological examination of a breast tumour is essential, as in addition to primary 
breast cancers, other types of cancer occur in breast tissue including lymphomas, 
neuroendocrine tumours and sarcomas, together with benign breast disease and 
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lesions associated with an increased risk of developing invasive breast cancer, such as 
lobular carcinoma in situ (LCIS) and ductal carcinoma in situ (DCIS). Broadly breast 
cancers are categorised as non-invasive carcinomas in situ (DCIS and LCIS) or invasive 
breast cancer (Tobias and Hochhauser, 2010).  
 
1.2.2.1.1 Morphological appearance of invasive breast cancer 
Invasive breast cancer includes lobular, ductal, tubular, cribriform, mucinous, 
inflammatory and medullary cancers. Invasive ductal cancers comprise the largest 
group of invasive breast cancers, account for nearly 70% of breast cancers diagnosed 
in the UK (West Midlands Cancer Intelligence Unit, 2009). They are defined as having 
the morphological features of an infiltrating cancer with less than 50% of the 
characteristic of the other types of invasive breast cancers (Pathology Reporting of 
Breast Disease, 2005). Invasive lobular cancers are the next most frequent histological 
type of breast cancer, making up around 10% of breast tumour diagnosed (West 
Midlands Cancer Intelligence Unit, 2009). 
 
1.2.2.1.2 Histological grade in invasive breast cancer 
Invasive breast tumours are graded according to the Bloom Richardson Score. This 
score grades invasive breast cancers as one, two or three, calculated from a score from 
three to nine based upon tubule/acinar/glandular formation, nuclear 
atypia/pleomorphism and frequency of mitoses (Pathology Reporting of Breast 
Disease, 2005). Grade one tumours (well differentiated tumour with a score of 3-5) 
have the best prognosis with grade three tumours (poorly differentiated tumours with 
a score 8-9) having the worst. 
 
1.2.2.1.3 HER2 status in invasive breast cancer 
HER2 status is assessed to determine whether therapies targeted against HER2 will be 
beneficial. Tumours which are defined as being ‘HER2 positive’ are gene amplified as 
detected by fluorescence in situ hybridisation (FISH) or a score of 3+ as assessed with 
immunohistochemistry (IHC), with 3+ defined as uniform intense membrane staining 
of >30% of invasive tumour cells. A score of 2+ requires confirmation by FISH (Wolff et 
al., 2007). Tumours which do not meet these criteria are classified as ‘HER2 negative’. 
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1.2.2.1.4 Hormone receptor status in invasive breast cancer 
Oestrogen receptor (ER) status is assessed in breast tumours in order to determine 
whether endocrine therapy may be beneficial. This can be done on a core biopsy or 
surgical specimens using IHC. Tumours are scored for intensity of staining and 
percentage of nuclear staining using the Allred Score, with a maximum score of eight 
(scores of 0-5 for percentage of staining and 1-3 for intensity)  (Pathology Reporting of 
Breast Disease, 2005).  
 
1.2.2.2 Staging of invasive breast cancer 
Full staging of early breast cancer requires examination of the resected primary breast 
tumour for size (T) and lymph nodes for involvement with cancer (N). Clinical 
assessment with radiological investigation as indicated are used to assess for the 
presence of metastases (M). These features combine to give an overall staging of I-IV, 
with stage IV identifying the presence of metastatic disease (Edge SB et al., 2010). The 
tumour should also be assessed for the adequacy of the resection margins and the 
presence of lymphovascular invasion.  
 
1.2.3 Prognostic features of invasive breast cancer 
1.2.3.1 Pathological features and prognosis 
Traditionally pathological features useful in predicting survival in early breast cancer 
are tumour size, number of involved lymph nodes and histological grade as used in the 
Nottingham Prognostic Index (NPI). The NPI groups tumours into six categories ranging 
from excellent prognosis with a 10 year survival of 96% to very poor prognosis with a 
10 year survival of 38% (Lee and Ellis, 2008). The NPI was originally based on survival 
figures derived from a prospective study started in 1973, before the introduction of 
adjuvant therapy. The figures quoted above are derived from data between years 
1990-1999, following the introduction of adjuvant therapy and improvements in 
pathological examination of surgical specimen, including the examination of resection 
margins (Lee and Ellis, 2008). These figures demonstrate an improvement in survival 
compared with the original figures and indicates that future attempts to identify 
prognostic features may be skewed by improvements in diagnosis, staging, surgery and 
adjuvant treatments. 
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Other prognostic indicators include urokinase-type plasminogen activator (uPA) and its 
inhibitor, plasminogen activator inhibitor-type 1 (PAI-1) levels (Annecke et al., 2008), 
the presence of lymphovascular invasion in node negative breast cancer  (Lee et al., 
2006a) and HER2 expression (Slamon et al., 1987), with all identifying tumours 
associated with a poorer prognosis. Other tools being developed include the 
assessment of the expression of five proteins using IHC; SLC7A5, HTF9C, p53, NDRG1, 
and CEACAM5 from which a Mammostrat score can be calculated. The test can predict 
prognosis in early-stage, ER-positive tamoxifen treated breast cancer and potentially in 
node negative or ER-negative tumours (Bartlett et al., 2010). 
 
1.2.3.2. Genetic profiling in breast cancer  
The ability to genetically profile tumours has lead to the identification of gene 
signatures which can be used to predict the likelihood of recurrence in patients with 
early breast cancer. These include Oncotype DX and MammaPrint, which are in clinical 
use and PAM50, which is still undergoing validation.  
 
Oncotype DX utilises reverse transcriptase polymerase chain reaction (RT-PCR) on RNA 
extracted from formalin fixed paraffin embedded tissue for 16 cancer genes (including 
HER2, ER and PR) and five reference genes. Normalised expression scores are used to 
calculate a recurrence score (RS) from 0-100, with 100 indicating a higher likelihood of 
recurrence in patients with hormone receptor positive, node negative breast cancer. 
The recurrence scores were stratified based on the breast cancer recurrence rates in 
women with hormone receptor positive, node negative breast cancer who received 
adjuvant therapy with tamoxifen as part of the National Surgical Breast and Bowel 
Project (NASBP) 14 trial. Those patients estimated to be of low risk (RS < 18) had a 
distant recurrence rate of 7% at 10 years compared with the intermediate risk (RS 18–
30) of 14% and in the high risk (RS≥31) of 31% (Paik et al., 2004). Oncotype DX can also 
be used to identify patients who may not benefit from adjuvant chemotherapy 
(discussed in section 1.2.4.1.2) 
 
MammaPrint uses the expression profiling of a 70 gene signature, performed on fresh 
breast cancer tissue. The signature classifies tumours as high or low risk for recurrence 
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in women under the age of 61 years, with tumours measuring less than 5 cm and node 
negative disease (Buyse et al., 2006; van de Vijver et al., 2002).  
 
The PAM50 examines 50 genes in RNA extracted from formalin fixed breast tissue. It 
categorises tumours as luminal A, luminal B, basal-like, HER2-enriched, and normal-like 
and calculates a risk of recurrence score. In patients with ER positive breast cancer, 
who received adjuvant tamoxifen therapy alone, it is able to identify a group of women 
with a low risk of recurrence (Nielsen et al., 2010). In ER positive breast cancer PAM50 
has been compared directly with Oncotype DX. There is significant agreement in the 
identification of high and low risk of recurrence between both tests; in the those 
identified as having an intermediate risk of recurrence by Oncotype DX, nearly 50% 
were classified as low risk by PAM50 (Bastien et al., 2011). This test is still undergoing 
validation, but potentially may further stratify the group of patient identified as at 
intermediate risk of recurrence by Oncotype DX. 
 
1.2.4 Treatment of invasive breast cancer 
The management of patients with breast cancer is multimodal and includes surgery, 
radiotherapy, chemotherapy, endocrine and targeted therapies together with 
emotional and psychosocial support. It is recommended that treatment decisions are 
made by a multi-disciplinary team, guided by features such as tumour size, nodal, 
hormone and HER2 status, co-morbidities and patient choice (National Institute for 
Health and Clinical Excellence, 2009b).  
 
1.2.4.1 Treatment of early invasive breast cancer 
1.2.4.1.1 Surgery 
Surgery remains the key modality in achieving long term disease control in patients 
presenting with localised breast cancer. It is performed with the key aims of achieving 
local disease control and to provide staging information from both the primary and 
ipsilateral axillary nodes. This information guides the use of systemic therapy and 
enables the prediction of prognosis. Reconstructive surgery is also important for those 
women who undergo a mastectomy. 
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Over the last 30 years surgical techniques have evolved and breast conserving surgery 
followed by radiotherapy in those patients in whom adequate resection margins can 
be achieved, has become standard. In a 20 year analysis the procedure has been 
demonstrated to be comparable with a mastectomy in terms of local disease control, 
progression free survival (PFS) and OS (Fisher et al., 2002). In women with large breast 
tumours compared to breast size, who would normally require a mastectomy, 
chemotherapy can be given pre-operatively (neo-adjuvant chemotherapy) (Fisher et 
al., 1997; van der Hage et al., 2001). The aim of this approach is to increase the breast 
conservation rate, but also provide an in vivo measure of chemosensitivity as response 
in the primary tumour can be measured clinically, radiologically and pathologically 
after resection.  
 
Axillary staging increasingly utilises the technique of sentinel lymph node sampling in 
those patients with clinically negative lymph nodes. This saves those patients without 
involved sentinel lymph nodes from the morbidity associated with axillary node 
dissection (Mansel et al., 2006) without compromising local disease control, disease 
free survival (DFS) or OS (Krag et al., 2010). Patients with clinically involved lymph 
nodes undergo an ultrasound guided fine needle aspiration. If the cytology is negative 
patients can undergo sentinel lymph node sampling; those with positive cytology are 
recommended axillary node dissection. 
 
Breast cancer has long been recognised as systemic disease as borne out by the 
observation that despite obtaining local disease control, many patients present with 
metastatic disease years later. The role of adjuvant therapy is important, as only five 
percent of breast cancer patients present with metastatic disease and therefore the 
majority of patients dying from the disease, initially presented with localised disease 
(Statistics and Outlook for Breast Cancer, 2009). The selection of those patients who 
stand to benefit from adjuvant therapy either with chemotherapy, trastuzumab and/or 
endocrine therapy is complex and needs to take into account tumour size, nodal 
status, ER status and pre-existing co-morbidities.  
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1.2.4.1.2 Adjuvant Chemotherapy 
In the adjuvant setting the benefit of combination therapy with cyclophosphamide, 
methotrexate and 5-Fluorouracil (5-FU) (CMF) following surgery for breast cancer was 
first reported by Bonadonna et al. in 1976, with benefits in terms of PFS and OS 
(median OS increased from 104 months to 137 months) confirmed after 20 years of 
follow-up (Bonadonna et al., 1995). By the late 1990’s anthracycline based regimens 
were established and a 15 year meta-analysis demonstrated their benefit over non-
anthracycline based regimens (EBCTCG, 2005).  
Taxanes are widely used in women with node positive disease, especially if hormone 
receptor positive, though there is some controversy. The PACS01 trial compared six 
cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) with a sequential 
regimen of three cycles of FEC followed by three cycles of docetaxel (FEC-D) as 
adjuvant treatment for women with node-positive early breast cancer. Five-year OS 
rates were 86.7% with FEC and 90.7% with FEC-D, demonstrating a 27% reduction in 
the relative risk of death (unadjusted P = .014; adjusted P = .017) (Roche et al., 2006). 
In the BCIRG 001 study, 1491 women with axillary node-positive breast cancer were 
randomised to six cycles of treatment with docetaxel plus doxorubicin and 
cyclophosphamide (TAC) or fluorouracil plus doxorubicin and cyclophosphamide (FAC). 
Treatment with TAC resulted in a 30% reduction in the risk of death (P=0.008) (Martin 
et al., 2005). However, the TACT study which recruited 4162 women with node-
positive or high-risk node-negative operable early breast cancer did not demonstrate 
any benefit from the addition of docetaxel to standard anthracycline based 
chemotherapy (Ellis et al., 2009). 
Overall patients with node positive breast cancer, ER negative disease and younger 
patients derive greater benefit from adjuvant chemotherapy (EBCTCG, 2005). In order 
to help identify specific groups of patients who stand to gain from receiving adjuvant 
chemotherapy, tools such as the computer programme Adjuvant! Online (Adjuvant! 
Online), measurement of uPA and PAI-1 (Annecke et al., 2008), the presence of bone 
marrow micrometastases (Pantel et al., 2009) and the gene signature Oncotype DX or 
Mammostrat can be useful. 
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The 21 gene signature known as Oncotype DX can be used to identify those patients 
with node negative, hormone receptor positive breast cancer who are unlikely to 
derive benefit from adjuvant chemotherapy. These data were derived from the NSABP-
20 study in which women were randomised to receive adjuvant, non-anthracycline 
based chemotherapy or not, in addition to five years of treatment with tamoxifen. 
Women with tumours with a high RS (≥31) derived the greatest benefit from adjuvant 
chemotherapy and those with low RS (<18), derived no significant benefit (Paik et al., 
2006). The TAILORx study has been designed to examine the addition of chemotherapy 
to hormonal therapy in ER and/or PR positive, lymph node and HER2 negative, breast 
cancer. Women with a RS of less than 10 will receive hormonal therapy and those with 
RS of 26 or greater, hormonal therapy and combination chemotherapy. Patients with 
RS between 11-25, are randomised between hormonal therapy alone or in 
combination with chemotherapy (National Cancer Institute, 2011d).  
 
Oncotype DX may also be useful in patients with node positive, hormone receptor 
positive breast cancer. Indicating that patients with low RS may not derive benefit 
from anthracycline based adjuvant chemotherapy, in addition to tamoxifen, despite 
having a high risk of relapse (Albain et al., 2010).  
 
The Mammostrat Score in the NSABP-20 population was able to stratify patients into 
high and low risk groups, with the low risk group benefiting from adjuvant 
chemotherapy by an improvement in 10 year recurrence free interval from 86% to 91% 
(HR, 0.4 (95% CI, 0.2-0.8); P = 0.01). In the high risk group, the absolute benefit was 
improved by 21%, from 64% to 85% (HR, 0.4 (95% CI, 0.2-0.9); P = 0.02) (Ross et al., 
2008). 
 
1.2.4.1.3 Adjuvant Endocrine therapy 
In 1896 Beatson reported the regression of metastatic breast cancer in two 
premenopausal women by oophorectomy (Beatson, 1896). Since this time endocrine 
manipulation has become a key modality in the management of patients whose 
tumours express ER and/or PR. Endocrine therapies today reduce the stimulation of 
breast tumours which express these receptors by the hormone oestrogen (Rutqvist et 
al., 1989). Endocrine therapies include reducing oestrogen production through ovarian 
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ablation or suppression, the selective oestrogen receptor modulator tamoxifen and 
aromatase inhibition with, for example, anastrozole or letrozole. Aromatase inhibitors 
prevent conversion of androgens to oestrogens, through the process of aromatisation 
within the adrenal gland and adipose tissue (Miller et al., 2008). This means that their 
use is restricted to post menopausal women, as in pre-menopausal women most 
oestrogen is produced by the ovaries. Therefore, tamoxifen remains the adjuvant 
endocrine therapy in pre-menopausal women with hormone receptor positive breast 
cancer (Burstein et al., 2010).   
 
In post menopausal women, adjuvant treatment with an aromatase inhibitor for five 
years improves DFS over tamoxifen, though sequential treatment with both tamoxifen 
and aromatase inhibitor is no different from treatment with an aromatase inhibitor 
alone for five years in terms of DFS and OS (Burstein et al., 2010).  
 
1.2.4.1.4 Adjuvant trastuzumab therapy 
HER2 is recognised to be associated with a more aggressive breast cancer with a 
shorter time to relapse (Slamon et al., 1987). It can be targeted by the monoclonal 
antibody trastuzumab and its use for one year following completion of adjuvant 
chemotherapy is recommended in patients with HER2 positive breast cancer (National 
Institute for Health and Clinical Excellence, 2009b). Trastuzumab reduces the risk of 
death with a hazard ratio of 0.66 (95% CI 0.47-0.91; p=0.0115) compared with 
observation alone with an absolute DFS difference of 6.3% (Piccart-Gebhart et al., 
2005; Smith et al., 2007). 52% of patients randomised to the observation arm, opted to 
receive adjuvant trastuzumab following the publication of the first interim analysis, 
with treatment beginning at a median time of 22.8 months from randomisation. These 
patients benefited from adjuvant trastuzumab with fewer DFS events (adjusted HR 
0·68; 95% CI 0·51-0·90; p=0·0077) (Gianni et al., 2011). This study (HERA study) 
scheduled trastuzumab following completion of chemotherapy. The FinHER study 
examined the use of trastuzumab in combination with docetaxel or vinorelbine. This 
study randomised 232 women with HER2 and node positive or high risk breast, to 
receive trastuzumab in combination with docetaxel or vinorelbine for nine weeks 
followed by three cycles of FEC chemotherapy. Distant DFS was higher in those treated 
with trastuzumab, docetaxel and FEC compared with docetaxel and FEC or  
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trastuzumab, vinorelbine and FEC (Joensuu et al., 2009). Therefore, trastuzumab is 
given sequentially following completion of adjuvant chemotherapy or concurrently 
with a taxane. 
 
1.2.4.1.5 Adjuvant radiotherapy 
Local radiotherapy is important in those women who have undergone breast 
conserving surgery as higher rates of local recurrence occur in those who do not 
receive radiotherapy (14.3% vs. 39,2% P<0.001) (Elkhuizen et al., 2000; Fisher et al., 
2002). Radiotherapy is also recommended in those patients who have undergone a 
mastectomy and are high risk for recurrence (large primary tumour, incomplete 
margins and multiple involved lymph nodes), those with a positive sentinel lymph node 
who are unable to undergo axillary dissection and those with locally advanced disease 
with supraclavicular fossa lymphadenopathy (National Institute for Health and Clinical 
Excellence, 2009a).  
 
1.2.4.2 Treatment of metastatic breast cancer 
Patients presenting with metastatic disease require histological confirmation of the 
type of cancer, HER2 and hormone receptor status to guide treatment. Currently, the 
reassessment of these features is not recommended in patients presenting with 
recurrent disease (National Institute for Health and Clinical Excellence, 2009a) but 
there is evidence that there may be discordance between the primary tumour and 
metastases (Curigliano et al., 2011; Simmons et al., 2009). The extent of disease is 
normally assessed using imaging including computed tomography, magnetic resonance 
imaging, plain radiography and/or bone scintigraphy (National Institute for Health and 
Clinical Excellence, 2009a). 
 
Surgical resection of the primary breast tumour or local radiotherapy may improve 
survival in patients with metastatic disease and is considered on an individual patient 
basis (Ly et al., 2010). Surgery and radiotherapy can also be used to treat symptomatic 
disease from brain or bone metastases or pathological fractures; bisphosphonates play 
a role in preventing fracture and improving pain (Rosen et al., 2004). However, the 
management of metastatic breast cancer is reliant upon systemic therapy to control 
and delay disease progression.   
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1.2.4.2.1 Endocrine therapy in metastatic breast cancer 
Endocrine therapy is useful in patients with ER positive and/or PR positive metastatic 
breast cancer. In post menopausal women, treatment with an aromatase inhibitor is 
more efficacious than tamoxifen (Mouridsen et al., 2001). A further option is the use of 
the pure ER antagonist, fulvestrant, which is able to achieve response rates of around 
7% in patients in whom two endocrine therapies have failed (Chia et al., 2008).   
 
1.2.4.2.2 Chemotherapy and targeted therapies in metastatic breast cancer 
Anthracyclines, taxanes, capecitabine, vinorelbine and gemcitabine (Albain et al., 2008; 
Jones et al., 2005; O'Shaughnessy et al., 2002; Sparano et al., 2009) all demonstrate 
efficacy in metastatic breast cancer. Patients usually receive sequential therapy with 
different regimens as tolerated and dependent upon previous chemotherapy 
exposure. In patients with HER2 positive breast cancer, the addition of trastuzumab to 
standard chemotherapy regimens, with either anthracyclines or taxanes, was first 
demonstrated to be beneficial in 2001 (Slamon et al., 2001). The observed higher rates 
of heart failure in combination with anthracyclines compared with paclitaxel, led to the 
clinical use of trastuzumab in combination with taxanes over anthracyclines.  
 
In patients whose tumours develop resistance to trastuzumab, further targeting of 
HER2 with the dual EGFR and HER2 tyrosine kinase inhibitor (TKI), lapatinib, is 
beneficial in combination with paclitaxel (Di Leo et al., 2008b) or capecitabine 
(Cameron et al., 2008) over either chemotherapy alone (discussed further in section 
1.9.5). 
 
In the HER2 negative patient group, the addition of the anti-vascular endothelial 
growth factor (VEGF) antibody bevacizumab, to taxane based chemotherapy, increases 
response and PFS rates but not OS (Gray et al., 2009; Miles et al., 2010). 
 
1.2.5 Future directions in the treatment of breast cancer 
The identification of HER2 as a marker of a disease with a poorer prognosis and the 
ability to target this receptor significantly altered the outlook and management of 
HER2 positive breast cancer. This has led to the identification of tumours on their 
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molecular features in addition to their morphological appearance, identifying ‘basal 
like’ tumours (ER, PR and HER2 negative, cytokeratin 5/6 positive and/or EGFR 
positive), HER2 positive ER negative (ER−, PR−, and HER2+), luminal A (ER and/or PR 
positive and HER2 negative), luminal B (ER and/or PR positive and HER2 positive) and 
unclassified (negative for all 5 markers) tumours (Carey et al., 2006). 
 
The term ‘triple negative breast cancer’ refers to a sub-group of breast cancers which 
are negative for the expression of ER, PR and HER2. Within this group, 60% of tumours 
express EGFR (Irvin and Carey, 2008). The ‘basal like’ sub-group of breast cancers are 
identified through the expression of genes (e.g. cytokeratins 5 and 17, caveolin-1, c-kit 
and EGFR) usually found in the basal/myoepithelial cells of the normal breast (Rakha et 
al., 2009). The terms triple negative and basal like breast cancers are often used 
interchangeably, but studies suggest that there is around 30% discordance between 
the two groups (Irvin and Carey, 2008; Rakha et al., 2009). Studies are ongoing to 
evaluate chemotherapy regimens within these specific groups, together with the 
benefit of targeting EGFR, given the higher rates of expression of this receptor. 
 
1.3 HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY 
1.3.1 Human epidermal growth factor receptor structure 
All receptors share a similar structure with extracellular, membrane spanning and 
intracellular domains (Figure 1.2). The extracellular domain in made up of four sub-
domains, including a ligand binding domain and a dimerisation arm. This domain 
differs between receptors, which are distinguished by their affinities for different 
growth factors. This is in contrast to the intracellular domain, which is highly conserved 
across the HER family and contains an intrinsic tyrosine kinase and a carboxyl tail 
(Yarden and Sliwkowski, 2001). 
 
1.3.2 Activation of human epidermal growth factor receptors 
Receptor activation can be induced by the binding of specific growth factors or 
through ligand independent mechanisms (discussed below). HER ligands are 
characterised by an EGF-like motif and 13 ligands have been identified to date, though 
none bind to HER2 (Table 1.1) (Yarden and Sliwkowski, 2001). Whilst the affinity for 
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each ligand differs between receptors, it can be altered by the dimerisation partner of 
a receptor (Karunagaran et al., 1996). For example, both EGF and betacellulin activate 
cell signalling in the absence of EGFR through HER2/HER3 heterodimers but are not 
able to activate HER2 or HER3 homodimers (Pinkas-Kramarski et al., 1998).  
 
Ligand EGFR HER2 HER3 HER4 
EGF +  +  
TGF-α +    
HB-EGF +   + 
Amphiregulin +    
Betacellulin +   + 
Epigen +    
Epiregulin +   + 
Neuregulin-1   + + 
Neuregulin-2   + + 
Neuregulin-3    + 
Neuregulin-4    + 
 
Table 1.1 Human epidermal growth factor receptors ligands 
TGF-α – transforming growth factor α 
HB-EGF- heparin binding-EGF 
 
1.3.2.1 Ligand-dependent activation 
Receptors exist either as monomers or dimers in a ‘tethered’ autoinhibited 
conformation or an extended conformation ready to bind ligand (Figure 1.2) (Dawson 
et al., 2007; Tao and Maruyama, 2008). EGFR has been shown to continually flux 
between these two states, with dimers requiring ligand binding for signalling (Chung et 
al.). Ligand binding to pre-formed dimers induces a rotational movement within the 
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transmembrane domain which may be responsible for ligand mediated receptor 
downstream signalling (Moriki et al., 2001).  
 
Ligand binding to monomeric receptors induces a conformational change exposing the 
receptors’ dimerisation arm, enabling the formation of dimers with other receptors 
with exposed arms (Figure 1.2) (Schlessinger, 2002). The exception to this is HER2, 
whose dimerisation arm is permanently exposed, so an activating ligand is not 
required leading to its continuous ability to form dimers with other receptors (Cho et 
al., 2003). 
 
 
 
 
 
Figure 1.2 Conformation of the human epidermal growth factor receptor 
The HER family share a similar structure with an extracellular, membrane spanning and 
intracellular domains. The extracellular domain is made up of four sub-domains, including 
dimerisation and ligand binding domains. Receptors can exist in preformed homo or 
heterodimers in a tethered, closed conformation which is not available for receptor 
dimerisation, or an extended, open conformation ready for ligand binding. Adapted from Tao 
& Maruyama, 2008. 
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1.3.2.2 Ligand-independent activation of HER receptors  
In addition to activation by ligand, ligand-independent phosphorylation of EGFR can be 
induced by ultra-violet radiation (Zwang and Yarden, 2006), ionising radiation (IR) 
(Rodemann et al., 2007; Schmidt-Ullrich et al., 1997), cytotoxic drugs (Ahsan et al., 
2010; Benhar et al., 2002; Van Schaeybroeck et al., 2006), oxidative stress (Khan et al., 
2006) and through the direct phosphorylation of EGFR by p38 (Benhar et al., 2002; 
Winograd-Katz and Levitzki, 2006; Zwang and Yarden, 2006).   
1.3.2.3 Human epidermal growth factor receptor dimers 
A hierarchy exists within the HER family with HER2 preferentially dimerising with other 
receptors, over the formation of homodimers (Graus-Porta et al., 1997; Tzahar et al., 
1996). HER3 and HER4 preferentially dimerises with HER2 over EGFR, but in the 
absence of HER2, dimers are formed with EGFR (Graus-Porta et al., 1997). 
Heterodimers have a number of distinct signalling advantages over homodimers; they 
have a higher affinity for ligand (Graus-Porta et al., 1997; Sliwkowski et al., 1994; 
Tzahar et al., 1996), are more potent activators of downstream signalling (Pinkas-
Kramarski et al., 1996) and transcription (Kim et al., 2009) and are more likely to be 
recycled back to the cell membrane after internalisation (Lenferink et al., 1998).  
 
EGFR is also able to dimerise with the platelet derived growth factor receptor (PDGFR) 
(Habib et al., 1998) and insulin like growth factor receptor (IGFR) (Burgaud and 
Baserga, 1996); the latter can also dimerise and phosphorylate HER2 (Balana et al., 
2001; Nahta et al., 2005).  This ability to form multiple dimers with other receptors 
introduces a high level of redundancy in receptor activation and indicates why 
alterations in the expression of any one HER receptor can produce marked effects on 
cell signalling (Yarden and Sliwkowski, 2001).  
 
1.3.3 Downstream signalling of human epidermal growth factor receptors 
The dimerisation of ligand bound receptors allows the carboxyl tail of one receptor to 
be phosphorylated by the other receptor (Figure 1.2). HER3 has been described as 
‘kinase dead’ or a ‘pseudokinase’ (Sierke et al., 1997) due to the substitution of amino 
acids at two sites (Guy et al., 1994) and is reliant upon dimerisation with other 
receptors for signalling. However, recent reports indicates that HER3 binds ATP in an 
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inactive conformation (Jura et al., 2009; Shi et al., 2010) and is able to trans-
autophosphorylate, though at a lower level than induced by receptor activation and 
dimerisation (Shi et al., 2010).   
 
Following ligand binding and phosphorylation of the receptor’s carboxyl tail, adapter 
proteins like growth factor receptor-bound 2 (Grb2) and src-homology 2 protein (SH2) 
are attracted and bind specific regions within the tail. These adapters link into the 
activation of a number of different downstream signalling pathways including the Ras-
Raf-MAPK, phosphatidylinositol-3-kinase-AKT (PI3K/AKT), phospholipase C-γ (PLC-γ) 
and single transducers and activators of transcription (STAT) pathways (Yarden and 
Sliwkowski, 2001). In addition activated receptors are internalised, degraded or 
transported to the nucleus (discussed further below) (Figure 1.3).  
 
1.3.3.1 Phosphatidylinositol 3-kinases signalling  
HER3 provides six docking sites for the PI3K regulatory subunit p85 (Hellyer et al., 
1998), though p85 can also dock with activated EGFR through the adapter proteins SH2 
and Grb2 associated binding protein 1 (Gab-1) (Rodrigues et al., 2000). This enables 
the p110 subunit of PI3K to phosphorylate, phosphatidyl-(4,5)-bisphosphate to 
produce phosphatidyl-(3,4,5)-triphosphate which recruits proteins containing a 
phospholipid binding domains to the plasma membrane including AKT and 3-
phosphoinositide-dependent protein kinase 1 (PDK-1). AKT is then phosphorylated by 
PDK-1 at its threonine 308-residue and/or serine 473 residue to become activated 
(Cantley, 2002). Phosphorylated AKT is able to activate a number of other cytoplasmic 
and nuclear proteins including p21 and p27 and murine double minute (MDM2) 
(Cantley, 2002). MDM2 leads to the degradation of p53, activates the anti-apoptotic 
protein, nuclear factor kappa β, and inhibits pro-apoptotic proteins like Bcl-2 
associated death promoter, forkhead transcription factors and caspase-9. PI3K 
signalling controls a wide variety of cellular functions including cell growth, survival, 
apoptosis, metabolism, cell cycle progression, transcription and translation (Marone et 
al., 2008). 
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1.3.3.2 Ras-Raf-MAPK pathway 
Phosphorylated EGFR and HER2 attracts the adapter protein SH2, which in turn 
attracts Grb2. Grb2 is bound by the protein son of sevenless (SOS) which recruits and 
activates Ras-GDP (Bianco et al., 2007). The resulting Ras-GTP triggers a signalling 
cascade activating B-Raf which activates MEK1&2, which activates the mitogen-
activated protein kinases, MAPK1, MAPK2, p38-MAPK and Jun terminal kinases (JNK). 
MAPK and JNK proteins can also be activated by EGFR through its interaction with PLC-
γ which activates protein kinase C (PKC).  MAPK translocates to the nucleus 
upregulating the expression of transcription factors involved in cell proliferation, 
inhibition of apoptosis and cell migration (Bianco et al., 2007).  
 
1.3.3.3 Signal transducers and activators of transcription  
The STAT family is made up of seven proteins, STAT1-5a, 5b and 6, which are activated 
by tyrosine or src kinases.  These proteins are located within the cytoplasm and upon 
phosphorylation, dimerise and translocate to the nucleus where they bind regulatory 
elements within the promoters of genes promoting cell proliferation, differentiation 
and apoptosis (Fox et al., 2008; Yang and Stark, 2008). STAT 3, 5a and 5b are 
constitutively activated or over-expressed in breast cancer compared with surrounding 
normal breast tissue, suggesting an oncogenic role (Clevenger, 2004). Overexpression 
of EGFR and HER2 correlates with ligand induced or constitutive activation of STAT3, 
STAT5a and STAT5b (Silva and Shupnik, 2007) and EGFR directly controls the activation 
of STAT proteins (Xia et al., 2002a) or acts through janus kinase (JAK) (Andl et al., 
2004).  In addition to activating STAT proteins, HER proteins can directly bind to STAT 
proteins allowing them to interact with genes promoters (discussed below). 
 
1.3.3.4 Receptor internalisation  
Inactive EGFR is constantly internalised and recycled back to the cell membrane (Burke 
and Wiley, 1999). EGFR internalisation can also be induced by the binding of ligand 
(Opresko et al., 1995) or activation by p38 MAPK in response to cellular stress (Benhar 
et al., 2002; Zwang and Yarden, 2006). The internalisation of EGFR in response to 
ligand requires EGFR activation (Johannessen et al., 2006), recruitment of Grb2 and the 
ubiquitin ligase, Casitas B-lineage lymphoma (Cbl) protein (Jiang et al., 2003; Levkowitz 
et al., 1999). The recruitment of Cbl leads to the ubiquitination of the cytoplasmic tail 
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of EGFR, enabling interaction with ubiquitin interaction motifs located within clathrin 
coated pits (Huang and Sorkin, 2005). These pits pinch off from the cell membrane to 
form vesicles, delivering the internalised EGFR complex to endosomes where they 
undergo sorting, either being recycled back to the cell membrane, entering lysosomes 
to undergo degradation so terminating the EGFR signal, entering the endoplasmic 
reticulum or Golgi apparatus, or transportation to the nucleus (discussed below) 
(Madshus and Stang, 2009; Wang et al., 2010).   
 
The internalisation of EGFR in response to phosphorylation by p38 MAPK is less well 
characterised but the recruitment of Cbl is not required (Adachi et al., 2009) and can 
occur into clathrin coated pits (Zwang and Yarden, 2006) or caveolae (Dittmann et al., 
2008; Khan et al., 2006). 
 
1.3.3.5 Nuclear translocation of human epidermal growth factor receptors 
Despite the fact that HER proteins are membrane located receptors, full length nuclear 
EGFR, HER2 and HER3 and a cleaved C-terminal 80kDa fragment of HER4, known as 
HER4 intracellular domain (4ICD), can be detected within nuclei using Western 
blotting, immunofluorescence (IF), confocal or electron microscopy and chromatin 
immunoprecipitation (ChIP) (Lin et al., 2001; Ni et al., 2001; Offterdinger et al., 2002). 
Transport of receptors can be induced by ligands (Lin et al., 2001), IR or cisplatin 
(Dittmann et al., 2005a) and requires the presence of a nuclear localisation sequence 
(NLS). The NLS is a conserved 13 amino acid sequence located within the 
juxtamembrane region of all HER receptors (Hsu and Hung, 2007), though HER3 has an 
additional NLS located within its C-terminal domain (Lin et al., 2001). 
 
Nuclear HER proteins are able to activate the transcription of specific genes (Wang et 
al., 2010). As they lack a DNA binding domain, they interact with DNA through the 
binding to transcription factors like STAT3, STAT5a and E2F1 located on gene 
promoters, allowing the receptor to utilise its transactivational ability to activate 
transcription (Lo and Hung, 2007; Wang et al., 2010). Examples include the binding of 
EGFR to STAT3 to regulate the transcription of cytokine inducible nitric oxide synthase 
(iNOS) and cyclooxygenase 2 (COX-2), to E2F1 to activate the transcription of β-Myb, 
and STAT5 to activated the Aurora-A promoter as well as regulating the transcription 
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of cyclin D1 directly (Hanada et al., 2006; Hung et al., 2008; Lin et al., 2001; Lo et al., 
2006; Lo and Hung, 2007). HER2 is also able to transactivate the transcription of 
cyclooxygenase 2 (COX2) (Wang et al., 2004) and thymidylate synthase (Kim et al., 
2009). 
 
1.3.3.6 Glucose transport 
There is evidence that EGFR stabilises the active sodium glucose co-transporter (SGLT) 
in a mechanism independent of its kinase activity, increasing the transport of glucose 
into cells and preventing cell death through autophagy (Weihua et al., 2008). 
 
 
 
 
Figure 1.3 Human epidermal growth factor receptor signalling 
The HER family signals into a number of downstream pathways including the PI3K/AKT, MAPK 
and STAT pathways.  
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1.4 HUMAN EPIDERMAL RECEPTOR EXPRESSION AND CANCER 
The HER family of proteins are expressed in variety of normal tissues but gain an 
oncogenic role through overexpression, gene amplification, constitutive activation, 
increased ligand stimulation or down-regulation of mitogen-inducible gene 6 (MIG6) 
also known as negative regulator erbB receptor feedback inhibitor (ERFFI1) and 
receptor-associated late transducer (RALT). 
 
1.4.1 Overexpression of human epidermal receptors 
Overexpression of HER proteins in tumours compared with normal tissue has been 
demonstrated in breast (Bieche et al., 2003), ovarian (Steffensen et al., 2008) and 
colorectal cancers (Ciardiello et al., 1991). The clearest link between a member of the 
HER family and cancer prognosis established so far occurs in breast cancer (Slamon et 
al., 1987).  
 
1.4.1.1 EGFR overexpression 
EGFR is a 170 kDA protein encoded on chromosome 7p12 and is detected in a wide 
variety of cancers, including head and neck, breast, oesophageal, non small cell lung 
cancers (NSCLC) and colorectal cancers. The oncogenic role of EGFR is demonstrated 
by the increase in EGFR expression between normal, hyperplastic, dysplastic and 
neoplastic tissue in squamous cancers of the head and neck. Increases in EGFR 
expression are also observed in the normal epithelium surrounding tumours, 
compared with non-cancerous controls, with a further increases in EGFR expression 
occurring between dysplastic tissue and carcinomas (Shin et al., 1994).  
 
In patients, EGFR expression rather than gene amplification appears to be a driver of 
tumours, with gene amplification only detected in 2% gastric cancers (Kim et al., 
2008c), 1.6% of triple negative breast tumours (Gumuskaya et al., 2010) and 8-12% of 
non small cell lung cancers (NSCLC) (Bell et al., 2005; Kim et al., 2008a). 
 
1.4.1.2 HER2 overexpression 
HER2 is a 185 kDa protein encoded on chromosome 17q21 and is expressed in normal 
breast tissue and detected in most breast tumours, with less than 5% of tumours 
reported as under-expressing HER2 compared with normal breast tissue (Bieche et al., 
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2003). In the 20-30% of tumours which overexpress HER2 as detected by IHC (Slamon 
et al., 1987; Toikkanen et al., 1992) all are HER2 amplified at a gene level (Willmore et 
al., 2005). In other cancers the link between expression and gene amplification is less 
clear cut; 10-34% of gastric tumours overexpress HER2 as detected by IHC with gene 
amplification detected in 39-84% of these (Allgayer et al., 2000; Bang et al., 2010; 
Tsugawa et al., 1993; Yan et al., 2010) and 10-30% of pancreatic adenocarcinoma 
(Komoto et al., 2009a; Stoecklein et al., 2004) with gene amplification detected in 40% 
of these but in 24% of all pancreatic tumours analysed (Stoecklein et al., 2004). 
 
1.4.1.3 HER3 overexpression 
HER3 is a 185 kDA protein encoded on chromosome 12p13 and overexpression occurs 
in 20-46% of invasive breast cancers and is associated with a poorer OS (Bieche et al., 
2003). A single study has reported HER3 overexpression in 58% of gastric tumours with 
a correlation with a poorer OS (Hayashi et al., 2008). HER3 gene amplification is less 
well investigated with a single report of occurrence in 27% of NSCLC (Cappuzzo et al., 
2005). 
 
1.4.1.4 HER4 overexpression 
HER4 is a 180 kDa protein encoded on chromosome 2q33 and its expression may 
actually be protective, with reduced expression noted in 40-80% of adenocarcinoma 
and up to 100% of squamous carcinoma (Srinivasan et al., 1998). In breast cancer the 
reported expression of HER4 varies widely, with underexpression reported in 20-30% 
of breast cancer and overexpression in up to 30%. In breast cancer overexpression of 
HER4 has been shown to be linked with longer DFS (Aubele et al., 2007; Pawlowski V et 
al., 2000; Sassen et al., 2008). This is not the case in colorectal cancer where HER4 
expression has been demonstrated to correlate with lymph node positivity 
(Kountourakis et al., 2006). 
 
1.4.2 Increase in the secretion of human epidermal growth factor receptor ligands 
HER ligands are type I transmembrane proteins, expressed on the cell surface. They are 
cleaved by cell surface proteases in a process of ectodomain shedding, forming soluble 
ligands (Higashiyama et al., 2008). The main proteases involved in the shedding of 
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these ligands are the a disintegrin and metalloproteinase (ADAM) family of enzymes 
(Singh et al., 2009; Xu and Derynck, 2010). 
 
Higher levels of amphiregulin are detected in colorectal tumours compared with 
normal tissue (Ciardiello et al., 1991), with increased levels of both amphiregulin and 
TGF-α in breast cancers compared with normal breast tissue (Panico et al., 1996). 
ADAM17 expression is increased in 90% of colorectal cancers compared with normal 
mucosa (Blanchot-Jossic et al., 2005) and its transfection into breast cancer cell lines 
increases the secretion of the EGFR ligand, TGFα, promoting EGFR signalling, cell 
proliferation, invasion and angiogenesis (Zheng et al., 2009). These data indicate that 
increases in ligand production can increase HER signalling. 
 
1.4.3 Constitutive activating mutations 
Activating mutations within EGFR were first recognised in glioblastoma, produced by 
an in-frame deletion in exons 2-7, deleting 267 amino acids from the receptor’s 
extracellular domain (Wong et al., 1992). This deletion produces a truncated EGFR, 
EGFR variant III (EGFR vIII), which is constitutively active and independent of EGF 
(Nishikawa et al., 1994). EGFR vIII is expressed in 20-30% of unselected glioblastoma 
(Gan et al., 2009), 5% of squamous cancers of the lung (Ji et al., 2006),  42% of head 
and neck squamous carcinomas (Sok et al., 2006) and 4% of breast cancers (Nieto et 
al., 2007). 
 
Whilst EGFR vIII is not detected in adenocarcinoma of the lung (Ji et al., 2006), in-frame 
deletions, in-frame insertions and mis-sense substitutions (Shigematsu et al., 2005) in 
exons 18-21 can be detected in 5-30%, with a higher incidence in female never 
smokers from East Asia (Riely et al., 2006; Shigematsu et al., 2005). In-frame deletions 
in exon 19 account for 45% of mutations and a further 45% are due to mis-sense 
substitutions in exon 21, with the commonest substitution, leucine for arginine at 
codon 858 (EGFR L858R) (Shigematsu et al., 2005). These mutations cluster around the 
ATP binding pocket of EGFR, prolonging EGF-induced signalling for up to three hours 
compared with 15 minutes in wild type receptors (Lynch et al., 2004) and are 
collectively known as EGFR activating mutations.  
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The type of EGFR mutation varies between tumours, with mutations in the tyrosine 
kinase domain of EGFR rare in glioblastoma (Marie et al., 2005), not detected in breast 
cancer (Bhargava et al., 2005), but more common in lung cancer. Mutations affecting 
the external EGFR domain occur more frequently in glioblastoma with 14% due to mis-
sense mutations (Lee et al., 2006b) and 20-30% due to the expression of EGFR vIII (Gan 
et al., 2009).  
 
Together this evidence demonstrates the importance of HER signalling within cancer 
cells and that the HER family can drive tumour growth through the increased receptor 
activity due to mutations resulting in constitutive activation of the affected receptor, 
increases in ligand expression driving receptor signalling or receptor overexpression. 
Therefore the ability to target specific receptors has been a major development in 
both enhancing our understanding of HER signalling and in the treatment of cancers. 
 
1.4.4 Regulation of human epidermal growth factor receptors by MIG6 
MIG6 is a transcriptionally induced negative feedback inhibitor of EGFR and HER2, 
inhibiting receptor activity and downstream signalling (Fiorentino et al., 2000; Xu et al., 
2005) through binding to the erbB-binding region of the receptors’ kinase domain 
(Anastasi et al., 2003). Research has focussed on the interaction between MIG6 and 
EGFR which results in the inhibition of receptor activity, endocytosis and delivery into 
lysosomes, leading to degradation thereby reducing receptor expression (Frosi et al., 
2010; Ying et al., 2010). The erbB-binding region is conserved across the HER family 
and MIG6 binds to all four receptors in vitro indicating a role in the regulation of all 
receptors (Anastasi et al., 2003).  
 
1.5 ANTI-HUMAN EPIDERMAL RECEPTOR TARGETED THERAPIES 
HER targeted therapies are classified into two groups; the small molecule receptor TKIs 
(e.g. gefitinib, erlotinib and lapatinib) and the monoclonal antibodies (e.g. 
trastuzumab, cetuximab, panitumumab and pertuzumab). These drugs bind to 
different domains of the HER proteins, with TKIs binding the intracellular tyrosine 
kinase containing domain and monoclonal antibodies to the extracellular domain. In 
addition to those anti-HER therapies that are in clinical use, there are a number agents 
undergoing evaluation in early phase clinical trials (Table 1.2) plus small molecule TKIs 
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research compounds e.g. the EGFR targeted TKI A1478 and the HER2 targeted TKI 
AG825.    
 
Drug Target Type 
Pertuzumab 
(Baselga and Swain, 2010) 
HER2 dimerisation 
arm 
Humanised mAb 
Canertinib 
(Rixe et al., 2009) 
HER1-4 Irreversible TKI 
BMS-599626 EGFR, HER2 & 
HER4 
TKI 
Neratinib (HKI-272) 
(Sequist et al., 2010) 
HER2 Irreversible TKI 
ARRY-334543 EGFR & HER2 Reversible TKI 
Afatinib (BIBW-2992) 
(Yap et al., 2010) 
EGFR & HER2 Irreversible TKI 
 
Table 1.2 Anti-HER targeted drugs undergoing evaluation in clinical trials 
Information obtained from http://clinicaltrials.gov/ct2/home 
 
1.5.1 Clinical HER targeted monoclonal antibodies 
1.5.1.1 Cetuximab (C225/Erbitux®) 
Cetuximab is a mouse chimeric monoclonal antibody with high affinity for EGFR, 
preventing ligand-induced phosphorylation and inhibiting tumour growth (Goldstein et 
al., 1995). In colorectal cancer cetuximab increases response rates and PFS in 
combination with chemotherapy in patients whose tumours express wild type K-ras 
(Bokemeyer et al., 2009; Van Cutsem et al., 2009) or as single agents in patients with 
irinotecan refractory colorectal cancer (Cunningham et al., 2004). In squamous cell 
cancer of the head and neck, cetuximab in combination with radiotherapy increases OS 
in patients with unresectable disease (Bonner et al., 2010), response rates in patients 
with metastatic disease in combination with cisplatin (Burtness et al., 2005) and OS in 
patients with recurrent or metastatic disease in combination with platinum and 5FU 
based chemotherapy regimens (Vermorken et al., 2008). In NSCLC, the addition of 
cetuximab to standard chemotherapy with cisplatin and vinorelbine increases median 
OS (Pirker et al., 2009) 
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Cetuximab binds to EGFR, occluding its ligand binding domain and preventing the 
receptor from adopting the extended conformation required for dimerisation 
(Brehmer et al., 2005), inhibiting the formation of EGFR homodimers and EGFR-HER2 
heterodimers (Patel et al., 2009). The binding of cetuximab to EGFR can induce 
receptor phosphorylation (Liao and Carpenter, 2009; Yoshida et al., 2008b) and 
internalisation, with both increased transport to the nucleus (Liao and Carpenter, 
2009) and inhibition, with accumulation in the cytoplasm demonstrated (Dittmann et 
al., 2005b). Despite the induction of EGFR phosphorylation, downstream signalling by 
AKT or MAPK is not stimulated (Yoshida et al., 2008b).  
 
1.5.1.2 Panitumumab (ABX-EGF/Vectibix®) 
Panitumumab is a fully humanised monoclonal antibody which binds to the external 
domain of EGFR. As a single agent it increases PFS in patients with chemorefractory 
metastatic colorectal cancer (Van Cutsem et al., 2007) and in combination with 
oxaliplatin or irinotecan based chemotherapy regimens in the first line setting 
(Douillard et al., 2010; Peeters et al., 2010).  
 
1.5.1.3 Trastuzumab (Herceptin®) 
Trastuzumab has been shown to effective in patients with HER2 positive breast cancer 
in both the adjuvant and metastatic setting (discussed in sections 1.2.4.1.4 and 
1.2.4.2.2). The addition of trastuzumab to standard cisplatin and 5-FU based 
chemotherapy is also beneficial in advanced gastric cancer, increasing median OS 
(Bang et al., 2010). 
 
Trastuzumab binds to the juxtamembrane of HER2 (Cho et al., 2003), inhibiting the 
formation of HER2-HER3 dimers (Junttila et al., 2009) and inducing the 
phosphorylation of HER2 (Diermeier et al., 2005; Scaltriti et al., 2009) leading to 
receptor internalisation, ubiquitination and degradation (Scaltriti et al., 2009).  Other 
actions include the Inhibition of PI3K/AKT signalling (Dubska et al., 2005; Junttila et al., 
2009) and the induction of a G0/G1 cell cycle arrest (D'Alessio et al., 2009). 
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1.5.2 Clinical HER targeted small molecule tyrosine kinase inhibitors 
1.5.2.1 Gefitinib (ZD 1839/Iressa®) 
Gefitinib is an oral low molecular weight quinazoline which is a potent selective and 
reversible competitive-ATP inhibitor for EGFR. In patients with NSCLC with activating 
EGFR mutations, gefitinib significantly increases PFS compared with chemotherapy 
with carboplatin and paclitaxel in the first line setting (Mok et al., 2009a). As discussed 
in section 1.4.3, activating EGFR mutations occur within the ATP-binding pocket, 
resulting in a constitutively active receptor (Lynch et al., 2004; Paez et al., 2004; Pao et 
al., 2004). In patients with NSCLC, who have received first line treatment with a 
platinum based chemotherapy regimen, gefitinib demonstrates non-inferiority to 
docetaxel chemotherapy, regardless of EGFR mutation status (Kim et al., 2008a). 
 
In vitro data indicates that gefitinib binds to EGFR when it is in an open conformation 
(Johnson, 2009), promoting the formation of EGFR homodimers and binding to EGF 
(Lichtner et al., 2001) whilst inhibiting EGFR, HER2 and HER3 receptor phosphorylation 
(Chun et al., 2006; Morgan et al., 2008; Sergina et al., 2007), reducing FOXM1 
(McGovern et al., 2009) and FOXO3a expression (Krol et al., 2007) inducing a G0/G1 
cell cycle arrest (D'Alessio et al., 2009; Krol et al., 2007). Gefitinib also inhibits the 
formation of HER2 and HER3 dimers through direct interaction with HER2 (Hirata et al., 
2005). 
 
1.5.2.2 Erlotinib (OSI-774/Tarceva®) 
Erlotinib is an oral reversible inhibitor of EGFR and is able to directly inhibit HER2 
(Schaefer et al., 2007). Erlotinib increases both PFS and OS in patients with NSCLC 
refractory to at least one chemotherapy regimen (Shepherd et al., 2005) and increases 
PFS in combination with gemcitabine in patients with pancreatic cancer over 
gemcitabine alone (Moore et al., 2007). 
 
Clinically, as with gefitinib, increased sensitivity is observed in patients with NSCLC 
expressing an activating EGFR mutation (Pao et al., 2004). Erlotinib has a similar 
mechanism of action to gefitinib, inhibiting EGFR and HER2 activation, therefore 
inhibiting PI3K/AKT and Ras-Raf-MAPK signalling (Schaefer et al., 2007). Erlotinib also 
inhibits the transcription of thymidylate synthase and its activity (a target of the active 
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metabolites of 5-FU) (Giovannetti et al., 2008) and increases the expression of the 
enzyme thymidine phosphorylase, which is required for the conversion of 5-FU into its 
active metabolites (Ouchi et al., 2006) (see section 1.8.4).  
 
1.5.2.3 Lapatinib (Tykerb®) 
Lapatinib is an oral quinazoline derived competitive reversible ATP-inhibitor, binding to 
the ATP binding site of both EGFR and HER2; the drug binds to the closed conformation 
of EGFR (Johnson, 2009). It increases time to progression and overall response rates in 
combination with chemotherapy is patients with HER2 positive breast cancer 
refractory to anthracyclines, taxanes and trastuzumab treatment (discussed in sections 
1.2.4.2.2 and 1.9.5 ). 
 
In vitro lapatinib inhibits the phosphorylation of HER2 but not the formation of dimers 
with other receptors (Scaltriti et al., 2009), including EGFR (Xia et al., 2002b). In turn it 
inhibits the activation of downstream signalling including the PI3K/AKT and Ras-Raf-
MAPK pathways (Konecny et al., 2006; Xia et al., 2002b), induces G0/G1 cell cycle 
arrest (Kim et al., 2008b), prevents the nuclear translocation of both EGFR and HER2 
(Kim et al., 2009) and reduces the expression of FOXM1 (McGovern et al., 2009) and 
thymidylate synthase (Kim et al., 2009). 
 
1.5.3 Differences between monoclonal antibodies and small molecule tyrosine 
kinase inhibitors on HER inhibition 
There are obvious differences between antibodies and TKIs including their size 
(monoclonal antibodies are around 150kDa and EGFR TKI 500Da which prevents them 
crossing the blood brain barrier), administration (intravenous versus orally) and half 
life (monoclonal antibodies have a half life measured in days, so can be given weekly 
and TKIs around 36-48 hours so are given daily) (Imai and Takaoka, 2006). Whilst TKIs 
bind to their target receptor with high affinity they are not specific, binding to other 
HER members and have a number of off target effects as they are able to enter cells 
and inhibit their targets regardless of location (Brehmer et al., 2005). In contrast, 
monoclonal antibodies are specific to their receptor target and require it to be located 
on the cell membrane. However, this may confer an advantage over TKIs, in that they 
can trigger complement and antibody-dependent cellular cytotoxicity which may 
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actually be enhanced by the chimeric nature of some monoclonal antibodies (Imai and 
Takaoka, 2006).    
 
The inhibition of HER signalling by monoclonal antibodies and TKIs is not the same in 
vitro, a fact which may explain clinical differences. This is demonstrated by the fact 
that the EGFR targeted antibody cetuximab and the anti-EGFR TKIs gefitinib or erlotinib 
produce a greater inhibition of the growth of cancer cell lines and xenografts in 
combination than either drug alone (Huang et al., 2004; Matar et al., 2004). Gefitinib is 
also able to inhibit the cell growth of cetuximab resistant cell lines (Huang et al., 2004), 
and in combination with cetuximab, induces greater inhibition of EGFR, AKT and MAPK 
activation (Matar et al., 2004).  
 
Differences in the targeting of HER2 with trastuzumab or lapatinib are also apparent. 
Firstly lapatinib is able to inhibit cell proliferation in cell lines resistant to trastuzumab 
(Konecny et al., 2006) and the combination of both drugs together produces a greater 
effect than either drug on its own in both breast and gastric cancer cell lines (Wainberg  
et al., 2010; Xia et al., 2005). This may be explained by the observed differences in the 
actions of each drug, as lapatinib inhibits the phosphorylation of HER2 homo or 
heterodimers and hence their internalisation increasing the accumulation of inactive 
HER2 on the cell membrane. This increases the availability of HER2 which can be 
bound by trastuzumab, leading to increased levels of immune mediated cytotoxicity 
(Scaltriti et al., 2009).  
 
1.6 DNA DAMAGING AGENTS IN ANTI-CANCER THERAPY 
The systemic treatment of cancer utilises a single or combination of cytotoxic drugs in 
the neo-adjuvant, adjuvant and palliative settings with drugs that damage DNA 
forming the base of a number of standard chemotherapy regimens. Nitrogen mustard 
was the first systemic anti-cancer agent introduced into clinical practice in the 1940’s 
(Goodman et al., 1984) and since its use in the treatment of lymphoma, many more 
drugs have been developed and are now in routine clinical use, including platinum (e.g. 
cisplatin, carboplatin and oxaliplatin), taxane (e.g. docetaxel and paclitaxel), 
epipodophyllotoxin (e.g. etoposide) and anthracycline (e.g. doxorubicin, epirubicin and 
idarubicin) drugs. Whilst DNA damaging agents such as IR and platinum drugs inflict a 
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variety of insults on cells, the importance of their ability to damage DNA in order to 
producing cell death is illustrated by the fact that cells with defects in specific DNA 
repair pathways are more sensitive to these agents (Hoeijmakers, 2009).  
 
1.6.1 Cisplatin 
Upon entry into a cell, the cisplatin molecule loses its chloride ions due to the lower 
intracellular low chloride concentration. These ions are replaced by water molecules 
which can readily be substituted for the N7 of guanine or adenine bases in DNA 
(Kartalou and Essigmann, 2001), thus forming monoadducts (Figure 1.4). Monoadducts 
can link with other nearby DNA monoadducts on the same strand of DNA forming 
intrastrand crosslinks, the complementary DNA strand forming interstrand crosslinks 
or proteins forming DNA-protein adducts (Figure 1.4) (Wang and Lippard, 2005). 
Intrastrand crosslinks account for 90% of cisplatin-induced DNA lesions, with 
interstrand crosslinks accounting for 5-8% (Dronkert and Kanaar, 2001). The latter 
lesion is reported to be the cause of the cytotoxicity of cisplatin by preventing DNA 
unwinding and separation required for DNA replication and transcription (Dronkert 
and Kanaar, 2001). 
 
 
Figure 1.4 Induction of DNA lesions by cisplatin 
On entry into a cell, cisplatin loses its two chloride ions through a series of spontaneous 
aquation reactions. The water molecules can be readily substituted for N7 sites of purine bases 
forming DNA protein adducts, mono adduct and intrastrand or interstrand crosslinks. 
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1.6.2 Topoisomerase II poisons 
The enzyme topoisomerase II (Topo II) is a target of both anthracyclines and 
epipodophyllotoxins, enabling these drugs to produce DNA double strand breaks 
(DSBs). 
 
1.6.2.1 Isoforms of the Topoisomerase II enzyme 
Two isoforms of Topo II enzyme exist in mammalian cells, topoisomerase IIα (Topo IIα 
and topoisomerase IIβ (Topo IIβ). These two isoforms demonstrate 72% similarity with 
the main differences occurring in the N and C terminals (Jenkins et al., 1992). Topo IIα 
expression alters with cell cycle phase with expression peaking during G2/M, in 
contrast with Topo IIβ, which is constantly expressed at the same level regardless of 
the cell cycle (Woessner et al., 1991). 
 
1.6.2.2 Topoisomerase II function  
Topo II plays an essential role in removing knots, supercoils and catenanes from DNA 
allowing the double helix to be unwound for replication and transcription (Pommier et 
al., 2010). Topo II acts as a homodimer with each molecule binding a strand of DNA, 
known as the G segment. Upon binding ATP, Topo II dimerises and undergoes a 
conformational change, forming a closed clamp cleaving the phosphodiester backbone 
of the DNA strand to form a DNA DSB (Figure 1.5) (Oestergaard et al., 2004).  
 
The free ends of DNA remain bound at their 5’ ends by Topo II, so that they can be 
rejoined. This complex is known as the cleavable complex and is transient in nature. 
The break in the DNA strand allows the passage of another section of DNA, known as 
the T segment, through the break, so resolving catenanes and knots. Following strand 
passage, the two free DNA stands within the cleavable complex are religated, with ATP 
hydrolysis releasing Topo II from the DNA (Pommier et al., 2010). 
 
In addition to enabling the replication and transcription of DNA, Topo II is required to 
separate intertwined sister chromatids before chromosome segregation can occur in 
mitosis (Holm et al., 1989b). 
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Figure 1.5 Mechanism of action of topoisomerase IIα poisons 
Topo II forms a homodimer and binds to a segment of the DNA helix, known as the G segment. 
It then introduces a DNA DSB within the G segment to form a cleavable complex, made up of 
the two free ends of DNA, bound by a molecule of Topo IIα. The DNA DSB allows a segment of 
the DNA double helix, the T segment, to pass through DNA double helix, following which the 
DNA break is religated and Topo IIα released from the G segment. Reprinted by permission 
from Macmillan Publishers Ltd: Nature Reviews Molecular Cancer, Nitiss 2009b, 9:338-350; 
©2009; http://www.nature.com/nrc/index.html 
1.6.2.3 Topoisomerase structure 
The full crystal structure of human Topo II has not been defined, but three functional 
regions have been identified, the N and C terminal regions and a catalytic core. These 
domains are conserved across eukaryotic Topo II (Nitiss, 2009a). The N-terminal region 
contains an ATP-binding site and is able to hydrolyse ATP, a process required for the 
passage of one strand of DNA through the Topo II produced DSB (Oestergaard et al., 
2004). The C-terminal domain is phosphorylated at serine and threonine residues with 
14 sites characterised to date (Grozav et al., 2009). These control the function and 
location of the enzyme, though are not required for catalytic activity in vitro 
(Oestergaard et al., 2004). The catalytic core of the enzyme is responsible for DNA 
cleavage and religation (Oestergaard et al., 2004) and is connected to the ATP-binding 
domain by the transducer domain (Oestergaard et al., 2004). The transducer domain is 
important for communication between the ATP-binding region of Topo II and the 
catalytic core, with mutations within this domain preventing DNA strand passage 
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despite not interfering with the binding of ATP or DNA cleavage (Oestergaard et al., 
2004). 
 
1.6.2.4 Targeting Topoisomerase II  
Topo II is targeted by two distinct types of drugs, poisons and inhibitors. Topo II 
poisons differ from inhibitors in that they require a functioning enzyme to form 
cleavable complexes. The poisons act either by preventing the religation of DNA within 
the cleavable complex, forming DNA single and double strand breaks, or by promoting 
the formation of cleavable complexes (Nitiss, 2009a). In contrast, Topo II inhibitors 
inhibit activity of Topo II, for example by preventing the enzyme from binding to DNA, 
therefore inhibiting its normal cellular action. This is thought to be the mechanism 
through which they produces cytotoxicity (Pommier et al., 2010). This explains the 
antagonism between Topo II poisons and inhibitors (Jensen et al., 1991), why 
sensitivity to Topo II poisons increases with increasing Topo II expression (Fry et al., 
1991) whereas sensitivity to Topo II inhibitors increases with falling Topo II expression 
(Davies et al., 1997). Drugs which poison Topo II in clinical use include etoposide, 
doxorubicin, m-AMSA, idarubicin and epirubicin. All of these drugs act as Topo II 
poisons by preventing DNA religation by Topo II within the cleavable complex (Nitiss, 
2009b). 
 
1.6.2.4.1 Etoposide 
Etoposide is a Topo II poison which targets both isoforms of Topo II, though most 
research has concentrated on investigating its effect on Topo IIα (Ross et al., 1984; 
Willmore et al., 1998). Drug sensitivity correlates with the expression and activity of 
Topo II (Kasahara et al., 1992). Etoposide is an ATP-dependent Topo II poison, with 
ATP-depletion conferring resistance to the drug (Sorensen et al., 1999). Two binding 
sites for the drug have been isolated, one in the catalytic core of Topo II and the other, 
a lower affinity site, in the N-terminal ATP-binding pocket (Vilain et al., 2003). 
Etoposide binds to a complex made up of DNA, Topo II and ATP, stabilising one half of 
the cleavable complex, forming a single strand break (Osheroff, 1989). Whether Topo II 
needs to be bound to DNA in order to be targeted by etoposide in vivo is unclear, but it 
can be targeted in the absence of DNA in vitro (Leroy et al., 2001).  The formation of a 
DSB requires one etoposide molecule to bind to each of the two Topo II molecules 
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which makes up a cleavable complex (Bromberg et al., 2003). DNA replication or 
transcription are important in the induction of cell death by etoposide (D'Arpa et al., 
1990; Holm et al., 1989a). This observation may be explained by the fact that Topo II 
rapidly religates DNA DSBs following removal of etoposide, as per its normal function 
and etoposide cytotoxicity relies upon the removal of Topo II from the DSB, which 
occurs during replication and transcription, converting the DSB into a permanent 
lesion (Nitiss, 2009b). 
 
1.6.2.4.2 Doxorubicin 
In vitro studies demonstrate that doxorubicin can induce a number of cytotoxic 
processes including intercalation with DNA, free radical formation leading to DNA 
damage, lipid peroxidation, DNA alkylation and the poisoning or inhibition of Topo II, 
leading to cell cycle arrest and apoptosis (Gewirtz, 1999). Its effects are dose 
dependent, with DNA intercalation and Topo II inhibition occurring at concentrations 
of 10 µM and greater. In vivo the main mechanisms of doxorubicin-induced 
cytotoxicity are mediated through the poisoning of Topo II, free radical and DNA-
adduct formation (Gewirtz, 1999).  Like etoposide, doxorubicin is dependent upon ATP 
to poison Topo II (Sorensen et al., 1999) and though the precise site at which 
doxorubicin targets Topo II is unresolved, the binding to DNA to form a tertiary 
structure is thought to be essential (Moro et al., 2004). 
 
1.6.3 Ionising Radiation  
IR describes types of radiation that have enough energy to detach electrons from 
atoms or molecules (ionising), producing ionised atoms and free electrons, examples 
include x-rays, γ-rays and ultra-violet radiation. IR induces DNA damage through the 
direct and indirect ionisation of DNA, producing single and double DNA strand breaks 
and modifying DNA bases. Approximately 1000 single strand breaks and 25-40 DSBs 
are produced per gray of IR in a single diploid cell, though this number can be altered 
by hypoxia and cellular levels of glutathione (Olive, 1998). 30% of DNA strand breaks 
are produced directly by IR, with indirect DNA damage due to the production of 
reactive oxygen species (ROS) and free radicals, accounting for the remaining 70% of 
damage (Wallace, 1998). These reactive species can also produce DNA single and 
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double strand breaks, DNA-protein crosslinks, alterations to DNA bases and DNA base 
loss (Wallace, 1998).  
 
1.7 RESISTANCE TO DNA DAMAGING AGENTS 
Resistance to DNA damaging agents arises through a number of different mechanisms, 
including evasion of the DNA damaging effects of drugs, the repair of DNA damage or 
the ability to tolerate the damage inflicted.  
 
1.7.1 Reduced intracellular drug concentration 
Reduction in the intracellular concentration of cytotoxic agents can lead to drug 
resistance. This arises due to a variety of factors which can alter the amount of drug 
reaching an individual cell, reduce uptake or increase efflux of the drug out of the cell. 
Water soluble drugs enter cells through membrane located transporters which are 
involved in the uptake of nutrients and resistance to a number of chemotherapy 
agents including cisplatin, methotrexate and 5-FU can be mediated through reduced 
transport of drugs into cells (Gottesman et al., 2002).   
 
The efflux of drugs out of cells confers resistance to a variety of drugs including 
anthracyclines, vinca alkaloids, taxanes and etoposide resulting in phenotype known as 
multi-drug resistance (Gottesman et al., 2002). The best characterised transporter 
protein is P-glycoprotein, which is expressed in a variety of tumours including breast 
cancer (Clarke et al., 2005; Gottesman et al., 2002). P-glycoprotein is encoded by the 
multi-drug resistance (MDR1) gene (Ueda et al., 1987) and is a member of the ATP 
binding cassette (ABC) family (Gottesman et al., 2002). This family has a number of 
sub-families including the seven members of the ABCC sub-family, known as 
membrane resistance proteins (MRP 1-7), and the breast cancer resistance protein 
(BCRP), a member of the ABCG sub-family (Gottesman et al., 2002). These proteins 
function as membrane located pumps which efflux drugs from cells, reducing 
intracellular drug concentration, so reducing their cellular effects (Gottesman et al., 
2002).  
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1.7.2 Conjugation to glutathione 
Glutathione-S-transferases (GST) are a group of enzymes which detoxify a variety of 
toxins through their conjugation with glutathione. Expression of glutathione-S-
transferase P1 (GSTP1) is linked to resistance to both doxorubicin and cisplatin (Huang 
et al., 2007). The conjugation of drugs with glutathione only explains a small fraction of 
this mechanism of resistance (Peklak-Scott et al., 2008) and GSTP1 activation in 
response to stress activates other key signalling pathway involved in cell survival 
including upregulation of MAPK p38, MAPK and nuclear factor kappa β signalling 
(Fiorentino et al., 2000). 
 
1.7.3  Modulation of drug targets 
Drugs which target specific enzymes to induce their DNA damaging effects include 5-
FU, Topo I and II poisons. Resistance to these drugs can be mediated by the 
modulation of their drug targets. As discussed in section 1.6.2.4, Topo II poisons like 
doxorubicin or etoposide, target Topo II preventing the religation of DNA strand breaks 
produced as part of the normal function of the enzyme. Therefore, their effectiveness 
is dependent upon the expression and activity of Topo II (Burgess et al., 2008) 
(discussed below). This is in contrast to 5-FU, which inhibits the enzyme thymidylate 
synthase and resistance to the drug can be mediated by the increased expression of 
the enzyme (Longley et al., 2001; Wong et al., 2001). 
 
1.7.3.1 Resistance to topoisomerase II poisons by reduction in the expression of 
topoisomerase II 
Topo IIα expression alters with the cell cycle with levels falling during G0/G1, unlike 
Topo IIβ which is constantly expressed (Pommier et al., 2010). Topo II poisons have 
activity against both Topo II isoforms, though the relative contributions of each 
isoform varies between drugs, with doxorubicin having little activity against Topo IIβ 
where as the Topo II poison, m-AMSA targets both equally (Errington et al., 2004; 
Willmore et al., 1998). Correlation between Topo IIα expression and sensitivity to Topo 
II poisons has been demonstrated by some clinical studies and in vitro (Burgess et al., 
2008; Di Leo et al., 2008a). However, both Topo IIα gene amplification and deletion 
have been shown to be associated with sensitivity to anthracyclines, an observation 
which is contradictory (Di Leo et al., 2008a) but may be explained by the regulation of 
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Topo II transcription and translation (Di Leo et al., 2008a). The transcription and 
translation of Topo IIα is highly regulated and linked to cell proliferation, with gene 
amplified cells expressing high levels of the proliferation marker Ki-67, expressing 
higher levels of Topo IIα protein than those with low levels of Ki-67, despite Topo IIα 
gene amplification (Di Leo et al., 2008a).  
 
1.7.3.2 Resistance to topoisomerase II poisons by alteration in the location of 
topoisomerase II 
Topo II can be detected in both cell nuclei and cytoplasm in cancer cell lines (Engel et 
al., 2004). In vitro, cells are able to traffic Topo IIα out of the nucleus through the 
nuclear envelope protein CRM1 (exportin-1), an act that results in resistance to 
etoposide (Engel et al., 2004) and doxorubicin (Turner et al., 2009). Resistance is due 
to the fact that cytoplasmic Topo II is no longer in contact with DNA and therefore 
unable to produce cleavable complexes, additionally cytoplasmic Topo IIα may bind 
Topo II poisons reducing the concentration reaching the nucleus. 
 
1.7.3.3 Resistance to topoisomerase II poisons by alteration in topoisomerase II 
activity  
Topo II undergoes a number of post translational modifications including 
phosphorylation (Heck et al., 1989), sumoylation (Lee and Bachant, 2009) and 
ubiquitination (Shinagawa et al., 2008).  Topo II is phosphorylated in a cell cycle 
dependent manner (Wells and Hickson, 1995) and a number of specific sites have been 
characterised within Topo IIα enzyme including serine 1524 (Wells et al., 1994), 
threonine 1342 (Ishida et al., 1996) and serine 1106 (Chikamori et al., 2003). Four 
specific site of phosphorylation have been isolated within Topo IIβ, serine 1395, 
threonine 1426, serine 1545 and tyrosine 656 which is important for the catalytic 
activity of the enzyme (Grozav et al., 2011). Alterations in both the phosphorylation of 
the Topo II catalytic domain and binding of ATP have been demonstrated to modulate 
the effects of Topo II poisons.  
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1.7.3.3.1 Alterations in ATP binding to topoisomerase II and resistance to 
topoisomerase II poisons 
The process of decatenation and unknotting of DNA by Topo II occurs in an ATP 
dependent process (Nitiss, 2009a). Some Topo II poisons have been identified as only 
being active when Topo II is bound to ATP, with ATP depletion conferring resistance 
leading to classification into two groups- ATP-dependent and independent poisons 
(Sorensen et al., 1999). Etoposide, doxorubicin, teniposide and daunorubicin are 
classed as ATP-dependent poisons (Sorensen et al., 1999) with amonafide, bactracyclin 
and menadione as ATP-independent (Wang et al., 2001). The evidence of the effects of 
ATP on the ability of m-AMSA to poison Topo II is contradictory with both ATP-
dependence and independence demonstrated (Sorensen et al., 1999; Wang et al., 
2001).  
 
1.7.3.3.2 Alterations in topoisomerase II phosphorylation and resistance to 
topoisomerase II poisons 
Another mechanism of resistance to Topo II poisons is through the alteration of the 
phosphorylation of the enzyme. Phosphorylation at serine-1106 in the catalytic domain 
of Topo IIα is demonstrated to regulate both its activity and sensitivity to Topo II 
poisons, with dephosphorylation at this site rendering cells resistant to etoposide or 
m-AMSA- induced DNA cleavage (Chikamori et al., 2003; Grozav et al., 2009).   
 
1.7.4 Cell cycle 
The cell cycle is able to modulate the infliction of DNA damage by chemotherapy 
drugs, its detection and the cellular response to the damage (discussed below). Cell 
cycle modulates the infliction of DNA damage by drugs which target cellular activities 
which only occur in a certain phase of the cell cycle. Examples include the Topo II 
poisons (discussed in section 1.7.3.1), taxanes and pyrimidine analogues such as 5-FU, 
cytarabine and gemcitabine.  
 
Taxanes act as microtubule inhibitors, stabilising GDP-bound tubulin, therefore 
preventing chromatid separation and mitosis (Hennequin et al., 1995). Pyrimidine 
analogues act by becoming incorporated into DNA in place of the pyrimidine bases 
thymidine and cytosine, preventing the DNA replication. 5-FU also prevents the de 
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novo production of thymidine through the inhibition of thymidylate synthase 
(discussed in section 1.8.4) (Longley et al., 2003). Therefore, the arrest of cells in 
G0/G1 protects cells from the effects of taxanes and 5-FU as the processes of mitosis 
and DNA replication are not active (Hennequin et al., 1995; Shah and Schwartz, 2001) 
and from Topo II poisons due to reduce expression of Topo IIα. 
 
1.7.5 DNA Repair 
Aside from the therapeutic use of DNA damaging agents, an individual cell is estimated 
to receive 20, 000 DNA damaging lesions every day. These arise from either normal 
cellular functions, such as the production of oxygen free radicals at sites of 
inflammation, during DNA replication or from the environment such as cigarette 
smoke, chemical dyes and ultra-violet radiation. To cope with this level of DNA damage 
cells have evolved a variety of mechanisms for detecting and repairing DNA damage, or 
triggering apoptosis when repair is not possible (Hoeijmakers, 2009). These same 
processes are involved in the repair of DNA damage induced by cancer treatments. 
 
The response to DNA damage is triggered by the recognition of the presence of DNA 
damage by the cell and the arrest of the cell cycle to allow its repair. Where damage 
cannot be repaired, cells should undergo apoptosis. This response is complex and 
requires the coordinated functioning a large number of proteins and pathways. DNA 
damage results in the activation of the ataxia–telangiectasia mutated (ATM) protein, 
ataxia–telangiectasia and rad3-related (ATR) and the checkpoint kinases CHK1 and 
CHK2. This results in increased levels of the cyclin dependent kinase inhibitor (CDKI), 
p21 or inhibition of CDK activators such as the Cdc25 phosphatases. Cyclin dependent 
kinases control the cell cycle and their inhibition by p21 leads to activation of the DNA 
damage check points at G1/S or G2/M transition points, arresting the cell cycle. Cells 
then undergo DNA repair, apoptosis or enter the senescence (Al-Ejeh et al., 2010; 
Malumbres and Barbacid, 2009).   
 
The exact processes involved in the repair of DNA damage inflicted by anti-cancer 
therapies are dependent upon the type of lesion produced, often utilising components 
of more than one repair pathway (Table 1.3). DNA repair pathways include Nucleotide 
Excision Repair (NER), Base Excision Repair (BER), Mismatch Repair (MMR), 
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Homologous Recombination (HR), Non-Homologous End Joining (NHEJ) and Single 
Strand annealing (SSA). 
 
DNA DSBs are recognised by a protein complex made up of MRE11, RAD50 and NBS1 
(MRN complex) which binds to the free DNA strands within a DSB. This complex plays a 
key role in the processing the free ends of DNA, keeping the ends in close proximity 
and signalling the presence of a DSB (Scott and Pandita, 2006). NHEJ, HR and SSA are 
all involved with the repair of DNA DSBs following the recognition of the free DNA ends 
by a the MRN complex. DNA DSB repair by HR is confined to the S/G2M phase of the 
cell cycle, due to the requirement of an identical sister chromatid, making  it an error 
free mechanism of DNA repair (Scott and Pandita, 2006).  
 
 
Table 1.3 Summary of types of DNA repair pathways involved in the repair of DNA damage 
NHEJ- non-homologous end joining, HR-homologous recombination, NER-nucleotide excision 
repair, BER-base excision repair, TLS-translesion synthesis, SSA-single strand annealing. 
 
 
Briefly, following recognition of the DSB by the MRN complex, HR involves a three step 
process, presynapsis, synapsis and postsynapsis. Presynapsis involves the processing of 
free single stranded DNA ends to 3’-OH ends, the formation of a presynaptic filament 
through binding of replication protein A (RPA), which has a high affinity for single 
stranded DNA. This allows the loading of RAD51 onto the single stranded DNA, forming 
a presynaptic filament which invades the DNA of the sister chromatid and searches for 
the specific DNA sequence it requires. This process requires a number of proteins 
known as RAD51 paralogs, XRCC2, XRCC3, RAD51C, RAD51D, plus BRCA1, BRCA2, 
 
DNA damaging 
agent 
 
Type of DNA lesion 
induced 
DNA repair pathway 
NHEJ HR NER BER TLS SSA 
Cisplatin Mono adducts  
DNA-protein adduct 
Interstrand Crosslink 
Intrastrand crosslink  
   
 
 
 
   
Topoisomerase II 
poisons 
Double strand break 
Single strand break  
      
 
Ionising radiation Single strand break 
Double strand break 
Altered DNA bases 
   
 
 
 
  
 
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RAD52 and RAD54 (Scott and Pandita, 2006; Wyman et al., 2004). Once the correct 
section of DNA is identified, DNA synthesis occurs to fill in the missing DNA using the 
sister chromatid as a template. Post synapsis involves the two DNA molecules 
disengaging from each other and ligating to form an intact DNA strand. 
 
In contrast to HR, NHEJ can occur during all phases of the cell cycle, though is more 
error prone. NHEJ relies on the binding of the DNA-activated protein kinase (DNA-PK) 
subunits Ku70 and Ku80, to the free DNA ends of a DSB. This in turn recruits the DNA-
PK catalytic subunit (DNA-PKcs), forming DNA-PK, which once activated recruits 
artemis, XRCC4, ligase 4 and DNA polymerase μ.  Artemis processes the DNA ends to 
make them suitable for ligation by ligase 4. DNA polymerase μ then fills in the missing 
DNA nucleotides (Hoeijmakers, 2009; Scott and Pandita, 2006).  
 
SSA is an error prone mechanism of repair DNA DSB, as a section of DNA is deleted, 
and utilises components of both HR and NHEJ (Valerie and Povirk, 2003). It involves the 
generation of single stranded DNA overhangs, the search for homology within the DNA 
strand, annealing at the site of homology and the trimming of the unwanted DNA, 
resulting in the loss of DNA sequences. 
 
1.7.5.1 Repair of cisplatin-induced DNA damage 
The repair of cisplatin-induced DNA damage is complex and requires processes to 
remove intrastrand and interstrand DNA crosslinks, DNA-protein adducts and DNA 
DSBs. The presence of a cisplatin adduct is signalled by the significant distortion it 
produces in the DNA double helix. These lesions are primarily repaired by NER which 
has two branches, each with different triggers, but both feed into the same repair 
pathway (Wang and Lippard, 2005). Transcription coupled repair (TCR) is activated by 
stalled RNA polymerases whilst transcribing DNA and hence are focused on repairing 
transcription blocking lesions. The other branch, known as global genomic repair 
(GGR), is activated by damaged DNA binding protein (DDB), XPC or XPE protein 
complexes and repairs the untranscribed portion of genes. Following detection of an 
adduct, DNA around the site is unwound by transcription factor IIH and helicase XPD 
and XPB, the resulting intermediate is stabilised by replication protein A (RPA) and XPA 
which orientate the two endonucleases ERCC1/XPF and XPG. They make 5’ and 3’ 
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excisions respectively, removing the damaged nucleotides. DNA is then synthesised 
across the gap, using the opposite DNA strand as a template (Muniandy et al., 2010).  
 
Interstrand crosslinks can be recognised and repaired by the process described above 
or through the stalling of an RNA polymerase or replication fork (Muniandy et al., 
2010). The current proposed mechanism of repair of interstrand crosslinks involves the 
attraction of proteins belonging to the Fanconi anaemia pathway to stalled replication 
forks, with repair involving NER, HR and the process of translesion DNA synthesis (TLS). 
Following recognition of an interstrand crosslink, the crosslink is ‘unhooked’ from one 
section of DNA through the action of ERCC1 and XPF, resulting in the formation of a 
DSB and an adduct attached to a single DNA strand only. The DSB is repaired by HR and 
the adduct removed by NER, with the gap left filled by TLS (Muniandy et al., 2010).    
 
The role of HR in modulating sensitivity to cisplatin has been recognised for nearly 20 
years (Caldecott and Jeggo, 1991) with breast tumours carrying BRCA1 mutations and 
hence defective HR, more sensitive to cisplatin than non-BRCA1 mutated breast 
tumours (Byrski et al., 2010). The NHEJ protein DNA-PK appears to be involved in 
modulating resistance to cisplatin in conjunction with EGFR (Dittmann et al., 2005a; 
Friedmann et al., 2006) (discussed below). However, in general the role of NHEJ in the 
repair of cisplatin-induced damage is less clear, with NHEJ deficient cell lines not 
demonstrating increased sensitivity to cisplatin (Helleday, 2010).  
 
1.7.5.2 Repair of ionising radiation induced DNA damage 
The repair of IR-induced DNA DSBs is thought to rely on the process of NHEJ, with 
damaged bases and single stand breaks repaired by BER and NER (Hoeijmakers, 2009). 
Increasingly there is evidence that these pathways contain proteins which interact with 
each other and may act in a coordinated manner to repair DNA damage (Mahaney et 
al., 2009). For example DNA-PK, a main component of NHEJ, is targeted by the BER 
protein XRCC1 in response to IR, which is involved in the repair IR-induced single 
strand breaks and altered bases (Mahaney et al., 2009). 
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1.7.5.3 Repair of Topo II poison induced DNA-damage 
Topo II poisons induce both single and double DNA strand breaks though investigation 
into their repair has focused on the DNA DSB contained within the Topo II bound 
cleavable complex. This DSB can normally be religated as part of the normal function 
of the Topo II enzyme (see Figure 1.5). Doxorubicin and etoposide prevent this 
religation step through the poisoning of Topo II, so the repair of the DNA DSB is 
dependent upon other cellular mechanisms of DNA repair. Additionally, cleavable 
complexes can be turned into permanent DSBs if they block replication or transcription 
(Fan et al., 2008). The first step in processing and repair involves the removal of the 
Topo II protein from the free DNA strands, allowing the signaling of the presence of a 
DSB through the formation of γH2AX foci and recruitment of repair proteins. This can 
be achieved through one of two pathways; transcription or replication dependent 
(Nitiss, 2009b). The transcription-dependent pathway degrades the Topo II-DNA 
covalent complex through proteolysis, with proteasome inhibition reducing the 
formation of γH2AX foci (Zhang et al., 2006).  The replication-dependent pathway uses 
nucleolytic digestion to remove the protein covalently bound to DNA. A nucleolytic 
step is also required following proteolysis of the cleavable complex, as some residual 
amino acids are left attached to DNA  (Nitiss, 2009b). 
 
The DNA DSB contained within the cleavable complex can be repaired by NHEJ, HR or 
SSA. NHEJ appears to be the main pathway involved in repair with increased sensitivity 
to Topo II poisons demonstrated following the silencing of ligase 4 (Toyoda et al., 
2008) and in NHEJ deficient cells (de Campos-Nebel et al., 2010). Additionally, DNA-
PKcs inhibitors delay the repair of Topo II poison-induced DNA DSBs (Toyoda et al., 
2008). The role of HR is more contentious with the knockdown of Rad54 not increasing 
sensitivity to etoposide or doxorubicin (Toyoda et al., 2008), though HR deficient cells 
are more sensitive to the Topo II poisons etoposide and idarubicin (de Campos-Nebel 
et al., 2010; Treszezamsky et al., 2007). Overall the process of NHEJ is able to repair 
Topo II-induced DNA DSB throughout the cell cycle, with HR active in the S and S/G2-
phases (de Campos-Nebel et al., 2010). 
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1.8 MECHANISMS OF ENHANCEMENT OF CYTOTOXICITY BY SMALL 
MOLECULE TYROSINE KINASE INHIBITORS  
There is a clear rationale for the combination of HER targeted therapies and cytotoxic 
agents based upon the correlation between EGFR expression and resistance to 
chemotherapy (Ang et al., 2004; Buchholz et al., 2005; Kumar et al., 2008; Scambia et 
al., 1995), radiotherapy (Giralt et al., 2005) and chemoradiotherapy (Kumar et al., 
2008; Noordhuis et al., 2009). In addition EGFR phosphorylation is induced in response 
to IR and chemotherapy drugs including cisplatin, doxorubicin, gemcitabine, irinotecan 
and paclitaxel (Bianco et al., 2002; Chinnaiyan et al., 2005; Kishida et al., 2005; Morgan 
et al., 2008; Schmidt-Ullrich et al., 1997; Van Schaeybroeck et al., 2006; Winograd-Katz 
and Levitzki, 2006; Yoshida et al., 2008a) and the transfection of EGFR into cancer cell 
lines confers resistance to cytotoxic therapies (Dickstein et al., 1995). These 
observations suggest that EGFR is involved in mediating resistance to cytotoxic agents 
and that the addition of anti-EGFR therapies may enhance cell killing. This has been 
demonstrated extensively in vitro with the combination of EGFR TKIs with cytotoxic 
drugs (Ciardiello et al., 2000; Friedmann et al., 2004; Ren et al., 2008; Sirotnak et al., 
2000) or radiation (Bianco et al., 2002; Chinnaiyan et al., 2005; Toulany et al., 2010; 
Zhou et al., 2004) and in xenograft models (Chun et al., 2006; Morgan et al., 2008; 
Ouchi et al., 2006). 
 
Unlike EGFR, the expression of HER2 and resistance to chemotherapy is mixed. The 
amplification of HER2 is associated with sensitivity to anthracyclines (Yamauchi et al., 
2001) and resistance to cisplatin (Calikusu et al., 2009). However, these observations 
are not explained by HER2 alone as the transfection of HER2 into cancer cells lines or 
xenografts is only able to modulate sensitivity to chemotherapy drugs in a cell line 
dependent manner (Pegram et al., 1997).   
 
The precise mechanisms through which EGFR targeting TKIs are able to enhance the 
effects of traditional anti-cancer therapies are being uncovered and include the 
modulation of a variety of cellular processes, which are discussed below. 
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1.8.1 Inhibition of EGFR activation by tyrosine kinase inhibition 
The phosphorylation of EGFR in response to chemotherapy or IR is mediated by the 
shedding of EGFR ligands through the activation of ADAM enzymes (Kim et al., 2005; 
Singh et al., 2009; Xu and Derynck, 2010). This process is dependent upon p38 MAPK 
(Xu and Derynck, 2010) and Src (Poghosyan et al., 2002) resulting in the shedding of 
the EGFR ligands amphiregulin, HB-EGF, TGF-α and heregulin, chiefly by ADAM 17 
(Kishida et al., 2005; Kyula et al., 2010; Xu and Derynck, 2010; Yoshida et al., 2008a). 
Irinotecan induced EGFR phosphorylation can be prevented by the inhibition of 
ADAM17, demonstrating the role of this pathway in activating EGFR in response to 
cytotoxic agents (Kishida et al., 2005).  
 
In addition to the release of EGFR ligands, the production of ROS by cytotoxic agents 
inhibits protein-tyrosine phosphatases preventing EGFR dephosphorylation, increasing 
EGFR signalling (Dittmann et al., 2009; Szumiel, 2006).  
 
Gefitinib, erlotinib and lapatinib inhibit the induction of EGFR phosphorylation by IR 
and chemotherapy (Bianco et al., 2002; Chinnaiyan et al., 2005; Chun et al., 2006; 
Morgan et al., 2008; Munk et al., 2007; Ren et al., 2008; Tanaka et al., 2008) and 
gefitinib is also able to reduce the transcription of amphiregulin and HB-EGF (Kishida et 
al., 2005). Therefore TKIs are able to prevent the phosphorylation of EGFR by EGFR 
ligands secreted in response to IR and a variety of chemotherapy drugs together with 
downregulating the transcription of some EGFR ligands.  
 
1.8.2 Inhibition of multi-drug resistance transporters by tyrosine kinase inhibitors 
TKIs reduce resistance to cytotoxic drugs in cells expressing ABC transporter proteins, 
including P-glycoprotein (Leggas et al., 2006; Yang et al., 2005), BRCP (Lopez et al., 
2007; Nakamura et al., 2005; Perry et al., 2010; Yanase et al., 2004), MRP-7 (Kuang et 
al., 2010), ABCB1 and ABCG2 (Dai et al., 2008). This is mediated through the direct 
binding of the TKI to the transporter, resulting in hydrolysis of ATP and accumulation 
of transporter substrate within the cell (Kitazaki et al., 2005; Shi et al., 2007). The 
transport of drugs by ATP-binding cassette member proteins is an active process using 
ATP (Gottesman et al., 2002). The stimulation of hydrolysis of ATP by both gefitinib and 
erlotinib indicates that these drugs are substrates for ABC transporters and therefore 
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reduce the efflux of other substrates including cytotoxic drugs (Shi et al., 2007). These 
data demonstrate that TKIs can increase the cytotoxicity of chemotherapy drugs by 
preventing their export via multi-drug resistance transporters leading to higher 
concentrations within cells. 
 
1.8.3 Inhibition of conjugation to glutathione by tyrosine kinase inhibitors 
EGF increases the level of intracellular glutathione which in turns protects cells from 
the effects of IR (Wollman et al., 1994) and EGFR can activate the enzyme GSTP1, 
increasing the conjugation of cisplatin with glutathione, neutralising its cytotoxic 
effects (Okamura et al., 2009). In cell lines, the TKI lapatinib inhibits EGF-induced 
activation of GSTP1 sensitising cells to cisplatin (Okamura et al., 2009) and the EGFR 
TKI AG1478 reduces intracellular glutathione content. Therefore, TKIs may increase 
cytotoxicity of chemotherapy drugs by reducing glutathione levels and inhibiting the 
phosphorylation of GSTP1, thereby reducing the ability of cells to detoxify these 
agents. 
 
1.8.4 Increasing sensitivity to 5-fluorouracil by tyrosine kinase inhibitors  
5-FU is a pyrimidine analogue which requires conversion into active metabolites 
including fluorodeoxyuridine monophosphate (FdUMP) and fluorodeoxyuridine 
triphosphate (FdUTP). The enzyme thymidine phosphorylase converts 5-FU into 
fluorodeoxyuridine, which is then converted into FdUMP and FdUTP. These 
metabolites affect a number of cellular processes, for example FdUMP inhibits the 
enzyme thymidylate synthase, preventing the de novo formation of thymidine required 
for DNA synthesis (Longley et al., 2003).  
 
TKIs can potentiate the cytotoxic effects of 5-FU through their action on multi-drug 
resistance transporters (discussed above), the reduced expression of thymidylate 
synthase (Giovannetti et al., 2008; Magne et al., 2003; Ouchi et al., 2006) and 
increased expression of the enzyme thymidine phosphorylase (Magne et al., 2003; 
Ouchi et al., 2006). The downregulation of thymidylate synthase expression is 
mediated by the inhibition the transcription factor E2F-1 (Giovannetti et al., 2008) and 
the inhibition of nuclear transport of both EGFR and HER2, which prevents activation 
of the thymidylate synthase gene promoter (Kim et al., 2009).  In addition, increased 
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expression of thymidine phosphorylase enhances the production of the 5-FU 
metabolites, FdUMP and FdUTP.   
 
1.8.5 Inhibition of DNA repair by tyrosine kinase inhibitors 
TKIs have been demonstrated to reduce DNA repair following IR (Chinnaiyan et al., 
2005; Li et al., 2008; Tanaka et al., 2008) or chemotherapy (Friedmann et al., 2004). 
The inhibition of DNA repair by TKIs may be due to the inhibition of the PI3K/AKT 
pathway, inhibition of nuclear transport of receptors and modulation of the activity of 
DNA-PK. 
 
1.8.5.1 Inhibition of PI3K/AKT pathway by tyrosine kinase inhibitors  
The phosphorylation of AKT is induced by IR (Tanaka et al., 2008; Toulany et al., 2010) 
and some chemotherapy drugs (Li et al., 2007) and appears to be a key requirement 
for successful combination of TKIs with cytotoxic agents.  Lapatinib inhibits cell growth 
in pancreatic cancer cell lines but only induces radiosensitivity when AKT 
phosphorylation is inhibited. In resistant cells, lapatinib does not inhibit AKT 
phosphorylation, but the addition of an AKT inhibitor can induce radiosensitivity 
(Kimple et al., 2010). Gefitinib induced inhibition of AKT is also crucial in drug 
combinations, with gefitinib following gemcitabine inhibiting AKT phosphorylation and 
increasing cell death, but when given prior to gemcitabine, no inhibition of AKT is 
observed and cells are resistant to gemcitabine (Chun et al., 2006). Studies which have 
examined cytotoxic agents in combination with TKIs on AKT activation, have 
demonstrated inhibition of AKT phosphorylation in successful combinations (Bianco et 
al., 2002; Li et al., 2007; Morgan et al., 2008). 
 
AKT is involved in DNA repair by NHEJ (Golding et al., 2009), activating DNA-PK 
(discussed below), up-regulating the expression of MRE11, a protein involved in the 
recognition of DNA DSBs (Deng et al., 2011) and controlling the expression of the HR 
protein RAD51 (Ko et al., 2009). This indicates that the inhibition of AKT signalling by 
TKIs could inhibit DNA repair through the modulation of both the recognition of DNA 
damage and the process of repair through NHEJ and/or HR. 
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1.8.5.2 Inhibition of nuclear translocation of EGFR and HER2 and inhibition of DNA 
repair  
The nuclear translocation of EGFR has been demonstrated in cell lines in response to 
both IR and cisplatin (Dittmann et al., 2005a; Hsu et al., 2009; Liccardi et al., 2011). 
Deletion of the NLS sequence from EGFR thereby reducing nuclear translocation, 
sensitises cells to the cytotoxic effects of cisplatin and reduces DNA end joining activity 
(Hsu et al., 2009).  HER2 transfected into the MDA-MB-468 breast cancer cell line also 
translocates into the nucleus following exposure to cisplatin, a process that is blocked 
by the deletion of the NLS sequence (Boone et al., 2009).  Lapatinib is able to inhibit 
the translocation of both EGFR and HER2 into the nucleus and this may be a potential 
mechanism through which TKIs inhibit DNA repair (Kim et al., 2009). Whilst the 
inhibition of chemotherapy-induced nuclear translocation of EGFR or HER2 by TKI has 
not been reported in the literature, this has been demonstrated in our laboratory using 
gefitinib. 
 
1.8.5.3  Modulation of DNA-activity and location 
Immunoprecipitation experiments have demonstrated the nuclear translocation EGFR, 
binding to DNA-PKcs and increase in its activity in response to IR and cisplatin 
(Dittmann et al., 2005a; Liccardi et al., 2011). DNA-PKcs plays a key role in the repair of 
DNA DSBs by NHEJ and its expression and activity is inhibited by erlotinib (Toulany et 
al., 2010) and gefitinib (Friedmann et al., 2006). Gefitinib treatment only inhibits the 
repair of cisplatin-induced interstrand crosslinks when EGFR is able to translocate to 
the nucleus, failing to inhibit repair in cells transfected with a mutated EGFR which 
does not translocate on exposure to cisplatin (Liccardi et al., 2011). This suggests that 
gefitinib inhibits cisplatin-induced nuclear translocation of EGFR, resulting in a 
reduction in nuclear DNA-PK activity, which inhibits DNA repair. 
 
1.9 COMBINATIONS OF ANTI-HER TYROSINE KINASE INHIBITORS WITH 
CHEMOTHERAPY 
1.9.1 Breast Cancer 
The addition of gefitinib to epirubicin, paclitaxel and docetaxel has been studied in a 
number of phase II studies. However, the objective clinical responses reported by 
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these studies are not significantly higher than those observed with chemotherapy 
alone (Ciardiello et al., 2006; Dennison et al., 2007; Fountzilas et al., 2005; Gasparini et 
al., 2005) (Table 1.4). Similar findings have been reported by a phase II study of 
erlotinib in combination with gemcitabine in patients with pre-treated metastatic 
breast cancer, where the response rates were lower than historical controls for single 
agent gemcitabine (Graham DL et al., 2005). 
 
Two phase III trials have examined the addition of lapatinib to chemotherapy in 
patients with metastatic breast cancer. The combination of lapatinib and capecitabine 
was granted FDA approval on the basis of a multicentre open label trial comparing 
capecitabine alone with lapatinib plus capecitabine in women with HER2 amplified 
breast cancer whose disease had progressed following treatment with trastuzumab, 
anthracyclines and taxanes (Cameron et al., 2008; Geyer et al., 2006). This study was 
stopped following an interim analysis of 324 enrolled patients. At this point, time to 
progression was reported as 27.1 weeks for lapatinib plus capecitabine versus 18.6 
weeks for capecitabine alone (hazard ratio, 0.57; p = .00013) (Geyer et al., 2006). The 
second phase III studied compared lapatinib plus paclitaxel against single agent 
paclitaxel as first line in the metastatic setting. Women were permitted to have 
received neo-adjuvant and adjuvant chemotherapy. HER2 status was assessed 
retrospectively and results for HER2-negative and HER2-positive groups analysed. In 
the HER2-negative group, there was no statistical significant difference in time to 
progression or overall response rates between chemotherapy alone or in combination 
with lapatinib. In contrast, the HER2-positive group demonstrated that combination 
treatment was superior with overall response rates of 63.3% vs. 37.8% (p 0.023), and 
delayed time to progression of 11 weeks (36.4 vs. 25.1 weeks (p0.005)) (Di Leo et al., 
2008b). Therefore lapatinib is able to produce increased clinical benefits in 
combination with capecitabine or paclitaxel. 
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Authors Phase Trial 
Drug Regimen 
Prior Therapy HER 
Status 
Response 
CR PR SD PD 
Geyer, 2006 
Cameron, 
2008 
III Lapatinib+ 
capecitabine vs. 
capecitabine  
alone  
At least 2 
regimens + 
trastuzumab  
Pos <1 
vs.  
0 
23 
vs.  
14 
38 
vs.  
29 
13 
vs. 
23 
Ciardiello, 
2006 
II Gefitinib 
+docetaxel 
Adjuvant 
therapy 
Mixed 12 42 14 32 
Dennison, 
2007 
II Gefitinib + 
docetaxel 
Adjuvant 
therapy 
Mixed 3 36 12 48 
Di Leo, 2008  III Lapatinib+ 
paclitaxel vs. 
paclitaxel  
Chemotherapy Pos 10 
vs. 
3 
53 
vs.  
35 
18 
vs. 
30 
14 
vs.  
22 
    Neg 3 
vs. 
2 
27 
 vs.  
21 
34 
vs. 
46 
25 
vs.  
25 
Fountzilas,  
2005 
II Paclitaxel+ 
carboplatin+ 
gefitinib  
Adjuvant 
chemotherapy 
Mixed 13 44 31 4.4 
Gasparini, 
2005 
I Weekly 
epirubicin + 
gefitinib 
Adjuvant or 
taxane or 
doxorubicin 
Mixed  14 50 38 
Twelves, 
2008 
Ib Dose escalation 
of erlotinib + 
docetaxel and 
capecitabine  
Chemotherapy 
No previous 
anti-HER2 
therapy 
Mixed 8 50 21 8 
Table 1.4 Clinical trials of tyrosine kinase inhibitors and chemotherapy in breast cancer 
 
1.9.2 Pancreatic Cancer  
The benefit of the addition of erlotinib to standard chemotherapy with gemcitabine in 
patients with advanced pancreatic cancer has been demonstrated in a randomised 
placebo controlled phase III trial in 559 patients (Moore et al., 2007). 17% of patients 
treated with gemcitabine alone lived for one year compared with 23% in patients 
treated with gemcitabine in combination with erlotinib (p 0.023). 
 
1.9.3 Lung Cancer 
Clinical trials in non small cell lung cancer provide the largest data set from randomised 
phase III trials comparing standard chemotherapy with the addition of a TKI or 
placebo, in over 4000 patients. INTACT 1 examined the combination of gefitinib 250 
mg or 500 mg daily or placebo with gemcitabine and cisplatin, in 1093 patients and 
found no benefit for the addition of gefitinib in terms of median survival, median time 
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to progression or response rates (Giaccone et al., 2004). INTACT 2 was a similar 
designed study examining the combination of gefitinib 250 mg or 500mg daily or 
placebo with paclitaxel and carboplatin. It also reported no significant difference in 
overall survival, time to progression or response rates (Herbst et al., 2004).  TRIBUTE 
investigated erlotinib or placebo in combination with paclitaxel and carboplatin in 
1059 patients, also finding no benefit of the addition of erlotinib in median survival, 
objective response or time to progression (Herbst et al., 2005). The combination of 
erlotinib or placebo with gemcitabine and cisplatin in 1172 patients also failed to 
demonstrate any benefit of the addition of erlotinib in terms of response rates, overall 
survival or time to progression (Gatzemeier et al., 2007). 
 
1.9.4 Head and Neck Cancer 
Erlotinib has been safely combined with cisplatin (Siu et al., 2007) and gefitinib in 
combination with cisplatin or 5-FU chemoradiotherapy with additional benefits over 
historical controls demonstrated (Chen et al., 2007; Cohen et al., 2010). However 
efficacy may be dependent upon the chemotherapy agent used, as gefitinib did not 
add any additional benefit in combination with paclitaxel and radiotherapy (Van Waes 
et al., 2010). Lapatinib has also been safety combined with cisplatin based 
chemoradiotherapy in a phase I study (Harrington et al., 2009). 
 
1.9.5 Colorectal Cancer  
Early phase studies have also examined the addition of gefitinib or erlotinib to 
standard chemotherapy regimens in colorectal cancer. Safety and additional activity 
over historical data has been demonstrated by the combination oxaliplatin and 5-FU 
based chemotherapy with erlotinib (Hanauske et al., 2007; Meyerhardt et al., 2006; 
Van Cutsem et al., 2008) and gefitinib (Fisher et al., 2008). Combination of irinotecan, 
folinic acid and 5-FU (FOLFIRI) with either erlotinib or gefitinib is associated with 
significant toxicity (Messersmith et al., 2004; Veronese et al., 2005) and a randomised 
phase IIb study of the addition of gefitinib to FOLFIRI in 100 patients failed to 
demonstrate any additional benefit from gefitinib (Santoro et al., 2008). 
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1.9.6 Ongoing Phase III studies combining lapatinib with chemotherapy 
There are a number of phase III clinical trials examining lapatinib in combination with 
chemotherapy in different tumours (Table 1.5). 
 
Trial Setting Chemotherapy regimen Primary 
outcome 
EGF104383 
Phase III 
First line HER2 +ve 
metastatic breast 
cancer 
Paclitaxel+trastuzumab+lapatinib vs. 
paclitaxel+trastuzumab+placebo 
TTP 
EGF108919 
Phase III 
Stage IV disease 
with HER-2 +ve 
breast cancer  
Taxane+lapatinib vs. 
taxane+trastuzumab 
PFS 
LPT109096 
Phase II 
Neo-adjuvant 
HER2 +ve breast 
cancer 
Trastuzumab+FEC then paclitaxel vs. 
lapatinib+FEC then paclitaxel vs.  
trastuzumab+lapatinib+FEC then 
paclitaxel  
pCR 
EGF111438 
Phase III 
Metastatic 
HER2+ve breast 
cancer following 
taxane or 
anthracycline 
Lapatinib+capecitabine vs. 
Trastuzumab+capecitabine 
CNS 
metastasis 
as first 
relapse 
EGF104578 
Phase III 
HER2 amplified 
advanced gastric 
cancer. Second 
line 
Weekly paclitaxel vs. weekly 
paclitaxel+lapatinib 
OS 
EGF110656 
Phase III 
HER2 +ve 
advanced 
adenocarcinoma 
of oesophagus or 
stomach 
Oxaliplatin+capecitabine vs. 
oxaliplatin+capecitabine+lapatinib 
PFS 
EGF102988 High risk resected 
squamous 
carcinoma of the 
head and neck 
Adjuvant chemoradiotherapy vs. 
chemoradiotherapy +lapatinib 
DFS 
Table 1.5 Ongoing clinical trials with lapatinib in combination with chemotherapy  
 
1.10 REASONS FOR FAILURE OF TYROSINE KINASE INHIBITORS IN 
COMBINATION WITH DNA DAMAGING AGENTS 
Despite a clear rationale for the combination of TKIs with cytotoxic agents and in vitro 
support, such combinations have generally failed to produce clinical benefits.  The 
evidence indicates this may be due to the failure to abrogate HER signalling through 
the PI3K/AKT pathways and highlights the importance of drug scheduling.    
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1.10.1 Failure to inhibit human epidermal growth factor signalling  
TKIs may not always inhibit HER signalling or activation of their downstream pathways. 
This can be due to EGFR mutations resulting in resistance to TKIs, mutations in key 
signalling regulators downstream of the membrane receptors (e.g. K-Ras or 
phosphatase and tensin homolog (PTEN)), or through continued HER signalling, either 
due to incomplete inhibition of receptors or through dimerisation with other, non-
inhibited receptors. This failure to prevent PI3K/AKT signalling may explain why TKIs in 
combination with DNA damaging agents have not translated into the clinical setting. 
 
1.10.1.1 EGFR mutations and resistance to tyrosine kinase inhibitors 
Secondary resistance to TKIs occurs in patients with NSCLC whose tumours initially 
expressed EGFR with an activating mutation. The commonest mechanism of resistance 
identified occurs through the acquisition of a mutation in which methionine is 
substituted for threonine at amino acid position 790 (T790M) in exon 20. The 
acquisition of this mutation accounts for around 50-60% of acquired resistance to 
EGFR targeted TKIs (Kobayashi et al., 2005; Oxnard et al., 2011; Pao et al., 2005). This 
mutation increases affinity of EGFR for ATP over gefitinib or erlotinib (Yun et al., 2008). 
The gain of other EGFR mutations, as reported in case reports, can also result in 
secondary resistance to TKIs (Balak et al., 2006; Bean et al., 2008) and the 
amplification of the hepatocyte growth factor receptor MET, is detected in around 20% 
of NSCLC with acquired resistance to TKIs. MET is able to phosphorylate HER3 and 
activate the PI3K/AKT pathways, potentially producing resistance to EGFR targeted 
TKIs (Engelman et al., 2007).  
 
Whilst the presence of an activating EGFR mutation in NSCLC predicts for an increased 
response to an EGFR targeted TKI in the first line setting, response rates are around 50-
70% (Mok et al., 2009a; Rosell et al., 2009; Sequist et al., 2008) and not all EGFR 
mutations confer sensitivity to EGFR targeted TKIs. There are case reports of patients 
with tumours which express the EGFR sensitising mutation L858R, together with the 
T790M mutation associated with resistance, prior to commencing TKI therapy and as a 
result are resistant to TKIs (Sequist et al., 2008; Shih et al., 2005). However the 
commonest EGFR mutation associated with primary resistance to EGFR targeted TKIs is 
an insertion mutation in exon 20 (Greulich et al., 2005; Sasaki et al., 2007). Though, 
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this mutation is only detected in around 2% of lung cancer (Sasaki et al., 2007; 
Shigematsu et al., 2005) and therefore is unlikely to account for the failure of TKIs in 
combination with chemotherapy.   
 
1.10.1.2 Mutant K-Ras and resistance to tyrosine kinase inhibition 
K-Ras is an important mediator in the Ras-Raf-MAPK pathway and links the activation 
of HER receptors to the activation of MAPK. Mutations in K-Ras produce a 
constitutively active protein resulting in the escape of the Ras-Raf-MAPK pathway from 
the control of membrane receptors (Jancik et al., 2010). Mutated K-Ras is a strong 
predictor of failure of EGFR monoclonal antibodies in colorectal cancer (Amado et al., 
2008; Karapetis et al., 2008). The exception to this, is a codon 13 mutation (G13D)  in 
which glycine is substituted for aspartate, as colon tumours with this mutation respond 
to cetuximab therapy (De Roock et al., 2010). 
 
Data on the influence of K-Ras mutations in TKI therapy is less clear cut, confused by 
the fact that the data for monoclonal antibodies is derived from clinical trials in 
colorectal cancer in contrast to TKI data, which is derived from trials in NSCLC. A recent 
meta-analysis of 22 trials in NSCLC concludes that K-Ras status is not able to predict for 
response to EGFR TKIs (Mao et al., 2010). This observation does not appear to be due 
to differences between TKI and antibodies, as mutant K-Ras does not predict for 
treatment failure of cetuximab in combination with chemotherapy in NSCLC 
(Khambata-Ford et al., 2010). Whether this observation is due to tumour type has yet 
to be ascertained, as currently no data on K-Ras status and response to TKI in tumours 
other than NSCLC, has been published. However, data looking at K-Ras status and 
response to cetuximab in non-colorectal cancers supports tumour specificity with no 
predictive value observed in oesophageal (Gold et al., 2010) or gastric cancer (Park et 
al., 2010). Therefore, mutations in K-Ras are unlikely to explain why TKIs in 
combination with DNA damaging agents have failed to translate into the clinic. 
 
1.10.1.3 Phosphatase and Tensin homolog 
In vitro studies have indicated that the expression of PTEN is an important mediator of 
sensitivity to gefitinib (She et al., 2003). PTEN is a negative regulator of AKT activation 
through the dephosphorylation of phosphatidylInositol (3,4,5)-trisphosphate, with 
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PTEN loss resulting in increased AKT signalling (Sansal and Sellers, 2004); PTEN null 
cells are resistant to the effects of gefitinib (She et al., 2003). The relevance of PTEN 
loss and gefitinib resistance has been demonstrated in glioblastoma (Mellinghoff et al., 
2005), and lung cancer (Endoh et al., 2006), but both studies are small and 
confirmation from larger studies is still required. In contrast to gefitinib, the activity of 
lapatinib is not affected by PTEN status (Xia et al., 2007). 
 
1.10.1.4 Failure to inhibit the PI3K/AKT signalling pathway 
The PI3K/AKT pathway is involved in modulating the response of cells to DNA damage 
through the control of apoptosis and modulation of key proteins involved in DNA 
repair (discussed in section 1.8.5.1) HER3 is a potent activator of the PI3K/AKT 
signalling pathway through dimerisation with either EGFR or HER2 and the inhibition of 
either or both these receptors by TKIs inhibits HER3 and PI3K/AKTs signalling (Kong et 
al., 2008; Sergina et al., 2007). However, this inhibition is short lived, with 
phosphorylated HER3 and AKT detectable in cells within 48 hours despite continued 
EGFR and HER2 inhibition (Kong et al., 2008; Sergina et al., 2007). These data suggest 
that at least two different mechanisms produce this effect. Firstly, inhibition of AKT 
signalling upregulates the expression of a number of receptor tyrosine kinases 
including HER3, IGFR1 and the insulin receptor (Chandarlapaty et al., 2011). The 
second separate mechanism, controls receptor phosphorylation.  
 
In HER2 amplified cells, receptor phosphorylation is dependent on HER2 activity. AKT 
inhibition alone induces the expression and phosphorylation of HER3, IGFR1 and the 
insulin receptor, but in combination with lapatinib (1 µM) receptor phosphorylation is 
inhibited but not increases in receptor expression (Chandarlapaty et al., 2011), 
indicating that the inhibition of HER2 alters receptor phosphorylation but not their 
expression. 
 
Under conditions where only partial or no HER2 inhibition occurs (e.g. ≤1µM gefitinib), 
EGFR inhibition induces the proteolytic cleavage of HER4 (Kong et al., 2008). This 
stimulates the autocrine release of the HER3 and HER4 ligands, betacellulin and 
heregulin, stimulating the production of HER2/HER3 and HER3/HER4 dimers, thus 
negating the effect of EGFR inhibition (Kong et al., 2008). Under conditions where 
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HER2 is inhibited in addition to EGFR, (e.g. ≥5µM gefitinib) a forward shift in the 
dephosphorylation-phosphorylation equilibrium of HER3 is produced, resulting in an 
increase in the steady state phosphorylation of HER3 and activation of the PI3K/AKT 
signalling pathway (Sergina et al., 2007).  
 
1.10.2 Why scheduling may be important? 
In vitro studies provide evidence that the schedule of TKI and chemotherapy is 
important with the schedule of TKI followed by chemotherapy being the least 
efficacious schedule in most studies (Chun et al., 2006; Giovannetti et al., 2008; Li et 
al., 2007; Morelli et al., 2005; Xu et al., 2003) though these finding are dependent 
upon the type of cytotoxic agent used (McHugh et al., 2007; Solit et al., 2005). The 
importance of scheduling is alluded to in a clinical trial of 154 patients with NSCLC. 
Patients were treated with gemcitabine and cisplatin plus erlotinib or placebo from 
days 15-28. Significant improvements in response rates and progression free survival 
were observed in the group treated with erlotinib (Mok et al., 2009b). Given that the 
large randomised trial of gemcitabine and cisplatin in combination with gefitinib or 
placebo, INTACT 1 failed to demonstrate any benefit from the addition of gefitinib, the 
schedule of erlotinib from days 15-28 may be more beneficial than continuous TKI use. 
 
1.10.2.1 Cell cycle arrest 
The DNA damaging and cytotoxic effects of some chemotherapy drugs are influenced 
by cell cycle phase as discussed in section 1.7.4. Pyrimidine analogues exert their 
effects during S-phase when DNA replication is occurring, paclitaxel in G2M-phase 
(Shah and Schwartz, 2001) with Topo II poisons inducing the greatest DNA damage 
during G2/M- phase of the cell cycle when Topo IIα expression is highest (Potter et al., 
2002; Potter and Rabinovitch, 2005).  
 
TKIs induce a G1 phase cell cycle arrest in cancer cell lines (Kim et al., 2008b; Krol et al., 
2007; Li et al., 2007), which may render cells resistant to the effects of some cytotoxic 
agents. This has been demonstrated with EGFR inhibition and IR, with the irradiation of 
cells in G1-phase demonstrating EGFR phosphorylation, transition into S-phase and cell 
death (Ahsan et al., 2009). Inhibition of EGFR phosphorylation by erlotinib, prevents IR-
induced EGFR phosphorylation with cells remaining in G1 and resistant to the cytotoxic 
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effects of IR (Ahsan et al., 2009). Similar results have been obtained with the pre-
treatment of cells with erlotinib or gefitinib which induces a G1 cell cycle arrest, with 
no alteration in cell cycle and less cytotoxicity induced by pemetrexed or gemcitabine 
compared with either continuous treatment with TKI and chemotherapy or 
chemotherapy followed by TKI (Chun et al., 2006; Li et al., 2007; Morgan et al., 2008)  
 
1.10.2.2 EGFR Internalisation and degradation 
The phosphorylation of EGFR in response to IR or chemotherapy leads to its 
internalisation in a p38 dependent process (Zwang and Yarden, 2006). This is followed 
by the ubiquitination and degradation of EGFR which correlates with sensitivity to 
cisplatin (Ahsan et al., 2010) and gemcitabine (Feng et al., 2007). In these studies, the 
inhibition of EGFR phosphorylation by the use of TKI prior to chemotherapy results in 
resistance to cell death, by preventing EGFR degradation (Ahsan et al., 2010; Feng et 
al., 2007). The need for EGFR to be degraded rather than just inactivated maybe 
explained by its’ non-kinase dependent role in glucose uptake (Weihua et al., 2008). 
This explains the observation that cells transfected with EGFR lacking an intrinsic 
kinase are able to survive (Ewald et al., 2003) and that knockdown of EGFR with siRNA 
produces a greater level of cell death than kinase inhibition alone (Weihua et al., 
2008).  
 
1.11 RATIONALE FOR THE INVESTIGATION OF THE MODULATION OF 
DNA DAMAGE INDUCTION AND REPAIR BY DURATION OF EXPOSURE 
TYROSINE KINASE INHIBITOR IN BREAST CANCER 
The HER family plays a key role in driving and controlling tumour growth and mediating 
resistance to traditional cytotoxic agents. Despite in vitro data indicating that TKIs in 
combination with cytotoxic agents produce greater benefits over cytotoxic agents 
alone, on the whole these have failed to translate into the clinical setting.  The reasons 
for this appear to be multiple and include primary resistance to the effects of TKIs (K-
Ras or PTEN), alterations in signalling pathways (EGFR degradation vs. nuclear 
transport in response to cellular stressors), or the ability to continue HER signalling 
despite continued exposure to a TKI.  
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Further work is required to understand the reasons why these combinations have 
failed to translate into the clinic if the potential benefits of TKIs are to be harnessed. 
Whilst lapatinib has an established role in the management of metastatic breast 
cancer, the use of gefitinib and erlotinib in breast cancer is still under investigation 
focussed on breast tumours identified as ‘triple negative’.  These tumours do not 
overexpress HER2 and are negative for ER and PR, though over 50% express EGFR 
(Burness et al., 2010).  
 
Breast cancer cell lines provide an ideal model in which to investigate the effects of 
duration of dual EGFR and HER2 inhibition on DNA damage and repair as the pivotal 
studies demonstrating continued HER3 signalling have also been demonstrated in 
these cell lines.  In addition the management of metastatic breast cancer utilises the 
DNA damaging effects of both anthracyclines and IR. 
 
1.12 HYPOTHESIS AND OBJECTIVES 
Hypothesis: Exposure to tyrosine kinase inhibitors for 48 hours fails to inhibit the 
repair of DNA damage by cytotoxic agents,  explaining why schedule is important when 
combining these inhibitors with cytotoxic agents.  
 
Objectives: 
1. Chapter three examines the ability of lapatinib to synergise with cisplatin and 
doxorubicin and the effect of schedule. 
2. Chapter four examines the modulation of induction of DNA strand breaks by 
cisplatin, IR, etoposide and doxorubicin by short and long exposure to gefitinib 
or lapatinib. 
3. Chapter five examine the modulation of topoisomerase IIα by gefitinib. 
4. Chapter six examines the role of HER2 in mediating resistance to cisplatin
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MATERIALS AND METHODS 
MATERIALS 
2.1 CELL LINES AND CULTURE CONDITIONS 
2.1.1 Breast cancer cell lines 
MCF-7 and MDA-MB-468 cells (CRUK London Research Institute, London, UK) were 
grown in Dulbecco’s Modified Eagle Medium (DMEM, Autogen Bioclear, UK), 
supplemented with 10% heat inactivated foetal calf serum (HI FCS) (Autogen Bioclear, 
UK), 2 mM L-glutamine (Autogen Bioclear, UK), 100U/ml penicillin and 100U/ml 
streptomycin (Sigma-Aldrich, UK).  
 
SK-Br-3 cells (CRUK, London Research Institute, London, UK) grown in McCoy’s SA 
Medium Modified (Sigma-Aldrich, UK) supplemented with 10% HI FCS, 2 mM L-
glutamine, 100 U/ml penicillin and 100U/ml streptomycin.  
 
2.1.2 HTETOP Cells 
The HTETOP cell line is a human fibrosarcoma HT1080 cell line in which Topo IIα 
expression can be depleted by the addition of tetracycline, a gift from Dr A Porter 
(Imperial College Faculty of Medicine, UK).  The creation of this cell line has been 
described by Carpenter and Porter (Carpenter and Porter, 2004). Briefly, these cells 
were created by transfecting the HT1080 cell line with a tetracycline transactivator. 
One of the resulting clones (HTET) was then stably transfected with a plasmid 
(pUHC13.3hygTOP) in which Topo IIα cDNA is linked to a tetracycline transactivator-
responsive promoter. Clones which express the pUHC13.3hygTOP-encoded Topo IIα 
transcripts (HTETOPwt) were then identified. The endogenous Topo IIα genes in clone 
HTETOPwt were then disrupted by gene targeting and confirmed using Southern 
analysis used to confirm disruption of both Topo IIα alleles.  
 
Cells were maintained in DMEM, FCS 10%, sodium pyruvate 100 mM (Sigma-Aldrich, 
UK), L-glutamine, 20 ml MEM amino acid solution (Gibco, USA) and G418 200 µg/ml 
(Sigma-Aldrich, UK). 
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2.1.3 MDA-MB-468 HER2 transfected cells 
The MDA-MB-468 cell line was transfected with either full length HER2 or a HER2 from 
which the 13 amino acid NLS sequence (676-KRRQQHIRKYTMRR-689) has been deleted 
(HER2-NLS), both obtained from Prof. Hung (MD Anderson Cancer Center, USA) and 
described previously (Giri et al., 2005). The plasmids contain a green fluorescence and 
kanamycin resistance gene to assist selection after transformation and selective 
pressure was maintained using G418 to created stably transfected cell lines. Three cells 
lines were created named MDA-MB-468-Vector, MDA-MB-468-HER2 (transfected with 
full length HER2) and MDA-MB-468-NLS (transfected with HER2 from which the NLS 
sequence has been deleted). The continued presence of the transfected plasmid was 
checked using fluorescence microscopy to confirm the fluorescence of the green 
fluorescence protein and using Western blotting to confirm the presence of HER2. The 
stably transfected cell lines were grown as documented in section 2.1.1, with the 
addition of G418 1g/ml. 
 
2.1.4 Cell line maintenance 
All cell lines were grown in flasks (BD Falcon, UK), in humidity-saturated (95%) 
incubators (Binder, Germany), at 37oC with 5% CO2. Procedures were carried out in 
Class II biological safety cabinet (ESCO, Singapore) using aseptic techniques. Cells were 
routinely sub-cultured when they reached 80% confluence. Medium was removed and 
2-10ml of trypsin-EDTA (Autogen Bioclear, UK) added, depending on flask size. Trypsin 
was left until cells had detached  (a maximum of five minutes) and media containing HI 
FCS added to stop the action of the trypsin (volume equal to the amount of trypsin 
used). Cells were then pelleted by centrifugation at 1500 rpm, the supernatant 
discarded and the cell pellet resuspended in fresh media before reseeding into culture 
flasks. Cells were passaged to a maximum of 25 times, before being discarded and new 
stocks grown. Mycoplasma testing was undertaken on all cell lines. 
 
2.1.5 Storage and retrieval from liquid nitrogen 
Frozen cell stocks were prepared for long term storage. Cells were grown in 175cm2 
flasks (T175) to 80% confluence, trypsinised and resuspended to a concentration of 
1x106cells/ml in freezing media (FCS containing 10% dimethyl sulfoxide, (DMSO) 
Sigma-Aldrich, UK). The cell suspension was aliquoted in 1 ml cryotubes and frozen at -
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80oC for 24-72 hours, prior to long-term storage in liquid nitrogen. In order to grow 
cells from frozen stocks, the cell suspension was thawed rapidly by holding the 
cryotube in a 37oC water bath until partially defrosted, and then mixed with warm 
media to complete the thawing process. Cells were pelleted and the supernatant 
containing the freezing mix discarded and the cell pellet resuspended in 10 ml of  
media, seeded into a 25cm2 flask (T25), and incubated until they reached 80% 
confluence. Cells were passaged at least twice before being used in experiments. 
 
2.1.6 Cell count 
Cells were counted using a haemocytometer. Following collection as documented 
above, cell pellets were resuspended in media and mixed thoroughly by repeated 
pipetting to produce a single cell suspension. 50 µl of cell suspension was mixed 1:2 
with 50 µl of 0.4% trypan blue stain (Sigma-Aldrich, UK) for one to two minutes to 
identify of dead cells which retain the blue stain due to disruption of the cell 
membrane. 20 μl of the cell/trypan blue suspension was then transferred to a chamber 
of the haemocytometer by papillary action.  The number of cells in four large 1mm2 
corner squares in a single chamber were counted, and then averaged to give the 
number cells per 1 mm2 square. Each 1 mm2 square holds a volume of 0.1 µl therefore 
the total number of cells obtained is multiplied by 1x104 and then by the dilution factor 
giving the number of cells per ml of cell suspension. 
 
2.2 CHEMOTHERAPEUTIC DRUGS AND OTHER REAGENTS 
Clinical grade gefitinib (Iressa/ZD1839 AstraZeneca (Macclesfield, UK)) and lapatinib 
(Tykerb/GW752016, kindly provided by GSK (Stevenage, UK)). Etoposide, doxorubicin, 
paclitaxel, menadione and m-AMSA (Sigma-Aldrich, UK) were diluted in DMSO, except 
for menadione which was diluted in sterile water. Cisplatin (DBL, UK) was also diluted 
in sterile water to a stock concentration 3.3 mM. Stock solutions were either prepared 
in advance or fresh prior to experiments according to stability of each compound.  
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Compounds Structure Dilution solvent 
Stock 
Concentration 
Supplier 
Cisplatin 
 
Sterile water 3.3 mM 
 
DBL, UK 
Etoposide 
 
DMSO 10 mM 
 
Sigma-Aldrich, 
UK 
Doxorubicin 
 
DMSO 1 mM 
 
Sigma-Aldrich, 
UK 
Gefitinib 
 
DMSO 10 mM 
 
Astra Zeneca, 
UK 
Lapatinib 
 
DMSO 10 mM 
 
GSK, UK 
m-AMSA 
(amsacrine) 
 
10mM 10 mM 
 
Sigma-Aldrich, 
UK 
Trastuzumab 
 
 
www.3dchem.com 
Sterile Water 21 mg/ml 
 
 
Roche, UK 
Table 2.1 Drug compounds  
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METHODS 
2.3 SULFORHODAMINE B ASSAY  
Experiments were conducted in 96 well plates, seeded with 2000-4000 cells  per well. 
The number of the cells plated was determined by the rate of proliferation of the 
individual cell lines. Plates were left to adhere overnight, for a minimum time of 18 
hours in a humid box at 37oC in 5% CO2. 
 
2.3.1 Determination of IC50 for single drugs 
Varying concentrations of drug were made up in the appropriate complete media. 
Media from the cells was replaced with 200 L of media containing the appropriate 
drug concentration. Each drug concentration was repeated in triplicate per 
experiment, with a control lane containing only the solvent used to dilute the drug. 
Plates were left to incubate for 96 hours.  
 
2.3.2 Drug combination assays 
To determine synergy a fixed dose of lapatinib was used at a sub-toxic concentration 
(concentration producing 10-20% inhibition of proliferation) and combined with a 
range of concentrations of different chemotherapy agents. For combination assays 
three schedules of drug dosing were used. In the first, both lapatinib and the 
chemotherapy drug were added at the same time and incubated continuously for 96 
hours. In the second, lapatinib was added for 60 minutes, followed by lapatinib plus 
chemotherapy for two hours and in the third, chemotherapy was given first. After the 
two hour incubation, the media was removed and replaced by drug free media (DFM) 
or media containing lapatinib only. Plates were then allowed to incubate for 96 hours 
in a humid box at 37oC in 5% CO2. 
  
After the incubation period, cells were fixed by adding 100 l of cold 10% (w/v) 
trichloroacetic acid (Sigma-Aldrich, UK) to each well and left for 30 minutes at 4oC. The 
acid was removed by flicking the inverted plates, followed by washing four times with 
water. The plates were then air dried overnight. Once the plates were dried, 100 l of 
0.4% (w/v) sulforhodamine B (SRB) (Sigma-Aldrich, UK) in 1% (v/v) acetic acid (Sigma-
Aldrich, UK) was added to each well. Plates were left for 20 minutes at room 
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temperature. The SRB stain was removed as described above and then washed with 
1% acetic acid to remove the remaining unbound SRB stain. Plates were washed a 
minimum of three times or until no further SRB could be removed. Plates were left to 
air dry overnight. 
 
2.3.3 Plate reading 
Before plate reading SRB was resolubilised by adding 100 l of a solution of 10 mM 
trizma base and 1 mM EDTA (Sigma-Aldrich, UK) to each well. Plates were left for 20 
minutes at room temperature and then shaken gently. Mean absorbance of each well 
was read at 540 nm using a Spectrafluor Plus plate reader (Tecan, UK). Percentage 
growth was calculated by averaging the absorbance for the three wells treated with 
the same drug conditions and expressing this as a percentage of the average of the 
control wells. 
 
% proliferation    =  OD treated   x   100  
OD control 
 
Data obtained are expressed as the average of three or more independent 
experiments. The IC50 being the drug concentration required to produce 50% growth 
inhibition, was calculated using the four parameter logistic regression model to curve 
fit. Data are presented on a semi-logarithmic scale of the mean±SD. 
 
2.3.4 Analysis of drug combinations 
2.3.4.1 Median effect analysis 
Median effect analysis was performed using the CalcuSyn Software (Biosoft, USA) as 
described by Chou (Chou, 2006). Combination index values were calculated for a non-
fixed ratio designed combination experiments as described above.  
 
2.3.4.2 Isobologram construction 
The isobologram method was used to assess the effects of the drug combinations. An 
isobologram graphically depicts a line of additivity by connecting two equally effective 
doses of the two drugs being investigated. For this analysis the IC50 of both 
investigational drugs was used. A normalised isobologram was constructed to account 
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for the alteration in ratio of the two drugs (fixed concentration of lapatinib with a 
range of chemotherapy concentration).  A classic isobologram plots the IC50 of the 
individual drugs on the x and y axis which can be used to analyse the effects of two 
drugs combined at fixed ratio (e.g. both drugs at IC20, IC30 etc). A normalised 
isobologram accounts for the fact in these experiments a fixed IC10-20  of lapatinib was 
used in combination with the second drug at IC varying from 0 to 100%.  
 
2.4 WESTERN BLOTTING ANALYSIS 
2.4.1 Drug treatment  
Cells were grown in T25 or T75 flasks seeded at a concentration of 5-15X104 cells and 
left overnight to adhere. For analysis of HER expression as documented in Chapter 
Three, cells were allowed to grow until 80% confluence. For TKI experiments, the 
following day the media was replaced with fresh media +/- TKI, with drug replacement 
every 24 hours if required. In the MDA-MB-468 HER2 transfected cell lines, following 
overnight adherence cisplatin +/- trastuzumab added to the culture media. Following 
one hour incubation with cisplatin, the media was replaced with fresh media +/- 
trastuzumab and cells left to incubate for a further 24 hours at 37oC 5% CO2
.  
 
2.4.2 Total protein extraction 
Media was poured off the cells, followed by washing twice with phosphate buffered 
saline (PBS), pH 7.3 (Sigma-Aldrich UK). 100-300 μL of celLytic (Sigma Aldrich, UK) 
containing phosphatase and protease inhibitor cocktail (Roche, UK) was pipetted over 
the adherent surface of the flask and left for five minutes. Cells scrapers (VWR, UK) 
were used to detach cells from the flask, collected into an collection tube and 
centrifuged for 20 minutes at 4oC 13,000 rpm, to clear insoluble material. The cell 
lysate was removed leaving behind the pellet of insoluble material, and placed in a 
fresh collection tube and stored at -80°C. 
 
2.4.3 Protein quantification and preparation 
Once extracted, proteins were quantified using the RC DC protein assay (Bio-Rad 
Laboratories, USA). 2 µl of each lysate was mixed with 18 µl of distilled water to which 
100 µl of a mixture of reagent A and S (20 µl of reagent S with 1 ml of reagent A) was 
added, followed by 800 µl of reagent B and left to incubated for 15 minutes at room 
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temperature. Absorbance (OD) was measured, against a control containing only 
distilled water at 750 nm on a Philips spectrophotometer (Beam PU8620 Series UV/Vis 
single). The total protein concentration was determined using the formula: 
 
Concentration (µg/µl) = OD*25. 
  
Immunoblotting was performed using 20-50 μg protein, to which a volume of loading 
dye (5X stock -250mM Tris HCl, pH 6.8, 500 mM DTT, 10% SDS, 0.5% bromophenol 
blue, 50% glycerol and distilled water) to make a final concentration of 1X was added. 
Samples were boiled at 100°C for five minutes to denature the proteins, allowed to 
cool, and centrifuged briefly to ensure mixing. 
 
2.4.4 Immunoblotting 
Pre-cast 3-8% or 7% Tris acetate gels (Novex pre-cast gels, Invitrogen, UK), were used 
depending upon the size of proteins being examined. The XCell SureLock™ Mini-Cell 
module (Invitrogen, UK) was used to run the gels, with  tri-acetate SDS running buffer 
(100mM Tris Base, 100mM Tricine, 70mM SDS). Gels were electrophoresed at 150V at 
room temperature until the proteins has been fully separated. Proteins were 
transferred using the XCell II Blot module (Invitrogen, UK). Briefly immobilon P 
membranes (Sigma-Aldrich, UK) were activated by immersion in 100% MeOH for 30 
seconds, followed by washing in distilled water and then transfer buffer (20% (v/v) 
MeOH, 25 mM Tris Base, 200 mM Glycine pH 8.3), for 10 minutes each. The tris-
acetate gels were released from their plastic casing, the top and bottom part of the gel 
cut away and an activated immobilon membrane placed on top of the gel, followed by 
a piece of pre-cut filter paper, a further piece of filter paper was placed on the reverse 
side of the gel. The resulting gel, membrane, filter paper sandwich was rolled with a 
glass pipette to ensure all air bubbles were removed. The gel sandwiched was then 
placed in the blot module on top of two sponges, pre-soaked in transfer buffer, with a 
further two sponges placed on top of the gel. The blot module was placed back into 
Surelock tanks and filled with transfer buffer. The outside section of the tank was filled 
with distilled water and the entire module placed into a 4oC cold cabinet and 
transferred at 38V overnight. Following transfer, membranes were washed for five 
minutes in tris-buffered saline (TBS-20 mM Tris Base, 0.5 M NaCl, pH 7.5 in distilled 
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water). Unbound sites on membranes were  blocked using blocking buffer: 5% Marvel 
milk in Tris-Buffered Saline with 0.1% Tween 20 (TBST Sigma-Aldrich, UK) when 
probing for non-phosphorylated proteins and 5% Bovine Serum Albumin (BSA) (Sigma-
Aldrich, UK) in TBST for phosphorylated proteins. Proteins were incubated using the 
appropriate antibody (Table 2.2), followed by incubation with the appropriate HRP-
conjugated polyclonal secondary antibodies.  
 
Antibodies Dilutions 
Dilution 
buffer 
Supplier 
Anti-EGFR 1/1000 5% BSA Cell Signaling Technology, USA 
Anti-phospho EGFR (PY1148) 1/1000 5% BSA Cell Signaling Technology, USA 
Anti-HER2 1/1000 5% BSA Cell Signaling Technology, USA 
Anti-phosphoHER2 
(PY1221/122) 
1/1000 5% BSA Cell Signaling Technology, USA 
Anti-HER3 1/1000 5% BSA Cell Signaling Technology, USA 
Anti-IRS1 1 µg/ml 5% Milk Milipore, USA 
Anti-phosphoHER3 (PY1289) 1/1000 5% BSA Cell Signaling Technology, USA 
Anti-Topo II 1/1000 5% Milk Gift from Prof Ian Hickson 
Anti-Topo IIβ 1/1000 5% Milk BD Bioscience, USA 
Anti-Akt 1/1000 5% BSA Cell Signaling Technology, USA 
Anti-phospho Akt (S473) 1/1000 5% BSA Cell Signaling Technology, USA 
Anti-MAPK (p42/44) 1/1000 5% BSA Cell Signaling Technology, USA 
Anti-phospho MAPK 1/1000 5% BSA Cell Signaling Technology, USA 
Anti-Mouse (ab6728) 1/2000 5% milk Cell Signaling Technology, USA 
Anti-Rabbit (ab6721) 1/2000 5% milk Cell Signaling Technology, USA 
Anti- a-tubulin (Clone B-5-1-2) 1/4000 5% milk Sigma-Aldrich, UK 
Table 2.2 List of antibodies used in Western Blotting 
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2.4.5 Protein visualisation  
Chemiluminescence detection (ECL system, Amersham Biosciences, UK) was used to 
visualise antibody binding. Blots were dried and incubated one minute with ECL 
reagents before covering them with cling film and exposing them to Kodak X-
OMAT™LS film for various times (two seconds to 10 minutes). Films were processed 
using a film processor (Konica Minolta, UK).  
 
Re-probing of membranes using different antibodies was performed after stripping the 
original bound antibody from the membranes. This was achieved by reactivating dried 
membrane in methanol followed by washing in TBST, and incubation stripping buffer 
(Thermo Scientific, Sweden). Membranes were washed twice 10 minutes in TBST, 
before blocking and re-probing as previously described.  
 
2.4.6 Quantitation  
Quantitation of Western blots was conducted by measurement of pixel density using 
Adobe Photoshop software version 8.0 (Adobe, USA). Values were expressed as a 
fraction of the control value which was assigned the value 1.0. 
 
2.5 SINGLE CELL GEL ELECTROPHORESIS (COMET) ASSAY 
The comet assay was first developed as a method to measure both single strand and 
double strand DNA breaks at a single cell level. However, a modification of this assay 
has been shown to achieve sensitive detection of interstrand crosslinks (Hartley et al., 
1999). 
 
2.5.1 Drug treatment 
Cells were plated at a concentration of 20x104cells per well of a six well plate and left 
overnight to adhere at 37oC in 5% CO2. Media from the cells was removed and 
replaced with 2 ml of media +/- TKI. Cells were treated for the required time, with 
media +/- drug replaced every 24 hours and one hour prior to exposure to the DNA 
damaging agent under investigation. DNA damaging drugs were added to the media 
containing TKI and left in contact with the cells for one to two hours, depending on the 
drug under investigation.  After exposure to DNA damaging agent cells were then 
collected by trypsinisation, pelleted and stored in 1 ml of freezing mixture at –80oC.   
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2.5.2 Study of DNA repair 
Cells were treated as above, but after exposure to the DNA damaging agent the media 
was replaced with fresh media +/- TKI, and cells left to incubate for the required time 
to allow DNA damage to repair. Cells were collected as above.  
 
For IR experiments, cells were trypsinised following incubation with media +/- TKI and 
resuspended at a concentration of 5x104 cells/ml in media +/- TKI. 1 ml of the cell 
suspension was placed into a 1.5 ml collection tube and cells irradiated on wet ice 
using an ionising radiation source (AGO, UK). Following irradiation, cells were placed 
into the incubator and collected at the required time points, as documented above. 
 
2.5.3 Assay methodology 
2.5.3.1 Modified Alkaline Comet assay 
To study DNA damage caused by the crosslinking agent cisplatin, cells were thawed 
and resuspended in ice cold media to a concentration of 2.5x104cells/ml. The cell 
suspension was divided into two aliquots of 2 ml for each time point. One aliquot was 
irradiated (12.5 Gy) on wet ice to deliver a fixed number of random DNA strand breaks, 
immediately before analysis. The Comet assay was run with irradiated and 
unirradiated controls for each time point as per the alkaline Comet assay protocol 
below. 
 
2.5.3.2 Alkaline and neutral Comet assays 
For strand breaking agents (IR, doxorubicin, etoposide and m-AMSA), cells were 
thawed, counted and diluted in ice cold media to a concentration of 2.5x104cells/ml 
and stored on wet ice. Following sample preparation as documented above, 0.5 ml of 
cell suspension was mixed with 1 ml 1% type VII agarose (Sigma-Aldrich, UK). 1 ml of 
this mixture was pipetted onto a glass microscope slide pre-coated with 1% type 1A 
agarose (Sigma-Aldrich, UK), covered with a glass coverslip, and left to set on ice. Once 
set the coverslip was removed and the slides stored in a plastic tray on ice. Two slides 
were prepared for each sample examined.  
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2.5.3.3 Alkaline Comet assay 
Cells were lysed in the dark on ice for one hour in ice cold lysis buffer (100mM 
disodium EDTA, 2.5 M NaCl, 10 mM Tris-HCl pH 10.5) containing 1% Triton X-100 
(Sigma-Aldrich, UK) added fresh. Slides were subsequently washed in ice cold distilled 
water for 15 minutes, four times. Slides were then placed in a electrophoresis tank, 
and  were then incubated in ice cold alkali buffer (50 mM NaOH, 1 mM disodium EDTA, 
pH 12.5), in the dark for 45 minutes, followed by electrophoresis in the same buffer for 
25 minutes at 18 V (0.6V/cm), 250 mA. The slides were removed and placed onto a 
drying tray, rinsed with 1 ml of neutralising buffer (0.5 M Tris-HCl, pH 7.5) and left for 
10 minutes, followed by washing with PBS and left to dry overnight. Slides were then 
re-hydrated for 30 minutes with distilled water and stained with propidium iodide 
(2.5µg/ml) for 20 minutes in the dark, washed in distilled water and left to dry in a 
drying oven and stored in the dark. 
 
2.5.3.4 Neutral Comet assay 
Cells were lysed in the dark on ice, for one hour in ice cold lysis buffer (100mM EDTA, 
2.5 M NaCl, 10 mM Tris-HCl pH 8.0) containing 0.5% Triton X-100 (Sigma-Aldrich, UK), 
1% N-lauroylsarcosine (Sigma-Aldrich, UK), 3% DMSO (Sigma-Aldrich, UK) added fresh 
and pH adjusted to 9.5. Slides were then washed in ice cold distilled water for 10 
minutes twice, followed by 400 µl of proteinase K solution 1m/ml (Roche, UK), 
pipetted onto each slide and incubated for two hours at 37oC. Slides were then washed 
with ice cold electrophoresis buffer (300 mM sodium acetate, 100 mM Tris-HCL, pH 
8.3) containing 1% DMSO added freshly) for 10 minutes, twice. Slides were covered 
with neutral electrophoresis buffer, incubated in the dark on ice for one hour, then 
placed in an electrophoresis tank, covered in two litres of fresh electrophoresis buffer 
and electrophoresed for 60 minutes at 30 V. Following electrophoresis the slides were 
removed and placed onto a drying tray, rinsed with 1 ml of neutralising buffer (0.5 M 
Tris-HCl, pH 7.5) and left for 10 minutes, followed by washing with PBS and left to dry 
overnight. The following day the slides were re-hydrated for 30 minutes with distilled 
water and stained with propidium iodide (2.5µg/ml) for 20 minutes in the dark, 
washed in distilled water and left to dry in a drying oven and stored in the dark. 
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2.5.3.5 Data analysis 
Images were visualised using a NIKON inverted microscope with high-pressure mercury 
light source, 510-560nm excitation filter and 590nm barrier filter at x20 magnification. 
Images were captured using an on-line charge-couple device (CCD) camera and 
analysed using Komet Analysis software (Kinetic Imaging, Liverpool, UK). For each 
duplicate slide 25 individual cells were analysed in the alkaline assay and 50 cells in the 
neutral assay. The Olive tail moment for each cell was calculated using the Komet 
Analysis software as the product of the percentage DNA in the comet tail and the 
distance between the means of the head and tail distributions, based on the definition 
of Olive et al.(Olive, 2002).  
 
For DNA strand breaking agents, the olive tail is representative of the number strand 
breaks. For cross linking agents results were expressed as percentage decrease in tail 
moment compared to untreated controls calculated by the following formula:  
 
 
 
2.6 MEASUREMENT OF γH2AX FOCI AND RAD51 FOCI 
2.6.1 Drug treatment 
SK-Br-3 cells were seeded at a concentration of 4×104 cells per well of a four well LAB-
TEK® II chamber slides™ (Nalge Nunc International, UK) and incubated overnight at 
37°C 5% CO2. The following day the media was removed and replaced with 500 µl of 
media +/- TKI with replacement every 24 hours and one hour prior to exposure to the 
DNA damaging agent under investigation. DNA damaging drugs or controls treated 
with 1 µl of DMSO were added to the media +/- TKI and left in contact with the cells 
for one to two hours, depending on the drug under investigation.  Following drug 
incubation, the media was replaced with fresh media +/- TKI. For cells exposed to IR, 
following incubation with TKI cells were irradiated for the required time whilst on ice 
and then placed back into the incubator for the required duration. Time points were 
1 - 
TMdi - TMcu
TMci - TMcu( )[ ]x 100% decrease in tail moment = 
TMdi = tail moment of drug-treated irradiated sample
TMcu = tail moment of untreated, unirradiated control
TMci = tail moment of untreated, irradiated control
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removed straight after exposure to the DNA damaging agent under investigation and 
at various time points following exposure. Controls of untreated cells and cell treated 
with TKI alone were also investigated at each time point. 
 
2.6.2 Cell fixation  
Following incubation for the required time, the chamber slides were removed from the 
incubator and placed on ice. Cells were then fixed by the addition of 0.5 ml of ice cold 
50% methanol:acetone (v/v) for eight minutes at 4 °C. This solution was then removed 
by aspiration and cells washed with ice cold PBS three times. Permeabilisation was 
then undertaken by the addition of 0.5 ml of permeabilisation solution (0.5% Triton X-
100 (Sigma, UK) in PBS) to each well for five minutes at room temperature. Cells were 
then washed twice and 0.5 ml of blocking buffer added per well (0.1% Triton X-100, 
0.2% skimmed dry milk in PBS) and incubated overnight at 4 °C  in a humidified box. 
 
2.6.3 Staining for γH2AX 
This procedure was conducted by Dr Jenny Wu. Blocked cells were incubated with 200 
µl per well of mouse monoclonal anti-γH2AX (Upstate, Hampshire, UK) diluted to 
1:10,000 in blocking buffer for one hour at room temperature. After washing three 
times with wash buffer (0.1% Triton X-100 in PBS), cells were incubated with Alexa 
Fluor 488 goat anti-mouse secondary antibody (Invitrogen, UK) at a dilution of 1:2000 
in blocking buffer for 1 h at 4 °C in the dark. Cells were washed with PBS and 
counterstained with 0.5 ml per well of propidium iodide (2 μg/ml) for three minutes. 
Stained cells were washed with cold PBS three times. 
 
2.6.4 Staining for RAD51 
This procedure was conducted by Dr Jenny Wu. Blocked cells were incubated with 
200 μL per well rabbit monoclonal anti-RAD51 (Santa Cruz Biotechnology, USA) diluted 
1:50 dilution in blocking buffer for one hour at room temperature. After washing three 
times with wash buffer (0.1% Triton X-100 in PBS), cells were incubated with Alexa 
Fluor 488 goat anti-rabbit secondary antibody (Invitrogen, UK) at a dilution of 1:2000 
in blocking buffer for 1 h at 4 °C in the dark. Cells were washed with PBS, 
counterstained with 0.5 ml per well of propidium iodide (2 μg/ml) for three minutes 
then washed with cold PBS three times. 
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2.6.5 Visualisation of foci 
This procedure was conducted by Dr Jenny Wu. Slides were mounted with Vectashield® 
(Vector Laboratories, Peterborough, UK), a cover slip added (25 × 80 mm, No. 1 
Thickness, VWR International, Leicestershire, UK) and edges sealed with clear nail 
polish. Images were visualised with a Zeiss LSM510 fluorescence microscope (100× oil 
immersion objective), equipped with a cooled CCD camera and two detector channels 
with 488 nm Argon ion and 543 nm HeNe excitation lasers. Foci were counted in 50 
cells per time point and results are expressed as mean number of foci per cell (±mean 
standard error) from three independent experiments.  
 
2.7 CELL CYCLE ANALYSIS 
Effect of drug treatment on cell cycle was studied using fluorescence activated cell 
sorting (FACS). 
 
2.7.1 Drug treatment 
100x104 cells were plated in T25 flasks and incubated at 37oC in 5%CO2 overnight. The 
following day media was replaced with new media or media plus drug, which was 
replaced every 24 hours as required by the experiment.  
 
2.7.2 Cell fixation and staining 
Cells were trypsinised and pelleted as documented previously, the supernatant 
removed and resuspended in PBS and spun at 1500 rpm for five minutes at 4oC. 
Supernatant was discarded and cells fixed with 2.5 ml of cold 70% ethanol overnight at 
–20oC. Samples were kept for up to a week at -20oC before staining. For staining, cells 
were pelleted by centrifugation at 1, 500 rpm or five minutes at 4oC. The supernatant 
was discarded and cells re-suspended in 500l of PI staining solution (50 μg/ml PI, 
0.1mg/ml RNAse A, 0.05% triton X-100 and PBS). Samples were incubated for 40 
minutes at 37OC in the dark. Following incubation, 3 ml of PBS was added and cells 
pelleted again, followed by re-suspension in 500 μl PBS for analysis. 
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2.7.3 Fluorescence activated cell sorting 
Red fluorescence from PI staining was analysed using Becton Dickinson FACscan (UK) 
on the channel FL2. Gates were drawn in order to only observe individual cells and 
eliminate clumped cells. 
 
2.7.4 Data analysis 
Data were analysed using Summit v4.3 software (Dako, USA) in order to quantify the 
number of cells in each phase of the cell cycle.         
  
2.8 ANNEXIN V APOPTOSIS ASSAY  
2.8.1 Drug Treatment 
Cells were plated and treated as described in section 2.5.1, together with an untreated 
control and cells treated with etoposide 150 µM for 24 hours to act as an apoptosis 
control. After exposure to DNA damaging agent for the required time, media was 
replaced with fresh drug free media or media containing TKI and incubated for 24 
hours.   
 
2.8.2 Cell staining 
After incubation, media was removed and cells washed is ice cold PBS and detached 
using cell disassociation fluid (Sigma-Aldrich, UK). Cells were then pelleted by 
centrifugation at 1500 rpm for five minutes at 4oC. Cells were resuspended in 500 µl of 
binding buffer (BioVision, USA) to which 5 µl annexin-V-PE solution (BioVison, USA) and 
1 µl Sytox red dead cell stain was added. Untreated and treated (150 µl etoposide for 
24 hours) controls were unstained or stained with annexin-V-PE and Sytox Red dye 
only. Cells were gently mixed and kept in the dark.  
 
2.8.3 Fluorescence activated cell sorting 
Cells fluorescence was detected using Becton Dickinson FACscan (UK) immediately 
after staining. Control gates were set using an untreated unstained control, an 
apoptosis control stained with annexin-V-PE only or Sytox Red only. 
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2.8.4 Data analysis 
Data were analysed using Summit v4.3 software (Dako, USA) in order to quantify the 
number of cells in each phase of the cell cycle.                
 
2.9 MEASUREMENT OF INTRACELLULAR DOXORUBICIN 
Doxorubicin is naturally fluorescent which can be measured using FACS.  
 
2.9.1 Drug treatment  
Cells were plated at a concentration of 20x104cells per well of a six well plate and left 
overnight to adhere at 37oC in 5% CO2 as described in section 2.5.1. Media was 
removed and replaced with 2 ml of media +/- TKI. Drug was replaced every 24 hours 
for the 48 hours experiments, and one hour before treatment with doxorubicin 5 μM. 
Cells were incubated with doxorubicin for two hours and then collected by 
trypsinisation, pelleted, frozen at –80oC in FCS +10% DMSO. 
 
2.9.2 Fluorescence activated cell sorting 
Prior to analysis cells were defrosted slowly on ice, pelleted and then washed twice in 
PBS, to remove free doxorubicin. Cells were then resuspended in PBS ready for 
analysis. As for the cell cycle analysis, cells were analysed with the FL2 channel, with 
boundaries identified using untreated control cells. 
 
2.9.3 Data Analysis 
Data were analysed using Summit v4.3 software (Dako, USA) to assess the frequency of 
events detected at each channel. Data were expressed as the mean fluorescence 
intensity (MFI) for each TKI treatment and controlled by subtracting the MFI for 
doxorubicin untreated, TKI treated samples. 
 
2.10 TOPOISOMERASE II ACTIVITY ASSAY  
Topo II activity was assayed using the Topo II assay kit from Topogen (Florida, USA). 
This assay examines the ability of extracted Topo II to decatenate, exogenous 
catenated DNA. 
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2.10.1 Drug treatment 
Cells were grown in T75 flasks seeded at a concentration of 25X104 cells and left 
overnight to adhere. The following day the media was replaced with fresh media +/- 
TKI, with drug replacement at 23 hours and 47 hours for cells exposed to TKI for 48 
hours. Following incubation, flasks were removed from the incubator and placed on 
ice. 
 
2.10.2 Nuclear extraction 
All the steps of this procedure were carried out on ice as Topo II is inactivated readily 
in vitro and easily proteolysed. Cells were gently scraped in media and pelleted in a 
pre-chilled 15 ml falcon tube, at 800 g for three minutes at 4oC. The supernatant was 
discarded and cells were resuspended in 4 ml of ice cold TEMP buffer (10mM Tris-HCl, 
pH 7.5, 1mM EDTA, 4mM MgCl2, 0.5mM PMSF) by pipetting. Cells were centrifuged as 
before and resuspended in 3 ml of TEMP. Samples were incubated on ice for 10 
minutes and dounced in tight fitting homogeniser with eight strokes. Nuclei were 
pelleted at 1500 g for 10 minutes at 4oC and subsequently resuspended in 1 ml of ice 
cold TEMP buffer. Suspensions were transferred in a collection tube and centrifuge at 
4,000 rpm for two minutes at 4oC. The supernatant was completely removed and 
pellets were resuspended in a small volume (no more than four pellet volumes) of TEP 
buffer (same as TEMP but lacking MgCl2). An equal volume of 1 M NaCl was added and 
solutions were vortexed for five seconds and incubated on ice for 45 minutes. Finally, 
suspensions were centrifuge at 15,000 g for 15 minutes at 4oC. The supernatant 
contains both topoisomerase I and II protein but the kit used is specific of Topo II 
activity. 
 
2.10.3 Assessment of decatenation activity 
1 µl of each sample was mixed with 10 times complete assay buffer (Topogen, Florida, 
USA), 2 µl of kinetoplast DNA (kDNA) and distilled water to 20 µl. Solutions were 
incubated for 45 minutes at 37oC. Since the extract contains high salt (0.5 M) care was 
taken not to poison the reaction with excessive amounts of the extract (different 
volumes of extract were used to define the least toxic volume giving the best results). 
Reactions were stopped by adding 4 µl of loading dye (5% sarkosyl, 0.125% 
bromophenol blue and 25% glycerol) and loaded, along with decatenated kDNA 
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control and linearised kDNA control, onto a 1% agarose ethidium bromide gel (using 
1xTAE – 2.5mM EDTA, 40mM Tris Base and 0.1% acetic acid). The gel was 
electrophoresed at 100V and photographed using a dual intensity ultraviolet 
transilluminator coupled with camera (UVP, UK). 
 
2.10.4 Quantitation 
Quantitation of Topo II activity was conducted by measurement of pixel density of the 
resulting DNA bands using Adobe Photoshop software version 8.0 (Adobe, USA). 
Values were expressed as a fraction of the control value which was assigned the value 
1.0. 
 
2.11 SMALL INTERFERING RNA (siRNA) TRANSFECTION 
SiRNA against HER2 was used to knockout the expression of HER2 in the MDA-MB-468-
HER2 cell line. SiRNA against four target sequences of HER2 (siGenome smart pool, 
Thermo Scientific, USA) and scrabbled siRNA pool 2 (siGenome smart pool 2, Thermo 
Scientific, USA) were used, as per the manufactures’ protocol. SiRNA  was resuspended 
in 50 µl of RNAase free water (Sigma-Aldrich, UK), the solution mixed by pipetting and 
then placed on an orbital shaker for 30 minutes at room temperature. The RNA 
concentration was quantified using UV spectrophotometry at 260 nm (NanoDrop, 
Thermoscientific, USA). This stock solution was separated into aliquots at stored at -
80oC. An initial experiment was undertaken to determine which transfection agent and 
concentration to use. This experiment ascertained that 2 µl DharmaFect 1 transfection 
agent (Thermoscientific, USA) yield significant knockdown of HER2 with acceptable 
levels of cell death. 
 
2.11.1 Preparation of siRNA 
20x104 cells were plated per well of a six well plate and left to adhere overnight. From 
the stock RNA solution a solution of RNA with a concentration of 2 µM was made in 
1xsiRNA buffer (Thermoscientific, USA). A solution of 1 ml siRNA was mixed with 1 ml 
of serum free media and a separated solution of 20 µl DharmaFect transfection agent 
1 plus 1.980 ml serum free media and incubated for five minutes at room temperature. 
The two solutions were then mixed by pipetting and incubated at room temperature 
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for 20 minutes. The siRNA solution was then made up to a total of 20 ml by the 
addition of 16 ml of DMEM, containing 10% HI FCS and 1% L-glutamine without 
antibiotics. In total two RNA solutions were prepared, one with siRNA against HER2 
and the second containing a control scrambled siRNA. 
 
2.11.2 Transfection with siRNA 
Cells were washed in sterile PBS at 37OC to remove any trace of HI FCS. 2 ml of media 
containing siRNA was then added to each well and cell incubated for 24 hours at 37oC 
in 5% CO2. Following incubation for 24 hours, the media was replaced with fresh media 
and cells left for a further 24 hours. At this point cells were either collected to assess 
HER2 protein expression by Western blotting as described in section 2.4 or treated 
with cisplatin 100 µM for one hour and collected for analysis using the alkaline Comet 
assay as described in section 2.5. 
 
2.12 CHROMATIN IMMUNOPRECIPITATION  
These experiments were undertaken in the MDA-MB-468 cell line transfected with 
HER2, using a vector transfected cell line as a control. Approximately 1X108 cells were 
grown in multiple T150 flasks and cells processed when they reached 80% confluence. 
This procedure was conducted by Dr Pawan Dhami. 
 
2.12.1 DNA-protein crosslinking 
On the day of immunoprecipitation, the media was removed and replaced with 50 ml 
of serum free media. DNA-protein and protein-protein interactions are cross-linked by 
adding formaldehyde (37%, BDH AnalaR); 1355 μL formaldehyde is added drop-wise to 
a final concentration of 1% to fix transcription factors. The flask was then placed on a 
flat shaker at room temperature, with constant but gentle stirring for 15 minutes. 
3.425 ml of ice-cold 2 M glycine was added to make a final concentration of 0.125 M 
with constant but gentle stirring for five minutes at room temperature to stop the 
cross-linking reaction. Cells were scraped and transferred to 50 ml centrifuge tubes 
and kept on ice whenever possible. The cells were pelleted by centrifuging at 259 g for 
six to eight minutes at 4°C, washed with 1.5 ml of ice-cold PBS and pelleted at 720 g at 
4°C for five minutes and the supernatant removed.  
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2.12.2 Cell lysis  
Cells were lysed by adding 1.5 x pellet volumes of ice-cold cell lysis buffer (CLB-10 mM 
Tris-HCl pH 8.0, 10 mM NaCl, 0.2% Igepal, 10 mM Sodium butyrate, 50 µg/ml PMSF, 1 
µg/ml leupeptin). The cell pellets were gently resuspended and incubated on ice for 10 
minutes. The nuclei were then recovered by centrifuging the samples at 1125 g for five 
minutes at 4°C. The supernatant removed and the nuclei lysed by resuspending the 
pellet in 1.2 ml of nuclei lysis buffer (NLB-50 mM Tris-HCl pH 8.1, 10 mM EDTA, 1% 
SDS, 10 mM Sodium butyrate, 50 μg/ml PMSF, 1 μg/ml leupeptin) and incubated on ice 
for 10 minutes. 
 
2.12.3 Sonication 
720 μL of IP dilution buffer (IPDB-20 mM Tris-HCl pH 8.1, 150 mM NaCl, 2 mM EDTA, 
1% Triton X-100, 0.01% SDS, 10 mM Sodium butyrate, 50 μg/ml PMSF, 1 μg/ml 
leupeptin) was added and the samples were transferred to 5 ml glass tubes. The 
chromatin was sonicated to reduce the DNA length to an average size of 600 bp using 
the Sanyo/MES Soniprep sonicator.  
 
The samples were allowed to cool on ice for one minute between each pulse (5 µl of 
the sheared chromatin was run on an agarose gel to check sonication). The sonicated 
chromatin was transferred to 2 ml microfuge tubes and spun down at 18000 g for 10 
minutes at 4oC . 
 
2.12.4 Immunoprecipitation 
The supernatant was transferred to a 15 ml falcon tube and 4.1 ml of IP dilution buffer 
added. Chromatin was precleared by adding 100 μL of normal rabbit IgG (Upstate 
Biotechnology). Samples were incubated for one hour at 4°C on a rotating wheel. 200 
μL of homogeneous protein G-agarose suspension (Roche, UK) was added to the 
precleared chromatin and the samples were incubated for three to five hours at 4°C on 
a rotating wheel. The samples were then centrifuged at 1620 g for two minutes at 4°C 
to pellet the protein G-agarose beads and the supernatant was used to set up various 
immunoprecipitation conditions in 2 ml microfuge tubes. An aliquot of 270 μL of 
chromatin was stored at -20°C to be used as input sample for array hybridisations and 
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real-time PCR. An NLB:IPDB buffer at the ratio of 1:4 was prepared to set-up IP 
conditions as follows: 
 
 No chromatin – 1350 μL NLB:IPDB buffer 
 No antibody – 675 μL chromatin + 675 μL NLB:IPDB buffer 
 Normal Rabbit IgG – 675 μL chromatin + 675 μL NLB:IPDB buffer + 10 μL 
rabbit IgG (Upstate Biotechnology) 
 Test IP conditions – 675 μL chromatin + 675 μL NLB:IPDB buffer + 5-20 
μg* of test antibody 
 
The samples were incubated at 4°C overnight on a rotating wheel. The next day the 
samples were centrifuged at 18000 g for five minutes at 4ºC and the lysate/antibody 
samples were transferred to fresh 2 ml microfuge tubes. 100 μL of homogeneous 
protein G-agarose suspension was added to each sample and the samples were 
incubated at 4°C for at least three hours on a rotating wheel. The samples were then 
centrifuged at 6800 g for 30 seconds at 4°C to pellet the protein G-agarose beads. The 
supernatant was removed and the protein G-agarose beads were carefully washed. For 
each wash, the wash buffer was added, the samples were vortexed briefly, were 
centrifuged at 6800 g for two minutes at 4°C and left to stand on ice for one minute 
before removing the supernatant. The washes were carried out in the following 
sequence: 
 
a) The beads were washed twice with 750 μL of cold IP wash buffer 1. The beads 
were transferred to a 1.5 ml microfuge tube after the first wash.  
b) The beads were washed once with 750 μL of cold IP wash buffer 2. 
c) The beads were washed twice with 750 μL of cold TE pH 8.0. 
 
2.12.5 Elution 
DNA-protein-antibody complexes were eluted from the protein G-agarose beads by 
adding 225 μL of IP elution buffer (100 mM NaHCO3, 1% SDS). The bead pellets were 
resuspended in IP elution buffer, briefly vortexed then centrifuged at 6800 g for two 
minutes at room temperature. The supernatant was collected in fresh 1.5 ml 
microfuge tubes. The bead pellets in the original tubes were resuspended in 225 μL of 
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IPEB again, briefly vortexed and centrifuged at 6800 g for two minutes. Both the 
elutions were combined in the same tube. 
 
2.12.6 Reversal of cross-links 
The reversal of cross-links step was carried out on the Input sample which was stored 
at -20°C previously. 0.1 μL of RNase A (10 mg/ml, 50, 000 units, ICN Biochemicals) and 
16.2 μL of 5 M NaCl (to the final concentration of 0.3 M) was added to the Input DNA 
sample. Similarly, 0.2 μL of RNase A (10 mg/ml, 50, 000 units) and 27 μL of 5M NaCl (to 
a final concentration of 0.3 M) was added to each of the IP test samples. All the 
samples including the input DNA sample were incubated at 65ºC for six hours to 
reverse the cross-links.  9 μL of proteinase K (10 mg/ml, 20 U/mg, GibcoBRL) was 
added to each sample and incubated at 45ºC overnight. 
 
2.12.7 Extraction of DNA 
2 μL of yeast tRNA (5 mg/ml, Invitrogen) was added to each sample just before adding 
250 μL of phenol (Sigma) and 250 μL of chloroform. The samples were vortexed and 
centrifuged at 18000 g for five minutes at room temperature. The aqueous layer (top 
layer) was collected in fresh 1.5 ml microfuge tubes and 500 μL of chloroform was 
added to each sample. The samples were vortexed and centrifuged at 18000 g for five 
minutes at room temperature. The aqueous layer was transferred to a fresh 2.0 ml 
microfuge tubes 5 μg of glycogen (5 mg/ml, Roche), 1 μL of yeast tRNA (5 mg/ml, 
Invitrogen) and 50 μL of 3 M NaAc (pH 5.2) was added to each sample and mixed well. 
The DNA was precipitated with 1375 μL of 100% ethanol and incubating at –70oC for 
30 minutes (or -20°C overnight). The samples were centrifuged at 20800 g for 20 
minutes at 4ºC. The DNA pellets were washed with 500 μL of ice-cold 70% ethanol and 
air-dried for 10-15 minutes. The DNA pellets of the IP samples were resuspended in 50 
μL of sterile filtered HPLC water and 100 μL for the Input DNA samples. 5 μL of each 
sample was run on a 1% agarose 1XTBE gel and visualised with ethidium bromide to 
check DNA size. Samples were stored at –20°C. 
 
2.12.8 Sample labelling and hybridisation to bacterial artificial chromosomes 
The ChIP DNA samples were labelled with Cy3 and genomic DNA with Cy5. Initially 
bacterial artificial chromosome (BAC) arrays were used to confirm the binding of ErbB2 
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to DNA clones. Each array contains 32,436 BAC clones, with an average size of 170 kbp, 
with 892 clones not mapping to genomic DNA. The labelled DNA was transferred to the 
MAUI Hyb (Biomicrosystems, USA) together with the BAC array and left to hybridise 
overnight. 
 
2.12.9 Quantitation 
ProScanArray express (Perkin Elmer, UK) was used to quantitate the fluorescence of 
each array spot. Mean signal intensity ratios (spot intensity minus background 
intensity) were calculated and data sets normalised to intensities achieved from the 
control rabbit IgG. The MDA-MB-468-Vector data set was set as the baseline level of 1 
and the mean ration and SD for the MDA-MB-468-HER data set calculated. The 
significance threshold was set at three standard deviations above the mean 
background level. 
 
2.13 GENE EXPRESSION ARRAYS AND REAL TIME PCR 
2.13.1 Cell treatment 
MDA-MB-468-Vector, MDA-MB-468-HER2 and MDA-MB-468-NLS cells were grown in 
T75 flasks plated at a concentration of 15x104 cells. Two DNA expression arrays were 
conducted, the first in cells treated with cisplatin under the same conditions as used to 
established differences in the ability to repair cisplatin-induced interstrand crosslinks 
as described (Boone et al., 2009). The second in untreated cells allowed to proliferate 
until they reached 80% confluence prior to RNA extraction. 
 
2.13.1.1 Drug treatment 
Cells were plated at a concentration of 25x104 cells in T75 flasks and left to adhere 
overnight. The following day the media was removed and replaced with fresh media 
+/- cisplatin 50 µM for one hour. Following incubation the media was replaced with 
fresh DFM and incubated at 37oC 5% CO2 for 24 hours. At this point cells were 
processed to extract RNA. 
 
2.13.2 RNA extraction and quantification 
Following incubation for the required time, cells were collected by trypsinisation, 
pelleted and washed is ice cold PBS and re-pelleted as described in section 2.1.4. The 
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RNeasy minikit (Qiagen, UK) was used to extract RNA using the method as described by 
the manufacturer. Briefly 600 μL of buffer RLT containing -mercaptoethanol was used 
to resuspend the cell pellet. The cells were then homogenised using a manual 
homogeniser and 600μl of 70% ethanol added to the homogenised cells. The solution 
was transferred to a RNeasy mini-column and filtered by centrifugation for 15 seconds 
at 13,000 rpm, with the filtrate discarded. 700 μL of RWI buffer was then added to the 
column which was centrifuged at 15 seconds at 13,000 rpm and the filtrate discarded. 
The columns were washed twice with 500 μL of buffer RPE. To extract the RNA, 40 μl 
of RNase-free water was added onto the membrane of the column and RNA eluted by 
centrifugation for one minute at 13,000 rpm. The RNA was quantified by measuring 
the absorbance at 260nm (NanoDrop, Thermoscientific, USA). 
 
2.13.3 Gene expression arrays 
This process was conducted by the scientific support service at UCL Cancer Institute 
(London, UK) using the Affymetrix GeneChip Human Exon 1.0 ST arrays. Each gene is 
represented by around 40 probes, with each exon covered by approximately four 
probes, with a total of 5.5 million probes on each array (Affymetrix, 2005).  Full details 
of this process can be found at 
https://www.affymetrix.com/support/downloads/manuals/expression_s2_manual.pdf 
 
Following assessment of the RNA for both quality and quantity the RNA was processed 
as follows: 
 
2.13.3.1 Total RNA labeling protocol 
Poly-A control stock, 2 µl was diluted with 38 µl poly-A control buffer. 2 µl of this 
solution was then added to 98 µl of poly-A control buffer to make a 1:50 dilution. This 
step was repeated to make a 2nd 1:50 dilution. 2 µl of this solution was then mixed 
with 1 µg of RNA   
 
This step utilises the GeneChip WT cDNA synthesis kit (Affymetrix). A working solution 
of 500 ng/µl of T7-(N)6 Primer was made by dilution in RNase-free water. This was kept 
on ice and 2 µl mixed with the 2 µl of the diluted RNA, together with 16 µl of RNase-
free water, controls were also made 100 ng RNA, 2 µl of the T7-(N)6
 primer solution 
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and 5 µl of RNase-free water.  This sample was incubated at 70°C for five minutes, then 
cooled at 4°C for a further two2 minutes, then spun and kept on ice. 
 
2.13.3.2 First cycle, first strand synthesis 
5 µl of  first-cycle, first strand master mix (2 µl of 5x1st Strand buffer, 1 µl 0.1M DTT, 0.5 
µl dNTP mix, 10 mM, 0.5 µl RNase inhibitor, 1 µl SuperScript II) was mixed with RNA 
T7-(N)6 Primer mix. This was spun and incubated at 25
oC for 10 minutes, then 42oC for 
60 minutes, then 70oC for 10 minutes. The sample was then cooled for at least two 
minutes. 10 µl of the first cycle second strand master mix (4.8 µl RNase-free water, 4 µl 
17.5 mM MgCl2
 0.4 µl dNTP mix 10 mM, 0.6 µl DNA Polymerase I and 0.2 µl RNase H) 
was then added and incubated in a thermal cycler at 16oC for 120 minutes then 75oC 
for 10 minutes. The sample was then cooled for two minutes at 4oC. 
 
The sample was then mixed with 30 µl of the IVT master mix (5 µl 10xIVT master mix, 
20 µl NTP mix, 5 µl enzyme mix) and the reaction incubated for 16 hours at 37oC. 
 
50 µl RNase-free water was added to the IVT reaction to make a final volume 100 µl 
and vortexed. Then 350 µl IVT cRNA binding buffer was added, vortexed again and 250 
µl ethanol added and mixed with by pipetting. This mix was applied to the cRNA 
cleanup column placed in a collection tube and centrifuged for 15 seconds at ≥ 8000g. 
The column membrane was washed with 500 µl IVT cRNA wash buffer, then spun for 
15 seconds at ≥ 8000g. The column was transferred to a new collection tube, 500 µl 
80% (v/v) ethanol was then added and spun for 15 seconds at ≥ 8000g. The cap of the 
column was then opened and the column spun at maximum speed for five minutes. 
The column was then transferred to a new collection tube, 15 µl of RNase-free water 
was applied to the spin column membrane and centrifuged for one minute at 
maximum speed to elute cRNA. This step was repeated with using the  elute, which 
was incubated for five minutes at room temperature and then centrifuges for one 
minute at maximum speed. The concentration and quality of cRNA was evaluated 
using a using  NanoDrop (Thermoscientific, UK). 
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2.13.3.3 Second cycle, first strand synthesis, cleanup and quantification of cRNA 
The cRNA was then mixed with 8 µl of random primer solution (1.5 µl random primers 
3µg/µl and RNase-free water). The mixture was incubated for five minutes at 70oC 
followed by five minutes at 25oC and the sample cooled at 4oC for two minutes. This 
was them mixed with the second cycle, first strand mastermix (4 µl of 5x1st Strand 
buffer, 2 µl 0.1M DTT, 1.25 µl dNTP+dUTP mix 10 mM, 4.75 µl SuperScript II) and 
incubated at 25oC for 10 minutes, then 42oC for 60 minutes, then 70oC for 10 minutes. 
The sample was then cooled sample cooled at 4oC for two minutes. 
 
1 µl of RNase H was then added to the sample and incubated at 37oC for 45 minutes, 
then 95oC for  five minutes, then 4oC for two minutes. Cleanup and RNA quality 
analysis was then undertaken as outline above. 
 
2.13.3.4 Fragmentation of cRNA 
5.5 µg of cRNA was mixed with up to 31.2 µl of RNase-free water and was added to 16 
µl fragmentation buffer (10 µl RNase-free water, 10x cDNA fragmentation buffer, 1 µl 
UDG, 1 µl APE1 10,000 U/µl). This was incubated at 37°C for 60 minutes, 93oC for two 
minutes then 4oC for two minutes.  The fragmentation product was then run on a 2% 
agarose gel at 120V for 30 minutes for confirmation of fragmentation. 
 
2.13.3.5 Hybridisation 
A hybridization mix was prepared from 60 µl fragmented cRNA, 3.7 µl 3 nM control 
oligonucleotide B2, 11 µl 20x eukaryotic hybridisation controls, 110 µl 2x hybridisation 
buffer, 15.4 µl DMSO and nuclease free water to a total volume of 220 µl.  This was 
then heated to 99°C for five minutes, then cooled to 45oC for five minutes and 
centrifuged for one minute as maximum speed. The Exon ST array was allowed to 
equilibrate to room temperature. 200 µl of the hybridization mix was then injected 
into the array, the array places in a hybridization oven at 45oC at 60 rpm and incubated 
for 17 hours. 
 
2.13.3.6 Washing and Staining 
SAPE stain solution was made by mixing 600 µl 2x stain buffer, 48 µl 50mg/ml BSA, 12 
µl 1mg/ml SAPE and 540 µl ddH2O making a final volume of 1200 µl. Antibody solution 
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was made by mixing 300 µl 2x stain buffer, 24 µl 50mg/ml BSA, 6 µl 10mg/ml Goat IgG 
stock (Sigma-Aldrich), 3.6 µl 0.5mg/ml biotinylated antibody and 266.4 µl distilled 
water.  The arrays are washed and stained using the automated Affymetrix wash 
station using the protocol EukGE_w52v5.450. 
 
2.13.3.7 Scanning  
This was performed using the Agilent SureScan (Agilent, USA).  Partek Genomic suite 
(Partek, USA) was used to obtain DAT image files which were then converted to CEL 
files containing information about the expression levels of the individual probes. 
 
2.13.4 Gene expression analysis 
Data were analysed using by the Bioinformatics department at the UCL Cancer 
Institute. Initial analysis examined whether the arrays had been successful by 
performing boxplot and principle component analysis. Cluster dendrograms were 
produced to demonstrate hierarchical clustering between the samples analysed. 
Differences in gene expression were identified by using analysis of variance (ANOVA) 
and gene list created based upon a false discovery rate of 0.05. For the second 
microarray investigation performed on proliferating cells, around a 1000 genes were 
differentially expressed between the cell lines. These genes were explored for those 
involved in DNA repair (see appendix one). 
 
2.13.5 Gene Ontology Analysis 
Functional pathway analysis was performed using Partek software, to identify 
potential pathway differences between the MDA-MB-468-Vector and MDA-MB-468-
HER2 cell lines. Pathways involved in DNA repair, cell proliferation and transcription 
and translation were investigated. 
 
2.13.6 Real time PCR 
This work was undertaken by Mr John Bingham. Briefly cDNA was synthesised from the 
RNA using the RNA samples from the MDA-MB-468-Vector, MDA-MB-468-HER2 and 
MDA-MB-468-NLS cell lines used to perform gene expression arrays. This was 
performed using a high capacity cDNA reverse transcription kit (Applied Biosystems, 
UK). Pre-designed FAM™-labelled primers for FANCC and IRS1 were used (TaqMan 
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Gene Expression, Applied Biosystems, UK). Briefly, 1 µl of TaqMan gene expression 
solution was mixed with 5 µl cDNA and 10 µl 2x TaqMan gene expression mastermix 
(Applied Biosystems, UK). 20 µl of the mixture was transferred to a single well of a 48 
well plate. Control samples were also prepared without primers and β-actin (TaqMan 
Gene Expression, Applied Biosystems, UK). The plate was covered, centrifuged and 
loaded into the 7500 real time PCR system for amplification (Applied Biosystems, UK). 
Amplification is measured by increasing intensity of the reporter FAM™ dye. Data were 
analysed using SDS v1.3.1 (Applied Biosystems, UK). 
 
2.14 STATISTICAL ANALYSIS 
Observations are presented as mean±SEM, unless stated otherwise. Comparison of 
means was performed using a one way ANOVA, followed by post analysis Tukey’s test, 
or a two way ANOVA followed by post hoc analysis Bonferroni test. All statistical 
analysis was performed using GraphPad Prism Software (USA). 
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Investigation into the effects of lapatinib in combination 
with chemotherapy on cell proliferation 
3.1 INTRODUCTION 
The dual EGFR and HER2 TKI lapatinib, inhibits cell proliferation in cancer cell lines with 
sensitivity correlating with the expression of HER2 (Konecny et al., 2006; Zhang et al., 
2008). In combination with cytotoxic drugs, lapatinib produces synergistic effects in 
breast, endometrial, gastric, pancreatic and ovarian cancer cell lines (Kim et al., 2008b; 
Komoto et al., 2009b; LaBonte et al., 2009; McHugh et al., 2007). This has translated 
into the clinical setting in combinations of lapatinib with capecitabine (Geyer et al., 
2006) or paclitaxel (Di Leo et al., 2008b) in patients with metastatic breast cancer. The 
precise mechanisms through which lapatinib produces synergy are still under 
investigation but include the inhibition of the PI3K/AKT and Ras-Raf-MAPK pathways 
promoting cell cycle arrest, growth inhibition and apoptosis (Konecny et al., 2006; 
Wainberg et al., 2010). Lapatinib also inhibits the nuclear translocation of EGFR and 
HER2, down regulating the transcription of thymidylate synthase, a target of 
capecitabine (Kim et al., 2009).  
 
3.1.1 Combining tyrosine kinase inhibitors and DNA damaging agents 
As discussed in Chapter One, section 1.8 the inhibition of HER signalling can increase 
sensitivity to cytotoxic agents through a number of mechanisms, including the 
inhibition of DNA repair. This suggests that the combination of agents which induce 
DNA strand breaks with HER inhibitors, should produce additional cell death over 
either agent alone. In the clinical setting, the addition of gefitinib or erlotinib to 
standard platinum based chemotherapy has been investigated in three separate trials 
in patients with NSCLC as discussed in section 1.9.3. Together these trials recruited 
nearly 4000 patients and failed to demonstrate any benefit from the addition of 
gefitinib or erlotinib over standard doublet chemotherapy alone (Gatzemeier et al., 
2007; Giaccone et al., 2004; Herbst et al., 2004; Herbst et al., 2005). Whilst there are a 
number of potential reasons for this, in vitro data suggests that the scheduling of 
gefitinib may be important. This has been demonstrated in colorectal and oesophageal 
cancer cell lines where the addition of gefitinib after exposure to chemotherapy drugs 
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produces at least additive effects and can produce synergy, an observation not seen in 
cells pre-treated with gefitinib prior to chemotherapy exposure (Chun et al., 2006; 
Morelli et al., 2005; Xu et al., 2003).   
 
3.1.2 Combining lapatinib with DNA damaging chemotherapy 
Unlike gefitinib, lapatinib has successfully translated into the clinical setting in 
combination with capecitabine or paclitaxel. In order to investigate if lapatinib might 
act by modulating the cellular response to DNA damaging agents, the inhibition of cell 
proliferation by doxorubicin or cisplatin in combination with lapatinib was investigated 
using the SRB assay in three breast cancer cell lines. 
 
Doxorubicin is used in the systemic management of breast cancer in the neo-adjuvant, 
adjuvant and metastatic settings. It induces cell death through the formation of oxygen 
free radicals, intercalating with DNA and RNA and poisoning Topo II resulting in the 
production of DNA DSBs (Takimoto and Calvo, 2008).  Cisplatin induces DNA damage 
through the formation of intra and interstrand crosslinks, which can result in the 
formation of DSBs as discussed in section 1.6.1. Cisplatin is not routinely used in the 
management of breast cancer but there is evidence that it may be useful in patients 
with ‘triple negative breast cancer’ (Silver et al., 2010). These tumours do not express 
ER, PR and are not HER2 gene amplified, hence their identification as ‘triple negative’; 
around 60% express EGFR (Nielsen et al., 2004). Therefore in this group, combinations 
of EGFR inhibitors and cisplatin may be beneficial. 
 
3.2 AIMS 
This chapter describes experiments to investigate the interaction between lapatinib 
and either cisplatin or doxorubicin with the following aims: 
 
1. Does lapatinib interact with the inhibition of cell proliferation by cisplatin or 
doxorubicin? 
2. What is the character of the interaction between lapatinib with either cisplatin 
or doxorubicin? 
3. Is the interaction between lapatinib and cisplatin or doxorubicin schedule 
dependent? 
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3.3 HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR EXPRESSION  
To investigate the effect of lapatinib in combination with DNA damaging agents three 
breast cancer cell lines, MCF-7, MDA-MB- 468 and SK-Br-3 were used. These cell lines 
were chosen as they express different levels of HER proteins. The characteristics of 
these cell lines as documented in the literature are outlined in Table 3.1; none carry 
mutations in the BRCA genes (Kenny et al., 2007; Lacroix and Leclercq, 2004). 
 
 MCF-7* MDA-MB-468 SK-Br-3 
Source Invasive ductal 
carcinoma from a pleural 
effusion 
Adenocarcinoma 
from a pleural 
effusion 
Invasive ductal 
carcinoma from a 
pleural effusion 
EGFR Low High Low 
HER2 Low/deleted Low/deleted High 
ER Expressed Negative Negative 
PR Expressed Negative Negative 
PTEN Expressed Negative Expressed 
Other 
gene 
mutations 
CDKN2A, PIK3CA p53, MADH4 and  
RB1 
Not reported 
Table 3.1 Characteristics of the MCF-7, MDA-MB-468 and SK-Br-3 cell lines  
Data taken from review by Lacroix and Leclercq, 2004 and Kenny et al., 2007.  
CDKN2A-cyclin kinase dependent inhibitor 2A, PIK3CA- phosphoinositide-3-kinase, catalytic 
alpha polypeptide, RB1- retinoblastoma protein. *The reported characteristics of the MCF-7 
cell line have been reported to vary 
EGFR, HER2, HER3 and HER4 expression were assessed by Western blotting (Figure 3.1) 
in the three cell lines. 
o The SK-Br-3 cell line expresses high levels of HER2, in addition to EGFR, HER3 
and HER4.  
o The MDA-MB-468 cell line expresses high levels of EGFR, with no HER2 
detected and low levels of HER3 and HER4.  
o The MCF-7 cell line expresses high levels of HER4 and low levels of HER3. EGFR 
and HER2 expression are not detected in normal proliferating cells by Western 
blotting (Figure 3.1).  
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Figure 3.1 HER expression in the MCF-7, MDA-MB-468 and SK-Br-3 cells lines 
Expression of the EGFR, HER2, HER3, HER4 and AKT were assessed in three breast cancer cell 
lines by Western blotting. Proliferating cells were lysed and immunoblotted with antibodies as 
indicated.  αtubulin used as loading control.  
 
3.4 DETERMINATION OF IC50 VALUES FOR LAPATINIB, CISPLATIN AND 
DOXORUBICIN 
The SRB assay was used to assess the effects of lapatinib in combination with either 
cisplatin or doxorubicin on cell proliferation. The SRB assay was first described in 1989 
and provides a reproducible and sensitive high throughput technique for assessing cell 
proliferation (Vichai and Kirtikara, 2006). The results of this assay correlate with the 
tetrazolium dye3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay, which assesses cytotoxicity (Vichai and Kirtikara, 2006).  
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For the investigations described below, cells were plated in 96 well plates at a 
concentration of 2000-4000 cells per well. This allowed approximately five cell 
doubling times in 96 hours without saturation of the assay. Drug treatment was added 
to each well as required, with three wells per drug concentration. 
 
3.4.1 Inhibition of cell proliferation by lapatinib 
Lapatinib inhibits cell proliferation in all three cell lines with differing sensitivities 
(Figure 3.2). The MCF-7 line is the least sensitive (IC50 5.42 μM ((95% CI 4.89-6.00 µM) 
and Sk-Br-3 the most (IC50 0.1 μM (95% CI 0.079-0.13 µM). 
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Figure 3.2 Effect of lapatinib on cell proliferation  
(A) The SRB assay was used to assess inhibition of proliferation by lapatinib in SK-Br-3(●), MCF-
7(■), and MDA-MB-468(▲) cell lines. Cells were plated in 96-well plates and treated with serial 
dilutions of lapatinib for 96 hours. Proliferation is expressed as a % of untreated control cell 
proliferation. Each experiment was repeated in triplicate and observations are presented 
mean± SD. (B) IC50 values for lapatinib in breast cancer cell lines. The IC50 and 95% confidence 
intervals (CI) were calculated using non linear regression, for three replicate experiments. 
 
Cell line IC50 (95% CI) 
SK-Br-3 0.10 μM (0.08-0.13) 
MCF-7 5.42 μM (4.89-6.00) 
MDA-MB-468 3.38 μM (2.82-4.04) 
B 
A 
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3.4.2 Inhibition of cell proliferation by chemotherapeutic agents 
Prior to conducting combination experiments, the IC50 for continuous exposure to 
cisplatin or doxorubicin was determined, in each cell line (Figure 3.3). The MDA-MB-
468 cell line is the most sensitive to cisplatin with an IC50 of 0.12 µM (95% CI 0.06-0.24 
µM), the SK-Br-3 cell line has an IC50 of 0.63 µM (95% CI 0.44-0.90 µM) and the MCF-7 
cell line an IC50 of 1.54 µM (95% CI 1.10-2.14 µM). For doxorubicin the IC50 ranged from 
5.39 nM (95% CI 3.34-8.71 nM) in the MDA-MB-468 cell line, 13.61 nM (95% CI 8.82-21 
nM) in MCF7 cells and 14.05 nM (95% CI 10.74-18.38 nM) in SK-Br-3 cells. 
  
127 
 
0.1 1 10 100 1000
0
20
40
60
80
100
120
Doxorubicin (nM)
%
Proliferation
0.1 1 10 100
0
20
40
60
80
100
120
Cisplatin (M)
%
Proliferation
 
IC50 
(95% CI) 
SK-Br-3 MCF-7 MDA-MB-468 
Doxorubicin (nM) 14.05 
(10.74-18.38) 
13.61 
(8.82-21.0) 
5.39 
(3.34-8.71) 
Cisplatin (µM) 0.63 
(0.44-0.90) 
1.54 
(1.10-2.14) 
0.12 
(0.06-0.24) 
 
Figure 3.3 Effect of doxorubicin and cisplatin on cell proliferation 
The SRB assay was used to assess the effects of (A) doxorubicin and (B) cisplatin in SK-Br-3(●), 
MCF-7(■) and MDA-MB-468 (▲) cell lines. Cells were plated in 96-well plates and treated with 
serial dilutions of (A) doxorubicin and (B) cisplatin for 96 hours. Proliferation is expressed as a 
% of untreated control cell proliferation. Each experiment was repeated in triplicate and 
observations are presented mean± SD. (C) IC50 values for cisplatin and doxorubicin. The IC50 
and 95% CI were calculated using non linear regression, for three replicate experiments. 
B 
A 
C 
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3.5 Combination of lapatinib with chemotherapeutic agents 
To investigate the effect of lapatinib in combination with cisplatin or doxorubicin a 
concentration of lapatinib which inhibited cell proliferation by 20% was studied in 
three different schedules: 
o both drugs continuously for 96 hours (continuous) 
o lapatinib treatment for 60 minutes followed by chemotherapy drug -/+ 
lapatinib for two hours, then drug free media or lapatinib for 96 hours (lapatinib first) 
o chemotherapy drug alone for two hours, followed by drug free media or 
lapatinib for 96 hours (chemotherapy first) 
 
Two techniques were used to assess the interaction between lapatinib and the 
cytotoxic drugs under investigation, median effect analysis and the normalised 
isobologram. Median effect analysis, as described by Chou et al., is based upon mass-
action law and uses the linear regression of dose response data to produce a median 
effect plot (Figure 3.4) (Chou, 2006). From this a combination index value, which 
describes the interaction between the two drugs at each dose point studied, can be 
calculated (Figure 3.4). The experiments described in this chapter use a non-constant 
ratio design employing a fixed dose of lapatinib which inhibits proliferation by 20%, 
with an increasing concentration of chemotherapy drug. This means that at each 
concentration the ratio of the two drugs in relation to each other alters. From this 
design a combination index value can be calculated for each drug combination 
investigated which describes the interaction between the two drugs (Figure 3.4B).  
 
3.5.1 Evaluating the impact of drug schedule on cell proliferation 
Both the schedules of chemotherapy first and lapatinib first allowed the use of the 
same concentration of chemotherapy drug, as both schedules utilise a two hour 
exposure to chemotherapy. For the schedule of continuous exposure, lower 
concentrations of chemotherapy drugs were used due to the 96 hours long drug 
treatment. In order to allow comparisons across schedules which use different drug 
concentrations, a combination index value at an isoeffective concentration is normally 
used e.g. IC20 or IC50. This can be done when experiments are performed using a fixed-
ratio design, as median effect analysis allows data simulation to calculate combination 
indices at isoeffective drug concentrations. Simulation is not possible in experiments 
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using a non-constant ratio design as presented here, due to the alteration in the ratio 
of chemotherapy to lapatinib as the concentration of the chemotherapy drug 
increases. To allow a direct comparison across the three schedules at an isoeffective 
drug concentration, a normalised isobologram was therefore constructed, with 
schedules compared at their IC50 level (Figure 3.4C). 
 
 
Figure 3.4 Drug interaction analysis 
(A) An example of a median effect plot. Cisplatin (×) and lapatinib-cisplatin (×). (B) Description 
of combination indices as calculated using median effect analysis, adapted from Chou et al.  (C) 
Normalised Isobologram demonstrating an isobole for a drug combination.  
A B 
C 
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3.5.2 Lapatinib in combination with doxorubicin 
The addition of lapatinib to doxorubicin inhibits cell proliferation producing synergistic 
effects at all but very high doxorubicin concentrations, in all three cell lines 
investigated (Figures 3.5, 3.6 and 3.7).  
 
3.5.2.1 SKBr-3 cell line  
The impact of schedule is less pronounced in this cell line,  with isobologram analysis 
demonstrating isoboles lying next to each other (Figure 3.5G). Median effect analysis 
supports this observation with combination indices between 0.45 and 0.89 for all 
doxorubicin concentrations less than 1 µM in all schedules, indicating a degree of 
synergy in all the schedules investigated (Figure 3.5).  
 
3.5.2.2 MDA-MB-468 cell line 
The schedules of continuous treatment and doxorubicin first, produce the same level 
of synergy as assessed by isobologram, though combination indices indicate that the 
schedule of continuous treatment produces the greatest level of synergy (Figure 3.6). 
The schedule of lapatinib first produces the least synergy of all three schedules 
investigated, but is still synergistic (Figures 3.6).  
 
3.5.2.3 MCF-7 cell line 
The schedule of doxorubicin first produces ‘strong synergy/synergy’ at 0.1 µM, 0.5 µM 
and 1.0 µM (combination indices 0.26, 0.29 and 0.34 respectively) which is the highest 
degree of synergy observed in all three cell lines and for all three schedules (Figure 
3.7). The schedule of lapatinib first also produces synergy at the same concentrations 
of doxorubicin, though to a lesser degree (combination indices 0.45, 0.48 and 0.59) 
(Figures 3.7). Median effect analysis demonstrates that the least synergy is produced 
with continuous treatment (Figure 3.7). The importance of schedule is also supported 
by isobologram analysis with the schedule of doxorubicin first producing the greatest 
synergy, with an isobole furthest away from the line of additivity (Figure 3.7G). 
 
Therefore, doxorubicin produces synergistic effects in combination lapatinib in all 
three cell line investigated. 
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Figure 3.5 Doxorubicin in combination 
with  lapatinib in the SK-Br-3 cell line 
The SRB assay was used to assess the 
combination of lapatinib with doxorubicin 
compared to doxorubicin alone on cell 
proliferation over 96 hours. (A) continuous 
treatment with both drugs, (C) doxorubicin 
alone for two hours, then lapatinib or DFM 
(doxorubicin first), (E) lapatinib/DFM for 60 
minutes, followed by doxorubicin± 
lapatinib for two hours, then lapatinib or 
DFM (lapatinib first),. Experiments were 
repeated three times and are presented as 
means ±SD. Combination index values for 
drug combinations (B, D and E) and 
isobologram (G). 
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Figure 3.6 Doxorubicin in combination 
with lapatinib in the MDA-MB-468 cell line 
The SRB assay was used to assess the 
combination of lapatinib with doxorubicin 
compared to doxorubicin alone on cell 
proliferation over 96 hours. (A) continuous 
treatment with both drugs, (C) doxorubicin 
alone for two hours, then lapatinib or DFM 
(Doxorubicin first), (E) lapatinib/DFM for 60 
minutes, followed by doxorubicin± 
lapatinib for two hours, then lapatinib or 
DFM (lapatinib first). Experiments were 
repeated three times and are presented as 
means±SD. Combination index values for 
drug combinations (B, D and F). Normalised 
isobologram (G). 
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Figure 3.7 Doxorubicin in combination with 
lapatinib in the MCF-7 cell line  
The SRB assay was used to assess the 
combination of lapatinib with doxorubicin 
compared to doxorubicin alone on cell 
proliferation over 96 hours. (A) continuous 
treatment with both drugs, (C) doxorubicin 
alone for 2 hours, then lapatinib or DFM 
(doxorubicin first), (E) lapatinib/DFM for 60 
minutes, followed by doxorubicin± lapatinib for 
2 hours, then lapatinib or DFM (lapatinib first). 
Experiments were repeated 3 times and data 
presented as mean±SD. Experiments were 
repeated three times and are presented as 
means ±SD. Combination index values for drug 
combinations (B, D and F). Normalised 
isobologram (G).  
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3.5.3 Lapatinib in combination with cisplatin 
Lapatinib also exhibits schedule dependent effects on the inhibition of cell 
proliferation in combination with cisplatin in all three cell lines investigated, as 
demonstrated by both changes in combination indices and the shifting of isoboles 
(Figures 3.8, 3.9 and 3.10).  
 
3.5.3.1 SK-Br-3 cell line 
The greatest level of synergy is observed with the schedule of cisplatin first, with a 
lowest combination index of 0.25, indicating ‘strong synergy’ (Figures 3.8C and 3.8D). 
The schedule of lapatinib first produces ‘slight synergism’ at best with a combination 
index of 0.87, and ‘moderate antagonism’ at worst, with a combination index of 1.42 
(Figure 3.8E). In a direct comparison between these two schedules, pre-treatment with 
lapatinib produces ‘moderate antagonism’ at 4 µM and 10 µM cisplatin (combination 
indices 1.36 and 1.42 respectively). This alters to synergy when cisplatin is given first 
(combination index 0.42 and 0.61). Isobologram analysis produces similar results with 
the greatest level of synergy observed with the schedule of cisplatin first and additive 
results with the schedule of lapatinib first (Figure 3.8G). Continuous treatment with 
both lapatinib and cisplatin produces an isobole which lies in between the effects 
observed with the other two treatment schedules (Figure 3.8G). Therefore, lapatinib in 
combination with cisplatin produces the greatest level of synergy when lapatinib 
exposure follows cisplatin treatment in SK-Br-3 cells. 
 
3.5.3.2 MDA-MB-468 cell line 
In the MDA-MB-468 cell line, continuous treatment with both lapatinib and cisplatin 
produces ‘moderate antagonism/antagonism’ at all cisplatin concentrations 
investigated as assessed by median effect analysis and the isobologram method at the 
IC50 concentration of cisplatin (Figures 3.9A, 3.9B and 3.9G).  The schedules of lapatinib 
first, or cisplatin first, produce isoboles which lie next to each other on the 
isobologram (Figure 3.9G). At 0.5 µM and 5.0 µM cisplatin there are no differences 
between the combination indices produced by these two schedules (Figures 3.9C and 
3.9E). This observation is dependent upon cisplatin concentration, as ‘moderate 
synergy’ is produced at 1.0 µM and 2.0 µM (combination indices 0.85 and 0.84 
respectively), which changes to ‘nearly additive’ effects when lapatinib is given first 
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(combination indices 1.04 and 0.99 respectively) (Figures 3.9C and 3.9E). Therefore, in 
the MDA-MB-468 cell line, the greatest level of synergy is produced when lapatinib 
follows cisplatin treatment. 
 
3.5.3.3 MCF-7 cell line 
Like the MDA-MB-468 cell line, median effect analysis demonstrates that MCF-7 cells 
treated continuously with lapatinib and cisplatin produce ‘nearly additive/moderate 
antagonism’ at all cisplatin concentrations and an isobole which lies on the line of 
additivity (Figures 3.10A and 3.10G).  A lesser degree of synergy is produced with the 
lapatinib first schedule compared with cells treated with cisplatin first, except at 100 
µM (Figures 3.10C and 3.10E). For example, cisplatin 50 µM produces a combination 
index of 0.60 (indicating synergy) when cisplatin is given first, but 0.92 (near additivity) 
with the schedule of lapatinib first, an observation supported by the constructed 
isobologram with the greatest synergy observed with the schedule of cisplatin first 
(Figure 3.10G). Therefore, like the SK-Br-3 and MDA-MB-468 cell lines, the greatest 
synergy is observed when lapatinib follows cisplatin exposure. 
 
These data are summarised in Table 3.2 and demonstrate that the effects of cisplatin 
on cell proliferation are schedule dependent in all three cell lines investigated, with the 
greatest impact of schedule observed in the SK-Br-3 cell line.  Schedule exerts  less 
influence in combination of lapatinib with doxorubicin, with all schedules 
demonstrating synergy.  
 Continuous 
cisplatin + 
lapatinib 
Cisplatin 
first → 
lapatinib 
Lapatinib 
first → 
cisplatin 
Continuous 
doxorubicin + 
lapatinib 
Doxorubicin 
first → 
lapatinib 
Lapatinib 
first → 
doxorubicin 
SK-Br-3 
Isobologram 
(CIX) 
 
Synergy  
(0.50) 
 
Synergy  
(0.25) 
 
Additive 
(0.87) 
 
Synergy 
(0.45) 
 
Synergy 
(0.58) 
 
Synergy 
(0.51) 
MDA-MB-
468 
Isobologram 
(CIX) 
 
Antagonism 
(1.34) 
 
Synergy 
 (0.73) 
 
Synergy  
(0.75) 
 
Synergy 
(0.44) 
 
Synergy  
(0.73) 
 
Synergy 
(0.50) 
MCF-7 
Isobologram 
(CIX) 
 
Additive 
(0.93) 
 
Synergy 
 (0.59) 
 
Synergy  
(0.75) 
 
Synergy 
(0.58) 
 
Synergy  
(0.20) 
 
Synergy 
(0.45) 
Table 3.2 Summary of the effect of lapatinib in combination cisplatin or doxorubicin 
Description of the effect of lapatinib on the inhibition of cell proliferation by cisplatin or 
doxorubicin as determined by analysis by normalised isobologram. The lowest combination 
index (CIX) value as determined by median effect analysis is shown in brackets for each 
schedule, with the lowest value across the three schedules highlighted in bold.  
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Figure 3.8 Cisplatin in combination with 
lapatinib in the SK-Br-3 cell line. The SRB 
assay was used to assess the combination of 
lapatinib with cisplatin compared to cisplatin 
alone on cell proliferation over 96 hours. (A) 
continuous treatment with both drugs, (C) 
cisplatin alone for two hours, then lapatinib 
or DFM (cisplatin first), (E) lapatinib/DFM for 
60 minutes, followed by cisplatin± lapatinib 
for two hours, then lapatinib or DFM 
(lapatinib first) Experiments were repeated 
three times and are presented as means ±SD. 
Combination index values for drug 
combinations (B, D, F). Normalised 
Isobologram (G). 
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Figure 3.9 Cisplatin in combination with 
lapatinib in the MDA-MB-468 cell line. The 
SRB assay was used to assess the 
combination of lapatinib with cisplatin 
compared to cisplatin alone on cell 
proliferation over 96 hours. (A) continuous 
treatment with both drugs, (C) cisplatin 
alone for two hours, then lapatinib or DFM 
(cisplatin first), (E) lapatinib/DFM for 60 
minutes, followed by cisplatin± lapatinib 
for two hours, then lapatinib or DFM 
(lapatinib first) Experiments were repeated 
three times and are presented as means 
±SD. Combination index values for drug 
combinations (B, D and F). Normalised 
isobologram (G).  
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Figure 3.10 Cisplatin in combination with 
lapatinib in the MCF7 cell line.  The SRB 
assay was used to assess the combination 
of lapatinib with cisplatin compared to 
cisplatin alone on cell proliferation over 96 
hours. (A) continuous treatment with both 
drugs, (C) cisplatin alone for two hours, 
then lapatinib or DFM (cisplatin first), (E) 
lapatinib/DFM for 60 minutes, followed by 
cisplatin± lapatinib for two hours, then 
lapatinib or DFM (lapatinib first). 
Experiments were repeated three times 
and are presented as means ±SD. 
Combination Index values for drug 
combinations (B, D and F). Normalised 
isobologram (G).  
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3.6 DISCUSSION 
This chapter describes experiments to investigate the effect of the dual EGFR and HER2 
TKI lapatinib on cell proliferation, both as a single agent and in combination with 
cisplatin or doxorubicin, together with the impact of schedule on combination 
treatment.  
 
3.6.1 Lapatinib inhibits cell proliferation in breast cancer cell lines 
Lapatinib inhibits cell proliferation in all three breast cancer cell lines investigated. The 
HER2 over-expressing cell line SK-Br-3 was 54 times more sensitive to lapatinib, with 
an IC50 0.10 µM, than the MCF-7 cell line with an IC50 5.42 µM (Figure 3.2). The EGFR 
expressing cell line, MDA-MB-468 has an IC50 3.38 µM. These results are in agreement 
with the published data which supports the determination of sensitivity to lapatinib by 
the level of expression of HER2 (Konecny et al., 2006; Zhang et al., 2008). The 
importance of HER2 and sensitivity to lapatinib is also supported by the observation 
that transfection of HER2 into low HER2 expressing breast cancer cell lines, 
significantly increases sensitivity to lapatinib. Conversely the knockdown of HER2 with 
siRNA in HER2 over-expressing cell lines, confers resistance (Konecny et al., 2006; 
Zhang et al., 2008). In the presence of over-expressed HER2, EGFR plays little role in 
conferring sensitivity to lapatinib, with knockdown of EGFR in the BT474 and SK-Br-3 
breast cancer cell lines, not altering sensitivity to lapatinib (Zhang et al., 2008). 
 
3.6.2 Synergy between lapatinib and DNA interactive agents 
The interaction between lapatinib and the two chemotherapy drugs investigated was 
assessed using the median effect and isobologram methods. Lapatinib produces 
synergy in combination with doxorubicin and cisplatin, in all cell lines, though the 
degree is schedule dependent (Table 3.2). In the experiments described in this chapter, 
the best method of comparing the effect of the addition of lapatinib to chemotherapy 
across all schedules, is to use the normalised isobologram. We constructed an IC50 
isobologram which examined the effect on the IC50 of the cytotoxic drug under 
investigation, of the addition of lapatinib.  
 
Lapatinib in combination with cisplatin demonstrates clear schedule dependence when 
combined with cisplatin in the SK-Br-3 cell line, with the schedule of cisplatin first 
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producing the greatest level of synergy, and lapatinib pre-treatment prior to cisplatin 
producing additive results (Figure 3.8). Schedule is also important in the MDA-MB-468 
cell line, with continuous treatment with cisplatin and lapatinib producing antagonism 
at all concentrations investigated as assessed by both median effect analysis and using 
the isobologram (Figure 3.9); this is not observed in the other schedules.  In the MCF-7 
cell line, continuous treatment with cisplatin and lapatinib produced additive effects 
on the inhibition of cell proliferation (Figure 3.10). The schedule of cisplatin followed 
by lapatinib produced more synergy than when lapatinib was given prior to and during 
cisplatin treatment. 
 
Schedule is less important when lapatinib is combined with doxorubicin with synergy 
seen in all schedules as assessed using median effect analysis and all isoboles lie below 
the line of additivity, in all cell lines and all schedules. The most marked influence of 
schedule was seen in the MCF-7 cell line, with doxorubicin followed by lapatinib 
producing strong synergy when compared to doxorubicin alone (Figure 3.7). 
 
Synergy has been shown by others using in vitro models (Table 3.3). Budman et al. 
examined the combination of the dual EGFR and HER2 TKI, GW282974X in combination 
with chemotherapy drugs continuously, using median effect analysis and the 
calculation of combination indices (Budman et al., 2006).  They demonstrated synergy 
with deoxy-5-fluorouridine (5’-DFUR), an active metabolite of capecitabine, in the 
three breast cancer cell lines MCF-7, SK-Br-3 and BT474. In combination with 
epirubicin, GW282974X produced synergy in the SK-Br-3 cell line only with a 
combination index of 0.5, where as in BT474 cells, which also over-expresses HER2, 
additivity was produced (combination index 1.1), and antagonism in the MCF-7 cell line 
(combination index 1.7) (Budman et al., 2006).  
 
Coley et al. have also demonstrated synergy using median effect analysis in the ovarian 
cancer cell line PEO1, with the combination of GW282974A (EGFR and HER2 TKI) and 
paclitaxel (Coley et al., 2006). In combination with cisplatin, results were additive or 
antagonistic (Coley et al., 2006). Lapatinib also produces additive results in 
combination with carboplatin and additive or synergistic results in combination with 
paclitaxel, docetaxel and doxorubicin in endometrial cancer cell lines (Konecny et al., 
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2008). Kim et al. have shown synergy with a continuous combination of lapatinib with 
5-FU, cisplatin, paclitaxel and oxaliplatin in two gastric cancer cell lines, also using 
median effect analysis (Kim et al., 2008b). Schedule was found to be important in 
combination with 5-FU, cisplatin and paclitaxel, but not with oxaliplatin, with the 
schedule of cisplatin or 5-FU followed by lapatinib producing the highest degree of 
synergy (Kim et al., 2008b). 
 
 
 
Cell Lines 
(Lapatinib IC50 -
µM) 
Chemotherapy Combination 
index level 
Drug concentrations 
Kim et al, 
2008 
Gastric cancer 
SNU-216 (0.02) 
NCI-N87 (0.01) 
5-FU, 
oxaliplatin, 
cisplatin 
paclitaxel 
FA50 0.1, 1, 3, 9, and 27XIC50  
lapatinib/ 
chemotherapy 
Coley et 
al, 2006 
Ovarian Cancer 
PEO1 
PEOTaxR 
PEOCarboR 
Cisplatin 
Paclitaxel 
Across all FA  
plus 
simulation 
Lapatinib analogue 
GW282974A 
No concentrations 
given 
Konecny 
et al, 
2006 
Endometrial 
Cancer 
USPC1 (0.61) 
USPC2 (0.05) 
RL-95-1 (0.93) 
HEC155 (0.79) 
Carboplatin 
Paclitaxel 
Doxorubicin 
Docetaxel 
Mean of all 
FA values. 
Lapatinib 
concentration; 
USPC1 &2 cell lines- 
0.031-1.0µM  
RL-95-1 and HEC155 
cell lines-0.31-10µM 
Budman 
et al, 
2006 
Breast cancer 
BT474 (4.8) 
MCF7/wt (7.6) 
MCF7/adr (6.8) 
SK-Br-3 (0.6) 
Docetaxel 
5-FU 
5’DFUR 
Epirubicin 
Gemcitabine 
FA50 Lapatinib analogue 
GW282974X 
lapatinib/ 
chemotherapy- 
0.03125N-8N 
N= value around IC50 
Komoto 
et al, 
2009 
Pancreatic cancer 
MiaPaca-2 
PANC-1 
Capan-1 
Capan-2 
S-1 components Full range FA 
results plus 
simulation 
4, 2, 1, 0.5, 0.25 and 
0.125X 2.5µM lapatinib 
 
Table 3.3 Lapatinib and chemotherapy combination studies.  
All studies used median effect analysis in a constant ratio design. IC50 values for lapatinib as 
single agent are given where published. The combination index level is the fraction affected 
(FA) level at which the drug combinations were assessed.    
 
3.6.3 Problems with in vitro drug combination experiments  
The studies described above all use a constant ratio design, whereas the experiments 
presented in this chapter use a non-constant ratio design. A constant ratio experiment, 
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differs from a non-constant experiment in that the concentration of lapatinib increases 
in line with the increasing concentration of cytotoxic drug; thereby maintaining the 
ratio of the two drugs to each other. The studies by Kim et al. and Budman et al. utilise 
a combination of EGFR and HER2 TKIs with chemotherapy drugs at their IC50 
concentrations and Coley et al., a ratio of chemotherapy to lapatinib of 1:1.25 
(Budman et al., 2006; Coley et al., 2006; Kim et al., 2008b). This is achieved by serially 
diluting a solution containing both drugs at four times the desired concentrations by 2, 
1, 0.5, 0.25 and 0.125 fold, to give a concentration range. This design is recommended 
for use with median effect analysis, as it allows the software to undertake 
mathematical modelling to simulate the interaction across the entire range of drug 
concentrations investigated. This cannot be done with a non-constant ratio design 
experiment (Chou, 2010). This is important as the ratio of the two drugs to each other 
influences the results of any analysis and Chou et al. recommend investigating 
different ratios. This is especially important when investigating drugs in cell lines which 
are very sensitive, as drug concentrations may lie well below clinically relevant levels 
(Chou, 2010).  
 
The SK-Br-3 cell line is highly sensitive to lapatinib with inhibition of proliferation 
occurring with concentrations as low as 10 nM (Figure 3.2). At this concentration HER2 
and AKT phosphorylation are only partially reduced by lapatinib and concentrations 
closer to 50 nM are required to inhibit signalling (Amin et al., 2010). The inhibition of 
nuclear translocation of EGFR and HER2 by lapatinib has been demonstrated in the 
gastric cell line SNU-216 (Kim et al., 2008c). This cell line is also highly sensitive to 
lapatinib with an IC50 of 20 nM, though concentrations of both 0.1 µM and 1 µM 
lapatinib are used to demonstrate inhibition of HER2 nuclear translocation (Kim et al., 
2009). Nuclear EGFR was also reduced, but the reduction was greater with 1.0 µM than 
with 0.1 µM of lapatinib (Kim et al., 2009). These observations are important when 
considering the experiments presented in this chapter and the SK-Br-3 cell line, when 
an IC20 concentration of lapatinib of 15 nM was used. Whilst synergistic effects were 
obtained in combination with either doxorubicin or cisplatin, these may have been 
underestimated as a concentration of 15 nM lapatinib does not fully inhibit HER2 
(Amin et al., 2010). Additionally this is not a concentration where the translocation of 
HER2 to the nucleus, which may be important in DNA repair, has been observed (Kim 
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et al., 2009). A constant ratio designed experiment could have solved this problem, as 
the concentration of lapatinib changes in line with the cytotoxic drug under 
investigation; so combination points where the lapatinib concentration was greater 
than 0.1 µM or more clinically relevant could have been examined specifically.  
 
Examining the published combination studies discussed above, it can be noted that the 
study by Kim et al only presents combination index values at the IC50 combination, 
when the lapatinib concentration was 0.01 or 0.02 µM (Table 3.3) (Kim et al., 2008b). 
Coley et al. and Komoto et al. present the combination indices for all points 
investigated, plus the graphical simulation, but do not publish the IC50 values for 
lapatinib alone, so the actual concentration of lapatinib investigated cannot be 
ascertained (Coley et al., 2006; Komoto et al., 2009b). This is important as in both 
studies, some drug combinations showed increasing antagonism with increasing drug 
concentration. Konency et al. present the mean of the combination index values across 
different concentration. Whilst this is an acceptable method as suggested by Chou et 
al. it prevents assessment as to whether the interaction between lapatinib and 
chemotherapy alters with increasing concentrations of both drugs (Chou, 2006).  
 
An alternative design would be to utilise concentrations of lapatinib known to fully 
affect protein function for short periods of time, then to allow cell growth for the 
desired duration. For example, 1 µM lapatinib for one hour prior to, in combination 
with or after chemotherapy. The clonogenic assay, which measures the number of cell 
colonies formed following exposure to different drugs and combinations, can also be 
used. We tried this technique, and whilst the cell lines used are reported to form 
colonies, we were unable to achieve this over the time period required. 
 
Whilst cell based assays may be able to ascertain drug combinations and schedules of 
interest, they are unable to isolate the mechanisms through which their effects occur. 
Identification of the key pathways inhibited by lapatinib to produce synergy or 
antagonism could be achieved using siRNA libraries to target specific proteins or entire 
pathways, such as those involved in EGFR and HER2 signalling or DNA repair including 
PI3K-AKT, Ras-Raf-MAPK, HER3, DNA-PK, ERCC1 and RAD51. This would allow a 
comparison between lapatinib and chemotherapy combinations in wild type and 
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transfected cell lines. The role of HER2 in the inhibition of cell proliferation by cytotoxic 
agents could also be investigated using this approach, though this would also result in 
the reduced expression of HER2. Lapatinib does not reduce the expression of HER2 
(Konecny et al., 2006), but inhibits its phosphorylation. The importance of the 
inhibition of HER2 phosphorylation by lapatinib in the production of synergy in 
combination with cytotoxic drugs, could be investigated by the creation and 
transfection of a HER2 which cannot be phosphorylated, into a non-HER2 expressing 
cell line and comparing the inhibition of cell proliferation by chemotherapy drugs with 
the same cell line transfected with a fully functioning HER2. 
 
3.7 CONCLUSIONS 
Lapatinib inhibits cell proliferation in breast cancer cell lines, with sensitivity 
determined by the level of expression of HER2. Cells that express low levels of EGFR or 
HER2 are also sensitive to lapatinib, indicating that the targeting of HER2 is not the sole 
mechanism through which lapatinib produces its effects.  
 
Lapatinib produces synergistic effects in combination with both cisplatin and 
doxorubicin, though the degree of synergy is affected by the scheduling of lapatinib. 
Overall the schedule of chemotherapy first, followed by lapatinib proves to be the 
most effective at producing synergy, when schedule is important. Cell based assays 
provide a high throughput method of assessing drug combinations in vitro, but fail to 
identify mechanisms through which these effects are mediated. When using targeted 
drugs, drug concentration may be important if different cellular effects are produced 
by different drug concentrations. This should be considered when using highly 
sensitive cell lines when very low concentrations of targeted drugs are used and it may 
be necessary to expose cells to higher concentrations of targeted agent, for shorter 
periods of time to allow the investigation of targeted agents at clinically relevant 
concentrations.  
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Investigation into influence of duration of exposure to 
lapatinib or gefitinib on the cellular effects of DNA 
damaging agents 
4.1   INTRODUCTION 
The results presented in Chapter Three demonstrate that lapatinib can synergise with 
doxorubicin and cisplatin in a schedule dependent manner. Gefitinib in combination 
with chemotherapy produces similar results in vitro (Milano et al., 2008; Solit et al., 
2005; Xu et al., 2003). Despite this, such combinations have failed to demonstrate a 
clinical benefit in phase III trials in lung cancer (Giaccone et al., 2004; Herbst et al., 
2004; Herbst et al., 2005; Ready et al., 2010). As discussed in Chapter Three, schedule 
may be important in mediating synergy between HER targeted TKIs and DNA damaging 
agents. One possible explanation for this is the reactivation of PI3K/AKT signalling 
following continued exposure to TKIs and its effect on promoting DNA repair. 
 
4.1.1 HER3 mediated resistance to small molecule tyrosine kinase inhibitors 
HER3 is a potent activator of the PI3K/AKT signalling pathway through dimerisation 
with either EGFR or HER2 and inhibition of either receptor by TKIs leads to inhibition of 
both HER3 and the PI3K/AKT signalling (Amin et al., 2010; Campbell et al., 2010; Kong 
et al., 2008). This inhibition is short lived, with phosphorylated HER3 and AKT 
detectable at 48 hours, despite continued EGFR and HER2 inhibition (Amin et al., 2010; 
Campbell et al., 2010; Kong et al., 2008; Sergina et al., 2007).  This process is driven by 
the initial inhibition of AKT phosphorylation which leads to an increase in HER3 
expression, which is subsequently phosphorylated. In addition to this pathway, 
increased HER2 expression occurs through TKI induced inhibition of receptor 
ubiquitination, reducing receptor degradation (Scaltriti et al., 2009) (Figure 4.1). 
 
The initial inhibition of AKT phosphorylation by TKI, reduces the phosphorylation of the 
FOXO transcription factors, resulting in their transport back into the nucleus where 
they activate the HER3 promoter, increasing HER3 transcription and hence expression 
(Amin et al., 2010; Chandarlapaty et al., 2011). This process of negative feedback 
resulting from the initial inhibition of HER3 and hence AKT phosphorylation is 
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demonstrated in cells transfected with a 4-hydroxy tamoxifen inducible AKT. The 
induction of AKT phosphorylation by tamoxifen in these cells reduces HER3 expression 
and also reduces the degree of increase in HER3 expression induced by lapatinib (Amin 
et al., 2010). In addition, the use of AKT inhibitors increases the expression and 
phosphorylation of HER3 (Chandarlapaty et al., 2011). These data demonstrate the 
regulation of HER3 expression by AKT phosphorylation. 
 
 
 
 
Figure 4.1 Diagram of the proposed mechanism through which HER3 and AKT signalling are 
reactivated in response to lapatinib concentrations of less than 5 µM 
Inhibition of HER2 phosphorylation by lapatinib inhibits the phosphorylation of HER3 and the 
phosphorylation of AKT initially. This increases transcription of HER3 due to transport of the 
FOXO transcription factor back into the nucleus. FOXO activated the HER3 promoter leading to 
increased HER3 expression. In addition, the inhibition of AKT inhibits HER3 phosphatases 
reducing receptor dephosphorylation as described by Amin et al., 2010. HER2 expression is 
increased due to reduced protein ubiquitination as described by Scaltriti et al., 2009. This 
increases the formation of HER2-HER3 dimers, which when phosphorylated activate AKT 
signalling. 
  
147 
 
The increase in expression of HER2 and HER3 drives the formation of HER2-HER3 
dimers (Amin et al., 2010; Chandarlapaty et al., 2011; Scaltriti et al., 2009). The 
mechanism through which the newly produced HER3 proteins are phosphorylated in 
the presence of continued TKI appears to be dependent upon TKI concentration and 
whether HER2 function is fully inhibited. Under conditions where only partial or no 
HER2 kinase inhibition occurs (for example ≤1µM gefitinib), the TKIs gefitinib and 
AG1478 induce the autocrine release of the HER3 and HER4 ligands, betacellulin and 
heregulin (Kong et al., 2008). This stimulates the formation of HER2/HER3 and 
HER3/HER4 dimers thereby negating the effect of low concentrations of TKIs on the 
inhibition of cell proliferation (Kong et al., 2008).  
 
Higher concentrations of gefitinib (for example 5 µM), induce a forward shift in the 
dephosphorylation-phosphorylation equilibrium of HER3. This results in an increase in 
the steady state phosphorylation of HER3, with activation of the PI3K/AKT signalling 
pathway observed following 48 hours of continuous exposure to gefitinib (Sergina et 
al., 2007). This process is dependent upon HER2, with the knockdown of HER2 
preventing the HER3 phosphorylation (Sergina et al., 2007).  
 
The phosphorylation of HER3 is dependent upon the residual kinase activity of HER2 as 
the knockdown of HER2 prevents HER3 reactivation (Sergina et al., 2007). High 
concentrations of lapatinib (≥5 µM) or erlotinib (≥40 µM) prevents the reactivation of 
HER3 and PI3K/AKT, which is thought to be due to the complete inhibition of HER2 
kinase activity (Amin et al., 2010). Another mechanism of HER3 activation is 
phosphorylation by MET (Engelman et al., 2007) and HER3 may not be completely 
devoid of kinase activity, able to autophosphorylate though at a lower level than that 
observed when dimerised with EGFR or HER2 (Di Leo et al.).   
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4.2 AIMS 
The reactivation of AKT signalling during prolonged exposure to TKI may explain why 
combinations of TKIs with DNA damaging agents have also not always translated into 
the clinical setting, especially as AKT plays a key role in the cellular response to DNA 
damage as discussed in Chapter One section 1.8.5.1 The results presented in this 
chapter examine whether the induction and repair of DNA lesions is affected by the 
duration of exposure to the TKI gefitinib and lapatinib with the following aims: 
 
1. Does continued exposure to lapatinib result in activation of HER3 and AKT 
signalling? 
2. Does the duration of exposure to either gefitinib or lapatinib affect the 
induction of DNA lesions produced by Topo IIα poisons, platinum or ionising 
radiation? 
3. Does the duration of exposure to TKI alter the repair of DNA lesion induced by 
Topo IIα poisons, platinum or ionising radiation? 
4. Does the duration of exposure to TKI alter the cytotoxicity of the 
chemotherapy agents under investigation? 
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4.3 DOES THE DURATION OF EXPOSURE TO LAPATINIB ALTER HER3 AND 
AKT SIGNALLING? 
Experiments were carried out in the SK-Br-3 breast cancer cell line as used by Sergina 
et al. They were the first to report the reactivation of HER3 and AKT signalling despite 
initial inhibition, with continued exposure to gefitinib for 48 hours (Sergina et al., 
2007). Initial experiments ascertained a suitable concentration of lapatinib to be 
investigated. Gefitinib was used at a concentration of 5 µM, as used in the experiments 
conducted by Sergina et al. (Sergina et al., 2007). Cells were treated with either 
gefitinib or lapatinib for one hour or continuously for 48 hours, with drug replacement 
at 23 and 47 hours. Replacement of TKI is required as without, HER3 signalling can be 
detected at 18 hours (Figure 4.2). Drug replacement at 23 hours initially reduces the 
level of phosphorylated HER3 detected but replacement at 47 hours has a lesser effect 
and by 72 hours, replacement of gefitinib has no effect. 
 
Figure 4.2 Effect of gefitinib replacement on HER3 phosphorylation 
The effect of gefitinib replacement on HER3 phosphorylation was assessed in the SK-Br-3 cell 
line using Western blotting. (A) Cells were treated with 5 µM gefitinib as indicated without 
drug replacement, (B) gefitinib was replaced at 23, 47 and 71 hours following which cells were 
lysed and immunoblotted with anti-pHER3. Relative densitometry values are provided to allow 
comparison of each time point. α tubulin is used as a loading control. Figure representative of 
two independent experiments. 
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4.3.1 Inhibition of HER signalling by lapatinib 
Lapatinib 0.1 µM reduces HER2 and HER3 phosphorylation with none detectable at 
concentrations higher than 1.0 µM (Figure 4.3). EGFR is less sensitive, with a reduction 
in receptor phosphorylation detected at concentrations above 2 µM. A concentration 
of lapatinib of 2 µM was chosen for further investigation as this inhibits the 
phosphorylation of EGFR, HER2 and HER3 and is clinically relevant (Lapatinib Cmin 
1.9µM and Cmax 3.5µM for lapatinib 900mg BD) (Burris et al., 2009).  
 
 
Figure 4.3 Inhibition of HER signalling lapatinib 
The effect of lapatinib 0.1- 5.0 µM on EGFR, HER2 and HER3 signalling was assessed in the SK-
Br-3 cell line using Western blotting. Cells were treated with the indicated concentration of 
lapatinib for one hour then lysed and immunoblotted as indicated. α tubulin is used as a 
loading control. Figure representative of two independent experiments. 
 
4.3.2 The effect of gefitinib and lapatinib on cell viability 
The trypan blue assay was used to assess cell viability to ensure that 2 µM lapatinib 
was a suitable comparison to 5 µM gefitinib (Figure 4.4). Continued treatment with 
either gefitinib or lapatinib produced a 12±1.4% and 16±1.4% fall in cell viability 
respectively, compared with untreated cells (98±0.5% for untreated or cells exposed to 
TKI for one hour, 86±1.4% with exposure to gefitinib for 48 hours and 84±1.4% with 
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lapatinib, P<0.001). There were no differences in cell viability between gefitinib or 
lapatinib for 48 hours, confirming 2 µM lapatinib as a suitable comparison to 5 µM 
gefitinib (Figure 4.4). 
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Figure 4.4 Effect of gefitinib and lapatinib exposure on cell viability  
Cell viability was assessed using trypan blue to identify dead cells. Cells were pre-treated with 
either drug free media (■), gefitinib 5 μM for 1 hour (■), lapatinib 2 μM for 1 hour (■), gefitinib 
5 μM for 48 hours (■), lapatinib 2 μM for 48 hours (■). Cell suspension was mixed with an 
equal volume of 0.4% trypan blue and cells counted using haemocytometer four separate 
times. Data are presented as the mean ±SEM of three experiments. * P< 0.001 compared with 
the drug free media. 
 
4.3.3 The effect of exposure to gefitinib or lapatinib for 48 hours on HER signalling 
The effect of duration of exposure to lapatinib or gefitinib on EGFR, HER2, HER3, AKT 
and MAPK signalling pathways was assessed by Western blotting. Gefitinib 5 μM 
inhibits the phosphorylation HER3, AKT and MAPK within an hour (Figure 4.5A). 
Despite replacement of gefitinib at 23 and 47 hours, HER3 and AKT phosphorylation 
can be detected at 48 hours, together with phosphorylated MAPK at a lower level 
(Figure 4.5A).  
 
Like gefitinib, lapatinib 2 μM inhibits the phosphorylation of HER3, AKT and MAPK 
signalling within one hour. Both AKT and MAPK signalling can be detected following 
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continuous exposure to lapatinib for 48 hours, though the level of AKT signalling is less 
than that observed with gefitinib, only detected following prolonged blot exposure 
(Figure 4.5B).  Unlike with continuous exposure to gefitinib, HER3 signalling can be 
barely detected following 48 hours exposure to lapatinib. 
 
 
 
Figure 4.5 Effect of duration of exposure to gefitinib and lapatinib on HER3, AKT and MAPK 
signalling 
The effect of duration of exposure to TKI on HER, AKT and MAPK signalling was investigated in 
the SK-Br-3 cells by Western blotting. Cells were treated with gefitinib 5 µM or lapatinib 2 µM 
as indicated for 1 or 48 hours, with replacement of TKI at 23 and 47 hours. Cells were then 
collected, lysed and immunoblotted as indicated. (B) An over-exposed blot is shown to allow 
the proteins with lower expression to be visualised. Figure is representative of three 
independent experiments.  
 
4.4 DOES DURATION OF EXPOSURE TO GEFITINIB OR LAPATINIB ALTER 
THE INDUCTION OF DNA DAMAGING LESIONS? 
As discussed in Chapter One section 1.8.5.1, the PI3K/AKT signalling pathway is 
involved in the regulation of cell proliferation and can promote resistance to cytotoxic 
drugs. Having established that this signalling pathway is initially inhibited by gefitinib 
and lapatinib but then reactivated, we wished to examine whether there are 
differences in the induction and repair of DNA lesions in cells treated for one or 48 
B    Over exposed blot A 
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hours with these drugs. DNA damaging agents which induce a variety of different DNA 
lesions were investigated. Cisplatin was used as inducer of intra and interstrand 
crosslinks and IR, etoposide and doxorubicin as inducers of DNA single and double 
strand breaks. 
 
4.4.1 The Induction of interstrand crosslinks by cisplatin 
Cells were treated with TKI for one or 48 hours prior to exposure to cisplatin (50 µM) 
for two hours and collected for analysis nine hours after the removal of cisplatin. This 
time point was chosen due to data from our laboratory which has demonstrated this is 
when the formation of crosslinks peaks (Clingen et al., 2008; Friedmann et al., 2004). 
This concentration of cisplatin was chosen as it produces detectable interstrand 
crosslinks and is a clinically relevant concentration (Go and Adjei, 1999). Following 
treatment, and immediately before analysis, cells were irradiated (15 Gy) to deliver a 
fixed number of DNA strand breaks which could be detected using the alkaline Comet 
assay as a Comet tail. The presence of an interstrand crosslink retards the migration of 
IR-induced DNA strand breaks, shortening the Comet tail in comparison to an 
untreated irradiated control. The difference in tail moment between untreated 
controls and cisplatin treated samples can be calculated as a percentage reduction 
compared with the control. Increases in the percentage reduction of the Comet tail, 
indicates the presence of a greater number of interstrand crosslinks. 
 
Cisplatin-induces interstrand crosslinks with a reduction in tail moment of 48.9±6.2%. 
Exposure to either gefitinib or lapatinib for one hour produces a non-significant 
increase in the induction of lesions, with a reduction in tail moment of 63.4±4.9% and 
62.4±1.2% respectively (p>0.05) (Figure 4.6). Continued exposure to either TKI for 48 
hours has no significant effect on the induction of interstrand crosslinks with a 
reduction in tail moment of 45.4±5.3% with gefitinib and 66.8±2.1% with lapatinib 
(p>0.05). Significantly fewer interstrand crosslinks are produced in cells treated with 
gefitinib for 48 hours compared with cells treated with lapatinib for the same duration 
(% reduction in tail moment 45.4±5.3% vs. 66.8±2.1 % p≤ 0.05). These data indicate 
that the number of interstrand crosslinks induced by cisplatin is not significantly 
altered by either gefitinib or lapatinib or the duration of exposure to these drugs. 
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However, fewer lesions are induced in cells treated with gefitinib for 48 hours 
compared with cells treated with lapatinib for 48 hours. 
 
0
20
40
60
80
100
% Reduction
 in Tail
Moment
 
 
 
 
 
Figure 4.6 Effect of duration of exposure to gefitinib or lapatinib on the induction of 
interstrand crosslinks by cisplatin.  
The modified alkaline comet assay was used to assess the induction of interstrand crosslinks by 
cisplatin in the SK-Br-3 cell line. Cells were pre-treated with either drug free media (■), 
gefitinib 5 μM for 1 hour (■), lapatinib 2 μM for 1 hour (■), gefitinib 5 μM for 48 hours (■), 
lapatinib 2 μM for 48 hours (■), before exposure to cisplatin (50 µM), After two hours the 
media was replaced with DFM or media containing TKI and cells collected after nine hours. 
Each experiment was repeated three times. Data are presented as mean±SEM * P≤ 0.05 
compared with cisplatin alone.  
 
4.4.2 Induction of DNA strand breaks 
IR produces both single and double strand DNA breaks which can be quantified using 
alkaline Comet assay as described in Chapter Two section 2.5, with an increase in the 
measured tail moment indicating a greater number of DNA strand breaks (Olive and 
Banath, 2006).  The Topo II poisons doxorubicin and etoposide induce single and 
Cisplatin        --            +    +        +             +                  +  
Gefitinib 1 hour              --           --                  +                 --             --     --                    
Lapatinib 1 hour       --           --    --       +             --                 -- 
Gefitinib 48 hour       --           --       --       --             +    -- 
Lapatinib 48 hours       --           --           --       --             --                 + 
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double DNA strand breaks, which can also be measured using the alkaline Comet 
assay. 
 
4.4.2.1 The induction of DNA strand breaks by ionising radiation 
Following exposure to TKI cells were irradiated (20 Gy) and processed immediately. 
This dose was chosen as it produces a tail moment of 12.3±0.34 which lies below the 
maximum sensitivity of the assay, allowing both decreases and increases in tail 
moment to be detected (Figure 4.7).  
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Figure 4.7 Induction of DNA strand breaks by ionising radiation  
The alkaline comet assay was used to assess the induction of strand breaks by IR in the SK-Br-3 
cell line. Cells were grown in DFM for 24 hours prior to exposure to IR, after which cells were 
collected, and analysed. Data represents mean±SEM of 50 cells per dose point. 
 
 
The induction of DNA strand breaks by IR was not affected by either TKI or duration of 
TKI treatment. IR alone produces a tail moment of 9.7±1.0, a tail moment of 9.2±0.5 in 
cells treated with gefitinib for one hour and 10.2±0.4 following gefitinib treatment for 
48 hours (p>0.05) (Figure 4.8). Pre-treatment with lapatinib also has no significant 
effect, with a tail moment of 8.5±0.7 in cells treated with lapatinib for one hour and 
11.0±0.2 in cells treated with lapatinib for 48 hours (p>0.05) (Figure 4.8). Therefore, 
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the induction of DNA strand breaks by IR is not affected by either the gefitinib or 
lapatinib or the duration of exposure to the drug. 
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Figure 4.8 Effect of duration of exposure to gefitinib or lapatinib on the induction of DNA 
strand breaks by ionising radiation  
The alkaline comet assay was used to assess the induction of strand breaks by IR in the SK-Br-3 
cell line. Cells were pre-treated with drug free media (■), gefitinib 5 μM for 1 hour (■), 
lapatinib 2 μM for 1 hour (■), gefitinib 5 μM for 48 hours (■), lapatinib 2 μM for 48 hours (■). 
before exposure to IR (20 Gy), after which cells were collected, and analysed. Data represents 
mean±SEM of three independent experiments.  
 
4.4.2.2    The induction of DNA stand breaks by doxorubicin and etoposide  
The induction of DNA strand breaks by doxorubicin was investigated across a range of 
concentrations from 2.5-50 µM. Doxorubicin produced strand breaks at all 
concentrations, with a concentration-dependent increase in strand breaks observed 
between 2.5-10 µM; 50 µM doxorubicin produced the fewest strand breaks (Figure 
4.9A).  
 
Ionising Radiation      --            +          +         +  +      +  
Gefitinib 1 hour          --            --                  +                 --  --       --                    
Lapatinib 1 hour      --            --                  --         +  --      -- 
Gefitinib 48 hour      --            --                  --         --  +            -- 
Lapatinib 48 hours      --            --                  --         --  --      + 
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Exposure to TKI for one hour has no significant effect on the induction of DNA strand 
breaks and there are no significant differences between lapatinib and gefitinib (for 
example at 5 µM doxorubicin alone- tail moment 4.4±0.8, plus gefitinib one hour 
3.9±0.2, and lapatinib 4.2±0.6 P>0.05). Exposure to either TKI for 48 hours significantly 
reduces the ability of doxorubicin to induce DNA strand breaks at all drug 
concentrations investigated (for example 5 µM doxorubicin plus gefitinib 48 hours 
produces a tail moment 0.43±0.19 and lapatinib 48 hours 0.10±0.17 p≤0.01) (Figure 
4.9A).  
 
Etoposide also produces DNA strand breaks in a concentration-dependent manner 
over a range of 50-200 µM, with 50 µM etoposide producing a tail moment of 3.0±0.3 
and 200 µM, a tail moment of 10.9±1.0 (Figure 4.9B). Exposure to TKI for one hour has 
no significant effect on the induction of DNA strand breaks (for example 100 µM 
etoposide alone produces a tail moment of 8.5±0.9, gefitinib 8.3±1.1 and lapatinib 
8.4±1.3 p>0.05) (Figure 4.9B). As with doxorubicin, exposure to TKI for 48 hours 
significantly reduces the number of DNA strand breaks produced at all etoposide 
concentrations (for example at 100 µM etoposide plus gefitinib tail moment 3.9±0.8 
and lapatinib 4.2±0.2 p≤0.05) (Figure 4.9B), though a concentration-dependent 
increase in tail moment can be observed. This indicates that the ability of doxorubicin 
and etoposide to induce DNA strand breaks is significantly inhibited by continued 
exposure to either gefitinib or lapatinib for 48 hours. 
 
Taken together these data indicate that continuous exposure to the TKI gefitinib or 
lapatinib, inhibits the production of DNA damage by the Topo IIα poisons but not 
cisplatin or IR. 
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Figure 4.9 Effect of duration of exposure to gefitinib or lapatinib on the induction of DNA 
strand breaks by doxorubicin or etoposide.  
The alkaline comet assay was used to assess the induction of strand breaks by (A) doxorubicin, 
(B) etoposide in the SK-Br-3 cell line. Cells were pre-treated with either drug free media (■ ), 
gefitinib (■ ) or lapatinib (■ ) for one hour, gefitinib (■ ) or lapatinib (■ ) for 48 hours prior to 
exposure to doxorubicin or etoposide at the stated concentration for 2 hours in the presence 
of TKI, after which cells were collected, and analysed. Each experiment was repeated in 
triplicate. * P≤ 0.05 compared with Topo II poison alone. 
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4.5 DOES THE DURATION OF EXPOSURE TO GEFITINIB OR LAPATINIB 
MODULATE DNA REPAIR? 
The effect of duration of exposure to gefitinib or lapatinib on the ability of cells to 
repair DNA lesions was investigated using the alkaline Comet assay plus measurement 
of γH2AX and RAD51 foci. For all assays, multiple time points were examined following 
removal of the cytotoxic drug under investigation, allowing the repair of DNA strand 
breaks to be investigated.  
The protein H2AX is phosphorylated at serine 139 to form γH2AX foci at sites flanking 
DNA DSBs, signalling their presence, location and recruiting repair proteins (Banath 
and Olive, 2003; Clingen et al., 2008). γH2AX foci can be induced either by agents that 
cause DSBs directly (for example IR or Topo II poisons), indirectly through the collision 
of replication forks with interstrand crosslinks, single strand breaks or damaged DNA 
bases, or during DNA repair (Banath et al., 2010; Clingen et al., 2008). Foci can be 
visualised and counted using confocal microscopy as described in Chapter Two, 
sections 2.6. The resolution of γH2AX foci over time following removal of the DNA 
damaging agent can be studied, with persistence of foci at 24 hours correlating with 
cytotoxicity (Banath et al., 2010). Due to the sensitivity of this assay, lower 
concentrations of DNA damaging agents were used in comparison to those used in the 
Comet assays.   
RAD51 plays a key role in the process of DNA repair by HR and is involved in the repair 
of DNA DSBs, including those produced as a result of stalled replication forks due to 
interstrand crosslinks. RAD51 is involved in presynapsis during which free single 
stranded DNA is processed and a presynaptic filament formed through binding of RPA, 
allowing the loading of RAD51 onto single stranded DNA (Scott and Pandita, 2006). 
RAD51 foci form in the same cells as γH2AX foci, though the two proteins are not co-
localised (Banath et al., 2010) and by examining their formation and resolution, 
insights into the role of HR in DNA repair can be gained.  
 
4.5.1 Repair of cisplatin-induced DNA damage 
The repair of cisplatin-induced DNA damage involves both NER and HR as discussed in 
Chapter One, section 1.7.5.1. The modified alkaline Comet assay allows the detection 
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of the unhooking a interstrand crosslink from one or both strands of DNA; this is the 
first step in the repair of this type of lesion (Muniandy et al., 2010). This unhooking 
step can be detected by the modified alkaline Comet assay as a fall in the percentage 
reduction in tail moment, as the unhooked interstrand crosslink no longer retards the 
migration of DNA (Hartley et al., 1999). The measurement of γH2AX foci allows the 
assessment of DNA damage signalling and RAD51 the role of HR in the repair of 
cisplatin-induced DNA damage. Cisplatin was used at a concentration of 50 µM for two 
hours in the alkaline Comet assay and 1 µM for two hours to assess γH2AX and RAD51 
foci induction and resolution. 
 
4.5.1.1 Repair of cisplatin-induced DNA interstrand crosslinks 
Cells were pre-treated for the required duration, exposed to cisplatin for two hours 
and the culture media replaced every 24 hours for the duration of the experiment. To 
allow comparison between treatments data are normalised to the nine hour time 
point, which is the time point at which the greatest number of interstrand crosslinks 
are observed in cells treated with cisplatin only. Therefore, the nine hour time point  
becomes 100% for each drug combination investigated and other time points are 
expressed as a percentage of this point, so that a fall in the ‘percentage of peak tail 
moment’ represents the unhooking of interstrand crosslinks (Figure 4.10).  
 
The number of interstrand crosslinks increases following incubation with cisplatin 
peaking nine hours following removal of cisplatin (Figure 4.10). From 24 hours onwards 
fewer interstrand crosslinks are detected, indicating their unhooking. In cells treated 
with cisplatin alone 25.4±8.0% of the interstrand crosslinks present at nine hours 
remain at 72 hours (Figure 4.10).  
 
Exposure to gefitinib for one hour prior to cisplatin treatment slows the rate of 
unhooking of interstrand crosslinks, reaching a statistical significant difference from 
cisplatin only treated cells at 72 hours (cisplatin alone 25.4±8.0%, gefitinib one hour 
64.2±5.5 p≤0.01) (Figure 4.10). Exposure to gefitinib for 48 hours prior to cisplatin, 
significantly inhibits the unhooking of interstrand crosslinks, with no reduction in tail 
moment detected from 24 hours onwards (Figure 4.10).   
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Figure 4.10 Effect of duration of exposure to gefitinib on the repair of cisplatin-induced DNA 
damage 
The alkaline comet assay was used to assess the modulation of the repair of cisplatin-induced 
interstrand crosslinks by gefitinib. Cells were pre-treated with drug free media or gefitinib for 
one hour or 48 hours, followed by the addition of cisplatin (50 µM) for two hours. Media was 
then replaced with either fresh DFM or media containing gefitinib which was replaced every 24 
hours, and cells collected at the time points as indicated. Data are presented as mean±SEM of 
three independent experiments. * P≤ 0.05 compared with cisplatin alone.  
 
Like gefitinib, pre-treatment with lapatinib inhibits the unhooking of cisplatin-induced 
interstrand crosslinks with 77.3±11.0% remaining at 72 hours (Figure 4.11A).  In cells 
treated with lapatinib for 48 hours, there was a notable increase in dead cells 72 hours 
after exposure to cisplatin, making the unhooking of interstrand crosslinks difficult to 
study at 72 hours. In the first 48 hours following cisplatin exposure, lapatinib pre-
treatment for 48 hours does not significantly alter the unhooking of cisplatin-induced 
interstrand crosslinks (Figure 4.11B). This is in contrast to the effect of gefitinib 
exposure for 48 hours as demonstrated in Figure 4.12. 
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Figure 4.11 Effect of duration of exposure to lapatinib on the repair of cisplatin-induced DNA 
damage 
The alkaline comet assay was used to assess the modulation of the repair of cisplatin-induced 
interstrand crosslinks by lapatinib. Cells were pre-treated with drug free media or lapatinib for 
one hour or 48 hours, followed by the addition of cisplatin (50 µM) for two hours. Media was 
then replaced with either fresh DFM or media containing lapatinib, which was replaced every 
24 hours and cells collected at the time points as indicated. Data presented as mean±SEM of 
three independent experiments. * P≤ 0.05 compared with cisplatin alone.  
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Figure 4.12 Differences in the effect of gefitinib and lapatinib for 48 hours on the unhooking 
of interstrand crosslinks. 
SK-Br-3 cells were pre-treated with gefitinib or lapatinib for 48 hours prior to treatment with 
cisplatin (50 µM) for two hours. Media containing TKI was replaced every 24 hours, and cells 
collected for analysis at the time points indicated. Data are presented as mean±SEM of three 
independent experiments. * P≤ 0.05.  
 
4.5.1.2 Modulation of cisplatin-induced γH2AX foci by gefitinib 
γH2AX foci induction peaks 10 hours following removal of cisplatin and then falls (data 
not shown). The peak number of foci produced is not significantly altered by gefitinib, 
regardless of duration of treatment (Figure 4.13).  Pre-treatment with gefitinib for one 
hour slows the resolution of γH2AX foci with significantly more foci persisting at 48 
hours compared with cells treated with cisplatin alone (cisplatin alone 3.2±0.2 foci/cell 
vs. one hour gefitinib 11.8±2.8 foci/cell p≤0.05), though by 72 hours there are no 
significant differences (Figure 4.13).  In cells pre-treated with gefitinib for 48 hours, a 
reduction in γH2AX foci is observed at 24 hours after which no further resolution of 
foci can be detected with significantly more foci persisting at, 24, 48 and 72 hours 
compared with cells treated with cisplatin alone  (Figure 4.13). 
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Figure 4.13 Effect of duration of exposure to gefitinib on the resolution of γH2AX foci 
Measurement of γH2AX foci was used to assess the repair of cisplatin-induced DNA damage 
following pre-treatment with DFM, gefitinib for one hour or 48 hours prior to the addition of 
cisplatin (1 µM). Following incubation with cisplatin for two hours the media was replaced with 
fresh DFM or gefitinib for the duration of the experiment.  Data are presented as mean ±SEM 
of three independent experiments. * P≤ 0.05 compared with cisplatin alone.  
 
4.5.1.3 Modulation of cisplatin-induced RAD51 foci by gefitinib 
RAD51 foci induction peaks at a level of 20.6±1.2 foci/cell at 24 hours in cells treated 
with cisplatin alone and then falls, reaching baseline at 48 hours (Figure 4.14). In cells 
treated with gefitinib for one hour prior to cisplatin exposure, the peak level of RAD51 
foci is lower than that observed in cells treated with cisplatin alone at 13.3±6.0 
foci/cell, and takes 72 hours to reach baseline levels. Pre-treatment of cells with 
gefitinib for 48 hours prior to cisplatin alters the peak of Rad51 foci, which occurs later 
at 48 hours and at a lower number of 20.0±0.2 foci/cell, with no resolution of foci 
observed in the 72 hour duration of the experiment (Figure 4.14). 
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Figure 4.14 Effect of duration of exposure to gefitinib on the resolution of RAD51 foci 
Measurement of RAD51 foci was used to assess the repair of cisplatin-induced DNA damage 
following pre-treatment with DFM, gefitinib for one hour or 48 hours prior to the addition of 
cisplatin (1 µM). Following incubation with cisplatin for two hours the media was replaced with 
fresh DFM or gefitinib for the duration of the experiment, and cells collected for analysis over 
72 hours. Data are presented as mean±SEM of two independent experiments. *P≤ 0.05 
compared with cisplatin alone.  
 
4.5.2 The modulation of the repair of DNA single and double strand breaks by 
duration of exposure to lapatinib and gefitinib 
The repair of DNA strand breaks produced by IR was studied using the alkaline Comet 
assay together with measurement of γH2AX and RAD51 foci. To investigate the repair 
of doxorubicin and etoposide-induced DSBs the alkaline Comet assay and 
measurement of γH2AX foci were used. As with the assessment of cisplatin-induced 
DNA damage, multiple time points after the removal of the DNA damaging agent were 
examined. 
 
4.5.2.1 The repair of ionising radiation-induced DNA damage 
4.5.2.1.1 Repair of DNA strand breaks  
The repair of IR-induced DNA strand breaks was investigated over four hours using the 
alkaline Comet assay. These data were normalised to the tail moment observed 
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directly after irradiation. This allows the comparison between the different treatment 
combinations.  
 
DNA strand breaks induced by IR (20 Gy) were repaired rapidly with 78.7±3.9% 
repaired within 30 minutes and only 2.7±1.7% of strand breaks remaining at four hours 
(Figure 4.15A). Exposure to lapatinib, regardless of duration,  does not alter the repair 
of IR-induced DNA strand breaks compared with treated with IR alone (Figure 4.15A).   
 
Pre-treatment of cells with gefitinib delays the repair of IR-induced strand breaks 
compared with cells treated with IR alone (Figure 4.15B). At one hour significantly 
fewer DNA strand breaks are repaired in cells pre-treated with gefitinib for one hour 
(66.2±4.4%) compared with cells treated with IR alone (87.9±5.4% p≤0.05), though 
there are no significant differences at 30 minutes, two and four hours (Figure 4.15B).  
Exposure to gefitinib for 48 hours prior to IR produces a greater inhibition of repair 
with 34.2±6.4% of lesions repaired at 30 minutes, compared with 68.7±3.9% repaired 
in cells treated with IR alone (p<0.001), and 60.8±7.2% repaired at one hour compared 
with 87.9±5.4% repaired in cells treated with IR alone (p≤0.01). Four hours following 
exposure to IR nearly all DNA strand breaks are repaired regardless of the duration of 
gefitinib treatment (Figure 4.15B). 
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Figure 4.15 Effect of duration of exposure to lapatinib or gefitinib on the repair of ionising 
radiation-induced DNA strand breaks  
The modulation of repair of IR-induced strand breaks by (A) lapatinib and (B) gefitinib was 
assessed in the SK-Br-3 cell line. Cells were pre-treated with drug free media, lapatinib or 
gefitinib for one hour or 48 hours, before exposure to IR (20 Gy), and then collected at the 
times indicated and analysed using the alkaline Comet assay. Data are presented as 
mean±SEM of three independent experiments. * P< 0.05 compared with IR alone.  
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4.5.2.1.2 Modulation of ionising radiation-induced γH2AX foci by gefitinib 
To investigate the repair of IR-induced lesions by measuring γH2AX foci, IR 2 Gy was 
investigated over 24 hours (Figure 4.16A). As with previous experiments, a lower dose 
of IR was used to enable individual foci to be counted. There are no significant 
differences in the induction of γH2AX foci in cells treated with IR alone and those pre-
treated with gefitinib for one or 48 hours. Near complete resolution of foci is observed 
in all treatment arms by 24 hours, with 4.5±1.4 foci/cell remaining in cells treated with 
IR alone compared with 2.2±2.0 foci/cell with gefitinib one hour and 1.7±0.9 foci/cell 
with gefitinib 48 hours (p>0.05) (Figure 4.16A). Closer examination of Figure 4.16A 
suggests that there may be differences in γH2AX foci resolution in the first two hours 
following IR, which have been missed due to the time points examined. To examine 
this further the resolution of γH2AX foci was investigated over a five hour period.  As 
this experiment was conducted only once no statistical analysis can be conducted, but 
it appears that treatment with gefitinib, regardless of duration, slows the resolution of 
γH2AX compared to cells treated with IR alone over five hours (Figure 4.16B).  
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Figure 4.16 Effect of the duration of exposure to gefitinib on the resolution of ionising 
radiation-induced γH2AX foci 
The induction and resolution of γH2AX foci following IR was studied in cells pre-treated with 
DFM, gefitinib for one hour or 48 hours over (A) over 24 hours and (B) over 5 hours. For Figure 
A, data are presented as mean±SEM of three independent experiments. * P< 0.05 compared 
with IR alone. Figure B was performed once and is presented as the mean foci of 50 cells. 
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4.5.2.1.3 Modulation of ionising radiation-induced RAD51 foci 
In cells treated with IR alone, RAD51 foci peaks four hours later at 24.9±4.0 foci/cell, 
and falls to baseline at 24 hours (Figure 4.17). Pre-treatment of cells with gefitinib for 
one hour results in a similar modulation of RAD51 foci, peaking at 23.9±5.1 foci/cell 
and a falling to baseline expression at 24 hours. In cells pre-treated with gefitinib for 
48 hours prior to exposure to IR, RAD51 foci fail to resolve within the 24 hours 
duration of the experiment, with 21.5±1.8 foci/cell remaining at 24 hours (Figure 4.17). 
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Figure 4.17 Effect of the duration of exposure to gefitinib on the resolution of ionising 
radiation-induced RAD51 foci 
The induction and resolution of RAD51 foci following IR was studied in cells pre-treated with 
DFM, gefitinib for one hour or 48 hours over 24 hours. Data are presented as mean±SEM of 
three independent experiments. * P< 0.05 compared with IR alone.  
 
4.5.2.2 The repair of Topoisomerase II poison-induced DNA strand breaks 
4.5.2.2.1 Repair of doxorubicin-induced DNA damage 
4.5.2.2.1.1 Repair of doxorubicin-induced DNA strand breaks 
The effect of lapatinib or gefitinib on the repair of doxorubicin-induced DNA strand 
breaks was investigated using the alkaline Comet assay. A concentration of 5 μM 
doxorubicin was chosen for investigation as this is  a clinically achievable concentration 
in vivo and a concentration at which Topo IIα poisoning occurs, producing DNA single 
and double strand breaks (Gewirtz, 1999).  
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As with IR, data are expressed as a percentage of the tail moment achieved 
immediately following removal of the Topo II poison under investigation. In order to 
investigate the formation and resolution of γH2AX foci, a tenth of the dose of Topo IIα 
poison used for the Comet assay was investigated. 
 
Following doxorubicin treatment 41.8±4.3% of strand breaks are repaired within the 
first four hours and by 10 hours, 62.8±7.7% of strand breaks are repaired (Figure 
4.18A). 
 
Lapatinib exposure for one hour has no effect on repair of DNA lesions within the first 
four hours (Figure 4.18A). By eight and 10 hours an increase in DNA strand breaks can 
be observed in cells these cells compared with cells treated with doxorubicin alone, 
reaching a statistically significant difference at 10 hours (Figure 4.18A). Prior exposure 
to gefitinib for one hour also has no effect on the initial repair of doxorubicin-induced 
DNA lesions, but an increase in DNA strand breaks can be observed at 10 hours (Figure 
4.18B).  
 
Doxorubicin produced few detectable strand breaks in cells treated with either 
gefitinib or lapatinib for 48 hours, for the duration of the experiment, so their repair 
cannot be studied (data not shown). 
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Figure 4.18 Effect of duration of exposure to lapatinib or gefitinib on the repair of 
doxorubicin-induced DNA strand breaks 
The alkaline comet assay was used to assess the repair doxorubicin-induced DNA strand breaks 
in cells treated with (A) lapatinib and (B) gefitinib. Cells were pre-treated with drug free media, 
lapatinib or gefitinib for one hour, before incubation with doxorubicin (5 µM) for two hours. 
Media was removed and replaced with fresh DFM or TKI and cells collected at the times 
indicated. Data are presented as mean±SEM of three independent experiments. * P< 0.05 
compared with doxorubicin alone.  
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4.5.2.2.1.2 Modulation of doxorubicin-induced γH2AX foci by gefitinib 
γH2AX foci formation peaks six hours after removal of doxorubicin at 61.1±7.0 foci/cell 
and remains elevated for the duration of the experiment (Figure 4.19). Following 
gefitinib treatment for one hour, the peak of doxorubicin-induced γH2AX occurs earlier 
at four hours, with fewer foci 48.3±9.6 foci/cell and then falls so that at six hours cells 
have 53% fewer foci than cells treated with doxorubicin alone (29.0±4.1 vs. 61.1±7.0 
foci/cell respectively p ≤0.01) (Figure 4.19).  Following this initial fall in foci, no further 
resolution is observed so that 24 hours following exposure to doxorubicin, 43% fewer 
foci are present in cells pre-treated with gefitinib for one hour compared with cells 
treated with doxorubicin only (gefitinib one hour 31.9±8.2 foci/cell vs. doxorubicin 
alone 56.5±7.0 foci/cell P≤0.05).  Significantly fewer foci are produced by doxorubicin 
in cells pre-treated with gefitinib for 48 hours at all time points investigated (Figure 
4.19). 
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Figure 4.19 Effect of duration of exposure to gefitinib on the resolution of doxorubicin-
induced γH2AX foci 
γH2AX foci following doxorubicin was studied in cells pre-treated with DFM, gefitinib for one 
hour or 48 hours prior to the addition of doxorubicin (0.5µM) for two hours. Media was then 
replaced with fresh DFM or TKI and cells collected at the time points indicated Data are 
presented as mean±SEM of three independent experiments. *P< 0.05 compared with 
doxorubicin alone 
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4.5.2.2.2 Repair of etoposide induced DNA damage 
4.5.2.2.2.1 Repair of etoposide-induced DNA strand breaks 
Etoposide is used at a concentration of 150 µM, which is far higher than that 
achievable clinically. This concentration was chosen as it allows the repair of DNA 
strand breaks produced after TKI exposure for 48 hours to be investigated, given the 
rapid rate of repair of these lesions.  
 
Etoposide-induced DNA strand breaks are repaired rapidly with 8.5±1.6% of the peak 
number of foci, remaining four hours after the removal of etoposide and 5.2±1.1% at 
10 hours (Figure 4.20A). Pre-treatment with lapatinib for one hour significantly delays 
the repair of etoposide-induced DNA strand breaks (Figure 4.20A), at 30 minutes 
28.2±4.5% are repaired compared with 49.8±5.3% in cells treated with etoposide alone 
(p<0.001). This trend continues with 55.3±4.4% repaired at two hours in cells pre-
treated with lapatinib for one hour, compared with 76.3±2.7% in etoposide only 
treated cells (p <0.001) and 78.1±5.9% repaired at four hours compared with 
91.5±1.6% (p≤0.05); by 10 hours there are few remaining DNA strand breaks. 
 
In cells treated with lapatinib for 48 hours, the etoposide-induced DNA strand breaks 
are repaired more rapidly, with 83.5±5.1% repaired within the first 30 minutes, 
compared with 49.8±5.3% in cells treated with etoposide alone (p<0.001) and all 
strand breaks are repaired by two hours (Figure 4.20A).  
 
Like lapatinib, exposure to gefitinib for one hour delays the repair of etoposide-
induced DNA strand breaks (Figure 4.20B). Two hours after exposure to etoposide 
64.4±2.5% of strand breaks are repaired in cells pre-treated with gefitinib for one hour 
compared with 76.3±2.7% in cells treated with etoposide alone (p≤0.05). This 
difference is greater at four hours, when 76.5±4.6% of strand breaks are repaired in 
cells with prior exposure to gefitinib for one hour, compared with 91.5±1.6% repaired 
in etoposide only treated cells (P≤0.01) (Figure 4.20B). Like lapatinib, gefitinib exposure 
for 48 hour hours prior to etoposide treatment increases the rate of repair of DNA 
strand breaks, with all strand breaks repaired by two hours (Figure 4.20B). 
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Figure 4.20 Effect of duration of exposure to lapatinib or gefitinib on the repair of etoposide-
induced DNA strand breaks 
The alkaline comet assay was used to assess the repair doxorubicin-induced DNA strand breaks 
in cells treated with (A) lapatinib and (B) gefitinib. Cells were pre-treated with drug free media, 
lapatinib or gefitinib for one hour or 48 hours before incubation with etoposide (150 µM) for 
two hours. Media was removed and replaced with fresh DFM or TKI and cells collected at the 
times indicated. Data are presented as mean±SEM of three independent experiments. * P< 
0.05 compared with etoposide alone.  
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4.5.2.2.2.2 Modulation of etoposide-induced γH2AX foci by gefitinib 
Measurement of γH2AX foci following etoposide (15 µM) peaks at two hours with 
64.4±11 foci/cell and then falls to 30.6±9.3 foci/cell by eight hours (Figure 4.21). The 
peak of foci production is not altered by gefitinib pre-treatment for one hour, though 
there are 50% fewer foci at 24 hours compared with cells treated with etoposide alone 
(23.3±5.4 vs. 46.6±5.3 foci per cell p< 0.05).  Continuous gefitinib exposure for 48 
hours results in significantly fewer γH2AX foci produced following etoposide treatment 
at all time point investigated (Figure 4.21). 
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Figure 4.21 Effect duration of exposure to gefitinib on the resolution of etoposide-induced 
γH2AX foci 
γH2AX foci following etoposide was studied in cells pre-treated with DFM, gefitinib for one 
hour or 48 hours prior to the addition of etoposide  (15µM) for two hours. Media was then 
replaced with fresh DFM or TKI and cells collected at the time points indicated Data are 
presented as mean±SEM of three independent experiments. *P< 0.05 compared with 
etoposide alone.  
 
4.6 DOES THE DURATION OF EXPOSURE TO GEFITINIB OR LAPATINIB 
MODULATE THE CELL CYCLE RESPONSE TO DNA DAMAGING AGENTS? 
Cell cycle arrest plays a key role in the cellular response to DNA damage, creating time 
to repair damage and preventing the passage of damaged DNA to daughter cells (Dai 
and Grant, 2010).  The cell cycle also determines which mechanism of DNA repair cells 
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have available, with HR limited to late S and G2M-phases of the cell cycle (Dai and 
Grant, 2010). In order to assess the effect of gefitinib and lapatinib on the cell cycle 
response to cytotoxic chemotherapy, FACS as described in Chapter Two section 2.7 
was used to assess the cell cycle. To enable direct correlation with the Comet assay 
data presented above, cells were treated in exactly the same way. Cells were collected 
for analysis 24 hours after removal of the cytotoxic agent under investigation.  
 
4.6.1 The effect of gefitinib and lapatinib on the cell cycle 
Exposure to either gefitinib or lapatinib increases number of cells in the G0/G1-phase 
of the cell cycle. In cells treated with gefitinib for 25 hours (one hour followed by 
incubation for 24 hours), 81.6±5.2% cells are in G0/G1 compared with 69.9±0.3% of 
untreated cells (Table 4.1 and Figure 4.22). This increases to 87.5±1.2% in cells treated 
with gefitinib for 72 hours (48 hours followed by 24 hours incubation). Lapatinib 
treatment for 25 hours results in 88.1±1.2% of cells in G0/G1. Fewer cells are in this 
phase following treatment with lapatinib for 72 hours (73.6±1.1%) due to an increase 
in the number of cells in sub-G1. In untreated cells, 3.3±1.4% of cells are identified in 
sub-G1, 4.9±0.5% in cells treated with lapatinib for 25 hours and 19.0±1.4% in cell 
treated with lapatinib for 72 hours.  
 
Cell cycle phase  Sub-G1 (%) G0/G1 (%) S (%) G2M (%) 
DFM  3.3±1.5 70.0±0.3 11.1±1.6 15.7±2.6 
Gefitinib  1 hour  
(25 hours in total)  
10.6±3.8 81.6±5.2 3.1±0.1 5.1±1.0 
Gefitinib 48 hours  
(72 hours in total) 
5.1±0.6 87.5±1.2 2.4±0.6 5.4±0.1 
Lapatinib 1 hour  
(25 hours in total)  
4.9±0.5 88.1±1.2 2.4±0.3 4.8±0.8 
Lapatinib 48 hours  
(72 hours in total) 
19.0±1.4 73.6±1.1 3.2±0.6 4.6±1.2 
 
Table 4.1 Effect of duration of exposure to gefitinib or lapatinib on the cell cycle 
Cells were plated in cell culture flasks and left overnight to adhere. Cells were then treated 
with DFM or TKI with replacement of media±TKI every 24 hours. All cells were grown for 72 
hours in total and collected at the same time for analysis 24 hours after drug treatment. 
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Figure 4.22 Example of cell cycle analysis obtained using FACS 
SK-Br-3 cells were treated with gefitinib 5 µM for the duration indicated. Cells were collected 
24 hours following drug treatment. Therefore for gefitinib treatment for one hour, cells were 
collected for analysis after a further 24 hours, making a total 25 hours of exposure to gefitinib. 
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4.6.2 The effect of duration of exposure to gefitinib or lapatinib on the modulation of 
the cell cycle by cisplatin 
Cisplatin treatment increases the number of cells in S-phase of the cell cycle to 
14.4±2.5% compared with 11.1±1.8% in untreated cells (Figure 4.23A). This is also 
observed in cells pre-treated with TKI for one hour, with cisplatin treatment of cells 
exposed to gefitinib for one hour inducing 19.7±0.2% of cells into S-phase compared 
with 3.1±0.1% in cells treated with gefitinib alone. Similar results are observed with 
lapatinib pre-treatment for one hour with 12.3±1.7% cells in S-phase following cisplatin 
compared with 2.4±0.3% in cells treated with lapatinib alone (Figure 4.23A).  
 
The pre-treatment of cells with TKI for 48 hours produces different results to those 
described above. In cells pre-treated with gefitinib for 48 hours, smaller increases in 
the number of cells in the sub-G1 (gefitinib alone 5.1±0.6% vs. gefitinib+cisplatin 
8.9±1.6%) and S-phases (gefitinib alone 2.4±0.6% vs. gefitinib+cisplatin 6.8±4.4%) of 
the cell cycle are observed. Cisplatin does not significantly alter the cell cycle of cells 
pre-treated with lapatinib for 48 hours compared with cells treated with lapatinib 
alone for 48 hours (Figure 4.23A). 
 
4.6.3 The effect of duration of exposure to gefitinib or lapatinib on the modulation of 
the cell cycle by ionising radiation 
IR doubles the number of cells in the S (11.1±1.6% to 21.2±7.7%) and G2/M (15.9±2.6% 
to 38.5±12.0%) phases of the cell cycle compared with untreated cells (Figure 4.23B). 
In cells pre-treated with either gefitinib or lapatinib prior to IR, fewer cells arrest in the 
G2/M (gefitinib+IR 22.1±1.3%, lapatinib+IR 22.7±3.4% and IR alone 38.5±12.0%) or S 
phase of the cell cycle (gefitinib+IR 6.5±1.7%, lapatinib+IR 6.1±2.4% and IR alone 
21.2±7.7%). The pre-treatment of cells with either gefitinib or lapatinib for 48 hours 
prior to IR, prevents an IR-induced alteration in the cell cycle distribution of cells 
except for an increase in the number of cells in the sub-G1 phase in cells pre-treated 
with lapatinib from 19.7±1.1% with lapatinib alone to 28.2±4.1% following IR. 
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Figure 4.23 Modulation of the cell cycle response to cisplatin and ionising radiation by 
duration of exposure to gefitinib and lapatinib  
Cells were treated with drug free, media, gefitinib or lapatinib for one or 48 hours prior to the 
addition of (A) cisplatin (50 µM) for two hours or (B) IR (20 Gy), after which media was 
replaced +/- TKI. Cells were then incubated for a further 24 hours, prior to collection, fixation 
and staining with propidium iodide. The fluorescence of 10, 000 cells was measured using 
FACS. Data  presented as the mean of three independent experiments.  
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4.6.4 The effect of duration of exposure to gefitinib or lapatinib on the modulation of 
the cell cycle by doxorubicin 
Doxorubicin increases the number of cells in S-phase from 11.1±1.6% in untreated cells 
to 21.2±7.2% (Figure 4.24A). An increase in S-phase cells is also observed in cells pre-
treated with TKI for one hour (gefitinib alone 3.1±1.0% to 12.3±2.0% with 
gefitinib+doxorubicin, and lapatinib alone 2.4±0.3% to 14.3±1.7% with 
lapatinib+doxorubicin) (Figure 4.24A). An increase in the number of cells in sub-G1 is 
observed, both in cells treated with doxorubicin alone and those pre-treated with TKI 
for one hour (DFM 3.3±1.4% to 11.4±4.5%, gefitinib 10.6±3.8% to 17.0±8.6% and 
lapatinib 4.6±0.5% to 30.1±4.5%); this does not occur in cells 6pre-treated with TKI 
continuously for 48 hours (gefitinib 5.1±0.6% to 6.2±0.5% and lapatinib 19.0±1.4% to 
15.4±2.4% (Figure 4.24A).  
 
Overall doxorubicin does not significantly alter the cell cycle distribution of cells 
treated with either gefitinib or lapatinib continuously for 48 hour, prior to doxorubicin 
exposure (Figure 4.24A). 
 
4.6.5 The effect of duration of exposure to gefitinib or lapatinib on the modulation of 
the cell cycle by etoposide 
Etoposide increases the percentage of cells in S-phase from 11.1±1.6% to 34.0±2.3% 
(Figure 4.24B). This is also observed in cells treated with either gefitinib or lapatinib for 
one hour though, as with doxorubicin, the number of cells in S-phase is  lower than 
that induced by etoposide alone (gefitinib alone 3.1±1.0.% to 12.4±4.4% with 
gefitinib+doxorubicin, and lapatinib alone 2.4±0.3% to 10.8±1.0% with 
lapatinib+doxorubicin). Etoposide increases the number of cells in sub-G1 in both 
untreated cells and those pre-treated with TKI for one hour. Again like with 
doxorubicin, this increase is not observed in cells pre-treated with either TKI for 48 
hours (DFM 3.3±1.4% to 11.5±1.1%, gefitinib one hour 10.6±3.8% to 16.4±2.7%, 
lapatinib one hour 4.6±0.5% to 16.7±4.1%, gefitinib 48 hours 5.1±0.6% to 8.3±2.5%, 
and lapatinib 48 hours 19.0±1.4% to 13.5±2.8%) (Figure 4.24B). Like doxorubicin, 
etoposide does not alter the cell cycle distribution of cells which have been treated 
with either gefitinib or lapatinib for 48 hours. 
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Figure 4.24 Modulation of the cell cycle response to doxorubicin and etoposide by duration 
of exposure to gefitinib and lapatinib  
Cells were treated with drug free ,media, acute or chronic gefitinib or lapatinib prior to the 
addition of (A) doxorubicin (5 µM) for two hours or (B) etoposide (50 µM) for two hours, after 
which media was replaced +/- TKI. Cells were then incubated for a further 24 hours, prior to 
collection, fixation and staining with propidium iodide. The fluorescence of 10, 000 cells was 
measured using FACS. Data presented as the mean of three independent experiments.  
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4.7 THE EFFECT OF DURATION OF EXPOSURE TO GEFITINIB OR LAPATINIB 
ON THE INDUCTION OF APOPTOSIS BY ETOPOSIDE AND DOXORUBICIN 
Section 4.4.2.2 demonstrates that cells treated with gefitinib or lapatinib continuously 
for 48 hours are resistant to the induction of DNA strand breaks by the Topo II poisons 
doxorubicin and etoposide. In order to investigate if these effects result in resistance 
to the cytotoxic effects of doxorubicin and etoposide, the induction of apoptosis was 
assessed by measuring annexin V expression. 
 
4.7.1 The Annexin V assay 
Annexins are a family of proteins which bind to negatively charged phospholipids in a 
calcium dependent manner (Huerta et al., 2007). Phosphatidylserine residues are 
negatively charged phospholipids which make up the cytoplasmic surface of cell 
membranes (Huerta et al., 2007). Cells undergoing apoptosis develop membrane 
asymmetry resulting in the transport of phosphatidylserine residues to the cell surface, 
thus allowing the identification of apoptotic cells. Annexin V specifically binds to 
phosphatidylserine residues and through the conjugation annexin V to a fluorochrome, 
FACS can be used to identify fluorescent and therefore apoptotic cells. Dual staining of 
cells with both annexin V and a DNA binding dye allows differentiation between cells 
undergoing early and late apoptosis (Huerta et al., 2007) as during late apoptosis the 
cell membrane is disrupted, allowing the penetration of DNA binding dyes. Cells which 
have undergone non-apoptotic cell death are stained by the DNA binding dye due to a 
permeable cell membrane but do not bind annexin V and cells which are alive, remain 
unstained (Huerta et al., 2007). Classically propidium iodide is used in combination 
with annexin V conjugated to a fluorochrome. Propidium iodide emits fluorescence at 
615 nm, but doxorubicin also emits fluorescence at this wavelength, so propidium 
iodide could not be used in cells treated with doxorubicin (Figure 4.25C). Doxorubicin 
fluorescence is not detected at 660 nm allowing the use of the red fluorescent dye 
Sytox red, to be used as DNA stain instead (Figure 4.25D). 
 
4.7.1.1 Drug fluorescence  
Cells treated with either gefitinib or lapatinib for 48 hours emit a fluorescence which is 
detected in all four channels available for FACS (Figures 4.25E, F, G and H). This meant 
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that the boundaries denoting unstained and alive cells had to be altered for cells 
treated with either gefitinib or lapatinib for 48 hours. This potentially introduces 
inconsistencies when comparing cell treated with chemotherapy alone with cells pre-
treated with TKI followed by chemotherapy. However, comparisons can be made 
between cells which have been treated with the same TKI for the same duration. 
 
 
Figure 4.25 Fluorescence of doxorubicin, gefitinib and lapatinib  
The fluorescence of unstained cells following treatment with TKI was detected by the FACS 
machine.  Two channels were assessed, PE-Texas red which detects emission at a peak of 
615nm and APC, which measures peak emission at 660nm. 10,000 cells were assessed 
following treatment with (A + B) DFM, (C+D) doxorubicin 5 µM for 2 hours, (E+F) 5 µM gefitinib 
48 hours and (G+H) 2 µM lapatinib 48 hours.  Images are representative of two independent 
experiments.  
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4.7.2 The induction of apoptosis by tyrosine kinase inhibitors 
In untreated cells, 17.1±3.8% of cells are identified as undergoing apoptosis, compared 
with 20.3±0.4% and 19.6±0.6% in cells treated with gefitinib one or 48 hours 
respectively. A greater degree of apoptosis is detected in cells treated with lapatinib 
for one hour (25.7±0.1%) and 48 hours (45.6±1.9%) than gefitinib treated cells (Figure 
4.26). 
 
Figure 4.26 Induction of apoptosis by gefitinib or lapatinib 
Cells were treated with (A) DFM, (B) 5 µM gefitinib 1 hour (C) 2 µM lapatinib 1 hour, (D) 5 µM 
gefitinib 48 hours and (E) 2 µM lapatinib 48 hours. The fluorescence of 10, 000 cells was 
measured using FACS. Representative images for each experiment are presented. Data are 
presented as the mean±SD % of 10,000 cells from two independent experiments.  
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4.7.3 The induction of apoptosis by doxorubicin and etoposide 
In cells grown in the absence of any drug for the 72 hours duration of the experiment, 
17.1±3.8% of cells are identified as undergoing apoptosis (Figure 4.27). This number 
increases with the addition of 5 µM doxorubicin to 59.5%±3.0% and to 43.0±8.1% with 
etoposide 50 µM (Figure 4.27). 
 
Figure 4.27 Induction of apoptosis by doxorubicin and etoposide  
Cells were grown for 48 hours prior to treatment with (A) DFM, (B) doxorubicin (5 µM) or (C) 
etoposide (50 µM) for 2 hours. Cells were then incubated for a further 24 hours in DFM, prior 
to collection and processing. The fluorescence of 10, 000 cells was measured using FACS. 
Representative images for each experiment are presented. Data are presented as the 
mean±SD % of 10,000 cells from two independent experiments  
 
4.7.4 The induction of apoptosis by doxorubicin and etoposide in cells treated 
gefitinib or lapatinib for one hour 
Following gefitinib treatment for one hour, 20.3±0.4% of cells are identified as 
undergoing apoptosis (Figure 4.28A). Though doxorubicin increases this to 62±4.7%, 
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this is not higher that the 59.5±3.0% of cell identified as apoptotic with doxorubicin 
alone. Etoposide is able to increase the degree of apoptosis observed in gefitinib pre-
treated cells to 55.2±15.6%, which is greater than that produced by etoposide alone 
(43.0±8.1%)  (Figure 4.28).  
 
Figure 4.28 Induction of apoptosis by doxorubicin and etoposide following gefitinib exposure 
for one hour 
Cells were grown for 48 hours prior to treatment with gefitinib 5 µM for one hour (A)  followed 
by the addition doxorubicin (5 µM) (B) or etoposide (50 µM) (C) for two hours. Cells were then 
incubated for a further 24 hours in fresh media +/- gefitinib, prior to collection and processing. 
The fluorescence of 10, 000 cells was measured using FACS. Representative images for each 
experiment are presented. Data are presented as the mean±SD % of 10,000 cells from two 
independent experiments. 
 
Lapatinib treatment alone induces 25.7±0.1% of cells to undergo apoptosis (Figure 
4.29A). This increases to 50.6±1.5% in cells treated with doxorubicin following lapatinib 
for one hour, though this is lower than 59.5±3.0% of cells which are identified as 
apoptotic with doxorubicin alone. Etoposide increases the number of apoptotic cells 
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over both lapatinib alone (25.7±0.1%) and etoposide alone (43.0±8.1%) to 64.5±7.6% 
in cells pre-treated with lapatinib for one hour (Figure 4.29). 
 
 
Figure 4.29 Induction of apoptosis by doxorubicin and etoposide following lapatinib 
exposure for one hour 
Cells were grown for 48 hours prior to treatment with lapatinib 2 µM for one hour (A)  
followed by the addition doxorubicin (5 µM) (B), or etoposide (50 µM) (C) for two hours. Cells 
were then incubated for a further 24 hours in media +/- lapatinib, prior to collection and 
processing. The fluorescence of 10, 000 cells was measured using FACS. Representative images 
for each experiment are presented. Data are presented as the mean±SD % of 10,000 cells from 
two independent experiments. 
 
4.7.5 The induction of apoptosis by doxorubicin and etoposide in cells treated with  
gefitinib or lapatinib for 48 hours 
Gefitinib exposure for 48 hours induces 19.6±0.6% of cells to undergo apoptosis.  The 
addition of doxorubicin reduces this figure to 11.3±2.1% and 15.4±2.0% with etoposide 
(Figure 4.30). Similar results were seen in cells treated with lapatinib for 48 hours with 
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45.6±1.9% of cells treated with lapatinib alone undergoing apoptosis (Figure 4.31). This 
number is reduced by treatment with doxorubicin, to 22.3±7.7% and is unaltered by 
treatment with etoposide 45.6±7.2% (Figure 4.31). 
 
These results indicate that cells pre-treated with either gefitinib or lapatinib are 
rendered resistant to the cytotoxic effects of both doxorubicin and etoposide. Short 
exposure to gefitinib or lapatinib for one hour increases the cytotoxicity of etoposide 
but has little effect on doxorubicin-induced apoptosis 24 hours after exposure to the 
drug. 
 
Figure 4.30 Induction of apoptosis by doxorubicin and etoposide in cells treated with 
gefitinib continuously for 48 hours 
Cells were grown for 48 hours prior to treatment with gefitinib 5 µM for one hour (A)  followed 
by the addition doxorubicin (5 µM) (B), or etoposide (50 µM) (C) for two hours. Cells were then 
incubated for a further 24 hours in media +/- gefitinib, prior to collection and processing. The 
fluorescence of 10, 000 cells was measured using FACS. Representative images for each 
experiment are presented. Data are presented as the mean±SD % of 10,000 cells from two 
independent experiments.  
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Figure 4.31 Induction of apoptosis by doxorubicin and etoposide in cells treated with 
lapatinib continuously for 48 hours 
Cells were grown for 48 hours prior to treatment with lapatinib 2 µM for one hour (A)  
followed by the addition doxorubicin (5 µM) (B), or etoposide (50 µM) (C) for two hours. Cells 
were then incubated for a further 24 hours in media +/- lapatinib, prior to collection and 
processing. The fluorescence of 10, 000 cells was measured using FACS. Representative images 
for each experiment are presented. Data are presented as the mean±SD % of 10,000 cells from 
two independent experiments. 
 
4.8 DISCUSSION 
This chapter describes the results of investigations examining the effect of duration of 
exposure to gefitinib or lapatinib on the induction and repair of DNA lesions induced 
by cisplatin, IR, doxorubicin and etoposide. These data demonstrate that both lapatinib 
and gefitinib produce similar effects on the induction and repair of DNA lesions by 
doxorubicin and etoposide, but differ in their effects on cisplatin and IR-induced DNA 
lesions. The duration of exposure to either gefitinib or lapatinib prior to the addition of 
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DNA damaging agent alters the ability of doxorubicin and etoposide to induce DNA 
damage and alters the rate of repair of etoposide-induced DSBs. 
 
 4.8.1 The alteration of HER3, AKT and MAPK signalling by duration of lapatinib 
exposure 
Lapatinib inhibits the phosphorylation of HER3, AKT and MAPK within one hour (Figure 
4.5). With continued lapatinib treatment, both AKT and MAPK signalling resume at 48 
hours, though at a lower level than observed in untreated cells. Amin et al. have 
examined the effect of varying concentrations of lapatinib on HER, AKT and MAPK 
signalling (Amin et al., 2010). They report that concentrations of lapatinib as low as 50 
nM inhibit HER2, HER3, AKT and MAPK signalling within one hour. Despite continuous 
replacement of lapatinib every 24 hours, HER3, AKT and MAPK signalling resumes at 48 
hours onwards. However, this signalling is dependent upon the concentration of 
lapatinib used with 50 nM and 200 nM lapatinib allowing the full resumption of HER3, 
AKT and MAPK signalling. Concentrations of 1 µM lapatinib reduce the strength of 
signalling detected at 48 hours and 5 µM prevents HER3 and AKT phosphorylation with 
only slight MAPK phosphorylation detected at 48 hours; at all concentrations of 
lapatinib, no HER2 phosphorylation is detected (Amin et al., 2010). The mechanism 
through which HER3 is phosphorylated in the presence of HER2 inhibition is 
unresolved, but Amin et al. demonstrate an increase in HER2 and HER3 expression and 
that the reactivation of HER3 is driven by the initial reduction in AKT signalling induced 
by lapatinib (Amin et al., 2010). 
 
4.8.2 The modulation of the induction and repair of cisplatin-induced interstrand 
crosslinks by duration of exposure to gefitinib or lapatinib 
Cisplatin produces DNA interstrand and intrastrand crosslinks and DNA DSBs (Clingen 
et al., 2008). The pre-treatment of cells with TKI either for one or 48 hours does not 
significantly alter the number of interstrand crosslinks produced by cisplatin compared 
with those produced by cisplatin alone (Figure 4.6).  
 
One of the determinants of resistance to cisplatin is the ability to remove and repair 
the DNA damage produced by interstrand crosslinks. An early step in their repair is the 
unhooking of the crosslink from one strand of DNA (Clingen et al., 2008). The modified 
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alkaline Comet assay detects the unhooking of these lesions, allowing the investigation 
of this step in the repair process. γH2AX foci are also formed in response to cisplatin, 
due to the production of DNA DSBs produced by the collision of replication forks with 
interstrand crosslinks, and in response to their direct removal and repair (Clingen et 
al., 2008). The modulation of repair of cisplatin-induced DNA damage by gefitinib or 
lapatinib was investigated using the alkaline Comet assay together with the 
measurement of RAD51 and γH2AX foci induction and resolution. 
 
The pre-treatment of cells continuously with gefitinib for 48 hours markedly inhibits 
the unhooking of cisplatin-induced interstrand crosslinks (Figures 4.10). This 
observation is supported by the examination of γH2AX foci with persistence of foci for 
72 hours in cells pre-treated with gefitinib for 48 hours, in comparison with cells 
treated with cisplatin where the numbers of foci falls to baseline levels within 24 hours 
(Figure 4.13). The measurement of RAD51 foci indicates that these cells are unable to 
be repaired by the process of HR, as the number of foci remains raised for the 72 hours 
duration of the experiment (Figure 4.14). Gefitinib treatment for one hour has a lesser 
effect on the unhooking of interstrand crosslinks with a significant difference only 
detected at 72 hours (Figure 4.11). The resolution of γH2AX foci indicates a delay in the 
repair process though by 72 hours there are no significant differences in the number of 
residual foci compared with cells treated with cisplatin alone (Figure 4.13). The process 
of HR is active in cells pre-treated with gefitinib for one hour as demonstrated by a 
return to baseline levels of RAD51 foci within 72 hours (Figure 4.14). Though these 
data suggest that the process of HR maybe attenuated in these cells, as the peak 
number of foci is reduced compared with cells treated with cisplatin alone (Figure 
4.14). 
 
These data require careful consideration regarding the effect of cell cycle on cellular 
repair processes. It is established that the repair of interstrand crosslinks in replicating 
cells utilises different processes to those used in non-replicating cells (Knipscheer et 
al., 2009; Muniandy et al., 2010).  In replicating cells, cells treated with cisplatin alone 
accumulate in the S-phase of the cell cycle (Figure 4.23A). This indicates that 
recognition and repair is ongoing with activation of the S-phase checkpoint. Within S-
phase, replication coupled repair dominates and involves the collision of replication 
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forks with interstrand crosslinks to form a DSB and the attraction of proteins belonging 
to the Fanconi anaemia pathway to stalled replication forks (Knipscheer et al., 2009; 
Muniandy et al., 2010). Replication coupled repair has been demonstrated to involve 
multiple processes including NER, HR and TLS (Muniandy et al., 2010). In cells pre-
treated with either gefitinib or lapatinib for one hour, cell cycle analysis 24 hours after 
removal of cisplatin demonstrates a greater percentage of cells in S-phase compared 
with cells treated with either TKI alone (Figure 4.23A), indicating the activation of the 
S-phase check point and possibly that an attempt at repair is occurring even in the 
presence of TKI. This is supported by the Comet assay, γH2AX and RAD51 data which 
show gradual falls in the number of interstrand crosslinks, γH2AX and RAD51 foci 
(Figures 4.10, 4.13 and 4.14).  
 
In non-replicating cells, the presence of an interstrand crosslink can be detected by 
both the recognition of its distorting effect on the helical structure of DNA and during 
transcription, attracting recognition proteins linked to the NER, BER and MMR 
pathways (Muniandy et al., 2010). Cell cycle analysis demonstrates that cells treated 
with TKI for 48 hours alone enter G0/G1 cell cycle arrest, which is not altered by 
cisplatin (Figure 4.23A). In cells treated with gefitinib for 48 hours, no unhooking of 
interstrand crosslinks can be detected (Figure 4.10) and γH2AX and RAD51 foci do not 
resolve (Figures 4.13 and 4.14). Unlike the modified alkaline Comet assay, the 
measurement of γH2AX foci is not specific for the presence of an interstrand crosslink 
as they can be induced by the repair of other DNA damage, including DNA base repair 
(Banath et al., 2010; Clingen et al., 2008). This potentially explains why despite no 
unhooking of interstrand crosslinks is detected with gefitinib treatment for 48 hours, 
though around a third of γH2AX foci resolve (Figures 4.10 and 4.13). 
 
Lapatinib differs from gefitinib in its modulation of the repair of cisplatin-induced 
interstrand crosslinks. The Comet assay demonstrates that there is no significant 
inhibition of the unhooking interstrand crosslinks in cells pre-treated with lapatinib for 
48 hours, in comparison with no unhooking detected in cells treated with gefitinib for 
the same duration (Figure 4.12).   
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4.8.3 The modulation of the induction and repair of ionising radiation-induced DNA 
strand breaks by duration of exposure to gefitinib or lapatinib 
The induction of DNA stand breaks by IR is not altered by either gefitinib or lapatinib, 
or the duration of exposure (Figure 4.8). Marked differences are observed between the 
effects of gefitinib and lapatinib on the repair of IR-induced strand breaks (Figure 
4.15). Lapatinib, regardless of the length of treatment, has no effect on the repair of 
IR-induced DNA strand breaks (Figure 4.15A), though gefitinib for one or 48 hours 
exposure slows the repair of DNA strand breaks as assessed using the alkaline Comet 
assay (Figure 4.15B).  These results cannot be explained by alterations in cell cycle as 
both lapatinib and gefitinib produced similar effects when given for one hour or 
continuously for 48 hours (Figure 4.23) indicating that the modulation of the repair by 
gefitinib but not lapatinib may be due to differences between the two drugs.  
 
4.8.4 Differences between the effects of gefitinib and lapatinib? 
Data examining the repair of cisplatin-induced interstrand crosslinks and IR-induced 
DNA strand breaks following treatment with TKI for 48 hours provides evidence that 
the effect of lapatinib and gefitinib are not the same, despite both inhibiting EGFR and 
HER2 signalling and producing similar effects on the cell cycle.   
 
Differences between the effects of EGFR targeted TKIs (gefitinib, erlotinib, AG1487) 
and HER2 targeted TKIs (lapatinib and AG825) are supported by the literature. Firstly 
AG1487 and gefitinib, whilst inhibiting the phosphorylation of EGFR, induce the 
formation of EGFR homo and heterodimers and the binding of EGF (Arteaga et al., 
1997; Liao and Carpenter, 2009; Lichtner et al., 2001) whereas lapatinib does not (Liao 
and Carpenter, 2009). Liao et al. demonstrate that the anti-EGFR antibody cetuximab 
promotes the internalisation and nuclear transport of EGFR, which is further enhanced 
by the EGFR targeted TKIs erlotinib, gefitinib and AG1478 (Liao and Carpenter, 2009). 
However, lapatinib (1 µM) is not able to enhance cetuximab-induced nuclear 
transport, but actually blocks it (Liao and Carpenter, 2009).  
 
Further differences between HER2 targeted TKIs and EGFR targeted TKIs can be 
derived from differences in their ability to sensitise cells to IR. Erlotinib (5 µM) is able 
to sensitise cells to the effects of IR as measured by the ability of two lung cancer cell 
195 
 
lines to form colonies, yet the HER2 TKI AG825 (10 µM) has no effect on colony 
formation over IR alone (Toulany et al., 2010). At the concentrations of erlotinib and 
AG825 investigated both drugs produce similar effects on HER and PI3K/AKT signalling 
when given as single agents (Sergina et al., 2007), yet erlotinib inhibits IR-induced AKT 
activation, but AG825 does not (Toulany et al., 2010).  
 
Differences also occur in the production of HER2 cleavage products by IR with IR-
induced activation of HER2 occurring through dimerisation with EGFR, producing the 
phosphorylated HER2 cleavage products p95 and p135 (Toulany et al., 2010). Inhibition 
of EGFR by the TKI BIBX13682BS inhibits their production yet the HER2 targeted TKI 
AG825 does not, suggesting that despite EGFR and HER2 inhibition, dimerisation and 
the production of HER2 cleavage products can still occur (Toulany et al., 2010). 
Together these data may indicate that gefitinib and lapatinib have different effects on 
cellular process, despite both inhibiting EGFR, HER2 and HER3 phosphorylation. 
 
Resistance to the cytotoxic effects of IR have been linked to the ability to modulate the 
localisation and activity of DNA-PK (Dittmann et al., 2005a; Dittmann et al., 2005b; 
Mahaney et al., 2009). IR-induced DNA-PK activity is reduced by cetuximab (Dittmann 
et al., 2005b) and gefitinib (Friedmann et al., 2006) and phosphorylation of DNA-PK 
catalytic subunit can be inhibited by erlotinib or the knockdown of HER2 by siRNA, but 
not by the TKI, AG825 (Toulany et al., 2010). Treatment with cetuximab inhibits the 
nuclear transport of both EGFR and DNA-PK in response to IR, with 
immunoprecipitation experiments demonstrating their co-localisation in the cytoplasm 
(Dittmann et al., 2005b). Additionally, DNA-PK is involved in the repair of cisplatin-
induced DNA damage (Friedmann et al., 2006; Shao et al., 2008) and nuclear EGFR 
promotes resistance to cisplatin (Hsu et al., 2009).  
 
Together these data suggest that differences between the effects of gefitinib and 
lapatinib on EGFR dimerisation, nuclear transport and activation of DNA-PK may 
explain the TKI dependent differences on the repair of cisplatin and IR-induced DNA 
damage presented in this chapter. NHEJ is the main pathway in mammalian cells, at all 
stages of the cell cycle, by which IR-induced DNA damage is repaired and DNA-PK plays 
a key role in this system (Mahaney et al., 2009). The fact that lapatinib, regardless of 
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duration, has no effect on the repair of IR-induced DNA strand breaks could be due to 
the failure of lapatinib to inhibit the phosphorylation of DNA-PKcs as demonstrated by 
Toulany et al. (Toulany et al., 2010).  
 
The repair of interstrand crosslinks is more complicated utilising a number of different 
DNA repair pathways. The increase in cells in S-phase following cisplatin alone and 
following TKI exposure for one hour, suggests involvement of the Fanconi anaemia 
DNA repair proteins which activate the S-phase checkpoint (Knipscheer et al., 2009; 
Muniandy et al., 2010). This is not observed following TKI exposure for 48 hours, when 
cells are in G0/G1 arrest. This may mean that cells are more reliant upon DNA-PK to 
repair cisplatin-induced DNA damage, explaining why cells treated with lapatinib for 48 
hours are able to repair interstrand crosslinks (DNA-PKcs still active) in contrast to 
gefitinib where no repair is seen (DNA-PKcs inhibited).  
 
Data from our own laboratory demonstrates that EGFR needs to be in an active 
conformation in order to bind the DNA-PK catalytic subunit (Liccardi et al., 2011). 
Gefitinib, erlotinib and AG1487 also bind and stabilise EGFR when it is in an active 
conformation (Johnson, 2009). However, lapatinib only binds to EGFR when it is in an 
inactive conformation (Johnson, 2009) and therefore is not able to bind EGFR which is 
bound to the DNA-PK catalytic subunit, which may explain why no alteration in the 
repair of IR-induced DNA lesion is observed in lapatinib treated cells.   
 
4.8.5 The modulation of the induction and repair of doxorubicin and etoposide-
induced DNA strand breaks by duration of exposure to gefitinib or lapatinib 
In contrast to cisplatin and IR, both doxorubicin and etoposide induce fewer DNA 
strand breaks in cells treated with TKI for 48 hours, as detected by both the alkaline 
Comet assay and measurement of γH2AX foci (Figure 4.9, 4.19 and 4.20). This 
translates into resistance to Topo II poison-induced apoptosis, with fewer cells 
undergoing apoptosis following treatment with TKI for 48 hours, than observed with 
TKI alone (Figures 4.30 and 4.31). Therefore, the treatment of cells with TKI for 48 
hours renders them resistant to the cytotoxic effects of doxorubicin and etoposide 
through the inhibition of the production of DNA strand breaks. 
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Another interesting observation is that doxorubicin, at all concentrations examined, is 
unable to induce significant numbers of DNA strand breaks in cells treated with TKI for 
48 hours. However, etoposide induces strand breaks in a concentration-dependent 
manner, though at a significantly lower level than produced by etoposide alone, or in 
cells pre-treated with TKI for one hour (Figure 4.9). These breaks are also repaired 
more quickly than those produced by etoposide alone or in cells pre-treated with TKI 
for one hour (Figures 4.20). This indicates that either the mechanism of repair, or the 
type of DNA lesions produced by etoposide following TKI treatment for 48 hours, are 
different. The latter hypothesis is supported by data from analysis of γH2AX foci. 
Etoposide-induced DNA DSBs correlate with the induction of γH2AX foci, allowing its 
use as a surrogate marker for DSBs (Smart et al., 2008). In cells pre-treated with 
gefitinib for 48 hours, significantly fewer foci are induced by etoposide or doxorubicin 
(Figures 4.19 and 4.21). This observation is not due to inhibition of γH2AX foci 
production in cells treated gefitinib for 48 hours, as both cisplatin and IR induce similar 
peak levels of foci in cells treated under the same conditions  (Figures 4.13 and 4.16) 
nor is it due to the reduced concentration of chemotherapy drug used, as significantly 
more foci are induced in cells treated with chemotherapy drug alone, than in cells pre-
treated with gefitinib for 48 hours (Figures 4.19 and 4.21). Therefore, these data 
indicate that following gefitinib treatment for 48 hours, etoposide is unable to induce 
DNA DSBs, as indicated by a fall in peak foci production from 64.3±11 foci/cell with 
etoposide alone, to 9.6±3.0 foci/cell in cells pre-treated with gefitinib for 48 hours, 
representing an 85% fall in the production of DNA DSBs (Figure 4.21). The production 
of DNA DSBs by etoposide is reported to represent only 3% of the strand breaks 
produced by the drug, with the remaining 97% accounted for by single strand breaks 
(Muslimovic et al., 2009). This may explain why the alkaline Comet assay continues to 
detect etoposide-induced strand breaks in cells treated with TKI for 48 hours but there 
is a marked reduction in the production of γH2AX foci under the same conditions 
(Figure 4.21). 
 
The alkaline Comet assay data does not demonstrate any modulation of the repair of 
doxorubicin-induced strand breaks by TKI exposure for one hour, though there are 
significantly more strand breaks at 10 hours compared with doxorubicin alone, 
indicating a second process which produces strand breaks coming into play (Figure 
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4.18). γH2AX foci following gefitinib for one hour also produces an interesting 
observation, with the peak of foci occurring earlier and at a lower level than in cells 
treated with doxorubicin alone (Figure 4.19). Additionally, γH2AX foci start to fall six 
hours after removal of doxorubicin in gefitinib pre-treated cells, indicating a delay but 
not inhibition of foci resolution (Figure 4.19). The significance of the resolution of 
γH2AX foci in terms of cell survival is unclear, as foci are part of a signalling system and 
their removal does not necessarily indicate that DNA has been fully repaired. However, 
persistence of γH2AX foci at 24 hours is linked to cell death (Banath et al., 2010).  
 
Pre-treatment of cells with TKI for one hour modulates the repair of etoposide induced 
DNA strand breaks by delaying, but not inhibiting their repair as assessed by the 
alkaline Comet assay (Figure 4.20). This indicates that TKIs interfere with DNA repair 
processes though these can be overcome, as demonstrated by near complete repair of 
strand breaks by 10 hours, fewer residual γH2AX foci at 24 hours and no increase in 
apoptosis (Figures 4.20, 4.21, 4.30 and 4.31).  
 
4.8.6 The induction of DNA strand breaks by doxorubicin  
Doxorubicin produces DNA strand breaks through interaction with Topo IIα directly 
and through non-Topo IIα methods, with strand breaks produced after the removal of 
the drug through production of ROS for example (Binaschi et al., 1990; Yan et al., 
2009). This may explain the observed increase in DNA strand breaks after removal of 
doxorubicin observed in cells pre-treated with TKI for one hour and would be expected 
in cells pre-treated with TKI for 48 hours (Figure 4.18). The fact that in cells pre-treated 
with TKI for 48 hours, significant numbers of DNA strand breaks are not induced by 
doxorubicin, even at 24 hours indicates that not only is doxorubicin unable to poison 
Topo IIα, it is also unable to produce non-Topo IIα mediated DNA damage in these 
cells.  
 
4.9 CONCLUSIONS 
Continuous exposure to the TKI gefitinib or lapatinib for 48 hours induces the 
reactivation of both AKT and MAPK signalling, despite initial inhibition. TKIs modulate 
both the induction and repair of DNA lesions, in a manner dependent upon the TKI 
drug, the duration of TKI inhibition and the type of DNA damaging agent. Cells pre-
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treated with TKIs for 48 hours are resistant to the DNA damaging effects of 
doxorubicin and etoposide but not the induction of DNA lesions by IR or cisplatin.   
 
Lapatinib and gefitinib differ in their ability to modulate the repair of cisplatin-induced 
interstrand crosslinks and IR-induced DNA damage. Lapatinib does not affect the repair 
of IR-induced DNA damage and its inhibition of the repair of cisplatin-induced 
interstrand crosslinks is less pronounced than gefitinib, which inhibits the repair of 
both cisplatin and IR-induced DNA damage in cells pre-treated for 48 hours.  
 
Both TKIs investigated produce similar effects on the repair of DNA lesions induced by 
etoposide and doxorubicin, with TKI treatment for one hour inhibiting repair. In 
contrast, fewer DNA strand breaks were induced in cells treated with either TKI 
continuously for 48 hours and these breaks were repaired more quickly. This 
observation may be explained by an alteration in the type of lesion induced by Topo II 
poisons in cells following exposure to gefitinib or lapatinib continuously for 48 hours. 
 
Further work is needed to elucidate the reasons why gefitinib is able to modulate the 
repair interstrand crosslinks and IR-induced DNA damage yet lapatinib is not, and 
whether this translates into differences in cytotoxicity. If the inhibition of DNA 
interstrand crosslinks and DNA repair by gefitinib translates into increased cytotoxicity, 
a greater level of apoptosis should be observed in cells pre-treated with gefitinib prior 
to cisplatin or IR, compared with either agent alone or cells treated with lapatinib for 
48 hours. The induction of γH2AX foci by cisplatin or IR in cells pre-treated with 
lapatinib for 48 hours would also be expected to demonstrate no significant alteration 
in the peak number of foci or their resolution. If these results confirmed that gefitinib 
inhibits the repair of cisplatin and IR-induced DNA damage but lapatinib does not, one 
potential explanation is a difference in the modulation of DNA-PK by EGFR between 
the two drugs. A direct comparison between the two TKIs on DNA-PKcs 
phosphorylation, activity and nuclear transport in response to cisplatin or IR would be 
expected to demonstrate inhibition by gefitinib but not lapatinib. 
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The modulation of the cellular effects of topoisomerase 
II poisons by duration of exposure to gefitinib or 
lapatinib 
 
5.1 INTRODUCTION 
The results presented in Chapter Four demonstrate that continuous exposure to 
gefitinib or lapatinib induces resistance to the cytotoxic effects of the Topo II poisons 
doxorubicin and etoposide, in part through the inhibition of DNA strand break 
production. Resistance to Topo II poisons can be mediated through a reduction in 
intracellular drug concentration, Topo II expression or Topo II activity as discussed in 
Chapter One section 1.7.3. This chapter describes investigations into the mechanism 
by which exposure to TKIs renders cells resistant to the cytotoxic effects of Topo II 
poisons.  
 
5.1.1 Topoisomerase II poisons 
A number of chemotherapy drugs used in the management of a wide variety of 
cancers poison Topo II, including doxorubicin, epirubicin, etoposide, mitoxantrone and 
m-AMSA. These drugs can be grouped according to their dependence on ATP or their 
ability to intercalate DNA (Nitiss, 2009b). Both doxorubicin and etoposide are classified 
as ATP-dependent Topo II poisons, with ATP depletion preventing their poisoning of 
Topo II and the induction of DNA breaks (Sorensen et al., 1999). Doxorubicin is an 
intercalating Topo II poison in contrast with etoposide, which is an non-intercalating 
drug (Nitiss, 2009b). In order to investigate whether TKI-induced resistance to the DNA 
damaging effects of Topo II poisons is due to their dependence on ATP, two further 
drugs m-AMSA and menadione were investigated. 
 
5.1.1.1 M-AMSA 
M-AMSA is an intercalating Topo II poison and is used in the systemic management of 
acute myeloid leukaemia (Nitiss, 2009b). Its dependence on ATP is not clear with in 
vitro studies demonstrating both ATP-independence (Sorensen et al., 1999) and ATP-
dependence (Wang et al., 2001). 
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5.1.1.2 Menadione (vitamin K3)  
Menadione is a synthetic compound that was chosen for investigation due to its 
classification as an ATP-independent Topo II poison (Sorensen et al., 1999; Wang et al., 
2001).  However, recent reports have confirmed that the drug’s main mechanism of 
action is through the depletion of glutathione, increasing the production of ROS 
producing single stranded DNA breaks (Marchionatti et al., 2009). 
 
5.1.2 Inhibition of the induction of DNA double strand breaks 
The γH2AX data presented in Chapter Four indicates that exposure to either gefitinib 
or lapatinib for 48 hours reduces the induction of γH2AX in response to doxorubicin 
and etoposide. DNA DSBs induce γH2AX foci and are often used as a surrogate marker 
for the identification of these lesions (Bonner et al., 2008). However, γH2AX foci 
induction is reliant upon the activity of PI3K-like kinases including DNA-PK, ATM and 
ATR (Bonner et al., 2008). The data presented in Chapter Four demonstrates that the 
induction of γH2AX foci by cisplatin or IR is not significantly altered by the duration of 
exposure to gefitinib, indicating that the mechanism for the formation of foci is not 
inhibited. Therefore, a reduction in the number of γH2AX foci induced by doxorubicin 
and etoposide observed in cells treated with TKI for 48 hours may indicate a reduction 
in the numbers of DNA DSBs produced under these conditions.   
 
A mechanism for assessing the presence of DNA DSBs more directly is the neutral 
Comet assay (discussed further in section 5.9.1). This assay was used to assess the 
modulation of the ability of Topo II poisons to induce DNA DSBs in cells treated with 
gefitinib for one or 48 hours. 
 
5.1.3 Modulation of topoisomerase II expression and activity by tyrosine kinase 
inhibitors 
Resistance to Topo II poisons can be mediated by a variety of methods and the 
literature supports two possible connections with HER inhibition. As demonstrated in 
Chapter Four, TKIs induce a G0/G1 cell cycle arrest, a state which is linked to reduced 
expression of Topo IIα (Pommier et al., 2010), which may be one mechanism through 
which resistance to doxorubicin and etoposide is mediated. The second mechanism is 
through an alteration in Topo II activity. Active Topo II, producing cleavable complexes, 
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is essential for Topo II poisons to function as they prevent the religation of the DNA 
DSB contained within the cleavable complex. Topo II poison activity is associated with 
the phosphorylation of Topo IIα at serine 1106 with hypophosphorylation at this site 
inducing resistance to the cytotoxic effects of both m-AMSA and etoposide (Chikamori 
et al., 2003).  Serine 1106 is phosphorylated by casein kinase Iδ (Grozav et al., 2009) an 
enzyme which is inhibited by gefitinib (Brehmer et al., 2005). Therefore, TKIs may 
inhibit the activity of the Topo II enzyme and induce resistance to Topo II poisons. 
 
5.2 AIMS 
 
1. Does the duration of exposure to gefitinib or lapatinib modulate the induction 
of DNA strand breaks by m-AMSA and menadione? 
2. Does duration of exposure to gefitinib and lapatinib modulate the expression 
and activity of Topo II? 
3. Does the reduction of Topo IIα expression modulate the production of DNA 
strand breaks by Topo II poisons? 
4. Does the duration of exposure to gefitinib modulate the production of DNA 
DSBs by Topo II poisons as detected by the neutral Comet assay? 
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5.3 THE EFFECT OF DURATION OF EXPOSURE TO GEFITINIB OR 
LAPATINIB ON THE DNA DAMAGING EFFECTS OF M-AMSA AND 
MENADIONE 
The ability of m-AMSA and menadione to induce DNA strand breaks in SK-Br-3 cells 
following exposure to gefitinib or lapatinib was assessed using the alkaline Comet 
assay. 
 
5.3.1 Induction of DNA strand breaks by m-AMSA and menadione 
M-AMSA induces strand breaks in a concentration dependent manner which is not 
significantly altered by the duration of exposure to either gefitinib or lapatinib (Figure 
5.1).  
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Figure 5.1 Effect of duration of exposure to gefitinib or lapatinib on the Induction of DNA 
strand breaks by m-AMSA  
The alkaline comet assay was used to assess the induction of DNA strand breaks by m-AMSA. 
Cells were pre-treated with either DFM (), gefitinib 1 hour (), gefitinib 48 hours (), 
lapatinib 1 hour (), or lapatinib 48 hours (), before addition of m-AMSA one hour.  Data 
are presented as the mean±SEM, *p<0.05 compared with m-AMSA. 
 
The inducer of ROS, menadione, also induces DNA strand breaks in a concentration 
dependent manner. This is not altered by the pre-treatment of cells with gefitinib for 
one hour, though significantly more strand breaks are induced in cells treated with 
gefitinib for 48 hours; this meant that concentrations above 25 µM could not be 
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examined due to the high levels of dead cells detected using the Comet assay following 
pre-treatment with gefitinib for 48 hours (Figure 5.2). 
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Figure 5.2 Effect of duration of exposure to gefitinib on the induction of DNA strand breaks 
by menadione 
The alkaline comet assay was used to assess the induction of DNA strand breaks by menadione 
Cells were pre-treated with either DFM (), one hour gefitinib (), 48 hours gefitinib () 
before the addition of menadione for one hour. Data are presented as the mean±SEM, 
*p<0.05 compared with menadione alone 
 
5.3.2 Repair of m-AMSA-induced DNA damage 
The repair of DNA strand breaks was assessed by examining the resolution of Comet 
tails as detected by the alkaline Comet assay and γH2AX foci following the treatment 
of cells with m-AMSA.  
5.3.2.1 Repair of m-AMSA-induced DNA strand breaks 
For the assessment of the repair of m-AMSA–induced DNA strand breaks, data are 
expressed as a percentage of the tail moment obtained immediately following 
incubation with m-AMSA. The repair of all strand breaks is completed within 72 hours 
in all drug combinations (Figure 5.3). Pre-treatment with TKI increases the rate of 
repair with 57.3±2.3% and 68.6±6.1% of strand breaks repaired within 30 minutes in 
cells treated with gefitinib for one or 48 hours and 46.5±7.0% and 54.5±1.2% of strand 
breaks in cells treated with lapatinib for one or 48 hours. This compares with only 
32.2±3.8% in cells treated with m-AMSA alone (P<0.05) (Figure 5.3). Therefore, 
205 
 
exposure to gefitinib or lapatinib, regardless of duration, increases the rate of repair of 
m-AMSA-induced DNA strand breaks as detected by the alkaline Comet assay.  
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Figure 5.3 Effect of duration of exposure to gefitinib or lapatinib on the repair of m-AMSA-
induced DNA strand breaks 
The repair of DNA strand breaks was assessed using the alkaline comet assay. Cells were pre-
treated with either DFM, (A) gefitinib or (B) lapatinib for one or 48 hours before the addition of 
m-AMSA (5 µM) for one hour. Media was replaced ±TKI and cells harvested at the indicated 
time points. Data are presented as the mean±SEM of three independent experiments. *p>0.05 
compared with m-AMSA alone.  
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5.3.2.2 Modulation of m-AMSA-induced γH2AX foci by gefitinib 
The induction of γH2AX foci by m-AMSA (0.5 µM) peaks at four hours at 39.3±3.5 
foci/cell. A small fall in foci occurs between four and six hours but then no further 
resolution of foci is observed (Figure 5.4). Exposure to gefitinib for one hour reduces 
the peak number of γH2AX foci to 29.1±4.5foci/cell, though this is not statistically 
significant. There is also no significant difference in the rate of resolution of γH2AX foci 
between cells treated with m-AMSA only and those pre-treated gefitinib for one hour 
(Figure 5.4). In cells treated with gefitinib for 48 hours, the peak of γH2AX foci 
induction is significantly reduced to 2.1±0.8 foci/cell (p<0.01), with significantly fewer 
foci observed at all time points for the duration of the experiment (Figure 5.4). These 
data indicate that fewer γH2AX foci are produced in cells pre-treated with gefitinib for 
48 hours at all time points investigated suggesting that fewer DNA DSBs are produced 
under these conditions. 
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Figure 5.4 Effect of the duration of exposure to gefitinib on the induction and resolution of 
m-AMSA-induced γH2AX foci 
The induction and resolution of γH2AX foci following m-AMSA was studied in cells pre-treated 
with DFM or gefitinib for one or 48 hours before the addition of m-AMSA (0.5 µM) for one 
hour. Media was replaced±TKI and cells harvested at the indicated time points. Data are 
presented as the mean±SEM of three independent experiments. *p>0.05 compared with m-
AMSA alone.  
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5.4 THE MODULATION OF M-AMSA-INDUCED CELL CYCLE ARREST AND 
CYTOTOXICITY BY TYROSINE KINASE INHIBITION 
5.4.1 Modulation of m-AMSA-induced cell cycle arrest by gefitinib or lapatinib 
The effects of m-AMSA on the cell cycle were assessed in cells 24 hours after exposure 
to m-AMSA for one hour. M-AMSA (5 µM) increases the number of cells in S-phase to 
40.9±6.9% from 11.1±1.6% in untreated cells (Figure 5.5). An m-AMSA-induced 
increase in S-phase is also observed in cells pre-treated with gefitinib for one hour with 
13.2±2.0% cells in S-phase compared with 3.1±1.0% in cells treated with gefitinib 
alone, though this is lower than the 40.9±6.9% of cells in S-phase following m-AMSA 
alone (Figure 5.5). Similar results are obtained with exposure to lapatinib for one hour 
with 2.3±0.3% of lapatinib only treated cells in S-phase compared with 11.8±2.8% in 
cells treated in combination with m-AMSA. M-AMSA does not alter the cell cycle in 
cells pre-treated with either gefitinib or lapatinib continuously for 48 hours (Figure 
5.5). 
 
Figure 5.5 Effect of m-AMSA on the cell cycle 
SK-Br-3 cells were treated with gefitinib or lapatinib for one or 48 hours prior to the addition of 
5 µM m-AMSA for one hour. Cells were collected 24 hours later and the DNA content analysed 
by staining with propidium iodide. Data presented as the mean of three independent 
experiments.  
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5.4.2  Modulation of m-AMSA-induced apoptosis by gefitinib or lapatinib 
M-AMSA induces 56.5±4.7% of cells to undergo apoptosis 24 hours after exposure, 
compared with 17.1±3.8% in untreated cells, as assessed by the measurement of 
annexin V (Table 5.1 and Figure 5.6). In cells pre-treated with gefitinib or lapatinib for 
one hour, 64.1±13.9% or 64.8±10.3% of cells respectively are undergoing apoptosis, 
compared with 20.3±0.4% and 25.7±0.1% with either TKI alone. M-AMSA is unable to 
induce apoptosis in cells treated with continuously either TKI for 48 hours over that 
produced by TKI alone, with 18.1±1% and 43.0±8.3% of cells treated with gefitinib or 
lapatinib respectively undergoing apoptosis compared with 19.6±0.6% and 45.6±1.9% 
apoptosis observed in cells treated with TKI alone (data for TKI alone presented in 
Chapter 4, 4.7.2). 
 
 
 
m-AMSA 5 µM + 
Alive±SD 
(%) 
Apoptosis±SD 
(%) 
Necrotic±SD 
(%) 
DFM 41.5±4.6 56.5±4.7 2.1±0.1 
Gefitinib 1 hour 34.7±13.6 64.1±13.9 1.2±0.4 
Gefitinib 48 hours 81.6±1.9 18.1±1.9 0.3±0.1 
Lapatinib 1 hour 34.0±9.5 64.8±10.2 1.2±0.7 
Lapatinib 48 hours 55.3±10.4 43.0±8.3 1.6±2.1 
 
Table 5.1 Induction of apoptosis by m-AMSA in cells treated with gefitinib or lapatinib 
Cells were treated with drug free media, gefitinib for 1 or 48 hours or lapatinib for 1 or 48 
hours hour. Cells were then treated with m-AMSA 5 µM for two hours. The media was then 
replaced with fresh media +/- TKI and cells collected 24 hours after exposure to m-AMSA. Cells 
were dual stained with sytox red and anti-annexin V antibody conjugated to a fluorochrome to 
identify apoptotic and necrotic cells (see Figure 5.6). The fluorescence of 10, 000 cells was 
measured using FACS. Data are presented as the mean±SD% of 10,000 cells from two 
independent experiments.  
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Figure 5.6 Induction of apoptosis by m-AMSA 
Cells were treated with (A) drug free media, (B) gefitinib 1 hour (C) lapatinib 1 hour, (D) 
gefitinib 48 hours and (E) lapatinib 48 hours, followed by m-AMSA 5 µM for two hours. The 
media was then replaced with fresh media +/- TKI and cells collected 24 hours after exposure 
to m-AMSA. Cells were dual stained with sytox red and anti-annexin V antibody conjugated to 
a fluorochrome. The fluorescence of 10, 000 cells was measured using FACS. Representative 
images for each experiment are presented. Data are presented as the mean±SD% of 10,000 
cells from two independent experiments. 
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5.5 Modulation of the intracellular uptake of doxorubicin by gefitinib or 
Lapatinib 
As discussed in Chapter One section 1.7.1, multi-drug resistance transporters can 
induce resistance to many chemotherapy drugs, including doxorubicin and etoposide 
(Gottesman et al., 2002). Both gefitinib (Kitazaki et al., 2005; Leggas et al., 2006; 
Nakamura et al., 2005; Yang et al., 2005) and lapatinib (Dai et al., 2008; Kuang et al., 
2010) are able to inhibit multi-drug resistance transporters increasing intracellular 
chemotherapy concentrations as discussed in Chapter One section 1.8.2. These studies 
used short exposure to TKI, measured in hours, to demonstrate an increase in 
substrate uptake and the effect of longer exposure is not known. Whilst the SK-Br-3 
cell line is not reported to express a multi-drug resistance transporter, the intracellular 
concentration of doxorubicin following exposure of cells to TKI was investigated using 
FACS to examine if TKI exposure was modulating the intracellular concentration of 
doxorubicin. 
 
As demonstrated in Chapter Four Figure 4.25, doxorubicin emits a fluorescence that 
can be detected using FACS. The level of doxorubicin fluorescence was measured in 
cells treated with doxorubicin (5 µM) alone, or following TKI exposure for one or 48 
hours. Intracellular doxorubicin is detected as an increase in fluorescence which shifts 
cells to the right on the FACS dot plot and the mean cell fluorescence (MFI) can be 
calculated (Figure 5.7). As also demonstrated in Chapter Four, both lapatinib and 
gefitinib emit fluorescence in cells treated for 48 hours and the MFI of TKI only treated 
cells was used to normalise the doxorubicin fluorescence data, which is expressed as a 
percentage of the MFI obtained from cells treated with doxorubicin alone (Figures 5.7 
and 5.8).  
 
These results demonstrate that there is no increase in the doxorubicin fluorescence in 
cells treated with either gefitinib or lapatinib for one hour (Figure 5.7). Whilst the MFI 
of doxorubicin in cells treated with gefitinib for 48 hours is reduced by 17.4±1.1% and 
by 10.2±13.6% in cells treated with lapatinib for 48 hours, compared with cells treated 
with doxorubicin alone, this is non-significant difference (Figure 5.8). 
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Figure 5.7 Measurement of doxorubicin fluorescence 
 Drug fluorescence was measured using FACS, in SK-Br-3 cells treated with (B,D,F,H,J) and 
without (A,C,E,G,I) doxorubicin 5µM for 2 hours.  Figure representative of three independent 
experiments.  
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Figure 5.8 Modulation of intracellular doxorubicin by gefitinib or lapatinib 
FACS as used to measure the fluorescence of doxorubicin in SK-Br-3 cells pre-treated with 
DFM, gefitinib or lapatinib for one or 48 hours before addition of 5 µM doxorubicin for two 
hours, after which cells were collected and analysed. Data are presented as the mean±SEM of 
three independent experiments.  
 
5.6 DOES DURATION OF EXPOSURE TO GEFITINIB AND LAPATINIB 
MODULATE THE ACTIVITY AND EXPRESSION OF TOPOISOMERASE II? 
As discussed in Chapter One section 1.7.3 resistance to Topo II poisons can be 
produced through a reduction in Topo II enzyme activity through inhibition of enzyme 
phosphorylation or down-regulation of expression (Nitiss, 2009b). Topo II expression 
as measured using Western blotting demonstrates that Topo IIα expression is reduced 
in cells treated with either gefitinib or lapatinib continuously for 48 hours; Topo IIβ 
expression is unaffected (Figure 5.9A).  
 
To investigate Topo II activity, nuclear extracts were prepared from cells treated with 
TKI; these extracts contain both Topo IIα and Topo IIβ and their ability to decatenate 
kinetoplast DNA was assessed in an in vitro assay. Kinetoplast DNA is the mitochondrial 
DNA from the Kinetoplastid class of protozoa, which forms interlinked circles of DNA 
(Figure 5.9B). This assay examines the ability of extracted Topo II to separate the 
interlinked circles, which can be visualised as separate bands following gel 
electrophoresis. The results demonstrate that continuous exposure to either gefitinib 
213 
 
or lapatinib for 48 hours reduces the ability of cells to decatenate DNA, with a smaller 
fall occurring in cells treated for one hour (Figure 5.9C). 
 
Figure 5.9 Modulation of expression and activity of topoisomerase II by gefitinib or lapatinib 
(A) The effect of TKI on the expression of Topo IIα and Topo IIβ was investigated using Western 
blotting. Cells were treated as indicated, lysed and immunoblotted. Loading control is provided 
by αtubulin. (B) Representation of decatenation of kinetoplast DNA. (C) Nuclear extracts were 
prepared from cells treated with TKI and their ability to decatenate DNA in vitro assessed. 
Controls indicate the location of catenated, linear and decatenated DNA. Figure representative 
of three independent experiments and quantisation by densitometry as demonstrated. 
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5.7 DOES REDUCED TOPOISOMERASE IIα EXPRESSION MODULATE DNA 
STRAND BREAK INDUCTION BY TOPOISOMERASE II POISONS? 
Etoposide, doxorubicin and m-AMSA poison both Topo IIα and Topo IIβ (Pommier et 
al., 2010). As discussed above Topo IIα expression falls in cells treated TKI for 48 hours, 
though Topo IIβ expression is unaffected. The relative targeting of each isoform of 
Topo II by doxorubicin, etoposide and m-AMSA varies depending upon the method of 
assessment. Using purified Topo II in decatenation assays, both doxorubicin and m-
AMSA target both Topo II isoforms equally, with etoposide demonstrating a preference 
for Topo IIα (Perrin et al., 1998). However, cytotoxicity assays indicate that etoposide 
and doxorubicin are dependent upon Topo IIα expression to induce cell death (de 
Campos-Nebel et al., 2010; Toyoda et al., 2008), in contrast to m-AMSA, to which 
resistance can be mediated by the knockdown of Topo IIβ (Toyoda et al., 2008; 
Willmore et al., 2002).   
 
The trapped in agarose DNA immunostaining assay (TARDIS), which examines the 
formation of Topo IIα or Topo IIβ cleavable complexes specifically, demonstrates the 
targeting of both Topo II isoforms by doxorubicin, etoposide and m-AMSA. However, 
this assay does not allow the relative contributions of each enzyme to be compared 
due to possible differences in the efficacies of the Topo IIα antibody compared with 
the Topo IIβ antibody used in the assay (Errington et al., 2004; Willmore et al., 2002).  
 
In order to investigate the effect of the Topo II poisons used in this study on the 
formation of Topo IIβ-induced DNA strand breaks, a cell system in which Topo IIα 
expression can be reduced was utilised. The HTETOP cell line is derived from a human 
fibrosarcoma cell line in which endogenous Topo IIα has been disrupted and a 
tetracycline controlled exogenous Topo IIα transfected. This allows the suppression of 
Topo IIα expressing by the addition of a tetracycline (Carpenter and Porter, 2004).  
 
Doxycycline 1 µg for 24 hours reduces, but does not abolish the expression of Topo IIα 
(Figure 5.10A). The ability of doxorubicin, etoposide and m-AMSA to induce DNA 
strand breaks following reduction in Topo IIα expression using the alkaline Comet 
assay was assessed in cells treated with and without doxycycline.  
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Significantly fewer DNA strand breaks are produced by all three Topo II poisons in cells 
with treated with doxycycline (Topo IIα reduced) compared with untreated cells (Topo 
IIα expressing) (Figure 5.10 and Table 5.2).  The greatest effect on the induction of DNA 
strand breaks of the reduced expression of Topo IIα is observed with doxorubicin, with 
an 87-95% reduction in strand breaks (Figure 5.10B). Fewer DNA strand breaks are 
induced by both etoposide and m-AMSA, with a 74-86% reduction in DNA strand 
breaks when Topo IIα expression is reduced (Figure 5.10C & 5.10D). 
 
 
Figure 5.10 Effect of reduced topoisomerase IIα expression on the production of DNA strand 
breaks  
(A) Western blotting was used to assess the expression of Topo IIα and Topo IIβ following 
treatment with doxycycline in HTETOP cells. Densitometry values are as shown. The alkaline 
comet assay was used to assess the induction of DNA strand breaks by (B) doxorubicin 2 hours, 
(C) etoposide 2 hours, (D) m-AMSA 1 hour. Data are presented as mean±SEM of three 
independent experiments. *p<0.05.  
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Drug  
Concentration 
 (µM) 
Percentage of tail moment 
Doxorubicin 
(%) 
Etoposide 
(%) 
m-AMSA 
(%) 
2.5 4.8±2.4  16.2±2.5 
5.0 13.1±6.1  14.4±4.0 
10 11.4±4.0 16.6±7.9 24±2.4 
50  18.5±1.5  
150  25.8±4.8  
 
Table 5.2 Percentage reduction in tail moment by knockdown of topoisomerase IIα 
Data from Figure 5.10 are presented as the tail moment in HETOP cells which have been 
treated with doxycycline to reduce the expression of Topo IIα expressed as a percentage of 
that produced in cells with normal expression of Topo IIα. Data are presented as the 
mean±SEM of three independent experiments. 
 
5.8  The effect of gefitinib on topoisomerase II expression and the cell cycle 
Topo IIα expression alters with the cell cycle with the highest levels observed during 
G2/M (Pommier et al., 2010). In order to assess if the reduction in Topo IIα expression 
is due to cell cycle arrest, the effect of gefitinib (5 µM) on the cell cycle and Topo II 
expression was assessed over 72 hours, with gefitinib replaced daily. Gefitinib 
treatment for six hours has no effect on the cell cycle but by 24 hours, an increase in 
cells in G0/G1-phase can be detected at 83.6±3.4% from 62.8±1.5% in untreated cells 
(Figure 5.11). Despite G0/G1-phase cell cycle arrest, a small percentage of cells are 
able to progress through to G2/M over 72 hours with a constant number in S-phase 
(Figure 5.11).  
 
Western blotting demonstrates that Topo IIα levels start to fall after 24 hours exposure 
to gefitinib, with a marked reduction at 48 hours (Figure 5.11F). 
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Figure 5.11 Effect of gefitinib on the cell cycle and topoisomerase II expression  
SK-Br-3 cells were treated continuously with 5 µM gefitinib with replacement every 24 hours 
and the effect on cell cycle and Topo II expression investigated. (A-E) Cell cycle was assessed 
using FACS for 10, 000 cells over 72 hours. Data are presented as mean±SD of three 
independent experiments. *P<0.05 compared with cell treated with drug free media. (F) Topo 
II expression was assessed using Western blotting. αTubulin is used as a loading control. Image 
is representative of three independent experiments 
 
 
 
A 
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5.9 DOES THE DURATION OF EXPOSURE TO GEFITINIB MODULATE THE 
PRODUCTION OF DNA DSBS BY TOPOISOMERASE II POISONS? 
The Topo II poison m-AMSA induces the same numbers of DNA strand-breaks, 
regardless of the duration of exposure to gefitinib or lapatinib. However, measurement 
of γH2AX foci indicates that following exposure to gefitinib for 48 hours, fewer DNA 
DSBs are produced, matching the findings with doxorubicin and etoposide. As 
discussed in Chapter Four, this observation cannot be explained by inhibition of γH2AX 
foci formation by gefitinib, as foci are formed in response to both cisplatin and IR 
despite exposure to gefitinib. This observation suggests that Topo II poisons are unable 
to produce DNA DSBs following continued TKI treatment but continue to produce 
single strand DNA breaks, which are detected by the alkaline Comet assay. As γH2AX 
foci are a surrogate marker for DNA DSBs (Bonner et al., 2008), the neutral Comet 
assay was used to confirm the hypothesis that gefitinib exposure for 48 hours reduces 
the production of DNA DSBs by Topo II poisons.  
 
5.9.1 Differences between the alkaline and neutral Comet assays  
The alkaline Comet assay uses an alkaline buffer to relax, unwind and denature DNA, 
with the presence of DNA single or double strand breaks producing fragmentation of 
DNA (Olive and Banath, 2006). During electrophoresis these DNA fragments migrate 
further producing a Comet tail. As the number of single and double DNA strand breaks 
increases, DNA becomes more fragmented resulting in the production of a longer 
Comet tail. The neutral Comet assay employs a neutral non-denaturing buffer which 
maintains DNA super coiling. When the cells are electrophoresed the super coiled DNA 
is pulled to one side, producing the visualised Comet tail that can be seen even in 
untreated cells (Figure 5.12). The presence of single or double DNA strand breaks 
causes relaxation of the super coils allowing DNA migration, producing a longer Comet 
tail due to the greater the degree of relaxation. Due to maintenance of the super 
coiled structure, a DNA DSB break produces a greater degree of relaxation and 
migration than a single strand break (Olive and Banath, 2006). This can be tested by 
using hydrogen peroxide which produces a 1,000 fold more single strand breaks than 
double strand breaks (Wojewodzka et al., 2002). In the alkaline comet assay hydrogen 
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peroxide produces a long comet tail whereas in the neutral version, the tail is not 
significantly longer than that produced in untreated cells (Figure 5.12). 
 
 
 
Figure 5.12 Differences between the alkaline and neutral Comet assays 
In the alkaline comet assay DNA is relaxed and unwound by alkaline buffer, allowing DNA 
fragments to migrate during electrophoresis. (B) In the neutral assay, the DNA supercoils 
remain intact and are pulled towards the cathode during electrophoresis. The presence of a 
DNA DSB increases the migration of DNA. (C) Cells treated with hydrogen peroxide or ionising 
radiation, collected and analysed using the alkaline and neutral Comet assays. 
C 
A B 
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5.9.2 Modulation of topoisomerase II poison-induced DNA double strand 
breaks by duration of exposure to gefitinib 
The ability of the Topo II poisons doxorubicin, etoposide and m-AMSA to induce DNA 
DSBs was investigated over a range of concentrations. Both etoposide and m-AMSA 
induce DSBs in a concentration dependent manner, which is not observed with 
doxorubicin (Figure 5.13). Gefitinib exposure for one hour has no significant effect on 
the induction of DSBs by doxorubicin, etoposide or m-AMSA, except at the 
concentration of 10 µM (m-AMSA alone tail moment of 8.2±0.7, compared with  
5.2±0.9 in combination with gefitinib for one hour p<0.05) (Figure 5.13).  
 
Gefitinib treatment for 48 hours significantly inhibits the ability of all Topo II poisons to 
induce DNA DSBs with doxorubicin (5 µM) inducing 84% fewer DNA DSBs compared 
with cells treated with doxorubicin alone, etoposide (50 µM) 77% and m-AMSA (5 µM) 
58% fewer (Figure 5.13). In these cells etoposide retains its ability to increase the 
number of DSB with increasing drug concentration but this is lost with m-AMSA with 
similar tail moments measured across all concentrations of the drug investigated 
(Figure 5.13). 
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Figure 5.13 Induction of DNA double strand breaks by topoisomerase Iiα poisons 
The neutral Comet assay was used to assess the induction of DNA DSB strand breaks in the SK-
Br-3 cell line. Cells were pre-treated with either DFM (), gefitinib 1 hour (), gefitinib 48 
hours () before the addition of doxorubicin, etoposide or m-AMSA for one or two hours, 
after which cells were collected and analysed. Data are presented as the mean±SEM of three 
independent experiments *p<0.05 compared with Topo II poison alone. 
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5.10 DOES EXPOSURE TO GEFITINIB FOR 48 HOURS INCREASE THE 
NUMBER OF DNA STRAND BREAKS PRODUCED BY REACTIVE OXYGEN 
SPECIES? 
Topo II poisons, particularly doxorubicin, produce ROS in addition to poisoning Topo II 
(Pommier et al., 2010). Continuous TKI exposure for 48 hours has no effect on the 
induction of DNA strand breaks by m-AMSA as measured by the alkaline Comet assay 
yet significantly fewer DNA DSBs as measured by the neutral Comet assay and γH2AX 
foci. This indicates that m-AMSA is mainly inducing single strand breaks in cells treated 
with TKIs for 48 hours. These strand breaks may be produced through the increased 
production of ROS by m-AMSA, given that the inducer of ROS, menadione significantly 
increases the production of DNA strand breaks following continuous exposure to 
gefitinib for 48 hours (Figure 5.2) and exposure to  gefitinib for 48 hours is known to 
stimulate the production of ROS (Sergina et al., 2007).  
 
To investigate the contribution of ROS in the production of DNA strand breaks in cells 
treated with continuous TKI, strand break production in the presence of the free 
radical scavenger N-acetylcysteine (NAC) was assessed using the alkaline Comet assay.  
 
NAC (3 mM) was added to cells treated with gefitinib for 48 hours, one hour prior to 
exposure to the Topo II poisons doxorubicin, etoposide and m-AMSA. NAC had no 
effect on the induction of DNA strand breaks by m-AMSA though it significantly 
reduced the induction of strand breaks by etoposide (Figure 5.14). Doxorubicin failed 
to produce significant numbers of DNA strand breaks regardless of the presence of 
NAC. 
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Figure 5.14 Effect of free radical scavenger on DNA strand production 
SK-Br-3 cells were treated with gefitinib 5 µM for 48 hours, with drug replacement every 24 
hours. At the final addition of gefitinib 3 mM of NAC was added for 1 hours, followed by 
exposure to doxorubicin, m-AMSA or etoposide. Cells were collected after one or two hours 
and analysed using the alkaline comet assay. –NAC () and +NAC (). Data are presented as 
the mean±SEM of three independent experiments. *P<0.05.  
 
5.11 MIGHT TYROSINE KINASE INHIBITORS RENDER CELL RESISTANT TO 
TOPOISOMERASE II POISONS IN THE CLINIC? 
In the experiments described in both this Chapter and Chapter Four lapatinib is used at 
a concentration of 2 µM, a concentration which is achievable in patients at the 
licensed dose of lapatinib (Burris et al., 2009). However, gefitinib is used at a 
concentration of 5 µM to induce a reactivation of HER3 and PI3K signalling as 
demonstrated by Sergina et al. (Sergina et al., 2007). In patients, lower concentrations 
of gefitinib are achieved at the licensed dose which produces plasma concentrations of 
around 1-2 µM, though concentrations as high as 20 µM can be detected in tumours 
(Haura et al., 2010; McKillop et al., 2005). In order to investigate if the reduction in 
DNA strand breaks following continuous gefitinib exposure for 48 hours is due to the 
high concentration of gefitinib used in this study, the effect of 2 µM gefitinib on the 
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induction of strand breaks by Topo II poisons was investigated using the alkaline 
Comet assay. 
 
5.11.1 Effect of exposure to 2 µM gefitinib on the induction of DNA strand breaks by 
doxorubicin and etoposide 
Cells were pre-treated with 2 µM gefitinib for 48 hours, with drug replacement at 23 
and 47 hours. Cells were then treated with varying concentrations of doxorubicin or 
etoposide for 2 hours, then collected and processed for analysis using the alkaline 
Comet assay. The results demonstrate that pre-treatment of cells with gefitinib 2 µM 
for 48 hours produces resistance to the induction of DNA strand breaks by etoposide 
and doxorubicin (Figure 5.15). 
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Figure 5.15 Effects of 2 µM gefitinib on the induction of DNA strand breaks 
SK-Br-3 cells were treated with drug free media (), 2 µM gefitinib 1 hour (), or 2 µM 
gefitinib 48 hours (), prior to the addition of doxorubicin (A) or etoposide (B) for two hours. 
Cells were then collected and DNA strand breaks assessed using the alkaline Comet assay. Data 
are presented as the mean±SEM of three independent experiments. *P<0.05 compared with 
Topo II poison alone.  
A 
B 
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5.11.2 Modulation of topoisomerase gene expression by lapatinib 
Whilst the concentration of lapatinib used in this study is clinically relevant, the 
reduction in the expression of Topo IIα by lapatinib may not translate into the clinical 
setting. To explore this further we obtained the gene expression data for Topo II from 
eight patients with breast cancer treated with lapatinib (provided by Dr J Chang, Baylor 
College of Medicine, USA). These patients received neo-adjuvant treatment, for breast 
cancer with lapatinib for six weeks. Tumour biopsies were taken before and after 
treatment and gene expression assessed using gene microarray. Raw expression data 
were normalised for median gene expression to allow comparison.   
 
The array contained two probe sets for Topo IIα and one for Topo IIβ. Topo IIα gene 
expression fell in both probe sets by at least 50 % (Figure 5.16), in contrast Topo IIβ 
levels were unaltered. These data suggest that at the gene level, lapatinib reduces 
Topo IIα gene expression in patients treated with lapatinib. 
 
 
Figure 5.16 Modulation of the gene expression of topoisomerase by lapatinib 
The effect of lapatinib on Topo IIα and Topo IIβ gene expression was investigated by probing 
the microarray data obtained from eight patients treated with neo-adjuvant lapatinib for six 
weeks. Tumour biopsies were taken before and after treatment and gene expression assessed 
using gene microarray. Raw expression data were normalised for median gene expression to 
allow comparison.  The array contained two probe sets for Topo IIα and one for Topo IIβ.    
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5.12 DISCUSSION 
Data presented in Chapter Four demonstrated that exposure of SK-Br-3 cells to 
gefitinib or lapatinib for 48 hours reduces the ability of the Topo II poisons etoposide 
and doxorubicin to induce DNA stand breaks, as detected by both the alkaline Comet 
assay and measurement of H2AX foci. This chapter examines the influence of duration 
of exposure to TKIs on the effects of the Topo II poison m-AMSA, Topo II expression 
and activity, the cell cycle and production of DNA DSBs by doxorubicin, m-AMSA and 
etoposide.  
 
5.12.1 Modulation the effects of m-AMSA by gefitinib and lapatinib 
In contrast to doxorubicin and etoposide, the production of DNA strand breaks by m-
AMSA is not significantly altered by the duration of TKI exposure as assessed using the 
alkaline Comet assay (Figure 5.1). Both measurement of γH2AX foci and the neutral 
Comet assay demonstrate that in cells pre-treated with gefitinib for 48 hours, fewer 
DNA DSBs are produced by m-AMSA (Figures 5.4 and 5.13). This indicates that the 
strand breaks measured by the alkaline Comet assay following continuous TKI 
treatment contain a higher proportion of single strand breaks than cells treated with 
m-AMSA alone. We hypothesised that these single strand breaks were produced by an 
increase in ROS. This is supported by a significant increase in the induction of strand 
breaks by the ROS generator menadione in cells treated with gefitinib for 48 hours 
(Figure 5.2). However, the free radical scavenger NAC does not affect the induction of 
strand breaks by m-AMSA in cells treated with gefitinib for 48 hours, indicating that 
these breaks are not produced by free radicals (Figure 5.14). 
 
5.12.2 Modulation of topoisomerase II expression by gefitinib and lapatinib 
The Topo II poisons doxorubicin, etoposide and m-AMSA all prevent the religation of 
DNA DSBs produced as part of the normal function of Topo II (Pommier et al., 2010).  
The data presented in this chapter demonstrates that Topo II function is reduced, 
though not abolished by gefitinib or lapatinib treatment for 48 hours and that Topo IIα 
but not Topo IIβ expression falls.  
 
Topo IIα expression is known to increase during S and G2/M- phases of the cell cycle 
whereas Topo IIβ levels remains constant (Pommier et al., 2010). A reduction in Topo 
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IIα expression would be expected with continuous TKI treatment due to the induction 
of a G0/G1 cell cycle arrest. Gefitinib induces a G0/G1 cell cycle arrest at 24 hours, 
which is sustained over a 72 hour period (Figure 5.11) and Topo IIα levels fall at 24 
hours with little protein detected at 48 hours onwards (Figure 5.11). This raises the 
question as to whether the fall in Topo IIα level is purely a reflection of G1 cell cycle 
arrest, or a direct effect of gefitinib. The precise mechanisms through which cell cycle 
arrest is mediated by TKIs are still under investigation though the dephosphorylation 
of the forkhead transcription factor FOXO3a, in response to the inhibition of AKT 
phosphorylation, has been implicated (Krol et al., 2007). 
 
In SK-Br-3 cells, gefitinib treatment induces the transport of unphosphorylated FOXO3a 
back into the nucleus. This in turn increases the expression of the cell cycle control 
protein p27kip1, producing G1 cell cycle arrest (Krol et al., 2007) and reducing the gene 
and protein expression of another forkhead transcription factor, FOXM1 (Francis et al., 
2009). FOXM1 has been shown to bind to the promoter of the mouse Topo IIα gene 
and activate its transcription (Wang et al., 2009). This is a possible mechanism through 
which gefitinib could reduce the expression of Topo IIα (illustrated in Figure 5.17). 
However, in the study by McGovern et al. following 48 hours gefitinib treatment, 
increases in RNA and protein levels of FOXM1 could be detected (McGovern et al., 
2009). It is unclear if this is due to the development of resistant cell clone, as suggested 
by the investigators, or due to the washout of gefitinib as it is not reported whether 
gefitinib was replaced every 24 hours in this study (McGovern et al., 2009).  
 
Overexpression of FOXM1 has been linked to the overexpression of HER2 in both 
breast cancer cell lines and tissue and the knockdown of HER2 expression reduces the 
expression of FOXM1 (Francis et al., 2009). Lapatinib 1 µM also reduces the expression 
of FOXM1 within 12 hours, with G1 cell arrest occurring later, indicating that the fall in 
expression is not due to cell cycle arrest (Francis et al., 2009).  
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Figure 5.17 Possible mechanism of down-regulation of topoisomerase IIα expression by 
gefitinib or lapatinib 
Both gefitinib and lapatinib have been demonstrated to down-regulate the expression of the 
transcription factor FOXM1 which may be regulate the transcription of topoisomerase IIα. 
 
We have obtained the Topo II gene expression data for eight patients treated with pre-
operative lapatinib. Whilst this small data set indicates that Topo IIα expression is 
reduced by lapatinib it should be remembered that Topo II gene status and protein 
expression do not always correlate, with gene amplification or deletion not necessarily 
resulting in a detectable alteration in Topo IIα expression (Mueller et al., 2004; Usha et 
al., 2008).  
 
5.12.3 Modulation of topoisomerase II activity by gefitinib and lapatinib 
Continuous exposure to gefitinib significantly reduces the induction of γH2AX foci by 
doxorubicin, etoposide and m-AMSA, indicative of a reduction in the number of DSBs. 
This is supported by the neutral Comet assay data which confirms a reduced induction 
of DNA DSBs in cells treated with gefitinib for 48 hours (Figure 5.13). These data also 
demonstrate a reduction in the number of DSBs induced by 5 µM and 10 µM of m-
AMSA in cells pre-treated with gefitinib one hour which is not observed with either 
228 
 
doxorubicin or etoposide (Figure 5.13). A reduction in the number of DSBs breaks in 
cells treated with TKI for one or 48 hours may explain the observation of faster repair 
of DNA strand breaks, as assessed by the alkaline Comet assay (Figure 5.3). However, 
at the concentration of 5 µM m-AMSA used in the alkaline Comet assay, the neutral 
Comet assay demonstrates only a small and non-significant decrease in DSB induction 
in cells pre-treated with gefitinib for one hour compared with cells treated with m-
AMSA alone (Figure 5.13). Despite this, the repair of DNA lesions as assessed by the 
alkaline Comet assay following gefitinib for one or 48 hours exactly mirrors each other, 
suggesting that the faster repair observed in these cells is not due to a reduction in the 
number of DSBs produced (Figures 5.3). This means that the gefitinib promoted 
increase in the rate of repair of m-AMSA-induced DNA strand breaks is due to an 
ability to repair the predominant DNA single strand breaks more quickly. 
 
Topo II-DNA cleavable complexes are reversible and Topo II is able to ligate the DNA 
DSB that makes up the cleavable complex (Nitiss, 2009b). Doxorubicin, etoposide and 
m-AMSA prevent the ligation of the DNA DSB contained within the cleavable complex 
(Pommier et al., 2010). However, the binding of a Topo II poison to Topo II is 
reversible, and the dissociation of the poison from Topo II allows the enzyme to 
function normally (Nitiss, 2009b).  Therefore the increased rate of repair of m-AMSA 
induced DNA strand breaks may be explained by a reduced affinity of the poison for 
Topo II, so that on removal of the drugs the DNA strands can be religated by Topo II, as 
per its normal function. 
 
As discussed in Chapter One, section 1.7.3.3.2, Topo II activity is controlled by 
phosphorylation with the phosphorylation at ser1106 within the catalytic domain of 
Topo IIα important in controlling the sensitivity to etoposide and m-AMSA (Chikamori 
et al., 2003).  Amino acid substitution at this site produces a two-four fold reduction in 
the formation of etoposide-induced cleavable complexes. This site is phosphorylated 
by the serine/threonine kinase casein kinase 1δ and 1ε (Grozav et al., 2009). Casein 
kinase 1δ inhibition has been demonstrated with gefitinib, though at a high 
concentration (Brehmer et al., 2005). This indicates the possibility that the activity of 
Topo IIα is inhibited by gefitinib, through the inhibition of casein kinase 1δ. 
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5.12.4 HER2, topoisomerase IIα and casein kinase 1δ 
Clinical studies have confirmed that the HER2 gene amplification is able predict for an 
improved benefit for treatment with anthracyclines in breast cancer (Pritchard et al., 
2008). As both HER2 and Topo IIα are located in close proximity on chromosome 17q 
investigations have focussed on whether Topo IIα gene amplification in HER2 amplified 
breast cancer explains the clinical benefit from anthracyclines. Within HER2 over-
expressing tumours, co-amplification of Topo II is reported in between 32-54% of 
tumours and gene deletions in 14-35% (Slamon and Press, 2009), both of which are 
associated with clinical response to anthracyclines (O'Malley et al., 2009). 
 
Direct action by HER2 on Topo IIα activity is not supported by the literature with the 
transfection of HER2 into cell lines not increasing sensitivity to doxorubicin (Pegram et 
al., 1997).  As postulated above inhibition of casein kinase Iδ activity by gefitinib may 
provide a link between TKI and reduced Topo II expression and activity. Interestingly 
casein kinase Iδ is located on chromosome 17q, like HER2 and Topo IIα and may 
provide the link between HER2 amplification and sensitivity to anthracyclines in HER2 
positive breast cancer. 
 
5.13 CONCLUSIONS AND FUTURE WORK 
Continued TKI exposure for 48 hours renders cells resistant to the effects of Topo II 
poisons through the down regulation of their target, Topo IIα, and possibly through the 
modulation of Topo IIα activity.   
 
Further work is needed to clarify the effect of TKI exposure on the expression of Topo 
II in clinical samples. If this is confirmed it would give a clear indication that TKI use 
concurrently or immediately prior to Topo II poison use may not be clinically beneficial. 
This is important as clinical trials are currently being conducted examining the 
combination of liposomal doxorubicin and lapatinib and neo-adjuvant lapatinib in 
patients with breast cancer (National Cancer Institute, 2011a; National Cancer 
Institute, 2011c). This could be achieved by the analysis of Topo II expression by IHC in 
tissue samples from patients before and after treatment with lapatinib or gefitinib. For 
example in patients with breast cancer prior to surgery, allowing comparison of Topo II 
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expression in diagnostic and post surgical specimens or in patients with NSCLC with 
accessible lymph nodes or subcutaneous nodules.  
 
In addition, the effects of TKI exposure on the ability of drugs to poison Topo II 
warrants further investigation, especially the effect of TKI on the phosphorylation of 
Topo II. This area of investigation is limited by the lack of useful phosphorylated Topo II 
site specific antibodies, and requires the use of mass spectrometry requiring specific 
expertise; this also prevents the analysis of phosphorylation of Topo II in clinical 
samples.  
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HER2 mediated cisplatin resistance 
6.1 INTRODUCTION 
HER2 targeted antibodies increase the cytotoxic effect of cisplatin in breast and 
ovarian cancer cell lines (Hancock et al., 1991). The role of HER2 in mediating 
resistance to cisplatin is further supported by the observation that the transfection of 
HER2 into MCF-7 cells reduces their sensitivity to cisplatin by two-four times (Benz et 
al., 1992). Sensitisation to cisplatin by HER2 targeted antibodies is through the 
inhibition of DNA repair, with a reduction in unscheduled DNA synthesis and reduced 
repair of cisplatin-induced adducts observed (Pietras et al., 1994). These findings 
translate into the clinic with the combination of the HER2 antibody, trastuzumab with 
cisplatin, producing higher clinical response rates than historical controls in patients 
with metastatic breast cancer (Pegram et al., 1998).  As discussed in Chapter One 
section 1.8.5.2, EGFR translocates to the nucleus in response to cisplatin and IR, 
modulating the repair of DNA damage though its interaction with DNA-PKCS (Dittmann 
et al., 2005b; Hsu et al., 2009). The precise mechanisms by which HER2 increases 
resistance to cisplatin have yet to be elucidated.  
 
Cisplatin forms interstrand and intrastrand DNA crosslinks, together with DNA-protein 
adducts, preventing DNA replication (Wang and Lippard, 2005). The removal of these 
lesions requires the DNA repair processes of NER, HR and TLS as discussed in Chapter 
One, section 1.7.5.1. Like EGFR, full length HER2 can be detected in the nuclei of HER2-
expressing breast cancer cell lines and in breast cancer tissue (Beguelin et al., 2010; 
Wang et al., 2004), where it has been shown to bind and transactivate the promoters 
of genes through binding to a specific sequence of  nine nucleotides within the 
promoter region (Wang et al., 2004) or through the formation of a complex with STAT3 
to activate the cyclin D1 promoter (Beguelin et al., 2010). 
 
6.1.1 Nuclear transport of HER2 
As discussed in Chapter One section 1.3.3.5, nuclear transport of HER proteins is 
dependent upon a 13 amino acid sequence, conserved across the four receptors, 
known as the NLS (Hsu and Hung, 2007). The transport of HER2 into the nucleus is 
dependent upon its phosphorylation, with transport inhibited by the tyrosine kinase 
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inhibitor AG825 (Wang et al., 2004). Following phosphorylation, the membrane 
located receptor is endocytosed, interacts with importin β and the nuclear pore 
protein Nup358, to enter the nucleus (Giri et al., 2005). Nuclear translocation and the 
interaction with importin β is dependent upon the NLS with deletion of this sequence 
reducing translocation of HER2 into the nucleus, through reduced interaction with 
importin β (Giri et al., 2005).  
 
6.1.1.1  Nuclear HER2 and the repair of cisplatin-induced crosslinks 
We transfected the HER2 negative MDA-MB-468 cell line, with the HER2 constructs 
used by Giri et al. to demonstrate the requirement of the NLS to mediate the nuclear 
transport of HER2. Cells transfected with full length HER2 were more resistant to the 
inhibition of cell proliferation by cisplatin (Boone et al., 2009). This effect is mediated 
through an increase in the rate of repair of cisplatin-induced interstrand crosslinks 
(Boone et al., 2009). Using cells transfected with a HER2 from which the 13 amino 
acids NLS has been deleted, we demonstrated that reduced HER2 nuclear translocation 
increases cellular sensitivity to cisplatin, through reduced repair of cisplatin-induced 
interstrand crosslinks (Boone et al., 2009).  
 
Nuclear HER2 binds directly to a nine nucleotide sequence (called HER2-associated 
sequences) within promoter regions of targeted genes, stimulating their transcription. 
Gene promoters containing HER2-asscociated sequences include the COX2, p53 
related protein kinase, matrix metalloproteinase-16 and the Fanconi anaemia 
complementation group C (FANCC) genes (Wang et al., 2004). FANCC is of interest as it 
is involved in the repair of interstrand crosslinks, assembling with seven other Fanconi 
anaemia proteins to form a nuclear ubiquitin ligase complex known as the Fanconi 
anaemia core complex (D'Andrea, 2010). This complex monoubiquitinates the proteins 
FANCI and FANCD2 which form DNA-repair foci involved in the repair of cisplatin-
induced interstrand crosslinks (D'Andrea, 2010). The ability of the nuclear 
translocation of HER2 to promote the repair of cisplatin-induced interstrand crosslinks 
together with the discovery that nuclear HER2 can regulate gene transcription, 
indicates that HER2 may mediate resistance to cisplatin through gene regulation, 
possibly through up-regulation of FANCC gene expression. 
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6.1.2  Mechanisms for identifying the targets of nuclear HER2 
In order to identify other potential targets of HER2, the techniques of gene expression 
microarray and ChIP were utilised to generate hypotheses as to the nuclear targets of 
HER2.  
 
6.1.2.1  Chromatin Immunoprecipitation  
ChIP allows the interaction between proteins and DNA to be examined. This technique 
was used by Wang et al.  to identify the binding of the COX2 promoter by HER2 (Wang 
et al., 2004). ChIP involves the reversible crosslinking of DNA using formaldehyde, 
which fixes DNA-protein interactions. The protein of interest (HER2) is 
immunoprecipitated using an antibody directed against it, isolating HER2-DNA 
complexes from which the bound DNA is eluted. Identification of the specific DNA 
sequences can be achieved with high throughput mass sequencing. 
 
6.1.2.2  Gene expression microarray 
Gene expression arrays allow the comparison of gene expression between cells lines 
under different conditions. Each gene is represented by around 40 probes, with each 
exon covered by approximately four probes, with a total of 5.5 million probes on each 
array (Affymetrix, 2005). 
 
6.2 AIMS  
This chapter describes experiments conducted to identify the mechanism through 
which HER2 increases the rate of cisplatin-induced interstrand crosslink repair. 
Experiments were conducted in MDA-MB-468 breast cancer cells transfected with a 
vector control (MDA-MB-468-Vector), HER2 (MDA-MB-468-HER2), or a mutated HER2 
lacking the NLS sequence (MDA-MB-468-NLS). 
1. To characterise the transfected MDA-MB-468 cell lines and the activity of 
HER2. 
2. To investigate the DNA targets of nuclear HER2 using the technique of 
chromatin immunoprecipitation. 
3. To identify the transcription targets of nuclear HER2 using DNA expression 
array. 
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6.3 CHARACTERISATION OF MDA-MB-468 HER2 TRANSFECTED CELL 
LINES 
The MDA-MB-468 breast cancer cell line is derived from a pleural effusion of a woman 
with a metastatic adenocarcinoma of the breast as discussed in Chapter Three. It is 
recognised to overexpress EGFR, have low expression of HER2 and be PTEN deleted 
(Lacroix and Leclercq, 2004). This cell line was stably transfected using a vector 
containing a fluorescence green protein (MDA-MB-468-Vector), full length wild type 
HER2 (MDA-MB-468-HER2) and a mutant HER2 from which the NLS sequence has been 
deleted (MDA-MB-468-NLS), all a kind gift from MC Hung (MD Anderson, USA). 
 
6.3.1 HER2 expression in transfected MDA-MB-468 cells 
Following the creation of stably transfected cell lines, the expression of HER2 protein 
was assessed using Western blotting. No HER2 is detected the MDA-MB-468 cells 
transfected with vector alone, but is present in cells transfected with either full length 
HER2 or HER2 with a deletion of the 13 nucleotide NLS (Figure 6.1) 
 
 
Figure 6.1 HER2 expression in transfected MDA-MB-468 cell lines 
MDA-MB-468 cells were stably transfected with vector (MDA-MB-468-Vector), full length HER2 
(MDA-MB-468-HER2) or HER2 with a deleted NLS (MDA-MB-468-NLS). HER2 expression was 
assessed using Western blotting with αtubulin as a loading control. Jurkat cells which do not 
express HER2 were used as a negative control and SK-Br-3 cells which over express HER2 as a 
positive control. Image is representative of more than three individual blots. 
 
6.3.2 The effect of HER2 on cell proliferation  
HER2 is an oncogene, driving tumour growth (Pegram et al., 1997) and identifies a 
more aggressive type of breast cancer with a poorer survival (Slamon et al., 1987). In 
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order to assess if the transfection of HER2 into the MDA-MB-468 cell line increases the 
rate of cell proliferation, the SRB assay was used to assess cell doubling times. The 
expression of full length HER2 increases the rate of cell proliferation with the number 
of cells doubling within 21 hours compared with control cells, which took 55 hours to 
double (Figure 6.2). In comparison, the transfection of HER2 with a deleted NLS, 
slowed the rate of cell proliferation in the first 48 hours but there was a rapid growth 
between 48 and 72 hours. 
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Figure 6.2 HER2-induced modulation of cell proliferation 
MDA-MB-468 cells were stably transfected with a vector (●), full length HER2 ( ) or HER2-NLS 
(▲). Cells were plated at a concentration of 4x104 cells/ml (A) or 6x104 cells/ml (B) in 96 well 
plates and left overnight to adhere. Cells were then grown for 72 hours and plates removed 
every 24 hours, the absorbance measured and normalised to level at time zero. Data are 
presented a mean±SEM. 
A 
B 
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6.3.3 The effect of trastuzumab on HER2 phosphorylation 
HER2 has no identified ligand, though the induction of HER2 phosphorylation can be 
stimulated by ligands targeted against EGFR and HER3 (Kong et al., 2008). HER2 
phosphorylation is also induced by the monoclonal antibody trastuzumab in the SK-Br-
3 cell line (Scaltriti et al., 2009). Trastuzumab induced HER2 phosphorylation in both 
the MDA-MB-468-HER2 and MDA-MB-468-NLS cell lines, with the effect more 
pronounced in the MDA-MB-468-HER2 cell line (Figure 6.3). This indicates that the 
transfected HER2 and the HER2-NLS are capable of undergoing phosphorylation. 
 
 
Figure 6.3 Induction of HER2 phosphorylation by trastuzumab 
MDA-MB-468 cells stably transfected with a vector, full length HER2 or HER with a deleted NLS 
were treated with trastuzumab 40 µg/ml. Cells were lysed at the indicated times and 
phosphorylated HER2 detected using Western blotting. 
 
6.3.4 The induction of nuclear translocation of HER2 by cisplatin 
The localisation of HER2 and the induction of nuclear translocation were investigated 
using confocal microscopy. No HER2 fluorescence can be detected in the MDA-MB-
468-Vector cell line under any condition (Figure 6.4). In MDA-MB-468-HER2 cells, the 
HER2 protein can be visualised mainly located on the cell membrane in untreated cells 
(Figure 6.4). Treatment with trastuzumab reduces the level of HER2 protein located on 
the cell membrane but increases the level within the cytoplasm. Cisplatin treatment 
induces the translocation of HER2 into the nucleus, a process prevented by the 
addition of trastuzumab (Figure 6.4). The deletion of the NLS sequence from HER2 
results in membrane located HER2, with no increase in nuclear HER2 observed 
following cisplatin treatment (Figure 6.4). 
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Figure 6.4 Cisplatin-induced HER2 translocation to the nucleus is inhibited by trastuzumab 
MDA-MB-468 cells were stably transfected with vector (MDA-MB-468-Vector), full length HER2 (MDA-MB-468-HER2) or HER2 with a deleted NLS (MDA-MB-468-
NLS). Cells were treated with 100 µM cisplatin for one hour, trastuzumab 40 µg/ml or both drugs in combination followed by trastuzumab 40 µg/ml continuously. 
The cellular localisation of HER2 24 hours following exposure to cisplatin was visualised by confocal microscopy. Picture taken from Boone et al. 2009. 
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6.3.5 The dependence of MDA-MB-468-HER2 cells on HER2 expression 
We have demonstrated that trastuzumab inhibits the repair of cisplatin-induced 
interstrand crosslinks in the MDA-MB-468-HER2 cell line (Boone et al., 2009). In order 
to assess if these cells have become dependent upon HER2 to repair cisplatin-induced 
interstrand crosslinks, the effect of HER2 knockdown on their repair was investigated 
using the modified alkaline Comet assay. The expression of HER2 was reduced by the 
transfection of siRNA against HER2 (Figure 6.5A). Cisplatin produces interstrand 
crosslinks in both cell lines, but cells with reduced expression of HER2 are unable to 
repair any of these interstrand crosslinks (Figure 6.5B). These results demonstrate that 
a reduction in HER2 expression in the MDA-MB-468-HER2 cell line inhibits the repair of 
cisplatin-induced interstrand crosslinks, indicating that these cells are dependent upon 
the expression of HER2. 
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Figure 6.5 Effect of reduced HER2 expression on the repair of cisplatin-induced interstrand 
crosslinks 
HER2 expression in the MDA-MB-468-HER2 cell line was reduced by the transfection of HER 
targeted siRNA (A). The effect of the knockdown of HER2 expression on the repair of 
interstrand crosslinks was investigated using the modified Comet assay. MDA-MB-468-HER2 
control cells (●) and cells transfected with siRNA against HER2 () were treated with cisplatin 
100 µM for one hour followed by replacement with DFM. Cells were collected at the time 
points indicated and analysed using the modified alkaline Comet assay. Data are presented as 
the mean±SEM of two independent experiments. *p>0.05. 
B 
A 
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6.4 CHROMATIN IMMUNOPRECIPITATION TO IDENTIFY THE DNA 
TARGETS OF NUCLEAR HER2 
ChiP was carried out in the MDA-MB-468-HER2 cell line as described in Chapter Two 
section 2.12 and outlined Figure 6.6. Extracted DNA was hybridised to BAC arrays to 
examine if the process of HER2-ChIP could be used to identify the DNA targets of HER2. 
Each BAC array contains over 32, 000 clones, covering the entire human genome with 
the average size of a clone of 170 base pairs. 
 
 
 
Figure 6.6 Process of chromatin immunoprecipitation 
A pictorial representation of the process of chromatin immunoprecipitation.  
Following treatment of cells, formaldehyde is added to crosslink DNA bound proteins. Cells are 
then collected and subjected to sonication to fragment DNA, followed by the addition of an 
antibody against the protein of interest. DNA fragments bound by the protein of interest are 
isolated through immuoprecipitation with agarose beads. The DNA fragments are then 
separated from the protein of interest by reversal of the crosslinks and the DNA isolated. 
 
The initial experiment yielded hybridisation to 150 clones. In order to further validate 
the use of BAC arrays as a screening tool to investigate DNA-protein interactions the 
experiment was repeated a further three times. Unfortunately these experiments 
proved that our initial results were not reproducible, with only two clones in common 
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across the four experiments (Table 6.1). In view of this ChiP-sequencing was not 
performed as the process is time consuming, expensive and was unlikely to be 
reproducible. It is unclear from these experiments whether this approach failed due to 
technical issues or that under these conditions HER2 is not bound to DNA. Technical 
problems include the fact that ChIP grade antibodies against HER2 do not exist. We 
used the same antibody as used by Wang et al. who have identified the nucleotide 
sequence bound by HER2 (Wang et al., 2004) but despite this our results were not 
reproducible. Another consideration may be that BAC arrays are not sensitive enough 
to identify potential genes. 
 
  Experiment 1 Experiment 2 Experiment 3 
No. of Clones identified  457 115 227 
 
Table 6.1 HER2-Chromatin immunoprecipitation and hybridisation to bacterial artificial 
chromosome arrays 
ChiP was performed using an antibody against HER2 in the MDA-MB-468-HER2 cell line. The 
isolated DNA was hybridised to BAC arrays to examine if the process of ChiP was successful. 
Rabbit IgG was used as a control antibody and for normalisation.  
 
6.5 DNA EXPRESSION MICROARRAY TO IDENTIFY THE TRANSCRIPTION 
TARGETS OF NUCLEAR HER2 
The technique of RNA expression arrays were used to assess to identify potential gene 
targets of HER2. Gene expression was assessed in MDA-MB-468-Vector, MDA-MB-468-
HER and MDA-MB-468-NLS cells to ascertain whether the transfection of HER2 up-
regulated gene expression. Two separate experiments were conducted; the first in 
cells treated with and without 100 µM cisplatin for one hour followed by RNA 
extraction 24 hours later. The second experiment in cells that were grown for 3-5 days 
and RNA extracted from cells at 80% confluence. 
 
In both experiments the MDA-MB-468-HER2 and MDA-MB-468-NLS cell lines clustered 
close together and separate from the MDA-MB-468-Vector cell line. Differentially 
expressed genes were identified using ANOVA and gene lists created based upon a 
false discovery threshold of 0.05. Analysis of the both sets of arrays using box plot 
analysis confirmed that the arrays were successful with all array distributions 
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clustering around the same median. Principle component analysis and hierarchical 
clustering demonstrated that the MDA-MB-468-Vector cell line separated from both 
the MDA-MB-468-HER2 and MDA-MB-468-NLS cell lines (Figure 6.7) 
 
 
  
 
Figure 6.7 An example of the hierarchical clustering of MDA-MB-468 HER transfected cell line 
gene expression 
Gene expression in MDA-MB-468 stably transfected with vector control, full length HER2 or 
HER2-NLS was studied using gene expression analysis. The example above is from proliferating 
cells at 80% confluence when RNA was extracted for analysis. 
 
 
6.5.1 The modulation of gene expression by HER2 and cisplatin 
Gene expression data were assessed in three different comparisons. The first 
compared the expression of untreated cells with the same cell line treated with 
cisplatin, the second between the three cells lines following cisplatin treatment, and 
the third between the three different cell lines, in the absence of cisplatin. 
 
No significant differences were detected in gene expression between untreated cells 
and those treated with cisplatin 100 µM for one hour in either MDA-MB-468-Vector, 
MDA-MB-468-HER or MDA-MB-468-NLS cells (Table 6.2). Comparisons between the 
lines treated with cisplatin identified a single gene, lactate dehydrogenase B, is 
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significantly increased by 2.1 fold in MDA-MB-468-NLS cisplatin treated cells compared 
with MDA-MB-468- Vector cells treated with cisplatin.  
There are no differences in gene expression between MDA-MB-468-Vector and MDA-
MB-468-HER2 cells and MDA-MB-468-HER2 and MDA-MB-468-NLS cells following 
treatment with cisplatin (Table 6.2). 
 
Comparison No. Genes 
MDA-MB-468-Vector vs. MDA –MB-486-Vector+cisplatin 0 
MDA-MB-468-HER2 vs. MDA –MB-486-HER2+cisplatin 0 
MDA-MB-468-NLS vs. MDA –MB-486-NLS+cisplatin 0 
MDA-MB-468-Vector+cisplatin vs. MDA–MB-486-HER2+cisplatin 0 
MDA-MB-468-Vector+cisplatin vs. MDA –MB-486-NLS+cisplatin 1 
MDA-MB-468-HER2+cisplatin vs. MDA –MB-486-NLS+cisplatin 0 
MDA-MB-468-Vector vs. MDA –MB-486-HER2 0 
MDA-MB-468-Vector vs. MDA –MB-486-NLS 5 
MDA-MB-468-HER2 vs. MDA –MB-486-NLS 0 
 
 
Table 6.2 Gene expression profiles of MDA-MB-468 HER2 transfected cell lines 
MDA-MB-468-Vector, MDA-MB-468-HER2 and MDA-MB-468-NLS cells were treated with or 
without cisplatin 100 µM for one hour, then left to grow in drug free media for 24 hours 
before undergoing RNA extraction and gene expression analysis. Each experiment was 
conducted in triplicate and the number of significantly differentially expressed genes analysed 
between the cell lines, and cells treated with or without cisplatin. 
 
Comparisons between untreated cells identifies that the expression of five genes differ 
between MDA-MB-468-Vector and MDA-MB-NLS cells (Table 6.3). There are no 
significant differences in gene expression between the MDA-MB-468-Vector and MDA-
MB-468-HER2 cell lines or between the MDA-MB-468-HER2 and MDA-MB-468-NLS cell 
line (Table 6.2).  
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GeneBank ID Gene Symbol Regulation Fold 
Change 
Adjusted 
P Value 
Gene Name 
LDHB NM_002300 Up 2.28 0.006 Lactate dehydrogenase B 
IRS-1 NM_005544 Up 2.5 0.006 Insulin receptor substrate 1 
SCGB2A2 BC067220 Down 4.4 0.02 Secretoglobin family 2A member 2 
BACC1 NM_001080519 Up 2.2 0.03 BAH domain and coiled-coil 
containing 1 
DACHI NM_080759 Down 1.6 0.03 Dachshund homolog 1 (Drosophila) 
 
Table 6.3 Five genes are differentially expressed between the MDA-MB-468-Vector and 
MDA-MB-468-NLS cell lines 
 
6.5.2 Modulation of gene expression in proliferating MDA-MB-468 cells by HER2 
Further RNA expression arrays were conducted in MDA-MB-468 transfected cells. 
Unlike the experiment described in section 6.5.1, RNA was extracted from cells when 
they were 80% confluent. Differences were identified in gene expression between 
MDA-MB-468-Vector and MDA-MB-468-HER2 cells and MDA-MB-468-Vector and 
MDA-MB-468-NLS cells lines but not MDA-MB-468-HER2 and MDA-MB-468-NLS cells 
(Table 6.4). 
 
Comparison  Genes  
(p<0.05)  
MDA-MB-468-Vector vs. MDA –MB-486-HER2 962  
MDA-MB-468-Vector vs. MDA –MB-486-NLS 1052  
MDA-MB-468-HER2 vs. MDA –MB-486-NLS 0 
 
Table 6.4 Gene expression profiles of MDA-MB-468 HER2 transfected proliferating cells  
MDA-MB-468-Vector, MDA-MB-468-HER2 and MDA-MB-468-NLS cells were grown until 80% 
confluent and then subjected to RNA extraction and gene expression analysis. Each 
experiment was conducted in triplicate and the number of significantly differentially expressed 
genes analysed between the cell lines.  
 
6.5.2.1 Identification of genes of interest 
Due to the larger number of genes identified the data were mined for the presence of 
known genes involved in DNA repair, nuclear transport and other HER family members 
(gene lists are described in Appendix One). This work identifies alterations in seven 
genes between the MDA-MB-468-Vector and MDA-MB-468-HER2 cell lines (Table 6.5). 
None of the genes identified in Table 6.3 were identified as being differentially 
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expressed in this gene expression array experiment. Of specific interest in this 
experiment is the up-regulation of the HER2 gene and the HER2 interactive protein in 
MDA-MB-468-HER2 and MDA-MB-468-NLS cells.  
 
 
Table 6.5 Significantly differentially expressed genes of interest in the MDA-MB-468-HER2 
and MDA-MB-468-NLS cell lines compared with the MDA-MB-468-Vector cell line 
There are no significant differences in gene expression between the MDA-MB-468-HER2 and 
MDA-MB-468-NLS cell lines. ns= not significant. 
 
6.5.2.1.1 Gene set enrichment analysis for functional annotation  
In order to examine if certain cellular pathways were altered by the transfection of 
HER2, enrichment by protein function was performed using Partek Genomic suite 
software. This analysis involves the clustering of genes by their function as described 
by their gene ontology annotation and the calculation of an enrichment score based 
GeneBank 
ID 
Gene Function Regulation 
compared with 
MDA-MB-468-
Vector 
Fold 
Change 
MDA-MB-
468-HER2  
Fold 
Change 
MDA-MB-
468-NLS 
EGFR  Down 1.5 ns 
HER2  Up 19.6 18.5 
HER2IP HER2 interactive protein. Binds to the 
unphosphorylated HER2 receptor and 
regulates localisation and function 
(Borg et al., 2000).  
Up 87.8 76.0 
PIKFYVE Involved in the endosomal  transport 
of membrane receptors, including 
EGFR (Kim et al., 2007) 
Up 1.8 1.6 
ADAM10 Disintegrin and metalloproteinase 
domain-containing protein 10, which 
may be involved in the shedding of 
HER2 from the cell membrane (Liu et 
al., 2006). 
Down 1.2 ns 
FANCG The protein Fanconi complementation 
group G is also known as XRCC9 and is 
involved in the process of homologous 
recombination ((Wilson et al., 2001))  
Down 2.9 2.7 
BRCA2 Breast cancer 2 susceptibility protein, 
also known as FANCD1, is involved in 
homologous recombination and 
interstrand crosslink repair (Cipak et 
al., 2006).  
Down 1.4 ns 
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upon minus log value of the mean p-values within in a gene cluster. This essentially 
identifies statistically over-represented clusters of genes (Huang da et al., 2009). The 
enrichment score can be used as a guide to indicate if a specific cluster of genes are 
biologically significantly altered within the expression array analysis (Huang da et al., 
2009).   
 
Two comparisons were analysed, MDA-MB-468-Vector against MDA-MB-468-HER2 
(Table 6.6) and MDA-MB-468-Vector and MDA-MB-468-NLS (Table 6.7).  Five 
functional groups are highly enriched in both comparisons: localisation, prostanoid 
metabolic process, prostaglandin metabolic process, regulation of cell proliferation 
and negative regulation of epithelial cell proliferation.  
 
Table 6.6 Gene set enrichment analysis for MDA-MB-468-Vector with MDA-MB-468-HER2 
Gene enrichment scores were calculated for set of genes as defined by their function. The ten 
highest gene sets are presented. Five sets of gene functions (in black) are common between 
this analysis and gene enrichment analysis between MDA-MB-468-vector and MDA-MB-468-
NLS gene expression. Five gene sets (in red) are only enriched in this analysis. 
 
A further five functions are highly enriched in the comparison of MDA-MB-468-Vector 
with MDA-MB-468-HER2. These are the functions of EGFR activity, L-aspartate 
transmembrane transporter activity, aspartate transport, regulation of the cell cycle 
and protein localisation (Table 6.6). In the comparison of MDA-MB-468-Vector with 
MDA-MB-468-NLS gene expression the additional five enriched functions are 
Gene Ontology 
ID 
Enrichment 
Score 
Function 
 
No. altered 
genes 
Total No. of 
genes  
006 19.3405 Epidermal growth factor receptor activity 2 2 
51179 18.9658 Localisation  10 64 
6692 18.3621 Prostanoid metabolic process 3 6 
6693 18.3621 Prostaglandin metabolic process 3 6 
50678 15.7378 Regulation of epithelial cell proliferation 5 21 
15183 15.3737 L-aspartate transmembrane transporter activity 2 3 
15810 15.3737 Aspartate transport 2 3 
50680 14.7657 
Negative regulation of epithelial cell 
proliferation 3 8 
10564 14.7657 Regulation of cell cycle process 3 8 
8104 13.2254 Protein localisation 5 25 
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oncostatin-M receptor activity, establishment of chromosome localization, muscle thin 
filament tropomyosin, sugar:hydrogen symporter activity and bile acid binding (Table 
6.7).   
 
Gene Ontology 
ID 
Enrichment 
Score 
Function 
 
No. altered 
genes 
Total no. of 
genes  
6692 16.6413 Prostanoid metabolic process 3 6 
6693 16.6413 Prostaglandin metabolic process 3 6 
50678 14.0903 Regulation of epithelial cell proliferation 5 21 
4924 13.9874 Oncostatin-M receptor activity 2 3 
50680 13.3505 
Negative regulation of epithelial cell 
proliferation 3 8 
51303 13.3505 Establishment of chromosome localization 3 8 
5862 11.552 Muscle thin filament tropomyosin 2 4 
5351 11.552 Sugar:hydrogen symporter activity 2 4 
32052 11.552 Bile acid binding 2 4 
51179 10.2762 Localization 8 64 
 
Table 6.7 Gene set enrichment analysis for MDA-MB-468-Vector with MDA-MB-468-NLS 
Gene enrichment scores were calculated for set of genes as defined by their function. The ten 
highest gene sets are presented. Five sets of gene functions (in black) are common between 
this analysis and gene enrichment analysis between MDA-MB-468-vector and MDA-MB-468-
HER2 gene expression. Five gene sets (in red) are only enriched in this analysis. 
 
6.6 The modulation of insulin receptor substrate-1 by HER2 expression 
and cisplatin 
As demonstrated on section 6.5.1 there is a significant 2.5 fold increase in the gene 
expression of insulin receptor substrate1 (IRS-1) in MDA-MB-468-NLS cells compared 
with MDA-MB-468-Vector cells (p 0.006) and a 2.3 fold increase in the expression of 
IRS-1 gene in MDA-MB-468-HER2 cell line compared with MDA-MB-468-Vector cells (p 
0.05) (Table 6.3). As IRS-1 is implicated in the process of HR through an interaction 
with Rad51 (Jeon et al., 2008; Trojanek et al., 2003), the expression of IRS1 was 
investigated further using RT-PCR to confirm the RNA expression array results and 
using Western blotting to examine protein expression. 
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RT-PCR demonstrates that the gene expression of IRS-1 is increased in both the MDA-
MB-468-HER2 and MDA-MB-468-NLS cell lines compared with the MDA-MB-468-
Vector cells (Figure 6.8A). However, the expression of IRS-1 is reduced in both the 
MDA-MB-468-HER2 and MDA-MB-468-NLS compared with the MDA-MB-468-Vector 
cells (Figure 6.8B). 
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Figure 6.8 Modulation of IRS-1 gene and protein expression by HER2 and cisplatin  
(A) RT-PCR was performed on the same RNA samples as used in the gene expression array. 
Data are presented as the mean±SEM of three triplicate experiments (B) The expression of IRS-
1 in MDA-MB-468-Vector, MDA-B-468-HER2 and MDA-MD-468-NLS cells was assessed by 
Western Blotting. Figure is representative of three independent experiments. 
 
The modulation of IRS-1 by cisplatin in all three cell lines was investigated using 
Western blotting though this experiment was only conducted once. Treatment of the 
MDA-MB-468-HER2 cells with cisplatin or trastuzumab increases the phosphorylation 
of HER2 and the combination of cisplatin and trastuzumab has no effect on the level of 
A 
B 
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HER2 phosphorylation, over either drug given alone (Figure 6.9). In the MDA-MB-468-
NLS cell line the effect of cisplatin or trastuzumab on the phosphorylation of HER2 is 
less than that observed in the MDA-MB-468-HER2 cell line. The combination of 
cisplatin and trastuzumab increases the level of phosphorylation of HER2-NLS over that 
seen with either drug alone. No phosphorylated HER2 is detected in the MDA-MB-468-
Vector cell line under the conditions examined. 
 
IRS-1 expression increases in response to cisplatin in all three cell lines but the degree 
of increase maybe higher in both the MDA-MB-468-Vector and MDA-MB-468-NLS cells 
lines, compared with the MDA-MB-469-HER2 cell line (Figure 6.9). This experiment 
would need to be repeated to confirm this result. Trastuzumab in combination with 
cisplatin has no effect on the expression of IRS-1 in any of the three cell lines. 
 
 
 
Figure 6.9 Modulation of IRS1 protein expression by cisplatin 
The modulation of IRS1 expression by cisplatin and trastuzumab was investigated in the MDA-
MB-468-Vector, MDA-B-468-HER2 and MDA-MD-468-NLS cells. Cells were treated with 
cisplatin (50 µM) for one hour ± trastuzumab for 2 hours, followed by DFM or trastuzumab for 
24 hours. Cells were then lysed and immunoblotted for the expression of pHER2 and IRS-1. 
αtubulin is used as a loading control. This experiment has only been conducted once. 
 
6.7 The modulation of FANCC gene expression by HER2 
As discussed in the introduction, FANCC plays a key role in the repair of interstrand 
crosslinks and its promoter contains the specific sequence which is bound by nuclear 
HER2. Whilst this gene was not found to be significantly differentially expressed in 
either of the RNA expression arrays, in view of the fact that its promoter has been 
identified as a target of HER2 (Wang et al., 2004), we confirmed our results using RT-
PCR. These data demonstrate lower expression in the MDA-MB-468-HER2 and MDA-
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MB-NLS cell lines (Figure 6.10). If nuclear HER2 promoted the transcription of the 
FANCC gene, we would to observe a difference in the FANCC RNA levels between the 
MDA-MB-468-HER and MDA-MB-468-NLS cell lines. RT-PCR demonstrates that there is 
no difference in the FANCC RNA levels between MDA-MB-468-HER2 and MDA-MB-
468-NLS cells indicating that in the MDA-MB-468 cell line, nuclear HER2 does not 
regulate the transcription of FANCC. 
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Figure 6.10 Modulation of FANCC gene expression by HER2 transfection 
RT-PCR was performed on the same RNA samples as used in the gene expression array. Data 
are presented as the mean±SEM of three triplicate experiments.  
 
 
6.8  DISCUSSION 
This chapter describes experiments to investigate the mechanism through which HER2 
is able to mediate resistance to cisplatin and increase the rate of repair of cisplatin-
induced interstrand crosslinks. The main aim of these experiments was to generate 
hypotheses to form the basis of further investigation. 
 
6.8.1 The modulation of cellular phenotype by HER2 expression 
The transfection of either full length HER2 or HER2 with a deleted NLS does not alter 
cell signalling in the key PI3K/AKT or Ras-Raf-MAPK pathways (Boone et al., 2009). In 
order to further characterise the activity of HER2 in MDA-MB-468 cells the effect on 
cell proliferation was further characterised. The transfection of HER2 increased the 
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rate of cell proliferation compared with cells transfected with the vector alone, 
whereas cell proliferation was initially slower in cells transfected with HER2 with a 
deleted NLS, but accelerated between 48 and 72 hours (Figure 6.2).  
 
Both forms of HER2 are phosphorylated in response to the anti-HER2 antibody 
trastuzumab (Figure 6.3). The dependence of MDA-MB-468 cells stably transfected 
with full length HER2 is demonstrated by the inhibition of the repair of cisplatin-
induced interstrand crosslinks when the expression of the transfected HER2 is reduced 
using siRNA (Figure 6.5). Taken together these results demonstrate that despite not 
altering the PI3K/AKT and Ras-Raf-MAPK pathways, transfected HER2 is able to alter 
the phenotype of transfected cells and is active 
 
6.8.2  Identification of the targets of HER2 
Given that HER2 is able to bind to a nine nucleotide sequence within gene promoters, 
we hypothesised that the explanation for HER2 induced resistance to cisplatin was due 
to the upregulation of specific genes by HER2. To identify possible genes two 
techniques were utilised, ChiP and gene expression analysis. HER2 bound DNA was 
immunoprecipitated from MDA-MB-468 cells transfected with either a vector or full 
length HER2. Whilst the initial results appeared promising, the experiments were not 
reproducible, so ChiP-sequencing was not undertaken. The reasons for this failure 
include the lack of specific ChiP antibodies against HER2 and that we used an antibody 
designed for used in the immunoprecipitation of proteins, though it has previously 
been used in ChiP experiments to identify the gene promoter targets of HER2 (Wang et 
al., 2004). 
 
RNA expression was studied in two separate experiments. The first identified five 
genes differentially expressed between the MDA-MB-468-Vector and the MDA-MB-
468-NLS cell lines, including IRS1. The modulation of IRS1 by cisplatin and trastuzumab 
was investigated further in view of published data indicating a role for IRS1 in HR 
(discussed further below).  
 
The second RNA expression study was carried out in cells allowed to grow to 80% 
confluence. This experiment yielded different results to the first, with a greater 
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number of genes identified as being differentially expressed between MDA-MB-468-
Vector cells and MDA-MB-468-HER2 and MDA-MB-468-NLS cells. Both RNA expression 
studies did not identify any differences in gene expression between the MDA-MB-468-
HER2 and MDA-MB-468-NLS lines.  
 
Analysis for the expression of genes known to be involved in DNA repair and the HER 
pathway identified the down-regulation of FANCG and BRCA2 in cells transfected with 
HER2 compared with the vector control; both these proteins are involved in HR (Scott 
and Pandita, 2006; Wyman et al., 2004). PIKFYVE, which involved in the nuclear 
transport EGFR (Kim et al., 2007), is upregulated in MDA-MB-468-HER2 cells. The 
expression of these genes will need to be quantitated using RT-PCR and their protein 
expression analysed. 
 
6.8.3 The modulation of IRS1 expression by HER2 transfection 
RNA expression arrays indicate that the IRS1 gene is significantly upregulated in MDA-
MB-468-NLS cells compared with the MDA-MB-468-Vector cell line by 2.5 fold (Table 
6.1). In addition there is a 2.3 fold increase in the MDA-MB-468-HER2 cells compared 
with the MDA-MB-468-Vector cell line, though the p value is 0.05. RT-PCR confirms an 
increase in IRS1 RNA levels in both MDA-MB-468-NLS and MDA-MB-468-HER cell lines 
compared with the MDA-MB-468-Vector cell line (Figure 6.7A). However, IRS1 protein 
expression is lower in cells transfected with either full length HER2 or HER2 with a 
deleted NLS, compared with cells transfected with the vector only (Figure 6.8B). Whilst 
at first this observation appears contradictory, this could be explained by an increase 
in signalling utilising IRS1, resulting in its degradation. 
 
IRS1 transmits signals between the insulin receptor and IGFR to the PI3K/AKT and Ras-
Raf-MAPK signalling pathways (Pollak, 2008). Activated IGFR, attracts and 
phosphorylates the protein IRS-1 which has a number of phosphorylation sites, 
including sites which bind Grb2, SH and the PI3K regulatory subunit, p85 (Pollak, 2008). 
IGFR signalling is highly complex and implicated in mediating resistance to 
chemotherapy (Hopkins et al., 2011). The formation of dimers between IGFR and HER2 
is an identified mechanism of resistance to trastuzumab, with insulin growth factor 
(IGF) stimulation of IGFR resulting in HER2 phosphorylation (Lu et al., 2001; Nahta et 
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al., 2005).  Therefore, IRS1 links to IGFR through the same downstream signalling 
pathways as the HER family. The role of IRS1 in HER2 mediated resistance to cisplatin 
warrants further investigation as there is evidence of its ability to regulate the process 
of HR as IRS1 binds RAD51, a key protein involved in the process of step of strand 
invasion and the search for homology within the sister chromatid both essential for HR 
(Trojanek et al., 2003). The phosphorylation of IRS1 through the activation of IGFR, 
releases RAD51 from the cytoplasmic IRS1/RAD51 complex allowing RAD51 to 
translocate to the nucleus and localise to sites of DNA damage (Trojanek et al., 2003).  
In contrast, transport of IRS1 into the nucleus in cells transformed by the viral proto-
oncogenes human polyomavirus JC (Trojanek et al., 2006a) and SV40 T-antigen 
(DeAngelis et al., 2006; Prisco et al., 2002), increases sensitivity to both cisplatin and IR 
through the co-localisation of IRS1 with RAD51 in the nucleus (Trojanek et al., 2006b) 
which inhibits HR (Urbanska et al., 2009).  
 
IGF1 reduces the apoptotic and DNA damaging effects of cisplatin through the 
inhibition of the nuclear translocation of IRS1 in response to cisplatin, indicating that 
phosphorylated IRS1 does not translocate to the nucleus (Jeon et al., 2008). Therefore, 
a hypothesis would be that the expression of HER2 in MDA-MB-468 cells, increases IGF 
signalling through dimerisation of HER2 with IGFR, increasing the phosphorylation of 
IRS1 preventing its translocation to the nucleus and releasing IRS1 from RAD51 
promoting the process of DNA repair by HR.  
 
However, this hypothesis is not supported by the data as the MDA-MB-468-NLS cells 
repair fewer interstrand crosslinks than the MDA-MB-468-HER cells (Boone et al., 
2009), despite increased IRS1 gene expression. In addition these cells repair fewer 
interstrand crosslinks than the MDA-MB-468-Vector cells, indicating that the deletion 
of the NLS, actually inhibits their repair. This observation could be explained by the 
initial slower rate of proliferation observed in MDA-MB-468-NLS cells (Figure 6.2) 
thereby slowing DNA repair or an alteration in the function or location of a critical 
protein due to the deletion of the NLS. This protein may be involved in cell to cell 
communication, as MDA-MB-468-NLS cells have a slower proliferation rate for the first 
48 hours after plating, which increases exponentially between 48 to 72 hours implying 
that cell confluence influences cell proliferation (Figure 6.2). This may also explain 
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differences in the two gene expression array studies undertaken. The first array 
investigated gene expression in cells allowed to grow for 48 hours, where as the 
second study investigated cells at 80% confluence which took 96-120 hours. 
 
6.9 CONCLUSIONS AND FUTURE WORK 
The transfection of HER2 into the HER2 negative MDA-MB-468 cells increases the rate 
of cell proliferation and resistance to cisplatin. HER2 transfected cells became 
dependent upon the HER2 protein, with its inhibition by trastuzumab rendering cells 
unable to unhook cisplatin-induced interstrand crosslinks.  
 
Examination of gene expression indicates that the IRS1 gene is upregulated in HER2 
and HER2-NLS transfected cells, yet the protein expression is reduced. Preliminary data 
indicates that IRS1 expression is increased in response to cisplatin and that there may 
be differences on the modulation of IRS1 between the three cell lines investigated. If 
these results are confirmed, further investigation into the modulation of IRS1 by HER2 
in response to cisplatin would be warranted to test the requirement for the 
phosphorylation of IRS1 to promote the process of HR, as reported in the literature. 
 
RNA expression analysis in cells allowed to reach 80% confluence indicates that a 
number of functional pathways are modulated by the expression of HER2. Prior to 
further work into the role of these pathways, confirmation of differences in the ability 
of these cells to repair cisplatin-induce interstrand crosslinks will need to be obtained.
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Conclusions 
The main aim of this study was to investigate the modulation of DNA damage induced 
by anti-cancer agents and its repair, by duration of exposure to TKIs targeted against 
EGFR and HER2. The second part of this study describes experiments to examine the 
role of HER2 in mediating resistance to the cytotoxic effects of cisplatin. 
 
Activation of HER family signalling is involved in mediating resistance to anti-cancer 
agents including IR and cisplatin, with the most widely studied mechanism the 
modulation of DNA-PK activity and localisation by EGFR, which interferes with the 
process of NHEJ. As discussed in Chapter One section 1.8, small molecule TKIs targeted 
against EGFR and HER2 are able to modulate the expression of thymidylate synthase 
and glutathione, inhibit multi-drug transporters, DNA repair and cell signalling 
pathways involved in cell proliferation. Despite this, combinations of chemotherapy 
drugs with TKIs have produced modest results in the case of lapatinib in combination 
with capecitabine or paclitaxel and studies conducted with gefitinib in lung cancer, 
failed to demonstrate any benefit from the addition of gefitinib to standard 
chemotherapy. 
 
Recent studies indicate that initial exposure to TKIs rapidly inhibits EGFR and HER2 
signalling within 60 minutes, but that with continued treatment, resistance can be 
induced through the stimulation of HER3 signalling. This raises the question as to 
whether this resistance can explain why combinations of TKIs with cytotoxic agents 
have not produced the results anticipated.  
 
The following objectives were studied: 
 The ability of lapatinib to synergise with cisplatin and doxorubicin and the 
effect of schedule (Chapter Three). 
 The modulation of induction of DNA strand breaks by cisplatin, IR, etoposide 
and doxorubicin by short and long exposure to gefitinib or lapatinib (Chapter 
Four). 
 The modulation of topoisomerase IIα by gefitinib (Chapter Five). 
 The role of HER2 in mediating resistance to cisplatin (Chapter Six). 
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7.1 THE IMPORTANCE OF SCHEDULE IN COMBINING LAPATINIB WITH 
CISPLATIN OR DOXORUBICIN 
Using the techniques of median effect and isobologram analysis, data presented in 
Chapter Three demonstrates that schedule produces a greater impact on the inhibition 
of cell proliferation by cisplatin, than doxorubicin. Across the three breast cancer cell 
lines investigated, the schedule of cisplatin first produces greater synergy than 
observed with the schedules in which lapatinib is given first, or both drugs 
continuously. Whilst isobologram analysis demonstrates a lesser influence of schedule 
on the inhibition of cell proliferation by doxorubicin, median effect analysis indicates 
that the least efficacious schedule is when lapatinib is scheduled before doxorubicin.  
 
Experiments were conducted with low concentrations of lapatinib which inhibited cell 
proliferation by around 20%. At these concentrations, lapatinib does not fully inhibit 
HER2 function and these experiments may have underestimated the full effects of 
lapatinib in combination with doxorubicin or cisplatin. When using targeted agents, it 
may be better to utilise a concentration of lapatinib which inhibits HER2 
phosphorylation for a shorter period of time. For example 1 µM lapatinib for one hour, 
prior to, in combination with or following chemotherapy, but then have allowed cells 
to grow in drug free media for the required duration. Furthermore, these drug 
combination assays do not identify the possible mechanisms through which lapatinib 
produces its effects. This could be achieved by using siRNA to knockdown specific 
genes of interest or entire signalling pathways, such as those involved in DNA repair. 
 
7.2 THE MODULATION OF DNA DAMAGE INDUCTION AND REPAIR BY 
DURATION OF EXPOSURE TO GEFITINIB OR LAPATINIB 
This study demonstrates that the exposure to either gefitinib or lapatinib for 48 hours 
results in the resumption of PI3K/AKT signalling despite initial inhibition, in agreement 
with the published data. Whilst duration of exposure to either gefitinib or lapatinib has 
no effect on the induction of interstrand crosslinks by cisplatin or DNA strand breaks 
by IR, gefitinib treatment for 48 hours significantly delays its repair. Lapatinib exposure 
for 48 hours has a lesser impact on the repair of DNA damage induced by either 
cisplatin or IR. The study of DNA repair using the Comet assay is limited by the fact that 
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cells are removed for analysis at different time points, rather than a single cell 
followed over time, as for example in a reporter assay. Additionally, over time cells are 
lost due to cell death, leaving behind cells which are either resistant to the DNA 
damaging agent under investigation or daughters of repaired cells. The Comet assay is 
unable to distinguish between cells which have fully repaired their damaged DNA and 
those that were undamaged, or are new. Comet tails are also lengthened during 
apoptosis due to DNA fragmentation and the assay relies on the visual recognition of 
cells undergoing apoptosis, over those with DNA strand breaks.  
 
The most striking observation in this study is the effect of continued exposure to 
gefitinib or lapatinib on the induction of DNA lesions by the Topo II poisons 
doxorubicin, etoposide and m-AMSA, with the production of DNA DSBS, inhibited 
following TKI exposure for 48 hours. This was demonstrated by both the alkaline and 
neutral Comet assays and assessment of γH2AX. The concentration of Topo II poison 
was substantially reduced to allow γH2AX foci to be counted, which may have altered 
the numbers and ratio of DNA single to double strand breaks induced by the poisons, 
impacting on the results presented. However, these data demonstrate significant 
differences in the production and resolution of γH2AX foci in cells treated with Topo II 
poison alone and those pre-treated with TKI for 48 hours. 
  
The repair of DNA strand breaks produced by Topo II poisons in cells treated with TKI 
for 48 hours could not be investigated due to the very low numbers detected, either by 
the Comet assay or measurement of γH2AX foci. Whilst this may have been possible if 
the dose of TKI had been reduced substantially, this would have altered the amount of 
reactivated AKT present in cells, as demonstrated Amin et al. with higher 
phosphorylated AKT detected in cells treated with lapatinib 200 nM for 48 hours 
compared with 1 or 5 µM (Amin et al., 2010), thereby significantly altering 
experimental conditions.  
 
7.2.1 Differences between topoisomerase II poisons 
In Chapters Four and Five clear differences in the DNA damaging effects of the three 
Topo II poisons investigated are reported. Doxorubicin-induces DNA strand breaks as 
detected by the alkaline and neutral Comet assays and γH2AX formation in cells 
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treated with TKIs for one hour, but this is significantly inhibited in cells treated for 48 
hours. Doxorubicin produces single and double strand breaks in an equal ratio 
(Pommier et al., 2010), yet the alkaline Comet assay detects few strand breaks, 
indicating that ability of doxorubicin to induce single or double strand breaks is 
significantly affected  following exposure to TKI for 48 hours.  
 
Like doxorubicin, etoposide-induces DNA strand breaks in cells treated with either TKI 
for one hour, and significantly fewer in cells treated with TKI for 48 hours, as indicated 
by the alkaline Comet assay. Data from the neutral Comet assay and measurement of 
γH2AX foci indicates that continuous TKI treatment for 48 hours significantly inhibits its 
ability to induce DNA DSBs. This suggests that the strand breaks detected in the 
alkaline Comet assay are single stranded DNA breaks and these are rapidly repaired 
following the removal of etoposide.  
 
M-AMSA induces strand breaks to the same degree regardless of the duration of TKI 
exposure as measured by the alkaline Comet assay. However, the neutral Comet assay 
and γH2AX foci formation indicate that fewer DSBs are produced in cells treated with 
TKI for 48 hours. TKI also promotes the repair of DNA strand breaks, regardless of the 
duration of TKI exposure, which cannot be explained by a reduction in the number of 
DSB, as TKI exposure for one hour reduces the production of DSB by a non-significant 
amount at the concentrations of m-AMSA investigated. These differences cannot be 
easily explained, though one possibility is that the reduced number of DSBs is enough 
to increase the rate of repair of DNA damage as detected in the alkaline Comet assay,  
despite no statistically significant difference in DSBs detected by both the neutral 
Comet assay and measurement of γH2AX foci. This hypothesis could be explored by 
increasing the number or repeat experiments performed in neutral Comet assay and 
measurement of γH2AX foci which would increase the sensitivity of the assay for 
detection of  smaller differences. An alternative possibility is that m-AMSA dissociates 
more easily from the Topo II enzyme, allowing it to function normally.  
 
It should be noted that the alkaline Comet assay detects both single and double DNA 
strand breaks, in contrast to the neutral assay and γH2AX foci which are more sensitive 
to the presence of DNA double stranded breaks.  
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7.2.2 Binding of topoisomerase II poisons to topoisomerase II 
There is little published data on the precise sites at which doxorubicin and m-AMSA 
bind to Topo II. Both drugs exert base preferences within the Topo II-DNA complex and 
it is felt they target the Topo II protein when it is bound to DNA (Nitiss, 2009a; 
Pommier et al., 2010). The binding of etoposide to Topo II is the most widely studied 
interaction between the Topo II enzyme and its poison. Etoposide binds to Topo II at 
two sites, one contained in the catalytic core and the other in the ATP-binding N-
terminal domain (Vilain et al., 2003). To form a DSB an etoposide molecule is required 
to bind each of the two Topo II molecules which make up the Topo II homodimer, with 
single strand breaks formed if only one Topo II molecule is targeted (Bromberg et al., 
2003). Etoposide produces 7-20 single strand breaks for every DSB (Pommier et al., 
2010).  
 
Hypophosphorylation of Topo IIα enzyme confers resistance to doxorubicin, m-AMSA 
and etoposide (Chikamori et al., 2003). The precise sites of hypophosphorylation and 
their relevance to the function of Topo II poisons have not all been investigated, 
though dephosphorylation at serine 1106 renders cells resistant to the cytotoxic 
effects of both m-AMSA and etoposide (Chikamori et al., 2003).  
 
Chapter Five demonstrates that continued exposure to either gefitinib or lapatinib for 
48 hours induces a cell cycle arrest and reduces the expression of Topo IIα, a 
mechanism which is known to render cells resistant to the effects of Topo II poisons 
(Nitiss, 2009b; Pommier et al., 2010). However, etoposide is still able to induce a 
concentration dependent increase in both single and double DNA strand breaks in cells 
treated with TKI for 48 hours, as detected in both the alkaline and neutral Comet 
assays. This indicates that the reduction in strand breaks induction is not just 
attributable to a reduction in the expression of Topo IIα, but may be due to reduced 
affinity of etoposide for Topo II, which is overcome by higher concentrations of the 
drug. This observation is in contrast to both doxorubicin and m-AMSA, as the neutral 
Comet assay does not demonstrate a concentration dependent increase in the number 
of DSBs produced by either drug in cells treated with gefitinib for 48 hours. These 
differences may be explained by the targeting of different sites on Topo IIα. This is 
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supported by the literature with etoposide inducing cleavable complexes at more than 
one DNA site, compare with m-AMSA and doxorubicin which act at a single site.  
 
7.3 FUTURE DIRECTIONS 
7.3.1  Does the scheduling of TKI following chemotherapy inhibit DNA repair more 
than concurrent treatment? 
Chapter Three examined the influence of schedule on the inhibition of cell 
proliferation by doxorubicin and cisplatin in combination with lapatinib. We found that 
schedules in which lapatinib is given following exposure to chemotherapy are the most 
efficacious. The use of short course intermittent TKI is supported by small phase II 
clinical trials in which erlotinib was given on days 5-15 (Riely et al., 2009) or days 15-28 
(Mok et al., 2009b) following gemcitabine and cisplatin or high dose erlotinib at a dose 
of 1500 mg given for two days prior to carboplatin and paclitaxel chemotherapy 
(Zwitter et al., 2011). 
 
Having demonstrated that continuous exposure to TKI leads to resistance to Topo II 
poisons, including doxorubicin, it would be interesting to examine the effect on DNA 
repair and apoptosis of treating cells with a DNA damaging agent first, followed by 
exposure to TKI and how it compares with the results presented here. 
 
7.3.2 Does exposure to gefitinib or lapatinib downregulate the targets of 
chemotherapy? 
Doxorubicin, epirubicin, etoposide and m-AMSA all target Topo IIα in order to produce 
DNA strand breaks. Topo IIα downregulation was observed in the SK-Br-3 cell line by 
48 hours, following treatment with gefitinib or lapatinib, leading to resistance to 
doxorubicin, etoposide and m-AMSA. If the downregulation of Topo IIα occurs in 
patients, this could also lead to resistance to drugs which target this enzyme.  
Therefore it is important to establish whether this finding translates into the clinic 
given a number of clinical trials currently being undertaken. These include the neo-
ALLTO trial investigating the use of neo-adjuvant lapatinib in patients with breast 
cancer who would be expected to receive adjuvant anthracycline based chemotherapy 
(National Cancer Institute, 2011c). If lapatinib leads to resistance to anthracyclines 
through the downregulation of Topo IIα, it could reduce the benefits of adjuvant 
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anthracycline based chemotherapy. In addition phase III randomised placebo control 
trials are being conducted to examine lapatinib in combination with liposomal 
doxorubicin in patients with metastatic breast cancer (National Cancer Institute, 
2011a) and in combination with epirubicin, cisplatin and capecitabine in patients with 
HER2 overexpressing gastric cancer (NCRI ST03 and EORTC 40071 trials).  
 
The expression of Topo IIα, could be investigated in patients with breast cancer who 
do not require neo-adjuvant chemotherapy.  These patients could be treated with 
gefitinib or lapatinib for two days or more, just prior to surgery, allowing the 
measurement of Topo II expression by IHC, in their diagnostic biopsy and the surgical 
specimens. Similar investigations could be undertaken in patients with NSCLC with 
subcutaneous nodules, cervical lymph nodes or pleural effusions who receive erlotinib 
in the second line setting, with biopsies taken just prior to commencement of erlotinib 
and a few days later. As well as assessing Topo IIα expression, other targets of 
chemotherapy drugs could be examined, including Topo I and thymidylate synthase, a 
target of 5-FU.  
 
As discussed in Chapter One, section 1.8.4, in vitro data demonstrates that TKIs can 
reduce the expression of thymidylate synthase and increase the expression of 
thymidine phosphorylase, enhancing sensitivity to 5-FU. This may explain why lapatinib 
in combination with capecitabine is more efficacious than capecitabine alone in 
patients with metastatic breast cancer. A clinical trial is currently being undertaken to 
examine lapatinib in combination with oxaliplatin and capecitabine in patients with 
HER2 overexpressing gastric or oesophageal cancer (National Cancer Institute, 2011b), 
to ascertain if this synergy translates into other tumour types. Mesothelioma is 
another tumour in which combinations of TKI with the thymidylate synthase inhibitor, 
pemetrexed could be investigated as around 50% of these tumours express EGFR 
(Destro et al., 2006). Mesothelioma also offers the opportunity to obtain repeat 
pleural fluid cytology or pleural biopsies to allow the examination of protein 
expression during treatment. 
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7.3.3 Is the effect of tyrosine kinase inhibition on topoisomerase II protein 
expression and activity linked to HER2? 
The enzyme casein kinase Iδ is known to regulate the activity and sensitivity of Topo 
IIα to Topo II poisons and casein kinase Iδ function is inhibited by gefitinib. It is not 
known if this inhibition is due to a direct, off target effect of gefitinib or due to the 
inhibition of EGFR and HER2 signalling. The first step in investigating a connection 
between HER signalling and Topo II, would be to confirm the in vitro observation of a 
reduction in Topo IIα expression in response to TKI exposure, occurs in the clinical 
setting.  
 
7.3.4 Are differences between the effects of gefitinib and lapatinib on the repair of 
cisplatin-induced interstrand crosslinks and IR-induced DNA damage explained by 
DNA-PK? 
DNA-PK is involved in the repair of DNA damage induced by both cisplatin and IR 
(Dittmann et al., 2005b; Friedmann et al., 2006) and the TKI erlotinib, which like 
gefitinib binds to EGFR when it is in an active conformation inhibits the 
phosphorylation of DNA-PKCS, but the HER2 targeted TKI AG825 does not (Toulany et 
al., 2010). Lapatinib, regardless of duration does not inhibit the repair of IR-induced 
DNA lesions and has a lesser effect on the repair of cisplatin-induced DNA lesions than 
gefitinib. This could be due to the fact that lapatinib does not inhibit the activity of the 
DNA-PKCS in contrast to gefitinib, due to differences in the inhibition of EGFR between 
gefitinib and lapatinib. This could be investigated by examining the effect of lapatinib 
on the phosphorylation of DNA-PKCS by both cisplatin and IR. In addition further 
experiments to examine differences between the two TKIs on the localisation of both 
EGFR and DNA-PK in response to cisplatin and IR could be investigated using confocal 
microscopy and proximity ligation assays. 
 
7.3.5 Are IRS1 and RAD51 modulated by HER2 leading to resistance to cisplatin in 
patients with HER2 amplified breast cancer? 
Data presented in Chapter Six requires further confirmation by the replication of the 
experiments as described. If these confirm differences in the expression of IRS1 in the 
MDA-MB-468-Vector, MDA-MB-468-HER2 and MDA-MB-468-NLS cells, further work on 
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the localisation of IRS1 and RAD51 in response to cisplatin may explain the observed 
alteration in the unhooking of cisplatin-induced interstrand crosslinks. This could be 
achieved through the use of confocal microscopy to examine the localisation of IRS1 
and RAD51 in response to cisplatin in the MDA-MB-468-Vector and MDA-MB-468-
HER2 cells. If HER2 is involved in the phosphorylation of IRS1, which releases RAD51, 
we would expect to observe a greater formation of RAD51 foci in response to cisplatin 
in the MDA-MB-468-HER2 cells than the MDA-MB-468-Vector cells, together with 
possible differences in the localisation of IRS1 between the two cell lines. If this was 
confirmed, further studies could be undertaken to assess if the NLS sequence is 
important in the link between HER2, IRS1 and RAD51, explaining why the MDA-MB-
468-NLS cells are less able to repair cisplatin-induced interstrand crosslink than their 
vector control. 
 
7.4 CONCLUSIONS 
We have established that continued exposure to gefitinib or lapatinib does not alter 
the induction DNA lesions induced by either IR or cisplatin, but differences exist 
between the two TKIs and DNA repair. In contrast, continued exposure to TKI renders 
cells resistant cytotoxic effects of the topoisomerase IIα poisons doxorubicin, 
etoposide and m-AMSA, through the down-regulation of the expression of 
topoisomerase IIα and the reduction in the induction of DNA double stand breaks as 
indicated by both the neutral Comet assay and the expression of γH2AX foci.  
 
Further work is needed to ascertain if the in vitro findings discussed here are relevant 
in the clinic. To date a number of randomised phase II and phase III trials examining 
the used of anti-EGFR therapies, either in the form of monoclonal antibodies or TKI in 
combination with standard chemotherapy in lung, colorectal and oesophagogasric 
cancer have not found a benefit from the targeting of EGFR (Gatzemeier et al., 2007; 
Herbst et al., 2005; Maughan et al., 2011; Rao et al., 2010).  If further ongoing 
combination studies are also negative, we may be in danger of throwing out useful 
drug combinations because we do not fully understand the role of EGFR and HER2 in 
modulating DNA repair and promoting resistance. There is evidence that inhibition of 
EGFR and HER2 phosphorylation alone may not be important, but also their cellular 
location, binding to DNA-PK or other proteins, the ability of cells to switch to 
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alternative mechanisms of activating key signalling pathways and the fact that their 
inhibition may downregulate the target of Topo II poisons, explaining why schedule 
has an impact on efficacy when combining TKIs with chemotherapy.  
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Appendix 
 DNA Repair Genes 
ABL1 ERCC5 MLH1 POLE3 RFC5 UBE2B 
ADPRT ERCC6 MLH3 POLE4 RIF1 UBE2D2 
ADPRTL1 EXO1 MMS19L POLG1 RPA1 UBE2D3 
ADPRTL2 FANCA MNAT1 POLG2 RPA2 UBE2I 
ADPRTL3 FANCB MPG POLH RPA3 UBE2L3 
ALKBH FANCC MRE11A POLI RPA4 UBE2N 
APEX1 FANCD2 MRE11B POLK RRM1 UBE2V2 
APEX2 FANCE MSH2 POLL RRM2 UNG 
APTX FANCF MSH3 POLM RRM2B WDR33 
ATM FANCG MSH4 POLN RUVBL2 WRN 
ATR BRIP1 MSH5 POLQ SHFM1 WRNIP1 
ATRX FANCL MSH6 POLS SMC1L1 XAB2 
BLM FANCM MUS81 PRKDC SMC2L1 XPA 
BRCA1 FEN1 MUTYH PTTG1 SMC3L1 XPC 
BRCA2 FLJ35220 N4BP2 RAD1 SMC4L1 XRCC1 
CCNH FRAP1 NBS1 RAD9A SMC1L2 XRCC2 
CDKN1A GADD45A NEIL1 RAD17 SMUG1 XRCC3 
CDK7 GADD45G NEIL2 RAD18 SPO11 XRCC4 
CETN2 G22P1 NEIL3 RAD21 SSRP1 XRCC5 
CETN3 GTF2H1 NTHL1 RAD23A SUMO1  
CHAF1A GTF2H2 NUDT1 RAD23B SUPT16H  
CHAF1B GTF2H3 NUDT3 RAD50 TDG  
CHEK1 GTF2H4 OGG1 RAD51 TDP1  
CHEK2 GTF2H5 PCNA RAD51C TEP1  
CIB1 H2AFX RAD51AP1 RAD51L1 TERF1  
CKN1 HEL308 PMS1 RAD51L3 TERF2  
CRY1 HMGB1 PMS2 RAD52 TERT  
CRY2 HMGB2 PMS2L1 RAD52B TINF2  
CSNK1D HUS1 PMS2L2 RAD54B TOP1  
CSNK1E KUB3 PMS2L4 RAD54L TOP2A  
DCLRE1A LIG1 PMS2L5 RAD9A TOP2B  
DCLRE1B LIG3 PMS2L8 RAD9B TOPBP1  
DCLRE1C LIG4 PMS2L3 RBBP4 TOP3A  
DDB1 MAD1L1 PNKP RBBP8 TOP3B  
DDB2 MAD2L1 POLA RECQL1 TP53  
DEPC-1 MAD2L2 POLA2 RECQL4 TP53BP1  
DMC1 MBD1 POLB RECQL5 TP53I3  
DUT MBD2 POLD1 REV1L TP73  
EME1 MBD3 POLD2 REV3L TP73L  
ERCC1 MBD4 POLD3 RFC1 TREX1  
ERCC2 MBD5 POLD4 RFC2 TREX2  
ERCC3 MGC90512 POLE RFC3 UBE1  
ERCC4 MGMT POLE2 RFC4 UBE2A  
 
 
